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Foreword
The annual report of the International Narcotics Control Board (INCB) for 2013 marks a particu-
lar milestone: the 45th annual report of the Board since it was established in 1968 in accordance 
with the Single Convention on Narcotic Drugs of 1961.1 Over that period, there have been signif-
icant emerging challenges and efforts made in addressing the global drug problem. Notably, the 
1961 Convention is adhered to by almost all States, illustrating the commitment of Governments 
to the principle of shared responsibility in ensuring the availability of narcotic drugs for medical 
and scientific purposes while preventing their diversion and abuse. To address subsequent drug 
control challenges such as the abuse of psychotropic substances while ensuring their availability for 
medical purposes, the use of chemicals in the illicit manufacture of narcotic drugs and psycho-
tropic substances, and drug trafficking, States created and adopted the two other international drug 
control conventions in force today: the Convention on Psychotropic Substances of 19712 and the 
United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988.3 Those conventions too enjoy almost universal adherence.
Over the period that began with the Board’s establishment, the international community has affirmed 
and strengthened its commitment to shared responsibility in drug control, for instance at the twen-
tieth special session of the General Assembly and through the adoption in 2009, by the Commission 
on Narcotic Drugs and the General Assembly, of the Political Declaration and Plan of Action on 
International Cooperation Towards an Integrated and Balanced Strategy to Counter the World Drug 
Problem. Now, the international community is about to conduct, in March 2014, the high-level 
review of the Political Declaration and Plan of Action, to which INCB will contribute, on the basis 
of its work in monitoring and promoting the implementation of the three drug control conven-
tions. In addition, prepa rations are under way for the special session of the General Assembly on 
the world drug problem to be held in 2016, which will draw renewed, high-level attention to the 
issue and guide the way forward.
The INCB annual reports, accompanied by the annual reports on precursor chemicals and the tech-
nical publications on narcotic drugs and psychotropic substances, serve as a “stock-taking” of 
achievements made, challenges faced and additional efforts required. The present annual report for 
2013 concludes with a chapter containing recommendations for Governments and international and 
regional organizations aimed at improving the implementation of the conventions and ultimately 
aimed at ensuring availability of controlled substances for medical and scientific purposes, while 
preventing diversion to illicit channels, illicit manufacture, trafficking and abuse.
In view of the upcoming high-level review and preparations for the special session of the General 
Assembly, INCB has decided to include in this report a thematic chapter on the economic conse-
quences of drug abuse. Considering drug abuse from that perspective provides a useful way of ana-
lysing the impacts of drug abuse. Drug abuse is in no way an independent variable and, indeed, is 
often part of a vicious cycle, as addressed by the Board in the thematic chapter on social cohesion 
in its annual report for 2011.4 Nevertheless, in planning, developing and implementing measures 
to prevent and treat drug abuse, it is valuable to consider the impacts of drug abuse and under-
stand their economic consequences.
Thus, chapter I reviews the economic consequences of drug abuse in the areas of health, public 
safety, crime, productivity and governance and discusses how investments in prevention, treatment 
and rehabilitation can lead to significant benefits in terms of the health-care and crime-related costs 
avoided, not to mention alleviating the immeasurable suffering experienced by drug-dependent 
 1 United Nations, Treaty Series, vol. 520, No. 7515.
 2 Ibid., vol. 1019, No. 14956.
 3 Ibid., vol. 1582, No. 27627.
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individuals, and their families and loved ones. However, estimates suggest that only one in six prob-
lem drug users worldwide receives the treatment they need—with significant regional variance. In 
addition to the drug-related deaths and increased morbidity arising, for instance, from the trans-
mission of infectious disease through injecting drug use, people under the influence of drugs can 
pose safety risks, for example, through drug-related accidents.
Crimes are often committed by people under the influence of drugs, to support drug addiction, 
and crime forms part of the violence between organized criminal groups involved in the traffick-
ing of drugs, as seen in Central America, but also on every other continent. The economic conse-
quences of drug-related crime include not only those directly resulting from the criminal act itself 
but also the associated costs of law enforcement, the judicial system and incarceration. Drug-related 
corruption can weaken governance, which in turn can be associated with increased illicit drug crop 
cultivation and illicit drug production, manufacture and trafficking—part of a vicious cycle— 
as explored in detail in the INCB annual report for 2010.5
Drug abuse also has environmental consequences. Illicit cultivation of coca bush and opium poppy 
results in deforestation and loss of biodiversity, as well as the loss of agricultural land that could 
otherwise be put to productive use. Environmental contamination can be caused by the precursor 
chemicals used in the illicit manufacture process and by the substance itself, and the aerial spray-
ing of illicit drug crops can also have negative effects. In addition, productivity losses can occur 
when people are unable to engage in employment while under the influence of drugs or while in 
treatment or incarcerated.
Drug abuse causes a disproportionate amount of harm to those most vulnerable: children, whose 
right to be protected from drug abuse is enshrined in the Convention on the Rights of the Child.6 
Prenatal exposure to drugs can cause emotional, psychological and physical disorders, and even 
death. In economic terms, this manifests itself in additional costs for care. Children exposed to 
drugs—whether through actual consumption or by living in an environment of drug abuse—may 
be exposed to a higher risk of physical and sexual abuse and are more likely to suffer anxiety and 
depression, have educational and attention problems, commit delinquent acts and become involved 
in crime and drug abuse. Urgent action must be taken to protect society’s most precious resource—
its children—from drug abuse and its effects.
Chapter I concludes with a selection of best practices and recommendations to reduce the eco-
nomic consequences of drug abuse, thereby improving social welfare. That brings us full circle to 
the underlying principle of the international drug control system and the three conventions upon 
which it is founded: concern for the health and welfare of humankind.
Drug abuse and the associated illicit cultivation, manufacture and trafficking cause an untold 
amount of suffering. The three drug control conventions set out the critical requirements for pre-
venting and reducing drug-related suffering and for ensuring access to essential controlled medi-
cines, which have been assessed to be of therapeutic value despite their potential to create 
dependence. Those measures are founded upon a balanced approach to drug control, which requires 
due attention to both demand reduction—through prevention, treatment and rehabilitation—and 
supply reduction—through law enforcement and judicial measures founded upon the principle of 
proportionality and respect for human rights.
The commitment of States parties to implementing the conventions must be translated into  tangible 
action and measurable results. Governments must ensure the sustainability of their prevention, 
treatment and rehabilitation programmes and their regulatory control systems. Even in times of 
financial austerity, such investment must be maintained. The alternative—losing the potential of 
citizens—could be the worst “investment choice” of all.
 5 E/INCB/2010/1.
 6 United Nations, Treaty Series, vol. 1577, No. 27531.
vThe international drug control system is founded upon the principle of shared responsibility—
between countries and at all levels of government within countries. Drug traffickers will choose 
the path of least resistance; so, it is essential that global efforts to tackle the drug problem are 
unified. INCB is concerned about some initiatives aimed at the legalization of the non-medical 
and non-scientific use of cannabis. Such initiatives, if pursued, would pose a grave danger to pub-
lic health and well-being, the very things the States, in designing the conventions, intended to 
protect. INCB looks forward to maintaining an ongoing dialogue with all countries, including 
those where such misguided initiatives are being pursued, with a view to ensuring the full imple-
mentation of the conventions and protecting public health.
 Raymond Yans
 President
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1Chapter I.
Economic consequences of drug abuse
1. Drug abuse inflicts immeasurable harm on public 
health and safety around the world each year, and threat-
ens the peaceful development and smooth functioning of 
many societies. An understanding of the economic costs 
of drug abuse is necessary to develop policies that reduce 
such costs. Attempts to calculate the global monetary 
burden of drug abuse, however, are mired in data limi-
tations in the many areas that must be taken into account 
to arrive at even a rough estimate of the total global cost 
of drug abuse. Analysis of the economic consequences of 
drug abuse must account for expenditure associated with 
policy choices and take into consideration any gains and 
externalities. Although accounting for the full, real dol-
lar costs of drug abuse worldwide is challenging, analys-
ing its consequences and understanding the domains it 
affects helps us to gain a clearer picture of the ways in 
which drug abuse affects the world. 
2. The present discussion analyses the consequences of 
drug abuse in five primary domains—health, public 
safety, crime, productivity and governance—using the 
available evidence. The effects of drug abuse on those 
domains depend upon a host of interconnections within 
and outside these fields, including other factors such as 
those discussed in chapter I of the annual report of the 
Board for 2011,7 e.g., social structures, cultural values 
and government policies. The present chapter focuses on 
the drugs that are under international control and does 
not delve into the consequences of abuse of specific 
drugs (especially given the prevalence of polydrug 
abuse). It is also important to keep in mind that costs 
and consequences vary widely across geographic regions. 
Costs are discussed in the context of the different 
 7 E/INCB/2011/1.
regions, although data limitations meant that this was 
not always possible. 
3. A brief discussion of the costs of alternative policies 
and the disproportionate economic impact of drug abuse 
on specific populations, including women, children, 
fami lies and the poor, are presented. The chapter con-
cludes with a number of conclusions, recommendations 
and best practices, rooted in evidence, to lower the global 
economic costs of drug abuse and improve the well-being 
of society.
A. Impact on health
4. A person’s health is greatly affected by drug abuse. 
Economically, this manifests itself in prevention and 
treatment costs, health-care and hospital costs, increased 
morbidity and mortality. 
Costs of drug prevention and treatment 
5. The phenomenon of drug abuse requires societies to 
dedicate resources to evidence-based prevention, educa-
tion and interventions, including treatment and rehabil-
itation. Although such activities can be resource-intensive, 
studies have shown that for every $1 spent, good preven-
tion programmes can save Governments up to $10 in 
subsequent costs.
6. Heroin, cannabis and cocaine are the drugs most fre-
quently reported by people entering treatment worldwide. 
It is estimated that only one in six problem drug users 
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worldwide, some 4.5 million people, receives the required 
treatment, at a global cost of about $35 billion annually. 
There is a wide variation from region to region. For 
example, in Africa only 1 in 18 problem drug users 
receives treatment. In Latin America, the Caribbean and 
Eastern and South-Eastern Europe, approximately 1 in 11 
problem drug users receives treatment, while in North 
America an estimated one in three problem drug users 
receives treatment interventions. If all dependent drug 
users had received treatment in 2010, the cost of such 
treatment would have been an estimated $200 billion-
 $250 billion, or 0.3-0.4 per cent of the global gross domes-
tic product (GDP). Research findings clearly show that 
investment in treatment is cost-effective compared with 
the cost of untreated and continuing abuse. Research con-
ducted in the United States of America reveals that every 
$1 invested in treatment yields a return of between $4 
and $12 in reduced crime and health-care costs.
Health care and hospitals
7. Visits to hospitals in connection with drug abuse are 
costly to society. Such visits occur as a result of overdoses, 
adverse reactions, psychotic episodes and symptoms of 
infectious diseases that can be transmitted through, inter 
alia, injecting drug use, such as hepatitis B and C,  HIV/
AIDS, tuberculosis, and other illnesses related to drug 
use. Additionally, hospitals often need to treat victims of 
drug-related crimes and accidents.
Morbidity and mortality
8. Globally, it is estimated that drug-related deaths 
account for between 0.5 and 1.3 per cent of all-cause 
mortality for people aged 15-64 years. It is estimated that 
there are 211,000 drug-related deaths annually, with 
younger people facing a particularly high risk. In Europe, 
the average age of death from drug use is in the mid-30s. 
It is important to note that little information regarding 
drug-related mortality is available for Asia and Africa. In 
addition to drug-related mortality, estimates indicate that 
of the 14 million injecting drug users worldwide, 1.6 mil-
lion are living with HIV, 7.2 million are living with hep-
atitis C, and 1.2 million are living with hepatitis B. A 
global scientific study estimated that the burden of dis-
ease attributable to drug use was substantial, rising in 
2010 relative to 1990. Out of 43 risk factors, drug use was 
nineteenth in the ranking of the top global killers (alco-
hol was third and tobacco was second). For people aged 
15-49 years, drug use was the sixth most common  reason 
for death.
B. Impact on public safety
9. Beyond health costs, people under the influence of 
drugs pose major safety risks and costs to people around 
them and the environment. For example, drug-affected 
driving accidents have emerged as a major global threat 
in recent years. Additionally, a greater awareness of the 
impacts on the environment of illicit drug cultivation, 
production and manufacture has emerged.
Drug-affected driving
10. The abuse of drugs affects perception, attention, 
cognition, coordination and reaction time, among other 
neurological functions, which affect safe driving. Cannabis 
is the most prevalent illicit drug detected in drivers in 
Canada and the United States and Europe and Oceania. 
Research has found that habitual cannabis use is linked 
to a 9.5-fold greater risk of driving accidents, cocaine and 
benzodiazepines increase the risk 2-10 times, ampheta-
mines or multiple drug use increase the risk 5-30 times, 
and alcohol in combination with drugs increases the risk 
of getting seriously injured or killed while driving by a 
factor of 20-200. That increased risk also has conse-
quences for passengers and others on the road, who may 
become victims of drug-affected driving.
Impact on the environment
11. The illicit manufacture and disposal of drugs and 
pharmaceuticals cause significant environmental contam-
ination, owing to the precursor chemicals required for 
manufacture, the manufacturing process itself and the 
active ingredient or substance. Disposal introduces those 
substances into the environment in sewage, from where 
they can enter sediment, surface and ground water and 
the tissues of vegetation and aquatic organisms. As a 
result, wildlife and humans can be chronically exposed 
to very low doses of drugs and the chemicals used in 
their illicit manufacture. That results in costs to indivi-
duals and to Governments, as they are responsible for 
ensuring public health.
12. Illicit cultivation of both coca bush and opium 
poppy has often resulted in the clearance of forests—in 
the case of illicit cultivation of coca bush, primarily in 
Bolivia (Plurinational State of), Colombia and Peru. 
Some devastating effects of illicit cultivation of cannabis 
plant, coca bush and opium poppy on biodiversity are 
the loss, degradation and fragmentation of the forests, 
and the loss of areas where food could be grown. In addi-
tion to the deforestation caused by illicit crop cultivation, 
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chemicals used for the processing of illicit drugs can be 
harmful to biodiversity, both in the immediate area and 
downstream, as a result of chemical run-off. There can 
also be negative effects associated with the aerial spray-
ing of crops.
13. Finally, the emergence of illicit drug cultivation and 
manufacture in residential areas brings with it concern 
about reduced quality of life for residents, neighbourhood 
decay and property damage resulting from child endan-
germent, criminal activity and explosions.
C. Relationship with crime
14. A generation of research has defined three major 
links between drugs and crime. The first drugs/crime 
nexus relates to the violence that can be associated with 
the use of drugs themselves: psychopharmacological crime. 
15. Crime committed under the influence of drugs is a 
major problem worldwide. For example, in a study in 
Dominica, Saint Kitts and Nevis, Saint Lucia and Saint 
Vincent and the Grenadines, as many as 55 per cent of 
convicted offenders reported that they were under the 
influence of drugs at the time of the offence, with 
19 per cent of the same set of offenders saying that they 
would still have committed the crime even if they had 
not been under the influence of drugs. 
16. The second drugs/crime link is economic- compulsive 
crime. This is the result of drug users engaging in crime 
to support their drug consumption and addiction. In the 
United States, for example, 17 per cent of state prisoners 
and 18 per cent of federal inmates said they had com-
mitted the offence for which they were currently serving 
a sentence to obtain money for drugs. In the United 
Kingdom of Great Britain and Northern Ireland, it is esti-
mated that economic-compulsive crime costs approxi-
mately $20 billion a year, the vast majority of those costs 
resulting from burglary, fraud and robbery.
17. The third link is systemic crime: the violence that 
occurs, for example, as a result of disputes over “drug 
turf ” or fighting among users and sellers over deals gone 
awry. This has been seen, starkly, in Latin America over 
the past 10 years, especially in countries such as Guatemala 
and Mexico, but it is also seen in the streets of every con-
tinent throughout the world.
18. Studies show that overall, drug-related crime is costly 
but varies from region to region. A study in Australia 
indicated costs of $3 billion a year, and in the United States 
it is estimated that drug-related crime costs $61 billion 
annually.
19. All those costs are related to burdens placed on law 
enforcement agencies and the judiciary, in addition to the 
increased incarceration rates resulting from behaviour 
related to drug use, which in the past few decades have 
grown substantially in many countries. 
D. Impact on productivity
20. A further cost of drug abuse that is often cited is 
the loss in productivity that can occur when drug users 
are under the influence of drugs or are experiencing the 
consequences of their drug use (e.g., while in treatment, 
incarceration or hospital). Studies have put the costs of 
lost productivity borne by employers at tens of billions 
of dollars.
Costs from labour non-participation
21. Productivity losses are calculated as work that 
would be reasonably expected to have been done if not 
for drug use (a loss of potential income and output and 
therefore GDP) as a result of a reduction in the supply 
or effectiveness of the workforce. Lost productivity in the 
United States as a result of labour non-participation is 
significant: $120 billion (or 0.9 per cent of GDP) in 2011, 
amounting to 62 per cent of all drug-related costs. Similar 
studies in Australia and Canada identified losses of 0.3 
per cent of GDP and 0.4 per cent of GDP, respectively. 
In those two countries, the cost of lost productivity was 
estimated to be 8 and 3 times higher, respectively, than 
health-related costs due to morbidity, ambulatory care, 
physician visits and other related consequences.
Costs from treatment participation, 
hospitalization, incarceration and  
premature mortality
22. While in treatment or when incarcerated, drug 
users may be unable to participate in work, education 
or training, adding to the economic loss, in addition to 
the cost of treatment or incarceration. It should be 
noted that these productivity costs will be lower if job 
opportunities are already scarce as a whole. In Europe 
in 2010, 56 per cent of patients entering drug treatment 
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programmes were unemployed, and that percentage has 
increased over the past five years.
E. Impact on governance
23. As discussed in chapter I of the Board’s annual 
report for 2010,8 drug traffickers in countries all over the 
world corrupt officials at all levels of law enforcement and 
government in order to continue with their criminal 
activities unimpeded. As a result, citizens in affected areas 
often live with compromised law enforcement institu-
tions. Today, this is seen in different continents, where 
illicit cultivation of cannabis plant, coca bush and opium 
poppy continue unbridled, resulting in less stable govern-
ment institutions and the corruption of government 
officials.
24. It is important to note that these connections may 
not be straightforward, as weak governance (resulting 
also from issues not related to drugs) can also lead to 
more illicit drug crop cultivation, illicit drug production, 
manufacturing and trafficking and more drug abuse. 
Traffickers establish new transit routes by exploiting weak 
governing institutions, financing corruption and terror-
ism with the gains made by engaging in illicit activity.
F. Impact on specific populations
Children
25. Prenatal exposure to drugs can result in an array of 
emotional, psychological and physical disorders. Children 
exposed to illicit drugs after birth may suffer significant 
problems that require additional care, resulting in both 
personal expenses and costs to society. Children exposed 
to drugs are at a significantly higher risk of both physi-
cal and sexual abuse as well as neglect and often have 
higher rates of anxiety, depression, delinquency and edu-
cational and attention problems. 
26. Parents who abuse drugs are more likely to live in 
homes in which relatives, friends, and strangers also use 
drugs, exposing children to possible emotional and phys-
ical harm. Additionally, children that have to be removed 
from such environments are more likely to engage in 
crime, drug use and delinquency.
 8 E/INCB/2010/1.
27. Drug abuse is of particular concern among street 
children throughout the world. Studies indicate that 
street children who use drugs were more likely to have 
been abused by their parents, have a history of arrests 
and engage in sex work, exposing them to sexually trans-
mitted diseases.
28. Drug abuse also affects children in conflict areas. 
In some regions, drugs are used as an instrument to 
engage and retain children and young people as child 
soldiers in civil wars, armed conflicts and regional con-
flicts and in terrorist activities. These children and young 
people can become subject to physical and sexual abuse, 
psychological problems, addiction and other harmful 
consequences.
Women
29. Gender differences have been identified as heavy 
determinants in the onset of addictive behaviours, includ-
ing drug abuse. Women are acutely affected by particu-
lar consequences of drug abuse, such as sexually 
transmitted diseases and the consequences of domestic 
violence, in addition to being more likely to be affected 
by drug-facilitated crime.
Low-income populations
30. Drug abuse and poverty are often linked in  multiple 
ways. Drug abuse may occur to relieve the stress associ-
ated with poverty, chronic social strain and other diffi-
cult events. In poorer neighbourhoods, there is often less 
access to support systems, health care and community 
organizations.
31. Additionally, the relationship between drugs and 
poverty can also work in the inverse direction: drug abuse 
can deplete users’ income, leading to a lack of care for 
family and loved ones and other responsibilities. 
G. Alternative policies
32. Some have argued that alternatives to the present 
control system would result in lower costs. They argue 
that enforcement costs resulting from the current inter-
national drug control regime, not drugs themselves, are 
the source of most costs.
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33. It is unclear, however, that costs related to enforce-
ment would necessarily decrease under policies that are 
not based on the current international drug control trea-
ties. In addition, it has been shown that government reve-
nue from the legal sale of alcohol and tobacco is less than 
the economic and health costs of their abuse. 
34. Additionally, there might be increased law enforce-
ment costs due to higher crime rates occurring under 
more permissive laws and control regimes. In many coun-
tries, alcohol, not drugs under international control, is 
responsible for far more arrests (for example, in the 
United States, in 2012 there were over 2 million alcohol-
related arrests—more than the 1.6 million arrests related 
to all illegal drugs combined). One reason for those 
higher alcohol-related costs is that in many countries 
alcohol abuse is far more prevalent than the abuse of sub-
stances under international control.
35. It is sometimes argued that criminal organizations 
might be deprived of revenues if drugs were legalized, as 
alcohol is. However, those criminal organizations obtain 
their resources not just from illicit drug sales, and such 
organizations may enter the licit market while remaining 
in the illicit market.
36. Legalizing drugs would not ensure that under-
ground markets dealing in them would cease. In fact, 
today there is a thriving black market for cigarettes in 
many countries, such as Canada and the United States 
and in Europe and other regions of the world. For exam-
ple, it has been shown that from 9 to 20 per cent of the 
United Kingdom’s domestic cigarette market now consists 
of smuggled cigarettes. In Canada, smuggled cigarettes 
represent about 33 per cent of all domestic cigarette con-
sumption, although that proportion varies from province 
to province. In the United States, three quarters of the 
cigarettes observed in a Chicago neighbourhood as part 
of a research study had no tax stamp, indicating that they 
came from black or grey market sources. 
37. Emerging data from the State of Colorado of the 
United States suggest that since the introduction of a 
widely commercialized “medical” cannabis programme 
(poorly implemented and not in conformity with the 
1961 Convention), car accidents involving drivers testing 
positive for cannabis, adolescent cannabis-related treat-
ment admissions and drug tests revealing cannabis use 
have all increased. 
38. One can also imagine states having to bear regula-
tion costs of such alternative drug regimes. Costs of regu-
lation include, among other things, monitoring and 
controlling cultivation, production, manufacturing and 
distribution, as well as monitoring use, and its impact. 
This has been seen in state-run medical cannabis pro-
grammes in the United States, where states have been 
unable to manage those new bureaucracies, according to 
independent audits. 
39. If currently controlled substances were regulated as 
alcohol is in many countries, more people would use 
them and become addicted, resulting in more adverse 
consequences.
H. Conclusions, recommendations 
and best practices to reduce the 
economic consequences of drug 
abuse
40. Since drug abuse places such a costly burden upon 
society in so many domains, it is important to discuss 
ways in which these costs can be reduced. What can soci-
ety do to reduce the overall cost of drug abuse? A brief 
overview of some proven measures follows:
 (a) Drug prevention is cost-effective. Generalized 
universal prevention programmes aim at building strong 
communities and families, mostly seeking to provide 
young people with the skills to make healthy choices and 
decisions. Specific and targeted prevention must also be 
an aim of Governments. Engaging the broader commu-
nity in prevention has shown to be successful in prevent-
ing drug abuse and reducing its adverse consequences. 
Community-based approaches have been tried in the 
Americas and other regions, and early studies indicate 
they are effective;9
 (b) For those who have initiated drug abuse but 
have yet to succumb to dependence, screening and brief 
interventions and referral to treatment mechanisms may 
be appropriate. Such services include an initial assess-
ment by general primary care physicians or counsellors 
to identify at-risk persons, brief advice and, if necessary, 
referral to treatment; 
 (c) For individuals with addiction, drug treatment, 
with behavioural and/or medical interventions, has 
proven to be effective. While there is a need to protect 
privacy, treatment should be given in the context of reha-
bilitation and social reintegration (e.g. therapeutic 
 9 United Nations Office on Drugs and Crime, “International stand-
ards on drug use prevention”, available from www.unodc.org.
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communities) and complemented by measures aiming at 
the reduction of the adverse consequences of drug abuse;
 (d) Recovery from drug addiction requires support 
from family and the community. It should also include 
education and job training, housing, childcare, transpor-
tation to and from treatment and work, case management 
and spiritual support, as well as relapse prevention, fam-
ily education, peer-to-peer services and coaching, self-
help and support group services. The Board urges wider 
application of such strategies recently implemented in 
various regions;
 (e) A more efficient justice system can deter drug 
abuse and offer alternatives to incarceration. The princi-
ple of proportionality, as the Board discussed extensively 
in its annual report for 2007,10 should be respected. Drug 
treatment courts rely on swift and modest sanctions cou-
pled with treatment and drug testing to promote absti-
nence from drugs, reduce crime and increase social 
reintegration. This may require a major reorientation of 
national drug control and justice policies and may also 
require significant investments. Such measures have had 
success among repeat criminal offenders with long drug 
abuse histories in some regions of the world;
 (f) A wide variety of social programmes not 
directly related to drug abuse have the potential to reduce 
the economic consequences of drug abuse. For example, 
vocational training programmes can be targeted so as to 
reach young people particularly at risk of becoming drug 
sellers, and interventions can target those vulnerable to 
homelessness, social deprivation, unemployment and 
exclusion from educational opportunities. Public housing 
projects should be designed so as to avoid physical niches 
that protect retail drug trafficking. While such measures 
and initiatives require significant investment, they are 
likely to reap benefits in the long term, not just by 
 10 E/INCB/2007/1.
reducing the economic consequences of drug abuse but 
by also yielding benefits in many other domains;
 (g) Policies and initiatives against drug trafficking 
must be integrated into development programmes in all 
countries, keeping in mind the key goal of strengthen-
ing institutions and shared responsibility at all levels of 
government. As recently highlighted in a major recom-
mendation by the Organization of American States Inter-
American Drug Abuse Control Commission in its review 
of its Hemispheric Drug Strategy, strengthening govern-
ment institutions is a key strategy for reducing the con-
sequences and costs of drug abuse in all countries;
 (h) The Single Convention on Narcotic Drugs of 
1961,11 the Convention on Psychotropic Substances of 
197112 and the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances 
of 1988,13 as well as the Political Declaration adopted by 
the General Assembly at its twentieth special session,14 
held in 1998, and the Political Declaration and Plan of 
Action on International Cooperation towards an 
Integrated and Balanced Strategy to Counter the World 
Drug Problem15 of 2009 provide a well-established frame-
work to implement the policies mentioned above and, in 
turn, reduce the economic consequences of drug abuse 
worldwide. States are urged to scale up their implemen-
tation of these evidence-based interventions and strate-
gies with the aim of reducing drug abuse and its 
consequences. The Board recommends, to that end, 
that Governments increase their collaboration, as well 
as partnerships with relevant international organiza-
tions, such as the United  Nations Children’s Fund.
 11 United Nations, Treaty Series, vol. 520, No. 7515.
 12 Ibid., vol. 1019, No. 14956.
 13 Ibid., vol. 1582, No. 27627.
 14 General Assembly resolution S-20/2, annex.
 15 See Official Records of the Economic and Social Council, 2009, 
 Supplement No. 8 (E/2009/28), chap. I, sect. C.
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Functioning of the international  
drug control system
A. Promoting the consistent 
application of the international  
drug control treaties
41. In discharging its mandate under the international 
drug control treaties, the Board maintains an ongoing 
dialogue with Governments by various means, such as 
regular consultations and country missions. That dialogue 
has been instrumental to the Board’s efforts to assist 
Governments in complying with the provisions of the 
treaties.
1. Status of adherence to the 
international drug control treaties
42. As at 1 November 2013, the number of States par-
ties to the Single Convention on Narcotic Drugs of 1961 
or that Convention as amended by the 1972 Protocol16 
stood at 186. Of those States, 184 were parties to the 1961 
Convention as amended by the 1972 Protocol. A total of 
10 States have yet to accede to the 1961 Convention or 
that Convention as amended by the 1972 Protocol: 
2  States in Africa (Equatorial Guinea and South Sudan), 
1 in Asia (Timor-Leste) and 7 in Oceania (Cook Islands, 
Kiribati, Nauru, Niue, Samoa, Tuvalu and Vanuatu).
43. The number of States parties to the Convention on 
Psychotropic Substances of 1971 remained 183. A total of 
13 States have yet to become parties to that Convention: 
3 States in Africa (Equatorial Guinea, Liberia and South 
Sudan), 1 in the Americas (Haiti), 1 in Asia (Timor-Leste) 
 16 United Nations, Treaty Series, vol. 976, No. 14152.
and 8 in Oceania (Cook Islands, Kiribati, Nauru, Niue, 
Samoa, Solomon Islands, Tuvalu and Vanuatu).
44. The number of States parties to the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 stood at 187. A total of 
nine States have yet to become parties to that Convention: 
three States in Africa (Equatorial Guinea, Somalia and 
South Sudan), one in Asia (Timor-Leste) and five in 
Oceania (Kiribati, Palau, Papua New Guinea, Solomon 
Islands and Tuvalu).
45. The Board reiterates the importance of universal 
application of the international drug control treaties and 
urges those States that have not yet done so, particularly 
those in Oceania, to take the steps necessary to accede to 
all the international drug control treaties without further 
delay. 
2. Evaluation of overall treaty 
compliance in selected countries
46. The Board reviews on a regular basis the drug con-
trol situation in various countries and Governments’ 
overall compliance with the provisions of the interna-
tional drug control treaties. The Board’s review covers 
various aspects of drug control, including the function-
ing of national drug control administrations, the ade-
quacy of national drug control legislation and policy, 
measures taken by Governments to combat drug traffick-
ing and abuse, and Governments’ fulfilment of their 
reporting obligations under the treaties. 
47. The findings of the review, as well as the Board’s 
recommendations for remedial action, are conveyed to 
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the Governments concerned as part of the ongoing dia-
logue between the Board and Governments to ensure 
that the international drug control treaties are fully 
implemented.
48. In 2013, the Board reviewed the drug control situ-
ation in Kyrgyzstan, the Netherlands, Peru and Timor-
Leste, as well as measures taken by the Governments of 
those countries to implement the international drug con-
trol treaties. In doing so, the Board took into account all 
information available to it, paying particular attention to 
new developments in drug control in those countries.
(a) Kyrgyzstan
49. Drug trafficking poses a serious threat in Kyrgyzstan 
because of the country’s proximity to Afghanistan. As a 
major route for drug trafficking (the so-called “northern 
route”) passes through Kyrgyzstan, the country is used as 
a transit area for transporting illicit consignments of 
drugs, primarily heroin and opium, from Afghanistan to 
countries in the Commonwealth of Independent States 
and Europe. Opiates originating in Afghanistan are 
increasingly being smuggled into Kyrgyzstan, crossing the 
country’s border with Tajikistan, which leads through 
1,000 kilometres of mostly mountainous terrain. 
50. Illicit drug production in Kyrgyzstan poses a signifi-
cant challenge to the Government’s efforts to address the 
drug problem. In Kyrgyzstan, cannabis plants grow wild 
on a total of about 10,000 hectares (ha). Cannabis and 
cannabis resin are illicitly produced in Kyrgyzstan for 
illicit markets in the country or the region. Ephedra 
plants, used for the illicit manufacture of methampheta-
mine, also grow wild in the country, on an area covering 
about 55,000 ha. Kyrgyzstan is experiencing a rise in the 
abuse of drugs, especially opiates and cannabis, as well as 
an increase in the abuse of drugs by injection and in HIV 
infection. Kyrgyzstan’s drug control efforts are often ham-
pered by poverty, unemployment, labour migration and 
corruption.
51. Kyrgyzstan, a party to the three international drug 
control treaties, has gradually strengthened its efforts in 
drug control since 1991, when it gained its independence. 
The country has adopted national drug control legislation 
in line with the international drug control treaties and 
designated the State Drug Control Service as the compe-
tent national authority responsible for the implementa-
tion of the treaties. In 2011, Kyrgyzstan established a 
national committee for drug control coordination. Various 
measures aimed at the prevention of HIV infection and 
drug addiction among adolescents and young people are 
being implemented by the Ministry of Education and 
Science and the Ministry of Health and by a range of 
non-governmental organizations.
52. The Board notes, however, that Kyrgyzstan has yet 
to update its last national drug control strategy, which 
covered the period 2004-2010. The Board encourages the 
Government of Kyrgyzstan to adopt a comprehensive and 
well-balanced national drug control strategy—one that 
sets clear goals and allocates resources to the prevention 
of drug abuse and the treatment and rehabilitation of 
drug-dependent persons, as well as to law enforcement. 
The Government should continue to cooperate closely 
with international partners, including the United Nations 
Office on Drugs and Crime (UNODC) and the donor 
community, to combat drug trafficking and reduce the 
illicit demand for drugs on its territory. 
53. The Board notes with appreciation that the 
Government of Kyrgyzstan has been effectively coop-
erating with the Board and has been complying with 
its reporting obligations under the international drug 
control treaties. 
(b) Netherlands
54. The Board has long-standing concerns regarding 
certain drug control policies adopted by the Government 
of the Netherlands, in particular the policy that allows 
small amounts of cannabis to be sold and abused in so-
called “coffee shops”. The Board is also concerned about 
the operation of so-called “drug consumption rooms”, 
facilities where drug addicts can abuse drugs. 
55. Over the years, the Board has maintained an ongo-
ing dialogue with the Government of the Netherlands on 
those and other issues. At the request of the Government, 
the President and the Secretary of the Board met with a 
delegation from the Netherlands in March 2013 to dis-
cuss the drug control situation in that country, in particu-
lar the latest policy developments regarding “coffee 
shops”. The delegation informed the President that some 
progress had been made: the Opium Act had been 
amended over the years, particularly with respect to the 
provisions prohibiting trade and production. In June 
2006, the maximum penalty for some offences established 
pursuant to the Opium Act had been increased and the 
elements “intentional contravention” and “large quanti-
ties” had been added to sections 10 and 11 of the Act. 
In November 2008, a large number of hallucinogenic 
mushrooms had been added to schedule II of the Opium 
Act and a ban on hallucinogenic mushrooms had entered 
into force.
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56. The Board was also informed that, as at 1 January 
2012, the policy for “coffee shops” had become stricter: 
access to “coffee shops” had been restricted to residents 
of the Netherlands aged 18 and older. The stricter policy 
rules, which had originally applied to “coffee shops” only 
in the southern provinces of Limburg, North Brabant and 
Zeeland, had been applied to all “coffee shops” in the 
Netherlands since 1 January 2013. The new system of con-
trol required persons purchasing cannabis in “coffee 
shops” in border areas of the country to present proof of 
residence in the form of a standard residence certificate 
issued by the municipality, together with their identifica-
tion card. The Board notes the measures taken by the 
Government of the Netherlands to implement stricter 
policies towards “coffee shops” and calls upon the 
Government to step up its efforts to ensure the full com-
pliance of the Netherlands with the provisions of the 
international drug control treaties.
57. The Board notes that drug policy remains an issue 
of high priority in the Netherlands and that the 
Government continues to spend considerable resources 
in drug control, including in drug demand reduction. The 
control of licit activities involving narcotic drugs, psycho-
tropic substances and precursor chemicals in the 
Netherlands is strict and effective, and the Government 
has cooperated closely with the Board on most issues. 
The Government has continued to strengthen law 
enforcement efforts to address the problem of illicit 
manu facture of amphetamine-type stimulants, in particu-
lar 3,4-methylenedioxymethamphetamine (MDMA, com-
monly known as “ecstasy”), and to cooperate with the 
Board in joint operations to improve precursor control.
58. The Board trusts that the Government of the 
Netherlands will also review its policy on “drug consump-
tion rooms” and urges the Government to take the meas-
ures necessary to ensure full compliance with the 
international drug control treaties. 
59. The Board appreciates the cooperation it has 
received from the Government and the detailed informa-
tion provided to the Board regarding the drug control 
situ ation in the Netherlands and looks forward to con-
tinuing its ongoing dialogue with the Government on 
issues related to drug control. 
(c) Peru
60. The Board notes that, following its continuous dia-
logue with the Government of Peru over the past few 
years, the Government has improved its level of cooper-
ation with the Board. The Government is committed to 
following an integrated approach to ensuring that con-
trolled substances are handled effectively and that their 
diversion from licit distribution channels is countered by 
effective control measures. The Government has adopted 
a comprehensive drug control strategy, which places 
emphasis on alternative development, and increased its 
efforts in the eradication of illicit coca bush cultivation. 
The Board also notes that the Ministry of Health of Peru 
has drafted a new directive to ensure adequate availabil-
ity of narcotic drugs and psychotropic substances for 
medical purposes in the entire country.
61. The Board notes, however, that the traditional habit 
of chewing coca leaf has not yet been abolished in Peru, 
as required under the 1961 Convention as amended by 
the 1972 Protocol. Some of the industrial uses of coca 
leaf by the national coca enterprise, such as the manufac-
ture of coca tea, coca soap and coca flour, are not in con-
formity with the provisions of the 1961 Convention as 
amended by the 1972 Protocol. 
62. Furthermore, the Board notes with concern that 
despite the coca bush eradication efforts of the Government 
and the fact that it has taken a lead role in promoting 
alternative development, Peru became the world’s largest 
producer of coca leaf with a total area of coca cultivation 
reaching 60,400 ha in 2012. The available data show an 
increasing trend in illicit coca bush cultivation after 2005, 
which continued until 2012, when some stabilization and 
a small reduction were recorded.
63. Following its high-level mission to Peru in May 
2012, the Board communicated its recommendations to 
the Government for implementation. The Board trusts 
that the Government will attach great importance to 
those recommendations to ensure that progress is made 
in addressing drug-related problems particularly with 
regard to the prevention and reduction of illicit cultiva-
tion of coca bush and trafficking of cocaine in the 
country. 
(d) Timor-Leste
64. Timor-Leste, a relatively young country, having 
gained its independence in 2002, is reportedly being used 
as a transit area for smuggling drugs such as metham-
phetamine, “ecstasy”, cannabis, cocaine and heroin into 
Australia and Indonesia. Pharmaceutical preparations 
containing pseudoephedrine and ephedrine are readily 
available in numerous pharmacies without adequate regu-
latory control. The weak and inadequate legal and insti-
tutional frameworks in Timor-Leste make the country 
particularly vulnerable to drug trafficking and abuse.
10  INCB REPORT 2013
65. Until 2012, the Government of Timor-Leste had not 
considered drug trafficking and abuse to be matters 
requiring immediate attention. However, several signifi-
cant drug-related arrests and the seizure of large amounts 
of drugs at the country’s international airport and at 
points along its border with Indonesia in 2012 seem to 
have alerted the Government of Timor-Leste to the need 
to address drug control issues. Timor-Leste has yet to 
adopt national drug control legislation and to put in place 
a national mechanism for drug control coordination. 
Implementation of the drug control measures required 
under the international drug control treaties is severely 
hindered by the lack of human resources and technical 
tools such as laboratories and forensic equipment. 
66. Timor-Leste is one of the few States in the world 
that have not acceded to any of the three international 
drug control treaties. The Board is concerned that fail-
ure to accede to those treaties may not only weaken the 
collective efforts of the international community to pre-
vent the diversion of internationally controlled sub-
stances into illicit channels but also expose Timor-Leste 
to the dangers of drug abuse, drug trafficking and related 
forms of crime.
67. The Board notes that the Government of Timor-
Leste has been taking steps towards ratification of the 
1988 Convention. While it welcomes this positive devel-
opment, the Board urges the Government to address the 
remaining obstacles to ratification and to ensure that 
Timor-Leste accedes to all three of the international drug 
control treaties as soon as possible. The Board calls upon 
the international community to provide the required 
assistance to the Government to enable Timor-Leste to 
ratify and implement those treaties.
3. Country missions
68. In pursuing its mandate under the international 
drug control treaties and as part of its ongoing dialogue 
with Governments, the Board undertakes a number of 
country missions every year to discuss with competent 
national authorities measures taken and progress made 
in various areas of drug control. The missions provide 
the Board with an opportunity to obtain not only first-
hand information, but also a better understanding of the 
drug control situation in each country that it visits, 
thereby enabling the Board to provide Governments 
with relevant recommendations and to promote treaty 
compliance.
69. Since the previous report of the Board, the Board has 
sent missions to the following countries: Benin, Cambodia, 
Canada, Haiti, Indonesia, Kenya, Lao People’s Democratic 
Republic, Malaysia, Mozambique and Singapore.
(a) Benin
70. A mission of the Board visited Benin in July 2013. 
Since the Board’s previous mission to the country, in 
1995, Benin has ratified the 1988 Convention; it is now 
a party to each of the three international drug control 
treaties. The Board notes with appreciation that the 
Government is fully committed to the objectives of the 
treaties. National legislation and administrative regula-
tions provide a good basis for the implementation of the 
provisions of the treaties. The drug control structures of 
the Government are in place, though their capacity needs 
to be strengthened.
71. Benin, owing to its location and the importance of 
the port of Cotonou, continues to be used by traffickers 
as a transit country for illicit drug consignments. In 
Benin, there is limited illicit cultivation of cannabis plants 
in some parts of the country, and the abuse of cannabis 
is common. The abuse of pharmaceutical preparations 
containing controlled substances is also a problem, but 
the most widely abused preparation is tramadol, an opi-
oid analgesic not under international control.
72. The Board notes that good cooperation and joint 
action involving Beninese law enforcement authorities 
and their counterparts in neighbouring countries has led 
to successful operations and drug seizures.
73. During the 2013 mission, members of the Board 
discussed with Beninese authorities ways to improve the 
accuracy of their reporting on licit activities involving 
substances under international control, in particular psy-
chotropic substances licitly manufactured in Benin. The 
issues discussed included the low availability of opioid 
analgesics for medical purposes and measures to increase 
the rational use of those substances and to address the 
abuse of tramadol.
(b) Cambodia
74. A mission of the Board visited Cambodia in 
December 2012 to review the compliance of Cambodia 
with its obligations under the three international drug 
control treaties, which that State has signed (although it 
has yet to invoke article 12, paragraph 10 (a), of the 1988 
Convention), and to monitor progress made in imple-
menting the recommendations made by the Board  during 
its previous mission to that country, in 2003. 
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75. Since the 2003 mission of the Board, the 
Government of Cambodia has focused its drug control 
efforts and prioritized the use of law enforcement 
resources in tackling drug abuse. Those issues have also 
been actively supported at a high political level. A new 
law on drug control was promulgated on 2 January 2012 
with a view to building on the progress achieved since 
the 2003 mission of the Board, including by addressing 
the issues of drug abuse and drug-related offences and 
by more effectively implementing the international drug 
control treaties.
76. While noting those positive developments, the 
Board remains concerned by the fact that, since 2003, 
Cambodia has increasingly been used as a regional hub 
for the transport of illicit consignments of heroin, cocaine 
and methamphetamine; moreover, there have been indi-
cations of illicit methamphetamine manufacture in the 
country. The Board is also concerned that the Government 
has not devoted sufficient resources to tackling drug traf-
fickers at higher levels, as lower-level drug traffickers and 
drug abusers continue to be the primary targets of drug 
control efforts in Cambodia and drug abusers are being 
treated in compulsory treatment centres. The Board urges 
the Government of Cambodia to continue developing 
community-based programmes for the treatment of drug 
abusers throughout the country. The Board also urges the 
Government to take further action to ensure adequate 
availability of opioid analgesics for use in the treatment 
of pain.
(c) Canada
77. In May 2013, a mission of the Board visited Canada. 
The Board’s last mission to Canada had been carried out 
in 2003. Canada is a party to each of the three interna-
tional drug control treaties, and the Government has 
repeatedly expressed its commitment to working with the 
Board to ensure full implementation of the country’s 
treaty obligations. Canada continues to experience high 
levels of abuse of prescription drugs among all age groups. 
In addition, the prevalence of drug abuse in Canada, in 
particular cannabis abuse among youth, continues to be 
high. Furthermore, weaknesses in the national control 
measures applicable to “medical cannabis” have increased 
the risk of diversion of cannabis into illicit channels.
78. The 2013 mission of the Board discussed Canada’s 
drug control framework with particular emphasis on the 
above-mentioned issues of concern. The Board notes 
with appreciation that several measures have been taken 
by the Canadian authorities to address the problem of 
the abuse of prescription drugs, including the adoption 
of the first comprehensive Government strategy to 
address the problem and the staging of Canada’s first 
national initiative for returning unwanted, unused or 
expired prescription drugs. The Board also notes the 
country’s comprehensive overhaul of regulations govern-
ing its “medical cannabis” scheme, which includes the 
phasing out of production of cannabis for personal use 
and the bolstering of measures to prevent the diversion 
of cannabis into illicit channels. Finally, the Board recog-
nizes the work done by Canadian authorities in work-
ing with aboriginal stakeholders to develop culturally 
appropriate initiatives for the prevention of drug abuse 
and the treatment and rehabilitation of drug-dependent 
persons.
79. Despite those positive developments, the Board con-
tinues to be concerned about the high prevalence of drug 
abuse among the general population and especially among 
youth and encourages the Canadian authorities to bolster 
efforts to prevent drug abuse, including campaigns to 
raise public awareness about the adverse health effects of 
drug abuse. The Board also encourages the Canadian 
authorities to invest additional resources in the prepara-
tion of national studies on the prevalence of drug abuse. 
Finally, the Board calls upon the Government of Canada 
to ensure the provision of adequate resources for aborig-
inal health initiatives. 
(d) Haiti
80. A mission of the Board visited Haiti in April 2013. 
A mission of the Board had previously visited Haiti in 
2001, and a technical mission had visited the country in 
2007. In addition to having not yet ratified the 1971 
Convention, Haiti is faced, among other things, with the 
challenge of creating a more effective and flexible drug 
control system to replace the current one, providing 
more effective monitoring of pharmaceutical prepara-
tions  containing controlled substances. 
81. The Board’s 2013 mission discussed with the 
Government of Haiti its efforts to combat drug traffick-
ing and related criminal activities, in particular money-
laundering. That was a key issue for legislators, who were 
debating the drafting of new legislation on the matter. 
While noting that great strides had been made in devel-
oping the police service of Haiti, the mission urged the 
Government to ensure that any new legislation to coun-
ter money-laundering was compliant with the recommen-
dations of the Financial Action Task Force (FATF) and to 
continue its active support of reform relating to the judi-
ciary and the legal code.
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82. The Board has noted that the Government of Haiti 
needs to do more to ensure the availability of controlled 
substances, in particular opioids, for medical purposes. It 
should also work with the donor community to build new 
facilities for the treatment of drug-dependent persons, to 
develop programmes to reduce the illicit drug demand 
and educate the public about the dangers of drug abuse, 
to provide effective alternatives to the uncontrolled sale 
of medicines by street vendors and to ensure the safe dis-
posal of seized, counterfeit and out-of-date pharmaceuti-
cal preparations.
(e) Indonesia
83. A mission of the Board to Indonesia in September 
2013 reviewed the situation in the country since the 
Board’s last mission, in 2004. The aim of the 2013 mis-
sion was to follow up on the progress made in the coun-
try since the Board’s last mission, specifically, regarding 
adequate availability of opioid medication for pain and 
palliative care; to assess changes in the current drug situ-
ation in the country; to review the drug treatment sys-
tem; to inform the Government about available INCB 
tools to counter trafficking in precursors; and, ultimately, 
to examine the Government’s efforts to comply with 
obligations under the three international drug control 
conventions.
84. Access to opioid medication for pain and palliative 
care, while improving, continues to be limited. Abuse of 
amphetamine-type stimulants—primarily methampheta-
mine—continues to increase in the country. The drug 
treatment system provides a variety of treatment modal-
ities and rehabilitation and aftercare services through a 
number of Government ministries and non- governmental 
organizations. While treatment capacity has increased, 
greater capacity is needed to address the size of the drug-
abusing population and the needs of specific populations, 
such as by providing gender-specific treatment services 
for females.
85. The Government is encouraged to expand its use of 
the tools available to counter trafficking in chemicals, 
such as establishing annual legitimate requirements for 
the import of ephedrine and pseudoephedrine in the 
form of pharmaceutical preparations, registering focal 
points with the INCB Precursors Incident Communication 
System (PICS), and actively using the Pre-Export 
Notification Online (PEN Online) system for exports of 
all precursors, regardless of their physical form.
(f ) Kenya
86. A mission of the Board visited Kenya in June 2013. 
The primary focus of the mission was to discuss with the 
relevant authorities the compliance of Kenya with its obli-
gations under the three international drug control trea-
ties, the availability of opioids for use in palliative care, 
issues related to precursor control and utilization of the 
Board’s tools for countering precursor trafficking and 
illicit drug manufacture. 
87. Several developments have taken place in Kenya 
since the Board’s previous mission to the country, in 2002. 
The Government ensures standards of care and licensing 
for all centres for the treatment of drug-dependent per-
sons; and the second national household survey on drug 
abuse was completed in 2012, making Kenya one of only 
a handful of countries in Africa that have made reliable 
assessments of the drug abuse situation. However, access 
to opioids for palliative care was found to be very poor 
in Kenya, and the Government is encouraged to find ways 
to ensure the rational use of opioids.
88. There are indications that the abuse of heroin and 
other drugs by injection is increasing in Kenya, particu-
larly along the coast and in large urban centres. In Kenya, 
the availability of services for the treatment of persons 
who abuse drugs by injection is low compared with the 
estimated number of such persons, and that is of particu-
lar concern given the increased likelihood of the spread 
of blood-borne diseases. 
89. While Kenya is a party to each of the three inter-
national drug control treaties, its national drug control 
legislation, adopted in 1994, has not kept pace with 
changes in drug trafficking and illicit drug manufacture 
in the country. There is no national drug control author-
ity and the Government has never adopted a national 
drug control strategy, despite the fact that those problems 
were identified during the 2002 mission of the Board. 
Lack of coordination among the various branches of the 
Government involved in drug control continues to be a 
cause for concern; and that problem is compounded by 
the country’s resource shortages and the limited capacity 
of staff in many national agencies and has resulted in the 
Government’s inability to prosecute drug-related cases 
swiftly and successfully. 
(g) Lao People’s Democratic Republic
90. A mission of the Board visited the Lao People’s 
Democratic Republic in March 2013, 10 years after the 
previous mission of the Board to that country. The 
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Lao  People’s Democratic Republic has long been asso-
ciated with illicit opium poppy cultivation and opium 
trafficking. It is in a vulnerable position because of the 
increasing abuse of amphetamine-type stimulants, both 
in the country and in the region, and because it is used 
as a transit country for drug trafficking in the region. 
In recent years, the situation has worsened, as the illicit 
cultivation of opium poppy and the abuse of and 
 trafficking in amphetamine-type stimulants have been 
increasing.
91. During discussions with Lao officials, the Board’s 
mission expressed concerns about the upsurge in illicit 
opium poppy cultivation and opium trafficking in the 
country. It was noted that although the Lao People’s 
Democratic Republic had ratified the international drug 
control treaties, it had not yet invoked article 12, para-
graph 10 (a), of the 1988 Convention. The Government 
was urged to address that issue, so that it could build 
on the success of its opium poppy eradication pro-
gramme. The Government was also strongly encouraged 
to finalize the national drug control master plan for the 
period 2014-2019 and to take steps to ensure adequate 
availability and rational use of pain-relieving medication 
and increase the number of trained and qualified pro-
fessionals who could administer opioid analgesics. The 
issue of treatment of drug addicts was also raised. It was 
recommended that community-based programmes for 
the treatment of drug addicts should be expanded, that 
persons should be admitted to such treatment pro-
grammes on a voluntary basis and that decisions on 
whether a person could enter or be discharged from such 
treatment programmes should be made by professional 
health-care staff.
(h) Malaysia
92. A mission of the Board visited Malaysia in 
September 2013. Malaysia continues to be used as a tran-
sit country for illicit drug consignments destined for 
illicit markets in other countries. However, increased 
illicit demand for drugs, particularly amphetamine-type 
stimulants, in Malaysia has resulted in drugs being 
smuggled into the country by organized criminal groups. 
The illicit manufacture of synthetic drugs in Malaysia 
has also increased in recent years. Malaysia has a coast-
line that is 4,675 km long; that, together with the coun-
try’s geographical location, poses a significant challenge 
for law enforcement authorities, particularly in the area 
of border control.
93. Malaysia is a party to each of the three inter-
national drug control treaties. The national drug control 
legislation is considered to be comprehensive, covering 
the prevention of drug abuse and the treatment and 
rehabilitation of drug-dependent persons, a reflection of 
the seriousness of the Government’s efforts to curb drug 
abuse and trafficking. The Government is implementing 
the national drug control strategy in an effort to ensure 
full compliance with the international drug control trea-
ties and has made significant progress in some areas. In 
2010, Malaysia took significant steps to move away from 
regimented treatment and rehabilitation of drug- 
dependent persons and to move towards a voluntary, 
open-access and comprehensive approach to such treat-
ment and rehabilitation, within the framework of the 
Government Transformation Programme, a broad-based 
initiative aimed at addressing key areas of concern to 
the public, including drug abuse.
94. The diversion and misuse of psychotropic sub-
stances and prescription drugs remain a source of con-
cern to the Government of Malaysia. Efforts continued to 
be made to address those problems, as evidenced by a 
series of legislative and administrative measures taken by 
the Government in recent years. The Government is com-
mitted to fulfilling its obligations under the international 
drug control treaties and has enhanced cooperation 
among law enforcement agencies aimed at preventing the 
diversion and misuse of psychotropic substances and pre-
scription drugs. 
(i) Mozambique
95. A mission of the Board visited Mozambique in 
December 2012. Mozambique is a party to all three 
international drug control treaties. The Board notes 
that, after its previous mission to Mozambique, in 1997, 
the Government had made some progress in certain 
areas of drug control, including the adoption of national 
drug control legislation, the establishment of a national 
committee for drug control coordination and the adop-
tion of a strategic plan for preventing drug abuse and 
combating drug trafficking for the period 2010-2014. 
While those important steps have demonstrated the 
Government’s commitment to drug control, significant 
challenges remain. 
96. Mozambique continues to be used as a transit coun-
try for illicit consignments of drugs such as cannabis 
resin, cannabis herb, cocaine and heroin, destined for 
Europe, and methaqualone (Mandrax), destined primar-
ily for South Africa. The Government is aware of the 
challenge posed by drug trafficking and has taken some 
steps to address that challenge, such as strengthening 
land and sea border control, enhancing law enforcement 
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capacity and carrying out drug abuse prevention activi-
ties targeting young persons. However, the Government 
lacks the capacity and resources to effectively counter the 
transit traffic.
97. Although the abuse of drugs, particularly canna-
bis, appears to be significant in Mozambique, no recent 
epidemiological studies of the drug abuse situation have 
been carried out, and therefore precise information on 
the extent of drug abuse in the country is not availa-
ble. Furthermore, the availability of narcotic drugs and 
psychotropic substances for medical and scientific pur-
poses remains inadequate. There is a need for the 
Government to take the measures necessary to address 
those problems.
(j) Singapore 
98. The Board undertook a mission to Singapore from 
30 September to 2 October 2013. The mission established 
a dialogue with officials regarding the situation and 
efforts related to countering drug trafficking, reviewed 
legislative measures and administrative policies for drug 
and chemical control that had been introduced in the 
country, and discussed issues related to opiate availabil-
ity in palliative care and the provision of drug abuse 
treatment services. 
99. Since the Board’s last mission to Singapore in 1995, 
several notable developments have taken place. Singapore 
signed the 1988 Convention in 1997 and implemented 
precursor controls, making active use of INCB tools to 
counter trafficking in precursors. Amphetamine-type 
stimulants have become increasingly problematic, and, 
most recently, the abuse of new psychoactive substances 
has emerged. In response, the Government introduced 
temporary scheduling measures for generic groups of 
substances, which included several new psychoactive sub-
stances, such as synthetic cannabinoids. 
100. Heroin abuse is on the increase, driven in large 
part by drug offenders who continue to struggle with 
their addiction after their release from prison. There is 
no opioid substitution therapy in Singapore. Drug treat-
ment in the country is compulsory, but treatment capac-
ity has been expanded, allowing access to services with 
little delay. A broad range of treatment modalities target-
ing individual user’s needs and addressing the risk of 
re offending are available, and aftercare and reintegration 
support are comprehensive. 
4. Evaluation of the implementation 
by Governments of recommendations 
made by the Board following its country 
missions 
101. As part of its ongoing dialogue with Governments, 
the Board also conducts, on a yearly basis, an evaluation 
of Governments’ implementation of the Board’s recom-
mendations pursuant to its country missions. In 2013, the 
Board invited the Governments of the following six coun-
tries, to which it had sent missions in 2010, to provide 
information on progress made in the implementation of 
its recommendations: Croatia, Gabon, Guatemala, India, 
Lebanon and Myanmar.
102. The Board wishes to express its appreciation to the 
Governments of Croatia, Guatemala, India, Lebanon and 
Myanmar for submitting the information requested. Their 
cooperation facilitated the Board’s assessment of the drug 
control situation in those countries and the Governments’ 
compliance with the international drug control treaties. 
103. In addition, the Board reviewed the implementation 
of the recommendations it had made following its 2009 
mission to Australia, as the Government had not provided 
the requested information in time for review in 2012. 
104. The Board notes that the Government of Gabon 
has yet to provide information on progress made in the 
implementation of the Board’s recommendations follow-
ing its 2010 mission to that country. The Board urges the 
Government to provide the requested information as 
soon as possible.
(a) Australia
105. The Board notes that the Government of Australia 
continues to allocate adequate resources for the develop-
ment and implementation of effective drug control  policy 
and initiatives. Australia has implemented the legislative 
frameworks necessary for the control of narcotic drugs, 
psychotropic substances and precursors, as required 
under the international drug control treaties. Australia 
has adopted a coordinated and integrated approach to 
drug control issues that utilizes the National Drug 
Strategy 2010-2015 (the three pillars of which are demand 
reduction, supply reduction and harm reduction) and the 
National Drugs Campaign.
106. The Board welcomes the successful implementa-
tion in Australia of the law enforcement initiatives to 
prevent and combat trafficking in drugs and their 
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precursors. Extending until 2015 the National 
Amphetamine-Type Stimulant Strategy 2008-2011 ena-
bled the continuation of efforts aimed at reducing the 
availability of and illicit demand for amphetamine-type 
stimulants while preventing their abuse and the associ-
ated harm in Australia. During the period 2010-2011, 
intelligence operations carried out by the law enforce-
ment agencies of Australia in relation to trafficking in 
amphetamine-type stimulants and cocaine resulted in, 
among other things, the identification of the organized 
criminal groups involved and the emerging threats posed 
by those drugs; in addition, the intelligence operations 
led to the investigation of related cases involving money-
laundering. The Government has worked on improving 
measures used for the detection, deterrence and disrup-
tion of cross-border drug trafficking. In particular, 
Operation Bergonia, carried out by Australian law 
enforcement agencies, resulted in the seizure of 464 kg 
of cocaine in 2010, the third largest single seizure of that 
drug in Australia.
107. The Government of Australia has continued its 
efforts to promote rational use and adequate availability 
of opioids for legitimate purposes, while preventing their 
diversion into illicit channels. The Government closely 
monitors and regulates the production of opiate raw 
material, as well as the use of preparations containing 
narcotic drugs, in the country. Australia is developing its 
first national strategy to reduce the misuse of pharma-
ceutical drugs and the associated harm while enhancing 
the quality use of such drugs. 
108. The Board notes the efforts of the Government of 
Australia in facilitating bilateral, regional and interna-
tional cooperation in drug control. In particular, the law 
enforcement authorities of Australia have been engaging 
with their counterparts in the region and beyond in 
building effective partnerships to combat transnational 
organized crime, including the smuggling of persons, as 
well as drugs, across borders. Recent achievements 
include the establishment of a liaison office of the 
Australian Federal Police within the National Narcotics 
Board of Indonesia and the interception of illicit ship-
ments of narcotic drugs as a result of collaboration with 
the Anti-Narcotics Force of Pakistan. The Australian 
Customs and Border Protection Service has continued to 
carry out a range of activities designed to strengthen the 
border management capabilities of Asia-Pacific countries, 
including through the South-East Asian border security 
programme. The Board appreciates the efforts of the 
Government of Australia in promoting regional and 
international cooperation and providing assistance in 
building the capacity of countries to prevent and combat 
illegal cross-border activities, including drug trafficking. 
109. The Board notes with concern that a “medically 
supervised injecting centre” continues to operate in 
Sydney, Australia. The operation of the centre on a trial 
basis commenced in May 2001, and legislation adopted 
at the state level in October 2010 made the centre a per-
manent fixture. The Board wishes to reiterate its view, 
which has been communicated to the Government of 
Australia on several occasions, that facilities in which per-
sons can abuse with impunity illegally acquired drugs 
contravene the principle of the international drug control 
treaties that drugs should be used only for medical and 
scientific purposes. 
(b) Croatia
110. The Board notes that progress has been made in 
drug control by the Government of Croatia following the 
mission of the Board to that country in 2010. Prior to 
becoming a member of the European Union, Croatia 
worked to harmonize its national legislation with 
European Union legislation in the area of drug control. 
The Government adopted the national strategy on com-
bating drug abuse for the period 2012-2017. Additional 
resources were provided to the office for combating drug 
abuse, and training was provided to its staff, in coopera-
tion with European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and other relevant institu-
tions of the European Union. With the support of 
EMCDDA, the Ministry of Health of Croatia conducted 
a survey on the prevalence of use of various drugs among 
the general population. The Board encourages the 
Government of Croatia to continue its efforts in that area, 
particularly with regard to the setting up of a standard-
ized national monitoring system for systematically report-
ing on the prevalence and nature of drug abuse in the 
country.
111. In Croatia, the adoption of a new criminal code, 
which entered into force on 1 January 2013, has made an 
important change in the legal framework related to com-
bating drug abuse. Provisions relating to drug-related 
crime have been amended, and provisions relating to the 
implementation of measures for the treatment of drug 
addiction have been updated. One of the novelties of the 
criminal code is that it contains a provision relating to 
offences committed in an educational institution or its 
immediate vicinity. Its long coastline and national bor-
ders make Croatia attractive to drug traffickers, who use 
it as a trans-shipment area for smuggling controlled sub-
stances. The Board notes the measures implemented by 
the Government to increase the capacity of law enforce-
ment authorities to combat drug trafficking and organ-
ized crime, in cooperation with their counterparts in 
16  INCB REPORT 2013
other countries and relevant international organizations. 
The Board encourages the Government to continue its 
efforts in that direction so that border control activities 
to counter drug trafficking can be enhanced.
112. The Ministry of Health of Croatia needs to address 
the problem of funding therapeutic communities and 
treatment centres for drug addicts and to provide train-
ing for health-care professionals working in that area. The 
Board encourages the Government of Croatia to provide 
adequate resources for the continued development of ser-
vices for the treatment and rehabilitation of drug addicts 
in the country and to ensure that such persons have 
access to a full range of treatment options. The 
Government should also implement more effective meas-
ures to prevent methadone and buprenorphine from 
being diverted from substitution treatment programmes 
into illicit channels.
113. While the level of consumption of narcotic drugs 
used for the treatment of pain in Croatia has increased 
steadily over the past decade, it remains relatively low, 
in particular when compared with the consumption 
level in many other member States of the European 
Union. The Board recommends that the Government of 
Croatia should undertake an assessment of the medical 
requirements for narcotic drugs in the country and iden-
tify whether there are any impediments to the availabil-
ity of those drugs and, if so, take steps to ensure that 
those impediments are removed. The Board trusts that 
the Government will continue strengthening its drug 
control efforts. The Board stands ready to continue its 
dialogue with the Government and, if necessary, to pro-
vide assistance.
(c) Guatemala
114. The Board notes that, following its mission to 
Guatemala in 2010, the Government has taken steps to 
implement the Board’s recommendations, particularly in 
the area of law enforcement. The Government has 
expanded the drug control functions of the Ministry of 
the Interior through the Fifth Vice-Ministry of the 
Interior, established the legal framework for exercising 
those functions and strengthened the Counter-narcotics 
Analysis and Information Division, part of the General 
Directorate of the National Civil Police. The Board trusts 
that those steps will contribute to strengthening the 
Government’s capacity to address drug trafficking and 
related corruption and violence.
115. In Guatemala, efforts have also been made in the 
area of precursor control. Authorities of Guatemala use 
the PEN Online system on a regular basis. In January 
2012, a committee on precursors was established, com-
prising all relevant institutions in Guatemala, such as the 
National Security Council, the Ministry of Health, the 
Ministry of the Interior, the National Institute of Forensic 
Sciences, the Supreme Court of Justice, the Ministry of 
Public Finance and the Public Prosecution Service, thus 
facilitating inter-institutional coordination on issues relat-
ing to precursor control. In 2013, the Government estab-
lished a unit for monitoring precursors and chemical 
substances, demonstrating its commitment to the aims of 
the international drug control treaties. 
116. Guatemala has participated in the Container 
Control Programme, implemented jointly by UNODC 
and the World Customs Organization, and has established 
a joint unit under the Programme to carry out operations 
relating to the control of narcotic drugs and psychotropic 
substances in maritime ports. 
117. The Board notes, however, progress is lacking in 
other areas where it has made recommendations to the 
Government of Guatemala, such as the introduction of 
reliable data-processing systems for the control of licit 
activities involving internationally controlled substances, 
the issue of availability of opioids for the treatment of 
pain, as well as the prevention of drug abuse and the 
treatment and rehabilitation of drug-dependent persons. 
The Board encourages the Government of Guatemala to 
take the steps necessary to ensure that progress is also 
made in those areas. 
(d) India
118. The Board notes the efforts made by the 
Government of India in the implementation of the 
Board’s recommendations following its mission to that 
country in 2010, demonstrating the continued commit-
ment of the Government to the aims of the international 
drug control treaties. 
119. In particular, increased efforts have been made in 
India to control licit activities involving narcotic drugs, 
psychotropic substances and precursors. In 2013, the 
Government of India issued an order on narcotic drugs 
and psychotropic substances, replacing the 1993 order. 
The 2013 order adds new substances to schedules and 
introduces new provisions, such as measures for the 
import and export of preparations containing ephedrine 
or pseudoephedrine, as well as codeine-based pharma-
ceutical preparations. The Government has decided to 
amend national legislation with a view to addressing the 
issue of divergent regulatory provisions in different states, 
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thereby ensuring India’s compliance with the interna-
tional drug control treaties on its entire territory. The 
Government is currently looking into the issue of Internet 
pharmacies and developing a system for the online regis-
tration and submission of returns by manufacturers of 
psychotropic substances; the system is to be fully func-
tional by December 2013. Preparations are being made 
for a system for narcotic drugs.
120. A series of measures have been taken by the 
Government of India to strengthen law enforcement 
capacity. Additional regional offices have been opened 
and a committee has been established to assess and 
upgrade the capacity of existing forensic laboratories. 
Continued efforts have also been made to curb the illicit 
cultivation of opium poppy. Satellite imagery is being 
used for the identification of areas under illicit opium 
poppy cultivation; that is followed by opium poppy 
eradication efforts undertaken jointly by law enforce-
ment agencies at the national and state levels. State gov-
ernments have been called upon to identify areas with 
a tradition of illicit opium poppy cultivation and to 
make plans for alternative development programmes as 
required.
121. Furthermore, steps have been taken by the 
Government of India in the area of demand reduction. 
A pilot survey on drug abuse is being carried out in a 
number of states, following a similar pilot survey con-
ducted in 2010, with a view to further defining the effi-
cacy of the sampling design and survey methodology. 
The results of the more recent pilot survey are expected 
to be available by June 2014 and will then be used as the 
basis for a nationwide survey. In addition to the inte-
grated rehabilitation centres for addicts, which provide 
counselling, treatment and rehabilitation services for 
drug-dependent persons, 122 centres or units for the 
treatment of such persons are located in hospitals 
throughout the country. A project has been initiated to 
provide training for doctors involved in detoxification 
and treatment programmes, and financial support is 
being provided to major hospitals in the country to 
strengthen their capacity in that area. 
122. The Board welcomes the measures taken by the 
Government of India in various areas of drug control and 
encourages the Government to continue those efforts. In 
particular, the Government should take further steps 
towards full compliance with its reporting obligations as 
required under the international drug control treaties. 
Additional efforts should be made to prevent the abuse 
of drugs and to prevent, in conformity with the provi-
sions of the 1961 Convention, the misuse of, and illicit 
traffic in, the leaves of the cannabis plant. 
(e) Lebanon
123. The Government of Lebanon has acted upon the 
recommendations made by the Board following its 2010 
mission to the country, and progress has been made in 
some areas. The Government has adopted a law to com-
bat money-laundering. It has also established a special 
commission of inquiry and an office for combating 
financial crimes and a public prosecution service to com-
bat such crime. Numerous drug-related awareness- 
raising and counselling activities involving bodies such 
as educational institutions and municipalities have been 
organized. 
124. The Government of Lebanon has indicated that 
controlled opioid analgesics used for medical treatment 
are available without undue restrictions, and patients can 
obtain the medicine in pharmacies and hospitals using a 
prescription issued by a physician. Data available to the 
Board suggest that some progress has been made by the 
Government in that area. 
125. The Board, while acknowledging the above- 
mentioned positive developments in drug control in 
Lebanon, notes with concern that the country still lacks a 
comprehensive national drug control strategy. In addition, 
progress has yet to be made in implementing the Board’s 
recommendations with regard to effective inter- ministerial 
drug control coordination and cooperation as well as 
measures to counter activities involving counterfeit 
Captagon tablets. The Board encourages the Government 
to continue its drug control efforts and, in particular, to 
take the steps necessary to ensure that a national drug 
control strategy is adopted as soon as possible and to take 
additional measures to counter the illicit cultivation of 
drug crops and trafficking in and abuse of drugs. 
B. Action taken by the Board to 
ensure the implementation of the 
international drug control treaties
1. Action taken by the Board pursuant 
to article 14 of the 1961 Convention and 
article 19 of the 1971 Convention
126. Article 14 of the 1961 Convention (and that 
Convention as amended by the 1972 Protocol) and arti-
cle 19 of the 1971 Convention set out measures that the 
Board may take to ensure the execution of the provisions 
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of those Conventions. Such measures, which consist of 
increasingly severe steps, are taken into consideration 
when the Board has reason to believe that the aims of the 
Conventions are being seriously endangered by the fail-
ure of a State to carry out the provisions of those 
Conventions.
127. The Board has invoked article 14 of the 1961 
Convention and/or article 19 of the 1971 Convention 
with respect to a limited number of States. The Board’s 
objective has been to encourage compliance with those 
Conventions when other means have failed. The States 
concerned are not named until the Board decides to bring 
the situation to the attention of the parties, the Economic 
and Social Council and the Commission on Narcotic 
Drugs (as in the case of Afghanistan). Following contin-
uous dialogue with the Board pursuant to the above- 
mentioned articles, most of the States concerned have 
taken remedial measures, resulting in a decision by the 
Board to terminate action taken under those articles 
 vis-à-vis those States.
128. Afghanistan is currently the only State for which 
action is being taken pursuant to article 14 of the 1961 
Convention as amended by the 1972 Protocol.
2. Consultation with the Government 
of Afghanistan pursuant to article 14 of 
the 1961 Convention
129. Consultations between the Board and the 
Government of Afghanistan pursuant to article 14 of the 
1961 Convention continued in 2013. On 12 March 2013, 
the President of INCB met with Zarar Ahmad Muqbel 
Osmani, Minister of Counter Narcotics of Afghanistan 
and Head of the Afghan delegation to the fifty-sixth ses-
sion of the Commission on Narcotic Drugs. The Minister 
updated the Board on the current drug control situation 
in Afghanistan, highlighting challenges the Government 
was facing in addressing the drug problem in the years 
ahead, particularly in view of the forthcoming conclusion 
of the International Security Assistance Force (ISAF) mis-
sion in Afghanistan in 2014. The President of the Board, 
while noting difficulties in addressing the drug problem, 
reiterated Afghanistan’s obligations to ensure that pro-
gress was made under article 14 of the 1961 Convention. 
130. The Secretary of the Board met with the Permanent 
Mission of Afghanistan in Vienna on a number of occa-
sions during the year to follow up on the Government’s 
implementation of the international drug control treaties. 
The meetings focused on issues of concern to the Board 
relating to Afghanistan, particularly with regard to the 
lack of progress in the prevention and reduction of illicit 
opium poppy cultivation, the worrying trend of illicit can-
nabis plant cultivation and the increased drug abuse and 
illicit trafficking. 
131. At the request of the Government of Afghanistan, 
the secretariat of the Board provided training to the 
Afghan regulatory and law enforcement agencies in Kabul 
in December 2012, in cooperation with the UNODC 
country office in Afghanistan. The training, aimed at 
improving Afghanistan’s capacity with regard to treaty 
compliance, covered various aspects of drug control, 
including the functioning of the international drug con-
trol treaties and the treaty-based reporting obligations. 
The training provided a favourable opportunity to discuss 
with the Afghan authorities the practical implementation 
of the provisions of the drug control treaties. 
Current drug control situation in Afghanistan 
132. Recent years have witnessed a deteriorating situa-
tion with regard to illicit cultivation of opium poppy in 
Afghanistan. The total areas under opium poppy cultiva-
tion have increased for three consecutive years since 
2009/10, when illicit opium poppy cultivation stood at 
123,000 ha. The high sale price of opium and the deteri-
orating security situation have been the main reasons for 
farmers engaging in that illicit cultivation.
133. In 2013, the total area under illicit opium poppy 
cultivation reached a record level of 209,000 ha, an 
increase of 36 per cent compared with 2012 (153,000 ha). 
The southern and western regions continued to be the 
centre of illicit opium poppy cultivation, accounting for 
89 per cent of the total cultivation in the country. Despite 
low yields, potential illicit production of opium also 
increased, by 49 per cent, from 3,700 tons in 2012 to 
5,500 tons in 2013, due to the extremely high level of 
cultivation.
134. The Governor-led eradication of opium poppy con-
tinued in 2013, involving 18 provinces in Afghanistan as 
in the previous year. However, the total area of opium 
poppy eradicated declined to 7,323 ha, a decrease of 
24 per cent as compared with 2012 (9,672 ha). The level 
of eradication in 2013 accounted for only 3.5 per cent of 
the total area of opium poppy under cultivation in 
Afghanistan. The areas eradicated in the three largest 
poppy-growing provinces, namely Farah, Helmand and 
Kandahar, were negligible, particularly in view of the high 
level of opium poppy cultivation in those provinces.
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135. Illicit cultivation of cannabis plant and production 
of cannabis resin remain a significant challenge in drug 
control in Afghanistan. In 2012, the total area under can-
nabis plant cultivation was estimated at 10,000 ha, a 
17  per cent decrease as compared with 2011. The total 
production of cannabis resin, however, increased by 
8  per  cent, reaching 1,400 tons because of the higher 
yields achieved. Like the opium poppy cultivation, most 
of the cannabis plant cultivation was concentrated in the 
southern provinces of Afghanistan, accounting for some 
54 per cent, and, to a lesser extent, in the east and north 
of the country. The lucrative nature of cannabis plant cul-
tivation has led to an increased number of farmers engag-
ing in the illicit cultivation of both opium poppy and 
cannabis plant. 
136. The Board notes that the eradication campaign car-
ried out in Uruzgan province in 2012 resulted in a sig-
nificant reduction in cannabis plant cultivation in that 
province, to less than 100 ha from more than 1,000 ha in 
2011. The Board, while welcoming this development, 
remains concerned about the lack of progress in various 
areas of drug control in the country and urges the 
Government of Afghanistan to effectively implement the 
concrete measures that have been adopted in the context 
of anti-drug trafficking, alternative development and drug 
demand reduction. 
Cooperation with the Board 
137. The Government’s cooperation with the Board has 
improved in recent years. On 20 March 2013, the Ministry 
of Counter Narcotics submitted to the Board its 2012 
report reflecting efforts made by the Government to 
implement the international drug control treaties. The 
Board notes that the Government has further strength-
ened the role and functions of the Ministry of Counter 
Narcotics in national drug control coordination. New ini-
tiatives have been taken to address the drug problem, 
such as identifying owners of large areas under opium 
poppy cultivation, expanding the “food zone” programme 
and developing a five-year plan on drug abuse. 
138. The Government took several steps in an effort to 
strengthen the control of licit activities related to narcotic 
drugs, psychotropic substances and precursor chemicals, 
including launching monitoring missions, developing a 
functional system for estimates and assessments and 
strengthening information-sharing with exporting 
countries. 
139. The Government’s treaty-based reporting has also 
improved, with statistical data on narcotic drugs, 
psychotropic substances and precursors being regularly 
submitted to the Board, as required under the interna-
tional drug control treaties. Afghanistan has increasingly 
been involved in various programmes and projects aimed 
at preventing diversion of precursor chemicals from licit 
sources into illicit channels. In August 2013, Afghanistan 
became a member of Project Cohesion, an initiative to 
monitor international trade in the precursor chemicals 
most commonly used in the illicit manufacture of heroin, 
cocaine and amphetamine-type stimulants.
Cooperation by the international community 
140. The reporting period saw continued activity under 
the programme for Afghanistan and neighbouring coun-
tries, led by the United Nations, with a focus on capa-
cities to collect and analyse data on drugs, cross-border 
controls and control of precursor chemicals, involving 
countries participating in the UNODC regional pro-
gramme and other countries in the region. Under the 
Triangular Initiative, a series of meetings were held in 
Kabul in August 2013 with senior officials of Afghanistan, 
Iran (Islamic Republic of) and Pakistan working to 
strengthen counter-narcotics cooperation. Joint opera-
tions, border liaison offices, communication and exchange 
of information were discussed. In June 2013, phase IV 
of the Paris Pact Initiative was launched,  demonstrating 
the continued commitment of the international commu-
nity to tackle trafficking in opiates originating in 
Afghanistan.
141. The Board notes that the “food zone” programme, 
which is aimed at promoting alternative development in 
opium poppy-growing areas, has expanded to four addi-
tional provinces: Badakhshan, Farah, Kandahar and 
Uruzgan. Combined with other alternative development 
measures, it is expected that the programme will con-
tribute to tangible progress in preventing and reducing 
illicit cultivation of opium poppy and cannabis plant in 
the country in the years to come. The Board will con-
tinue to closely monitor the drug control situation in 
Afghanistan, as well as the measures taken and progress 
made by the Government of Afghanistan in addressing 
the drug problem, with the assistance of the international 
community. 
Conclusions 
142. The drug control problem in Afghanistan and the 
neighbouring region remains of grave concern, particu-
larly in view of the deteriorating situation with respect to 
the illicit cultivation of opium poppy and cannabis plant 
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in Afghanistan in recent years. This situation seriously 
endangers the aims of the international drug control trea-
ties. The Board calls upon the Government of Afghanistan, 
the United Nations and the rest of the international com-
munity to continue their cooperation to achieve the goals 
set out in various important documents adopted by the 
international community. Bearing in mind the overarch-
ing objective of the National Drug Control Strategy of 
Afghanistan, the Government of Afghanistan, with assis-
tance from the international community, including, in 
particular, through UNODC, should translate its commit-
ment into specific actions and ensure that substantial, 
sustainable and measurable progress is achieved in coun-
tering drug trafficking, alternative development and drug 
demand reduction in the country.
C. Governments’ cooperation with 
the Board
1. Provision of information by 
Governments to the Board
143. The Board is mandated to publish each year two 
reports (the annual report and the report of the Board 
on the implementation of article 12 of the 1988 
Convention) and also publishes technical reports based 
on information that parties to the international drug 
control treaties are obligated to submit. These publica-
tions give Governments detailed analyses on estimates 
and assessments of requirements, manufacture, trade, 
consumption, utilization and stocks of internationally 
controlled substances.
144. The analysis of the data provided is crucial in 
order for the Board to monitor and evaluate treaty com-
pliance and the overall functioning of the international 
drug control system. If issues or problems are identified, 
measures can be recommended by the Board to help pre-
vent the diversion of narcotic drugs and psychotropic 
substances into illicit markets. The provision of data also 
helps account for the legitimate use of narcotic drugs 
and psychotropic substances for medical and scientific 
purposes. 
2. Submission of statistical reports
145. Governments are obliged to furnish to the Board 
each year, in a timely manner, statistical reports contain-
ing information required under the international drug 
control conventions. 
146. As at 1 November 2013, annual statistical reports 
on narcotic drugs (form C) for 2012 had been furnished 
by 164 States and territories (representing 77 per cent of 
the States and territories requested to submit such 
reports), although more Governments are expected to 
submit their reports for 2012 in due course. In total, 
186 States and territories provided quarterly statistics on 
their imports and exports of narcotic drugs for 2012, 
amounting to 87 per cent of the States and territories 
required to provide such statistics. A large number of 
Governments in Africa, the Caribbean and Oceania do 
not submit their statistics regularly, despite repeated 
requests by the Board to do so.
147. As at 1 November 2013, annual statistical reports 
on psychotropic substances (form P) for 2012, in con-
formity with the provisions of article 16 of the 1971 
Convention, had been submitted to the Board by 
135  States and territories, amounting to 63 per cent of 
the States and territories required to provide such sta-
tistics. In addition, 105 Governments voluntarily sub-
mitted all four quarterly statistical reports on imports 
and exports of substances listed in Schedule II of the 
Convention, in conformity with Economic and Social 
Council resolution 1981/7, and a further 61 Governments 
submitted some quarterly reports. The Board notes that 
the Governments of only three countries that trade in 
such substances failed to submit any quarterly report 
for 2012.
148. While it may be expected that some Governments 
will furnish form P for 2012 at a later date, it is of con-
cern that the total number of submissions of form P 
has gradually declined over the past five years. From a 
regional perspective, that worrisome development can 
be attributed to non-reporting by countries in Africa, 
the Caribbean and Oceania. It is of particular concern 
that the number of African countries that have not fur-
nished form P to the Board has been increasing, reach-
ing, with form P for 2012, a total of 34 countries and 
territories in Africa—almost 60 per cent—failing to 
report. Likewise, 13 countries and territories in the 
Caribbean and 11 in Oceania did not furnish form P 
for 2012. That might be an indication that those 
Governments have yet to establish the necessary legal 
or administrative structures to enable their competent 
authorities to collect and compile the required infor-
mation. It may also be an indication that those 
Governments are not fully aware of the specific report-
ing requirements on psychotropic substances as they 
relate to their territories and that they require capa city-
building in that regard. In contrast, form P for 2012 
was furnished by all countries but one in Europe and 
most countries in North and South America. With 
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respect to Asia, 14 Governments did not furnish form 
P for 2012. 
149. Among the countries not able to submit the annual 
statistical report on psychotropic substances before the 
deadline of 30 June 2012 were major manufacturing, 
importing and exporting countries, such as Australia, 
Brazil, Canada, China, France, Germany, India, Japan, the 
Netherlands, Pakistan and the United States. The Board 
notes that some of those countries have persistently failed 
to submit annual statistical reports in a timely manner. 
Mexico, the Republic of Korea and Singapore, which are 
significant importers or exporters of psychotropic sub-
stances, did not submit form P for 2012. Late submission 
or failure to submit statistical reports makes it difficult 
for the Board to monitor licit activities involving con-
trolled substances and delays the analysis by the Board 
of the worldwide availability of such substances for legiti-
mate purposes. Those shortcomings are often due to 
changes in the Government structure responsible for 
reporting to the Board or to changes of staff within the 
competent authorities. However, some Governments con-
tinued to experience difficulties in collecting the required 
information from their national stakeholders due to legis-
lative or administrative shortcomings. The Board there-
fore wishes to invite Governments to encourage dialogue 
with manufacturing and trading companies in the 
pharma ceutical industry with a view to improving the 
collection and reporting of statistical data on narcotic 
drugs and psychotropic substances.
150. The Economic and Social Council, in its resolu-
tions 1985/15 and 1987/30, requested Governments to 
provide the Board with details of trade (i.e., data broken 
down by countries of origin and destination) in sub-
stances listed in Schedules III and IV of the 1971 
Convention in their annual statistical reports on psycho-
tropic substances. For 2012, complete details on such 
trade were submitted by 129 Governments (95.5 per cent 
of all submissions of form P). The Board notes that the 
number of countries failing to submit any details of trade 
for 2012 is the lowest since 2007. 
151. The Board also notes with satisfaction that the 
number of countries that submit consumption data for 
psychotropic substances on a voluntary basis in accord-
ance with Commission on Narcotic Drugs resolution 54/6 
has continued to increase. Thus, in 2012, a total of 53 
countries and territories submitted data on consumption 
of some or all psychotropic substances, representing a 26 
per cent increase over 2011 in the number of countries 
and territories submitting such data. The Board appreci-
ates the cooperation of the Governments concerned and 
calls upon all other Governments to furnish information 
on the consumption of psychotropic substances, as such 
data are key to an improved evaluation of the availabil-
ity of psychotropic substances for medical and scientific 
purposes. 
152. Each year, parties to the 1988 Convention pro-
vide information, via a special form called “form D”, on 
substances frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, as required 
under article 12 of the Convention. As at 1 November 
2013, a total of 123 States and territories submitted 
form D for 2012. However, 74 countries did not sub-
mit the form on time, therefore failing to meet their 
obligations.
153. Of the 124 States and territories that provided data, 
49 per cent reported seizures of scheduled substances. 
However, details relating to those seizures were often 
lacking, such as name, quantity and type of precursor 
seized, and the modus operandi used by traffickers. By 
ensuring that they provide that information on form D, 
Governments would enable the Board to more effectively 
identify and analyse emerging trends in trafficking in pre-
cursors and illicit manufacture of drugs.
154. By accessing data related to trade in precursors, the 
Board is able to monitor legitimate international trade 
flows in order to identify patterns of suspected illicit 
activity, which can help to prevent the diversion of pre-
cursor chemicals. That information is provided by parties 
to the 1988 Convention in accordance with Economic 
and Social Council resolution 1995/20. As at 1 November 
2013, 112 States and territories had provided relevant 
information on licit trade, and 108 States and territories 
had informed the Board about the licit uses of and 
requirements for those substances.
155. Over the past year, the international community 
has used a variety of innovative tools to reinforce and 
bolster the precursors control regime. Domestic legisla-
tion tools were used by Australia, China, India, Peru and 
Viet Nam to strengthen controls over the manufacture, 
import and sale of scheduled substances predominantly 
used in the manufacture of amphetamine-type stimulants. 
In terms of regional cooperation mechanisms, the 
European Commission moved to strengthen legislation 
for control of acetic anhydride. The Board also notes the 
constructive use of bilateral agreements between 
Governments in order to resolve precursor-related issues, 
such as the agreement between China and Mexico.
156. The online system PICS is a secure tool for 
enhanced communication and information-sharing 
between national authorities on precursor incidents 
22  INCB REPORT 2013
(seizures, stopped shipments, diversions and diversion 
attempts, illicit laboratories and associated equipment) 
worldwide and in real time. PICS is now established as 
a key tool of the international precursor control regime, 
with an ever-increasing number of users communicat-
ing more and more incidents through it. As of 
1  November 2013, there were 350 registered users of 
PICS, from 80  Governments and 8 international and 
regional agencies, who used the system to communi-
cate more than 850  incidents spanning 84 different 
countries and territories.
3. Submission of estimates and 
assessments 
157. Pursuant to the 1961 Convention, States parties are 
obliged to provide the Board each year with estimates of 
their requirements for narcotic drugs for the following 
year. As at 1 November 2013, a total of 164 States and 
territories had submitted estimates of their requirements 
for narcotic drugs for 2014, representing 77 per cent of 
the States and territories required to furnish annual esti-
mates for confirmation by the Board. As was the case in 
previous years, the Board had to establish estimates for 
those States and territories that had not submitted their 
estimates on time, in accordance with article 12 of the 
1961 Convention. 
158. As at 1 November 2013, the Governments of all 
countries except South Sudan and all territories had sub-
mitted to the Board at least one assessment of their 
annual medical and scientific requirements for psycho-
tropic substances. The assessments of requirements for 
psychotropic substances for South Sudan were established 
by the Board in 2011, in accordance with Economic and 
Social Council resolution 1996/30, in order to allow that 
country to import such substances for medical purposes 
without undue delay. 
159. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances in Schedules II, III and IV of the 1971 Convention. 
Assessments for psychotropic substances remain in force 
until Governments modify them to reflect changes in 
national requirements. The Board recommends that 
Governments review and update the assessments of their 
annual medical and scientific requirements for psycho-
tropic substances at least every three years. 
160. Since 1 November 2012, a total of 80 countries and 
8 territories have submitted fully revised assessments of 
their requirements for psychotropic substances, and a fur-
ther 78 Governments submitted modifications to assess-
ments for one or more substances. Governments of 
21 countries and 1 territory have not submitted any revi-
sion of their legitimate requirements for psychotropic 
substances for at least three years. 
161. By estimating annual legitimate requirements of 
precursors commonly used in the manufacture of 
amphetamine-type stimulants, Governments can moni-
tor trade in those chemicals for suspicious import pat-
terns and possible cases of diversion. In its resolution 
49/3, the Commission on Narcotic Drugs requested 
Member States to provide to the Board annual estimates 
of their legitimate requirements for four substances 
 frequently used in the manufacture of amphetamine-
type stimulants—namely 3,4-methylenedioxyphenyl-2- 
propanone (3,4-MDP-2-P), pseudoephedrine, ephedrine 
and 1-phenyl-2-propanone (P-2-P)—and preparations 
containing those substances. As of 1 November 2013, 
153 Governments had provided 749 estimates for the 
above-mentioned substances, an increase from the pre-
vious year. First-time submissions were provided by 
Armenia and Cameroon.
162. Failure to submit adequate estimates or assess-
ments for narcotic drugs and psychotropic substances 
may undermine drug control efforts. If estimates or 
assessments are lower than the legitimate requirements, 
the importation or use of narcotic drugs or psychotropic 
substances needed for medical or scientific purposes may 
be impeded or delayed. Submission of estimates or 
assessments significantly higher than legitimately 
required increases the risk that imported narcotic drugs 
and psychotropic substances will be diverted into illicit 
channels. The Board calls upon all Governments to 
ensure that their estimates and assessments are adequate 
but not excessive. When necessary, Governments should 
submit to the Board supplementary estimates for nar-
cotic drugs or inform the Board of modifications to their 
assessments for psychotropic substances. The Board 
invites all Governments, in particular those of countries 
and territories with low levels of consumption of con-
trolled substances, to use the Guide on Estimating 
Requirements for Substances under International Control, 
developed by the Board and the World Health 
Organization for use by competent national authorities, 
published in February 2012. 
163. The Board wishes to remind all Governments that 
the totals of estimates of annual medical and scientific 
requirements for narcotic drugs, as well as assessments 
for psychotropic substances, are published in yearly and 
quarterly publications and that monthly updates are 
CHAPTER II. FUNCTIONING OF THE INTERNATIONAL DRUG CONTROL SYSTEM  23
available on the Board’s website (www.incb.org). Updated 
information on annual estimates of legitimate require-
ments for precursors of amphetamine-type stimulants are 
also available on the website.
4. Data examination and identified 
reporting deficiencies
164. The provision of statistical data by Governments 
allows INCB to monitor the functioning of the inter-
national drug control systems which, in turn, assists 
Governments in their response to possible diversions 
and illegitimate uses of internationally controlled 
substances. 
165. Countries that provide accurate statistical data to 
INCB in a timely manner typically have well-established 
national drug control agencies with the adequate human 
and technical resources required to carry out their respon-
sibilities on the basis of appropriate legislation and admin-
istrative regulations. Those agencies are also given the 
necessary authority to fulfil their role under the inter-
national drug control treaties. Further, they provide clear 
guidance at the national level on the requirements for 
engaging in the manufacture and trade of internationally 
controlled substances, which improves cooperation 
between national drug control authorities and industry. 
Such national drug control systems contribute signifi-
cantly to the effective functioning of international drug 
control. 
166. Late submission and the submission of incomplete 
or inaccurate data required under the international drug 
control treaties and resolutions of the Economic and 
Social Council and the Commission on Narcotic Drugs 
make a timely and relevant review and analysis of the 
data by the Board very difficult. Some Governments, 
among them major manufacturing countries, experience 
challenges in reporting accurately and in a timely man-
ner due to organizational changes or shortages in finan-
cial and human resources. To better respond to those 
difficulties, the Board encourages all Governments to take 
the necessary steps to establish mechanisms that allow 
competent authorities to maintain institutional memory 
and knowledge with regard to reporting requirements 
under the international drug control conventions during 
times of change. To assist Governments, the Board has 
developed tools and kits for use by competent national 
authorities, which are available on its website free of 
charge. Governments are invited to make increasing use 
of those tools in the execution of their functions under 
the international drug control treaties. 
D. Ensuring the implementation of 
the provisions of the international 
drug control treaties
167. The international drug control regime was estab-
lished with two equally important aims: first, to prevent 
the diversion of controlled substances into illicit channels 
for subsequent sale to drug abusers or, in the case of 
 precursor chemicals, for use in the illicit manufacture of 
narcotic drugs and psychotropic substances; and second 
in order to ensure the availability of internationally con-
trolled substances for legitimate use. For narcotic drugs 
and psychotropic substances, in particular, the conven-
tions are aimed at ensuring their availability for medical 
and scientific purposes. The drug control regime com-
prises the international drug control conventions and 
additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance the effectiveness of the provisions con-
tained in the drug control conventions to achieve the two 
main goals. Pursuant to its mandate, the Board regularly 
examines action taken by Governments to implement the 
treaty provisions and related resolutions of the Council 
and the Commission, points out problems that continue 
to exist in this area and provides specific recommenda-
tions on how to deal with such problems.
1. Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
168. Parties to the conventions need to adopt and 
enforce national legislation that is in line with the provi-
sions of the international drug control treaties. They also 
need to amend the lists of substances controlled at the 
national level when a substance is included in a schedule 
of an international drug control treaty or transferred from 
one schedule to another. Inadequate legislation or imple-
mentation mechanisms at the national level or delays in 
bringing lists of substances controlled at the national level 
into line with the schedules of the international drug con-
trol treaties result in inadequate national controls being 
applied to substances under international control. In 
some cases such deficiencies have led to the diversion of 
substances into illicit channels.
169. The Board notes that the establishment of “medi-
cal cannabis” programmes in some countries is permit-
ted pursuant to the Single Convention on Narcotic Drugs 
of 1961, but that these are subject to the strict control 
measures for cannabis cultivation, trade and distribution 
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set forth in articles 28, 23 and 30. The Board notes that 
in some countries the control measures mandated by the 
1961 Convention have not been fully implemented, giv-
ing rise to inconsistencies with the Convention. In addi-
tion, the Board notes that in a few countries, there have 
been legislative proposals intended to regulate the use of 
cannabis for purposes other than medical and scientific 
ones. Such proposals, if implemented, would be in con-
travention of the Convention.
170. The Board notes that some Governments appeared 
to have difficulties amending their national legislation to 
reflect changes introduced in the scope of control of the 
Convention on Psychotropic Substances of 1971. For 
example, although zolpidem was added to Schedule IV of 
the 1971 Convention in 2001, a number of Governments 
have not amended their national lists of controlled sub-
stances accordingly. The Board therefore sent a circular 
letter to Governments in April 2013 to solicit informa-
tion on control measures applied to zolpidem; by 
1  November 2013, replies from 48 Governments were 
received. The Board is pleased to note that all respond-
ing Governments have already placed zolpidem under 
national control, and that 46 of those Governments have 
also introduced an import authorization requirement for 
that substance, in accordance with Economic and Social 
Council resolutions 1985/15, 1987/30 and 1993/38. 
According to information available to the Board, a total 
of 117 countries and territories have placed zolpidem 
under national control; of those, 107 Governments have 
also introduced an import authorization requirement for 
that substance. The Board encourages all Governments 
that have not yet done so to provide it with the requested 
information on the control measures for zolpidem that 
are in place in their countries. The Board also encourages 
all Governments that have not yet introduced an import 
authorization requirement for zolpidem in accordance 
with the above-mentioned Economic and Social Council 
resolutions to do so as soon as possible. 
171. The Commission on Narcotic Drugs, in its deci-
sion 56/1 of March 2013, decided to transfer gamma-
hydroxybutyric acid (GHB) from Schedule IV to Schedule 
II of the 1971 Convention. The decision was communi-
cated by the Secretary-General to Member States and the 
Director-General of the World Health Organization 
(WHO) on 7 June 2013. In accordance with article 2, 
para graph 7, of the 1971 Convention, the decision of the 
Commission became fully effective with respect to each 
party 180 days after the date of that communication, i.e., 
on 4 December 2013.
172. The Board requests all Governments that have not 
yet done so to amend the list of substances controlled at 
the national level accordingly to adequately reflect the 
recent change in the control regime now applicable to 
GHB, and to apply to that substance all control measures 
foreseen for the substances included in Schedule II of the 
1971 Convention, including the introduction of a man-
datory import and export control requirement. 
173. Controlling precursors used in illicit drug manu-
facture is a complex task that has to take into account 
the constantly evolving modi operandi used by drug traf-
fickers. Taking that reality into account, the Board once 
again calls on countries to review their domestic control 
systems in order to ensure that, at a minimum, a system 
of end-user registration and declarations of end use is in 
existence; that they have knowledge of legitimate require-
ments in order to set realistic limits to importation, par-
ticularly for chemicals with little or no legitimate use; and 
that notifications of all exports are sent out prior to their 
departure.
174. By implementing those measures, countries limit 
their exposure to the risk of being targeted by illicit drug 
traffickers. It should also be underlined that by effectively 
monitoring stakeholders involved in domestic manufac-
turing and distribution of controlled substances, 
Governments will be in a position to more easily comply 
with their obligations related to preventing diversion.
(b) Prevention of diversion from 
international trade
Estimates and assessments of annual 
requirements for controlled substances
175. Among the main control measures used to prevent 
the diversion of controlled substances from international 
trade are the systems of estimates and assessments of 
legitimate annual requirements for controlled substances, 
which enables exporting and importing countries alike to 
ensure that trade stays within the limits determined by 
the importing Governments. For narcotic drugs, such a 
system is mandatory under the 1961 Convention, and the 
estimates furnished by Governments need to be con-
firmed by the Board before becoming the basis for the 
limits on manufacture or import. The system of assess-
ments of annual requirements for psychotropic sub-
stances was adopted by the Economic and Social Council 
and the system of estimates of annual requirements for 
selected precursors was adopted by the Commission on 
Narcotic Drugs to help Governments to identify unusual 
transactions that might indicate attempts by traffickers to 
divert controlled substances into illicit channels.
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176. The systems of estimates and assessments can be 
effective only if both exporting and importing countries 
adhere to it: Governments of importing countries should 
ensure that their estimates and assessments are in line 
with their actual requirements and that no import of 
controlled substances in quantities exceeding those 
requirements is taking place. If the actual requirements 
are found to have increased beyond the requirements 
previously submitted to the Board or to have decreased 
substantially below the level of those requirements, 
importing countries should inform the Board immedi-
ately. Governments of exporting countries should set up 
a mechanism to check all export orders involving con-
trolled substances against the estimates and assessments 
of importing countries and allow exports only when they 
are in line with legitimate requirements in the import-
ing countries.
177. In accordance with its mandate to identify gaps in 
the implementation of the control systems that could lead 
to diversion, the Board regularly investigates cases involv-
ing possible non-compliance by Governments with the 
systems of estimates and assessments. In that connection, 
the Board provides advice to Governments on the details 
of the estimates and assessments systems, as necessary. 
178. As in previous years, the Board found that in 2013 
the system of estimates for narcotic drugs continues to 
be respected by most countries. In 2012, nine countries 
were contacted regarding possible excess imports or 
exports identified with regard to international trade in 
narcotic drugs effected during 2012. Three cases were 
clarified as being due to (a) errors in reporting of imports 
or exports and (b) re-export trade. However, six coun-
tries confirmed that excess exports or excess imports had 
actually occurred. The Board contacted the Governments 
concerned and requested them to ensure full compliance 
with the relevant treaty provisions.
179. With respect to psychotropic substances, pursuant 
to Economic and Social Council resolutions 1981/7 and 
1991/44, Governments are requested to provide to the 
Board assessments of annual domestic medical and sci-
entific requirements for psychotropic substances in 
Schedules II, III and IV of the 1971 Convention. The 
assessments received are communicated to all States and 
territories to assist the competent authorities of export-
ing countries when approving exports of psychotropic 
substances.
180. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 22 Governments have 
not submitted a revision of their legitimate requirements 
for psychotropic substances for at least three years. The 
assessments valid for those countries and territories may 
therefore no longer reflect their actual medical and scien-
tific requirements for psychotropic substances. 
181. When assessments are lower than the actual legit-
imate requirements, the importation of psychotropic sub-
stances needed for medical or scientific purposes may be 
delayed. When assessments are significantly higher than 
legitimate needs, they may increase the risk of psycho-
tropic substances being diverted into illicit channels. The 
Board calls upon all Governments to review and update 
their assessments on a regular basis and to keep it 
informed of all modifications, with a view to preventing 
any unnecessary importation and, at the same time, facili-
tating the timely importation of psychotropic substances 
needed for medical purposes. 
182. As in previous years, the system of assessments for 
psychotropic substances continues to function well and is 
respected by most countries. In 2013, the authorities of 
13 countries issued import authorizations for substances 
for which they had not established any assessments or in 
quantities that significantly exceeded their assessments, 
and only two exporting countries exported psychotropic 
substances in quantities exceeding the respective assess-
ment. In most of those cases, the transactions concerned 
imports destined for re-export. The low number of excess 
imports and exports is a positive development attributa-
ble to the slight change made in 2013 to the system of 
assessments for psychotropic substances, aimed at mak-
ing it more transparent and effective. Since then, 
Governments are no longer requested to include esti-
mates for exports or re-exports in the annual assessments 
for psychotropic substances. 
183. Pursuant to resolution 49/3 of the Commission on 
Narcotic Drugs, entitled “Strengthening systems for the 
control of precursor chemicals used in the manufacture 
of synthetic drugs”, Governments submit estimates of 
annual licit requirements for the four substances com-
monly used in the illicit manufacture of amphetamine-
type stimulants. Governments of 152 countries currently 
use that system to check for and identify suspicious 
imports of the substances by looking at the amounts 
imported. In order to enhance the quality of the esti-
mates, and consequently the ability to effectively detect 
suspicious trade, a better understanding of domestic mar-
kets is needed, including knowledge of manufacturing 
companies, their capacities, end-users and legitimate end-
use. The need for this is particularly evident in countries 
in West Asia, Central America and the Caribbean and 
Oceania. 
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Requirement of import and export 
authorizations
184. The requirement for import and export authoriza-
tions is another main control measure to prevent the 
diversion of controlled substances from international 
trade, since it allows the competent national authorities 
to check the legitimacy of individual transactions prior 
to shipment. 
185. The Board therefore urges all Governments to 
ensure that they are able to provide pre-export notifica-
tions, particularly to the importing countries that have 
officially requested such notifications.
186. The Board noted that some countries expressed 
concern about the new regulations for the import author-
ization procedure (for test and reference samples) imple-
mented by Brazil. The paper import authorizations 
previously issued for import were being replaced by elec-
tronic import authorizations that did not comply with all 
the treaty requirements applicable to international move-
ments of controlled substances under the United Nations 
drug control conventions. 
187. Most importantly, the Board found that under the 
newly adopted procedure new import authorizations are 
now issued in PDF format and no longer contain an origi-
nal stamp and signature of the certifying officer, render-
ing them extremely vulnerable to possible falsification. 
The Board also found that under the new procedure there 
was no possibility foreseen for authorities of the export-
ing countries to effectively verify the authenticity of the 
electronic “import certificate”. While the Board welcomes 
and supports initiatives of Governments to make use of 
technological progress to improve domestic control over 
the licit movement of narcotic drugs and psychotropic 
substances, it reiterates that such initiatives must be 
implemented in conformity with the requirements of the 
international drug control treaties.
188. Import and export authorizations are mandatory 
for transactions involving substances under control pur-
suant to the 1961 Convention and any of the substances 
listed in Schedules I and II of the 1971 Convention. The 
competent national authorities must issue import author-
izations for transactions involving the importation of 
such substances into their country. The exporting coun-
tries must verify the authenticity of the import authori-
zations before issuing the export authorizations required 
to allow the shipments containing the substances to leave 
the country. 
189. The 1971 Convention does not require import 
and export authorizations for trade in psychotropic sub-
stances listed in Schedules III and IV of the Convention. 
To address the widespread diversion of those substances 
from international trade, the Economic and Social 
Council, in its resolutions 1985/15, 1987/30 and 1993/38, 
requested Governments to extend the system of import 
and export authorizations to cover all psychotropic 
substances.
190. To date, most countries and territories now require 
import and export authorizations for most of the psycho-
tropic substances in Schedules III and IV of the 1971 
Convention, in accordance with the above-mentioned 
Economic and Social Council resolutions. To assist 
Governments and to prevent traffickers from targeting 
countries in which controls are less strict, the Board has 
been disseminating to all competent national authorities 
a table showing the import authorization requirements 
for substances in Schedules III and IV applied pursuant 
to the relevant Economic and Social Council resolutions. 
That table is published in the secure area of the Board’s 
website, which is accessible only to specifically authorized 
Government officials, so that competent national author-
ities of exporting countries may be informed as soon as 
possible of changes in import authorization requirements 
in importing countries.
191. The Board once again encourages all Governments 
that do not yet require import and export authorizations 
for all psychotropic substances to extend such controls to 
all substances in Schedules III and IV of the 1971 
Convention as soon as possible and to inform the Board 
accordingly, pursuant to the above-mentioned resolutions 
of the Economic and Social Council.
192. A strong import and export control system 
involves issuing individual export authorizations for 
scheduled precursor chemicals. Those Governments that 
issue only general permits, or do not require any per-
mits at all for the import or export of scheduled precur-
sor chemicals, are leaving themselves open to the risk 
that drug traffickers will seek to exploit weak controls 
for their own ends. The Board therefore urges all 
Governments to ensure that permits are required to 
import and export controlled precursors and, where pos-
sible and necessary, that these permits be individual 
rather than general in nature. 
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Verifying the legitimacy of individual 
transactions, particularly those involving 
import authorizations
193. The Board wishes to remind the Governments of 
importing countries that it is in their interest to respond 
in a timely manner to all queries regarding the legitimacy 
of transactions that they receive from competent author-
ities or from the Board. Failure to respond quickly in such 
cases may hinder the investigation of diversion attempts 
and/or cause delays in legitimate trade in controlled sub-
stances, thus adversely affecting the availability of those 
substances for legitimate purposes.
194. For the international import and export authoriza-
tion system for narcotic drugs and psychotropic sub-
stances to function, it is indispensable that the competent 
authorities of exporting countries verify the authenticity 
of all import authorizations that they consider to be sus-
picious. Such action is particularly necessary in all cases 
where import authorizations have new or unknown for-
mats, bear unknown stamps or signatures or have not 
been issued by a recognized competent national author-
ity, or when the consignment consists of substances 
known to be frequently abused in the region of the 
importing country. The Board notes with appreciation 
that a number of Governments have adopted the practice 
of verifying with the competent authorities of importing 
countries the legitimacy of import authorizations or 
bringing to the attention of those authorities documents 
that are not in full compliance with the requirements for 
import authorizations under the international drug con-
trol conventions. 
195. The Board continues to receive requests from 
Governments of exporting countries to assist in verify-
ing the legitimacy of import authorizations, particularly 
when their own endeavours to receive feedback from 
the authorities of the importing countries fail. If the 
Board does not have sufficient information to confirm 
the legitimacy of those authorizations, it contacts the 
importing country to ascertain the legitimacy of the 
transaction. 
196. Importing countries have also become increasingly 
active in implementing the import authorization system. 
Many Governments of importing countries regularly 
inform the Board of changes in the format of their import 
authorizations and provide the Board with samples of 
revised certificates and authorizations for narcotic drugs, 
psychotropic substances and precursor chemicals, so that 
the Board may assist Governments of exporting countries 
in verifying the authenticity of documents. Some import-
ing countries send a copy of all import authorizations 
they have issued to the Board to expedite verification of 
their legitimacy. 
197. The Board welcomes the cooperation and support 
extended to it by Governments, as that information helps 
the Board to better assist the authorities of exporting 
countries to verify the legitimacy of import authorizations 
and thus prevent the diversion of narcotic drugs and psy-
chotropic substances from international trade. In that 
connection, the Board has noted that the format and the 
content of the import and export authorizations currently 
in use in some countries do not meet fully the pertinent 
requirements of the international drug control treaties. 
The Board therefore calls upon all Governments to review 
the format of import and export authorizations currently 
in use in their countries and, wherever necessary, to bring 
it into full conformity with the international drug con-
trol treaties.
Developing an international electronic import 
and export authorization system for narcotic 
drugs and psychotropic substances
198. Over the past few years, the Board, together with 
the international community, has been promoting the 
development of an international electronic import and 
export authorization system for narcotic drugs and psy-
chotropic substances: the International Import and Export 
System (I2ES). Governments will recall that in the report 
of the International Narcotics Control Board for 2012, the 
Board informed Governments of the initiative, and high-
lighted the progress made in the development work on 
the system.17
199. In its resolution 55/6 of March 2012, the 
Commission on Narcotic Drugs encouraged Member 
States to provide the fullest possible financial and politi-
cal support for developing, maintaining and administer-
ing an international electronic import and export 
authorization system for narcotic drugs and psychotropic 
substances. The Commission also requested UNODC to 
undertake the development and technical maintenance of 
the system, and invited the INCB secretariat to adminis-
ter the system during the start-up phase in the biennium 
2012-2013. Funding of the system was to rely completely 
on voluntary contributions from Governments.
200. With the generous support of a number of 
Governments, a prototype of the I2ES system was devel-
oped and demonstrated at a side event during the fifty-
sixth session of the Commission in March 2013. The I2ES 
 17 E/INCB/2012/1, paras. 209-213.
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system, which is designed to be web-based and user-
friendly, will facilitate and expedite the work of national 
competent authorities and reduce the risk of diversion of 
narcotic drugs and psychotropic substances, in accord-
ance with the international drug control conventions con-
cerning international trade in those substances.
201. In March 2013, the Commission on Narcotic Drugs 
in its resolution 56/7, welcomed the contributions of a 
number of Member States for the initial phase of I2ES 
and invited Member States to continue to provide volun-
tary financial contributions to UNODC for the further 
development and maintenance of the system. The 
Commission invited the secretariat of INCB to adminis-
ter the system, in line with its mandate, and encouraged 
Member States to provide the fullest possible financial 
support, including through extrabudgetary resources, for 
that purpose.
202. With the participation of selected competent 
national authorities from all regions of the world, on 
15  November 2013, a pilot testing phase of I2ES was to 
be initiated for the period ending 31 January 2014. An 
assessment of the pilot testing phase will be presented to 
Member States at the time of the fifty-seventh session of 
the Commission, to be held in March 2014, and should 
be rolled out in the course of 2014.
203. The Board invites all Governments to continue 
supporting the initiative and to provide the necessary 
resources for the administration of the system, pursuant 
to Commission resolution 56/7. 
Pre-export notifications for precursor chemicals
204. By invoking article 12, paragraph 10 (a), of the 
United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988, a 
country makes it mandatory for exporting countries to 
inform the competent authorities of an importing coun-
try that there is a planned export of precursors to their 
territory, prior to actual shipment. This allows the import-
ing country to be made aware of the trade and to verify 
its legitimacy. However, currently only 90 States and 3 
territories have formally requested pre-export notifica-
tions. While this is still an increase of 13 Governments 
compared with the previous year, there is still a signifi-
cant number of Governments that may not be aware of 
the import of controlled precursors into their territory. 
The Board calls upon all remaining Governments to fur-
ther strengthen the pre-export notification system by 
invoking the provisions of article 12, paragraph 10 (a), of 
the 1988 Convention without further delay. 
205. Launched in March 2006, the Board’s PEN Online 
system allows competent national authorities of import-
ing and exporting countries to inform each other about 
international trade of precursor chemicals in order to 
confirm the legitimacy of a given trade and help limit 
diversion. Since 2012, a further 11 countries have regis-
tered to use the system (bringing the total number to 
146 States and territories): Algeria; British Virgin Islands; 
Burkina Faso; Cabo Verde; Côte d’Ivoire; Liberia; Libya; 
Macao, China; Marshall Islands; Solomon Islands; and 
Tajikistan. The increased use of PEN Online and thus its 
increased coverage, has led to a rise in the number of 
pre-export notifications communicated through the sys-
tem, which now stands, on average, at over 2,000 each 
month. The Board therefore urges the remaining 51 States 
that have not registered with the PEN Online system to 
do so as soon as possible and calls on Governments to 
actively use the system. It also reminds all Governments 
exporting scheduled chemicals to countries that have 
invoked article 12, paragraph 10 (a), of the 1988 
Convention of their obligation to issue notifications of 
such shipments prior to departure and recommends that 
they use the PEN Online system for such notifications, 
pursuant to Security Council resolution 1817 (2008). 
(c) Effectiveness of the control measures 
aimed at preventing the diversion of 
controlled substances from international 
trade
206. The control measures described above are effective. 
Very few cases involving diversion of narcotic drugs or 
psychotropic substances from international trade into 
illicit channels have been identified in recent years.
207. Discrepancies in Government reports on interna-
tional trade in narcotic drugs are regularly investigated 
with the competent authorities of the relevant countries 
to ensure that no diversion of narcotic drugs from licit 
international trade takes place. Since May 2013, investi-
gations regarding trade discrepancies for 2012 have been 
initiated with 27 countries. The responses from the coun-
tries concerned indicated that the discrepancies were 
caused by clerical and technical errors in preparing the 
reports, reporting on exports/imports of preparations in 
Schedule III without indicating that fact on the form, and 
inadvertent reporting of transit countries as trading part-
ners. There were no identified cases indicating a possible 
diversion of narcotic drugs into illicit channels.
208. During the last year, only one case of diversion of 
a psychotropic substance from international trade into 
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illicit channels was identified. The case in question con-
cerned a diversion of an import of diazepam from China 
to Nigeria. In the case in question, the importing com-
pany claimed to have lost the related import permit and 
was provided by the Nigerian authorities with a replace-
ment permit. It was later determined that exports corre-
sponding both to the original permit and the replacement 
permit had taken place, as was corroborated by the 
Government of China. At present, it is not clear whether 
the diverted diazepam actually arrived in Nigeria or was 
diverted to another destination.
209. In addition, attempts to divert psychotropic sub-
stances from international trade continue to be detected 
by vigilant competent national authorities, which often 
work in close cooperation with the Board.
210. Falsified import authorizations continue to be used 
by traffickers to attempt diversion of controlled sub-
stances. In 2013, a diversion attempt was identified 
through the vigilance of the competent authorities of the 
Czech Republic, which stopped a shipment of phenter-
mine (Adipex capsules) that was to be exported to Yemen. 
The shipment was stopped as the import permit, which 
claimed the shipment was for a humanitarian emergency, 
had apparently been falsified and because the consign-
ment was to be delivered to a post office box address in 
Yemen. Upon inquiry with the authorities of Yemen, it 
was confirmed that the import permit in question had 
been falsified.
211. The Board trusts that Governments investigate all 
attempts to divert controlled substances, such as the 
attempt mentioned above, in order to identify and prose-
cute the persons responsible. The Board also urges 
Governments to remain vigilant and scrutinize import 
and export orders involving controlled substances to 
ensure that they are delivered to licit consignees.
212. In accordance with Commission on Narcotic Drugs 
resolution 50/11, Governments are encouraged to notify 
the Board of seizures of internationally controlled sub-
stances ordered via the Internet and delivered through 
the mail, in order to assess the extent of and trends per-
taining to that issue. In 2013, six countries reported such 
seizures (Chad, Finland, Norway, the Russian Federation, 
Singapore and Thailand). Chad reported a seizure in 2012 
of 5,436 capsules of diazepam, originating in Cameroon. 
Finland reported seizures of buprenorphine, methylphe-
nidate, zolpidem and some benzodiazepines in quantities 
ranging from 299 units to 10,745 units, from unknown 
sources. Norway reported seizures of 18 different psycho-
tropic substances, including significant quantities of 
alprazolam and diazepam, entering the country by mail 
from a number of countries. The Russian Federation 
reported seizures of 17 different psychotropic substances, 
most notably of almost 2 kg of amphetamine. Singapore 
reported seizures of small quantities of clonazepam, dia-
zepam and midazolam sent by mail from China and 
Pakistan. Thailand reported seizures of alprazolam and 
diazepam, which was mainly sent by mail from Thailand 
to the United Kingdom of Great Britain and Northern 
Ireland.
213. The controls currently in place have been effective 
to the point that traffickers are now seeking to exploit 
weaknesses at the domestic level rather than trying to 
divert controlled substances from international trade. 
However, it is also clear that some substances used in the 
illicit manufacture of amphetamine-type stimulants con-
tinue to be targeted for diversion from international 
trade, in particular preparations containing the precur-
sors ephedrine and pseudoephedrine. In addition, the 
evolving trend with regard to the diversion of non- 
scheduled chemicals will pose a challenge to existing con-
trol measures, for which new approaches may be required 
to respond effectively.
(d) Prevention of diversion from domestic 
distribution channels 
214. The diversion of narcotic drugs, psychotropic sub-
stances and precursors from licit domestic distribution 
channels has become a main source for supplying the 
illicit markets. The narcotic drugs and psychotropic sub-
stances involved are diverted mainly in the form of phar-
maceutical preparations. Some of the problems associated 
with the diversion of preparations containing narcotic 
drugs or psychotropic substances, which are predomi-
nantly diverted for subsequent abuse, and the actions to 
be taken to tackle those problems are described in sec-
tion E below.
215. Governments have no obligation to bring to the 
attention of the Board individual cases of diversion from 
domestic distribution channels. Consequently, for many 
substances found to have been diverted, there is little 
record of the point of diversion or of the actual methods 
used by traffickers or abusers to obtain those substances. 
Frequently, seizure data provide an indication of prob-
lems that continue to be experienced with such diversion. 
For narcotic drugs and psychotropic substances, data on 
substance abuse obtained either through drug abuse sur-
veys or from drug treatment and counselling centres also 
confirm the widespread availability of narcotic drugs and 
psychotropic substances that were diverted from licit dis-
tribution. Abusers that are seeking treatment can direct 
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the authorities to the sources of the substances in ques-
tion, including pharmacies that do not implement the 
prescription requirements, thefts and unethical behaviour 
by patients, such as “doctor shopping”. The Board recom-
mends that Governments inform it regularly of the major 
cases of diversion of controlled substances from domes-
tic distribution channels in their countries so that the les-
sons learned from such diversion cases can be shared with 
other Governments. 
216. For narcotic drugs and psychotropic substances, 
the substances most frequently diverted tend to be those 
that are most widely consumed for licit purposes. Among 
the psychotropic substances most frequently diverted are 
stimulants (amphetamines, methylphenidate and anorec-
tics) and sedatives such as benzodiazepines (especially 
diazepam, alprazolam, lorazepam, clonazepam, flunitraz-
epam and midazolam), barbiturates and GHB. 
217. The trend towards diversion of substances from 
domestic trade channels, which are then trafficked out of 
the country, a trend which has been previously signalled 
by the Board, continues. In general, countries should 
develop a better understanding of their domestic markets, 
including the role of manufacturing companies and end-
users of scheduled precursors, in order to limit opportu-
nities for domestic diversion that can be exploited by 
traffickers. 
218. In terms of scheduled precursors, diversion from 
domestic distribution channels is particularly noticeable 
for acetic anhydride, a precursor used in heroin manu-
facture. In order to raise awareness about this issue and 
develop better understanding of modi operandi used by 
traffickers of this substance, the Board initiated an inter-
national activity that focused on the verification of legiti-
macy of domestic trade in, and end-use of, acetic 
anhydride, under the auspices of Project Cohesion, the 
international initiative to combat trafficking in heroin 
precursors. The operation involved the participation of 
41 countries, and its results will be evaluated by the INCB 
Precursors Task Force and reported at a later date. The 
Board encourages Governments to actively participate in 
such intelligence-gathering activities under Project Prism 
and Project Cohesion.
219. Weaknesses in the controls over pharmaceutical 
preparations in countries of South-East and West Asia are 
of concern to the Board. High annual legitimate require-
ments for ephedrine and pseudoephedrine in some coun-
tries of those regions, in parallel with large numbers of 
seizures, point to the need to improve controls over dis-
tribution and estimates. The Board is also aware of domes-
tic diversions of pharmaceutical preparations in countries 
of South-East and West Asia, as well as in South Asia, 
communicated via PICS.
220. The continued success of control measures 
applied to international trade in potassium permanga-
nate have forced trafficking organizations to both obtain 
the substance from other sources and find alternatives 
with which to illicitly manufacture cocaine. For exam-
ple, authorities in Colombia estimate that between 60 
and 80  per cent of the potassium permanganate used 
in Colombia is obtained through illicit manufacture 
from manganese dioxide and not diverted from inter-
national trade. It is also believed that sodium perman-
ganate is being used as a possible substitute. The net 
result is that the ability of traffickers to manufacture 
cocaine in large quantities remains, and the Board is 
concerned by the growing threat of cocaine manufac-
ture spreading into Central America and other regions 
outside South America.
2. Ensuring the availability of 
internationally controlled substances for 
medical and scientific purposes
221. In line with its mandate to ensure the availability 
of internationally controlled substances for medical and 
scientific purposes, the Board carries out various activities 
related to narcotic drugs and psychotropic substances. The 
Board monitors action taken by Governments, interna-
tional organizations and other bodies to support the 
rational use of controlled substances for medical and sci-
entific purposes and their availability for those purposes.
(a) Supply of and demand for opiate raw 
materials 
222. INCB has an important role to play in the supply 
of raw materials required for the manufacture of all medi-
cations containing opiates. Pursuant to the 1961 
Convention and relevant resolutions of the Commission 
on Narcotic Drugs and the Economic and Social Council, 
the Board examines on a regular basis developments 
affecting the supply of and demand for opiate raw mate-
rials. The Board strives, in cooperation with Governments, 
to maintain a lasting balance between supply and demand 
for those materials. In order to analyse the situation 
regarding supply of and demand for opiate raw materi-
als, the Board uses information from Governments of 
countries producing opiate raw materials, as well as of 
countries where those materials are utilized for the 
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manu facture of opiates or substances not controlled 
under the 1961 Convention. A detailed analysis of the 
current situation with regard to the supply of and demand 
for opiate raw materials is contained in the 2013 techni-
cal report of the Board on narcotic drugs.18 The follow-
ing paragraphs provide a summary of that analysis. 
223. INCB recommends that global stocks of opiate raw 
materials be maintained at a level sufficient to cover 
global demand for approximately one year, in order to 
ensure the availability of opiates for medical needs in case 
of an unexpected shortfall of production, for example, 
caused by adverse weather conditions in producing coun-
tries, and at the same time, limit the risk of diversion 
associated with excessive stocks.
224. While global production of opiate raw materials 
rich in morphine was lower than global demand esti-
mated by Governments for those raw materials in the 
period 2006-2008, production exceeded demand from 
2009 to 2011. As a result, stocks increased and at the end 
of 2011 stood at about 493 tons, sufficient to cover the 
expected global demand for 14 months. In 2012, stocks 
remained at the same level (483 tons) as a result of pro-
duction exceeding demand, although the gap between the 
two was considerably reduced in comparison with 2011 
and still sufficient to cover the expected global demand 
for about 12 months. In 2013, global production of opi-
ate raw materials rich in morphine is expected to exceed 
global demand again, with the result that global stocks of 
those raw materials will further increase in 2013. Stocks 
were expected to reach 596 tons by the end of 2013, which 
is equivalent to about 15 months of expected global 
demand at the 2014 level. Producing countries plan to 
increase production in 2014. Stocks are anticipated to 
reach about 795 tons at the end of 2014, sufficient to cover 
several more months of expected global demand. The 
global supply of opiate raw materials rich in morphine 
(stocks and production) will remain fully sufficient to 
cover global demand.
225. In 2012, global production of opiate raw materials 
rich in thebaine was again higher than demand as 
reported by Governments, leading to a slight increase in 
stocks (to 183 tons) at the end of 2012, equivalent to 
global demand for 8 months. Production is expected to 
increase in 2013 and to grow further in 2014. By the end 
of 2013, global stocks of opiate raw materials rich in the-
baine will likely reach 244 tons, sufficient to cover global 
demand for 10 months, and at the end of 2014 reach 
353  tons, sufficient to cover several months of expected 
global demand. The global supply of opiate raw materials 
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rich in thebaine (stocks and production) will be more 
than sufficient to cover global demand in 2013 and 2014.
226. The stocks of opiate raw materials rich in morphine 
will be at the recommended level at the end of 2013 but 
will be above the recommended level (15 months) as at 
the end of 2014. Stocks of opiate raw materials rich in 
thebaine are expected to increase in 2013 and 2014 but 
will be below the recommended level.
227. The Board noted that data show that the amount 
of opiate raw material available for the manufacturing of 
narcotic drugs for pain relief is more than sufficient to 
satisfy current demand level as estimated by Governments 
and that global stocks are increasing. The Board noted 
that despite this, the consumption of narcotic drugs for 
pain relief is concentrated in a limited number of coun-
tries. The Board calls on Governments to ensure that 
substances under international control used for pain 
relief are available and accessible to people in need and 
asks Governments to make every effort to facilitate that 
process. 
(b) Consumption of psychotropic 
substances
228. While the submission by Governments of con-
sumption data on narcotic drugs to the Board is a treaty 
requirement under the 1961 Convention, such reporting 
for psychotropic substances is not required under the 
1971 Convention. As a consequence, consumption levels 
for psychotropic substances continue to be calculated by 
the Board on the basis of data furnished by Governments 
on manufacture, international trade, quantities used for 
industrial purposes and stocks. That situation makes it 
more difficult to come to reliable conclusions than in the 
case of narcotic drugs. 
229. To address that situation, the Commission on 
Narcotic Drugs, in its resolution 54/6, encouraged all 
Member States to furnish to the Board data on consump-
tion of psychotropic substances. The number of 
Governments that are furnishing such data has steadily 
increased since 2010. The Board is pleased to note that 
for 2012, a total of 53 Governments have already been in 
a position to submit data on consumption of psychotropic 
substances to it in accordance with the Commission reso-
lution 54/6. That development will enable the Board to 
more accurately analyse the consumption levels of psy-
chotropic substances in the countries and territories con-
cerned and to better monitor consumption trends in 
countries and regions with a view to identifying unusual 
or undesirable developments. 
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230. Consumption levels of psychotropic substances 
continue to differ widely among countries and regions, 
reflecting diversity in medical practice and related varia-
tions in prescription patterns. However, as the Board has 
repeatedly pointed out, high or low levels of drug con-
sumption in a country should be a matter of concern to 
the Government. High levels of consumption of psycho-
tropic substances that are not medically justified may lead 
to the diversion and abuse of the substances in question, 
whereas very low levels of consumption of psychotropic 
substances in some countries may reflect the fact that 
those substances are almost inaccessible to certain parts 
of the population. Where substances are not accessible on 
the licit market for genuine medical purposes, those sub-
stances, or counterfeit medicaments allegedly containing 
those substances, may appear on unregulated markets. 
The Board reiterates its recommendation to all 
Governments to compare the consumption levels in their 
countries with those in other countries and regions, with 
a view to identifying unusual trends requiring attention, 
and take remedial action where necessary. At the same 
time, the Board encourages all Governments to ensure the 
rational use of internationally controlled substances, in 
accordance with the pertinent recommendations of WHO. 
(c) Activities of intergovernmental and 
non-governmental organizations
231. A number of international organizations, intergov-
ernmental bodies and non-governmental organizations 
are undertaking activities focusing on the uneven con-
sumption of opioids for pain management.
232. UNODC continued to develop the global pro-
gramme to improve the management policies and proce-
dures related to controlled medication, particularly for 
prescription pain medication. The aim is to increase 
access to controlled drugs for medical purposes used for 
treatment of severe pain, thereby reducing existing bar-
riers to rational use and increasing the number of patients 
receiving appropriate treatment for conditions requiring 
the use of such medication, while minimizing diversion, 
misuse and abuse. The global programme has received 
funding from Australia, and while UNODC is continu-
ing to fundraise, it has decided, together with the Union 
for International Cancer Control, to start some of the 
activities foreseen by the programme in a pilot country.
(d) National activities
233. The Board notes that action has been taken in seve-
ral countries to improve the level of consumption of 
internationally controlled substances, in particular opioid 
analgesics.
234. In India, an amendment to India’s Narcotic Drugs 
and Psychotropic Substances Act was introduced to 
strengthen the Act with regard to opioid accessibility. The 
amendment was drafted through a cooperative effort by 
the Government of India’s Department of Revenue and 
palliative care non-governmental organizations in an 
effort to achieve a more balanced policy that ensured 
nationwide consistency in the licensing and movement of 
opioids between Indian states, while maintaining ade-
quate controls. The Board welcomes the effort of the 
Government of India and looks forward to the final 
approval of the amendment.
235. In August 2012, the Government of Viet Nam 
adopted the national target programme on drug abuse 
prevention and control for the period 2012-2015. The new 
programme updated the country’s drug control strategy 
and focuses on expanding methadone substitution treat-
ment among the country’s large population of HIV-
vulnerable injecting drug users.
(e) Information on specific requirements 
for travellers who carry medical 
preparations containing controlled 
substances for personal use
236. The Commission on Narcotic Drugs, in its resolu-
tions 45/5, 46/6 and 50/2, encouraged States parties to 
the 1961 Convention and the 1971 Convention to notify 
the Board of restrictions currently applicable in their ter-
ritory to travellers under medical treatment with prepa-
rations containing substances under international control, 
and requested the Board to publish that information in a 
unified form in order to ensure its wide dissemination 
and facilitate the task of government agencies.
237. As of 1 November 2013, the Board had received 
from 86 Governments information on the legal provisions 
and/or administrative measures currently applicable in 
their countries to travellers carrying medical preparations 
containing narcotic drugs or psychotropic substances for 
personal use. The Board, in cooperation with those 
Governments, has been putting the information received 
into a standard format so that travellers may receive com-
prehensive information on the requirements in their 
countries of destination. The Board urges Governments 
that have not yet done so to examine the standardized 
information on their national requirements and to inform 
the Board of their approval of that information. Once 
CHAPTER II. FUNCTIONING OF THE INTERNATIONAL DRUG CONTROL SYSTEM  33
approved, the standardized information will be posted on 
the website of the Board. 
238. The Board calls on all Governments that have not 
yet done so to submit to it their current national regula-
tions and restrictions applicable to international travellers 
carrying medical preparations containing internationally 
controlled substances for personal use, pursuant to 
Commission on Narcotic Drugs resolutions 45/5, 46/6 
and 50/2. In addition, Governments should notify the 
Board of any changes in their national jurisdictions in the 
scope of control of narcotic drugs and psychotropic sub-
stances relevant to travellers under medical treatment 
with internationally controlled substances, in accord-
ance with Commission resolution 50/2.
E. Special topics
1. Prescription drug disposal 
initiatives 
239. The Board has repeatedly drawn the attention of 
Governments to the growing public health threat caused 
by increasing global prevalence rates of prescription drug 
abuse. The abuse of prescription drugs has increased in 
all regions, with those prevalence rates, in some  countries, 
outpacing the rates for illegal drugs. 
240. While many factors may have contributed to that 
development, the Board notes that the increased preva-
lence in prescription drug abuse has, to a large extent, 
been driven by the widespread availability of those drugs, 
as well as to erroneous perceptions that prescription 
drugs are less susceptible to abuse than illicit drugs. The 
non-prescription use of those drugs for self-medication 
has further exacerbated the problem.
241. One of the main sources of prescription drugs 
diverted from licit channels for abuse identified by  public 
health officials is the presence in households of prescrip-
tion drugs that are no longer needed or used for medi-
cal purposes. Surveys of abuse prevalence undertaken in 
several countries have revealed that a significant percent-
age of individuals abusing prescription drugs for the first 
time obtained the drug from a friend or family member 
who had acquired them legally.
242. In the light of that situation, the international com-
munity has recognized that an effective means of address-
ing the growing threat posed by prescription drug abuse 
and addiction is to focus efforts on supply reduction and 
public awareness initiatives. Among the measures being 
increasingly used are prescription drug disposal initia-
tives, including prescription drug take-back days.
243. The setting-up of such initiatives in many jurisdic-
tions has yielded significant results at a relatively low cost. 
In the United States alone, since the staging of the first 
prescription drug take-back day in 2010, such initiatives 
have resulted in the removal of 1,733 tons of prescription 
drugs from circulation and possible abuse. In staging and 
publicizing these initiatives, public health authorities have 
helped increase public awareness of the dangers of pre-
scription drug abuse and of the importance of ensuring 
that unused prescription drugs that are no longer needed 
are disposed of safely. 
244. The importance of these measures has been recog-
nized by the international community, including by the 
States members of the Commission on Narcotic Drugs. 
Accordingly, in March 2013, the Commission adopted its 
resolution 56/8, entitled “Promoting initiatives for the 
safe, secure and appropriate return for disposal of pre-
scription drugs, in particular those containing narcotic 
drugs and psychotropic substances under international 
control”.
245. In its resolution 56/8, the Commission called upon 
States to consider the adoption of a variety of courses of 
action to address prescription drug abuse in cooperation 
with various stakeholders such as public health officials, 
pharmacists, pharmaceutical manufacturers and distribu-
tors, physicians, consumer protection associations and 
law enforcement agencies, in order to promote greater 
awareness of the risks associated with the non-medical 
use of prescription drugs, in particular those containing 
narcotic drugs or psychotropic substances. 
246. In adopting that resolution, the Commission has 
recognized that programmes for the safe disposal of pre-
scription drugs are an integral part of any strategy to 
address prescription drug abuse and may be an effective 
means of raising public awareness of the dangers of the 
harm caused by that abuse. 
247. Drawing on the encouraging results achieved in 
many States in the implementation of successful initia-
tives for the disposal of prescription drugs, in its resolu-
tion 56/8 the Commission encouraged Member States to 
exchange good practices, to be emulated in States that 
had not yet implemented such activities or that sought to 
strengthen or optimize existing measures.
248. The Board fully endorses the courses of action set 
forth in Commission on Narcotic Drugs resolution 56/8 
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and calls upon all States that have not already done so to 
develop comprehensive strategies to address prescription 
drug abuse, including mechanisms to ensure the safe 
return and disposal of medications possessing psychoac-
tive properties, particularly those containing narcotic 
drugs or psychotropic substances. The Board also recom-
mends that States consider expanding these programmes 
to include all substances having psychoactive properties, 
whether available with a prescription or without. 
249. Although the establishment of safe disposal initia-
tives is an important tool for addressing prescription drug 
abuse, that measure alone will not suffice. As such, the 
Board wishes to reiterate that any comprehensive strategy 
aimed at tackling the problem of prescription drug abuse 
must also address the root causes of the excessive supply 
of prescription drugs, including overprescribing by medi-
cal professionals, “doctor shopping” and inadequate con-
trols on the issuing and filling of prescriptions. 
2. Illegal Internet pharmacies
250. For several years, the Board has drawn the atten-
tion of Governments and other members of the interna-
tional community to the phenomenon of illegal Internet 
pharmacies and the need to better protect the public 
against the illegal distribution of preparations containing 
internationally controlled substances. Substances fre-
quently sold through such pharmacies include opioid 
analgesics, central nervous system stimulants and tran-
quillizers. To assist Governments in addressing the prob-
lem, the Board developed, with the support and 
contribution of national experts and relevant interna-
tional organizations, Internet service providers, financial 
services and pharmaceutical associations, Guidelines for 
Governments on Preventing the Illegal Sale of Internationally 
Controlled Substances through the Internet.19 The guide-
lines, which were launched in 2009, are aimed at assist-
ing Governments in formulating national legislation and 
policies for regulatory, law enforcement and other author-
ities with regard to the use of the Internet to dispense, 
purchase, export or import internationally controlled 
substances. 
251. To assess the implementation of the guidelines and 
to obtain information on good practices in addressing the 
unauthorized sale of internationally controlled substances 
using the Internet, the Board sent a questionnaire to 
Governments in March 2013; responses were received 
from 78 countries and territories throughout the world. 
Most Governments reported that, on their territory, the 
 19 United Nations publication, Sales No. E.09.XI.6.
sale of internationally controlled substances by Internet 
pharmacies was prohibited, and some expressly stated 
that not allowing Internet pharmacies to operate on their 
territory had limited the problem. 
252. Where Internet pharmacies are permitted, such 
pharmacies must generally meet the same legislative 
requirements that are applicable to storefront pharmacies. 
Some pharmacies do not use the Internet to sell interna-
tionally controlled substance, as they consider the risk of 
diversion to be too large. In some cases, applications to 
open Internet pharmacies are examined by law enforce-
ment authorities prior to being approved. 
253. Many Governments reported having implemented 
the guideline calling on Governments to adopt national 
legislation on the designated routing and inspection of 
mail and other items handled by international courier 
companies. Legislation and policies in place normally 
allow border service agencies to examine pharmaceuticals 
that are shipped by mail. The extent to which consign-
ments of medication containing internationally controlled 
substances are inspected varies. In some cases, all con-
signments containing any medicinal product are exam-
ined; in others, inspections are carried out at regular 
intervals with a view to detecting illegal shipments. In 
addition, countries may have in place specific require-
ments for the distribution of medicinal products by mail 
(or as one Government reported) may not allow narcotic 
drugs or psychotropic substances to be shipped through 
the postal system unless they are to be used as test or 
 reference standards. 
254. One central concern is the potential danger to 
the health of customers who have procured over the 
Internet pharmaceutical products containing interna-
tionally controlled substances. National efforts have 
been made to protect such customers from harm. The 
National Association of Boards of Pharmacy, for exam-
ple, which has members in Canada, New Zealand and 
the United States, has developed the Verified Internet 
Pharmacy Practice Sites (VIPPS) programme, whereby 
participating pharmacies must comply with a number 
of licensing and inspection requirements. Each VIPPS 
pharmacy site is identified by a hyperlink seal dis-
played on the website; by clicking on the seal, website 
visitors are able to access verified information about 
the pharmacy. Similarly, since 2 January 2013, member 
States of the European Union are required to apply 
directive 2011/62/EU of the European Parliament and 
of the Council of the European Union, which, inter 
alia, requires each member State to introduce a “com-
mon logo” on websites of legally operating online phar-
macies. The logo must be clearly displayed on every 
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web page of any online pharmacy offering pharmaceu-
tical products containing internationally controlled 
substances and should allow the identification of the 
member State in which the online pharmacy has been 
established. 
255. In several countries, particularly in Europe and 
North America, as well as in Australia and New Zealand, 
awareness-raising campaigns are regularly carried out, 
often on the Internet, to inform the public about the 
potential dangers of ordering pharmaceutical products 
over the Internet. Websites established specifically for this 
purpose may include information and verification tools 
to assist in identifying whether the pharmacy in question 
is a genuine enterprise. Some websites also have facilities 
for reporting suspected fake online pharmacies to the 
 relevant authorities.
256. Action against illegal Internet pharmacies involves 
multiple actors at the national level, usually the Ministry 
of Health and law enforcement agencies and, in many 
cases, other ministries such as the Ministry of Economics, 
the Ministry of Technology or the Ministry of Justice. An 
effective response therefore requires the collaboration of 
those Government agencies, as well as fruitful coopera-
tion within the private sector, particularly among Internet 
service providers. 
257. When asked about good practices in addressing 
the problem of illegal Internet pharmacies, Governments 
cited regular monitoring of the Internet and the inves-
tigation of suspected illegal pharmacies. Several 
Governments also reported examples of successful coop-
eration at the national and international levels that had 
resulted in the seizure of internationally controlled sub-
stances and the dismantling of organizations trafficking 
in such substances.
258. One example of effective international action is 
Operation Pangea, an annual operation that is coordi-
nated by the International Criminal Police Organization 
(INTERPOL), involves the World Customs Organization, 
the Permanent Forum on International Pharmaceutical 
Crime, the Heads of Medicines Agencies Working Group 
of Enforcement Officers, the Pharmaceutical Security 
Institute and the European Police Office (Europol) and 
is supported by the Center for Safe Internet Pharmacies, 
as well as companies in the private sector. Six such oper-
ations have been carried out since 2008. The latest, a 
one-week operation carried out in June 2013, resulted in 
the shutdown of more than 9,000 websites, in addition 
to the suspension of the payment facilities of illegal phar-
macies and the disruption of a substantial number of 
spam messages. 
259. The results of the Board’s 2013 survey on illegal 
Internet pharmacies also highlighted the digital divide. 
Most of the respondents were from regions in which a 
high percentage of the population uses the Internet, 
such as Europe and North America. Respondents from 
other regions often expressed a lack of awareness of ille-
gal Internet pharmacies and of action that could be 
taken against them. According to the International 
Telecommunication Union, however, between 2009 and 
2013, the number of households with Internet access 
grew fastest in developing countries—average annual 
growth was 27 per cent in Africa—and 15 per cent in 
Asia and the Pacific, the Arab States and the 
Commonwealth of Independent States. Those growth 
rates underscore the need to increase public awareness 
in those regions of the dangers of illegal Internet phar-
macies and to strengthen activities to build the capac-
ity of authorities involved in responding to crime 
involving the Internet.
260. Since 2004, the Board has been collecting informa-
tion from Governments on activities and measures tar-
geting illegal Internet pharmacies. As illegal Internet 
pharmacies are a global challenge, strengthened inter-
national action is required to effectively address the 
 problem. The Board calls on Governments to continue to 
provide it with information on the subject and to develop 
and promote good practices in that area so that sustained 
action can be taken against the problem. 
3. Global developments in the  
non-medical use of tramadol
261. The Board welcomes the adoption of Commission 
on Narcotic Drugs resolution 56/14, on tramadol, in 
which the Commission highlighted the concerns of 
Member States with respect to the expansion of the illicit 
manufacture and the illicit domestic and international 
distribution of tramadol in some countries, as well as the 
risk of illicit use of tramadol and its potential exploita-
tion by trafficking organizations. The Board highlighted 
in its annual report for 2012 that abuse of tramadol, a 
synthetic opioid not under international control, had 
become a serious problem in a number of African coun-
tries, notably in North Africa. In 2013, large seizures in 
Africa were once again reported.
262. In its resolution 56/14, the Commission invited the 
International Narcotics Control Board (INCB) to con-
sider incorporating in its annual report for 2013 infor-
mation on global developments in the non-medical use 
and abuse, illicit manufacture and illicit domestic and 
international distribution of tramadol.
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263. A questionnaire, made available on paper and 
online, was transmitted to Member States with the request 
that they provide information on the use and status of 
tramadol in their country. A total of 81 States responded.
264. The results show that almost all countries (80 of 
the 81 countries responding) reported that tramadol was 
used for medical purposes in their territory. In most 
countries (72 countries or 90 per cent), a prescription 
was required for all tramadol preparations, and in 
another 5  countries (5 per cent) a prescription was 
required for some preparations. However, only 33 coun-
tries (40  per  cent) of the responding countries reported 
that tramadol was controlled under national legislation. 
Only 13 countries (28 per cent) of the 46 countries 
responding to the specific question were considering 
placing tramadol under control, and the respondents for 
those countries commented that such a control measure 
would limit abuse of the drug but should not have an 
impact on its availability for medical use.
265. Thirty-three countries, approximately 42 per cent 
of those responding, reported non-medical use and/or 
abuse of tramadol, mostly providing anecdotal informa-
tion. With respect to trends observed, abuse of tramadol 
(two thirds of which is oral dosage form abuse) was 
increasing in 12 countries (38 per cent) of the countries 
reporting such abuse and was stable in a further 13 coun-
tries (42 per cent).
266. Thirty-three countries (72 per cent of 46 countries 
responding to the specific question) were not consider-
ing placing tramadol under control, expressing concern 
that the introduction of control measures would limit 
accessibility and make doctors more reluctant to prescribe 
the drug. 
267. A limited number of countries (five countries or 
15 per cent of the 32 countries responding to the specific 
question) indicated that abuse of tramadol posed a sig-
nificant risk to public health, while a larger portion (nine 
countries or 28 per cent) did not consider the abuse of 
tramadol to be a significant risk to public health.
268. In 20 countries (25 per cent of the countries 
responding) there was evidence of illicit distribution of 
tramadol, and in 17 countries (21 per cent) there was 
diversion into illicit distribution channels, mostly diver-
sion attributable to retailers or patients. Just 12 countries 
(15 per cent) had evidence of illicit import of tramadol, 
and 24 countries (32 per cent) reported seizures. Very few 
respondents indicated local illicit manufacture or export.
269. In conclusion, the picture emerging from the sur-
vey is that tramadol abuse seems to be a problem for a 
limited but significant number of countries (32 of the 
77  countries responding on that issue). Five countries 
reported that abuse of tramadol was a significant risk, 
while illicit trafficking was recorded in a limited number 
of countries. There were no clear data on abuse, only 
anecdotal evidence. It seems that a number of States do 
not intend to strengthen control measures for tramadol 
because they do not want to limit accessibility and because 
they do not have strong evidence of abuse and illicit 
trafficking.
270. The Board notes that abuse of tramadol is a signifi-
cant problem in a limited number of countries and that 
there are growing indications of non-medical use of tram-
adol and diversion to illicit channels. The Board notes 
that tramadol is controlled in most countries where it has 
been found to be abused and that a number of other 
countries that have encountered problems with such 
abuse are considering taking that measure. The Board 
notes that it is important to ensure that tramadol is avail-
able for medical purposes but that it is equally important 
for countries to ensure that it is not used for non- medical 
purposes. Therefore, the Board recommends that coun-
tries continue to monitor trends and collect data on the 
use, abuse, illicit domestic and international distribution 
and manufacture of tramadol and share those data with 
the Board and the World Health Organization.
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Chapter III.
Analysis of the world situation
HIGHLIGHTS
• In Africa, there has been a sizeable increase in the trafficking of opiates through East Africa and cocaine in North 
and East Africa, as well as a sizeable increase in the illicit manufacture and trafficking of methamphetamine in 
the region; abuse of opioids, cannabis, amphetamine-type stimulants and cocaine is also increasing.
• Central America and the Caribbean continue to be affected by drug trafficking and high levels of drug-related 
 violence. The region remains a significant transit route for cocaine destined for North America and Europe. Large-
scale illicit methamphetamine manufacture is a cause for serious concern.
• Use of cannabis in some states of the United States of America has not yet been adequately addressed by the 
federal Government in a manner consistent with the provisions of the drug control Conventions. 
• Canada has launched its first ever action plan to address prescription drug abuse.
• In South America, illicit coca bush cultivation in 2012 decreased to 133,700 ha, the lowest level since 1999.
• Increasing demand for heroin and amphetamine-type stimulants in East and South-East Asia have led Governments 
to expand drug treatment services and develop demand reduction strategies, while efforts continue to be focused 
on tackling drug trafficking and illicit drug manufacture.
• Record-setting illicit opium poppy cultivation and opium production in 2013 threaten an already fragile security 
situation in Afghanistan at a time when international security forces begin their planned withdrawal.
• Unprecedented numbers and varieties of new psychoactive substances have been reported in Europe, and their 
abuse continues to grow.
• In Western and Central Europe, abuse of narcotic drugs and psychotropic substances appears to be stabilizing at 
historically high levels; prescription opioids pose a major challenge in that subregion.
• Methamphetamine manufacture appears to be spreading to new locations in Europe.
• In Oceania, the increasing use and availability of new psychoactive substances poses considerable prevention, 
treatment, regulatory and law enforcement challenges, while cannabis remains the most prevalent drug of abuse.
38  INCB REPORT 2013
A. Africa
1. Major developments
271. There have been alarming trends affecting the illicit 
drug situation in Africa. There has been a sizeable increase 
in the manufacture and smuggling of methamphetamine 
and an increase in the abuse of opioids, cannabis, 
 amphetamine-type stimulants and cocaine in the region. 
In addition, there have also been sizeable increases in the 
smuggling of opiates through East Africa and the traffick-
ing of cocaine in North and East Africa. 
272. The political situation in West and Central Africa 
in 2012 and early 2013 was marked by several military 
coups, post-electoral violence and the rise of religious 
extremism. In its presidential statement of 10 December 
2012, the Security Council expressed grave concern 
about the consequences of instability in the north of 
Mali on the Sahel region and beyond. Even after the 
Government of Mali regained control of the national 
territory in January 2013, there continued to be serious 
security risks in the country and the subregion, includ-
ing drug trafficking. There have been reports that insur-
gents and extremists in the Sahel have been involved in 
and profiting from drug trafficking in the areas they 
control. 
273. Stability in Guinea-Bissau suffered a major setback 
with the coup of 12 April 2012. The Security Council, in 
its resolution 2048 (2012), expressed deep concern about 
the possible increase in illicit drug trafficking as a result 
of the military coup and imposed a travel ban on high-
ranking military officials for “seeking to prevent the res-
toration of the constitutional order”, which activities, the 
Council noted, were supported in part through the pro-
ceeds from drug trafficking. There have been reports that 
cocaine is being trafficked by air, land and sea, without 
being intercepted by transitional authorities or security 
forces, and that hundreds of kilograms of cocaine are traf-
ficked in each transaction. 
274. The political instability in North Africa, particu-
larly Egypt, creates a breeding ground for criminal activi-
ties and drug syndicates operating in the subregion, 
enabling them to engage in drug trafficking, with the con-
sequent drug abuse and related crime continuing to pose 
a threat. 
275. There has been an overall increase in the traffick-
ing of opiates through Africa. The 10-fold increase in 
seizures of heroin in East Africa since 2009 makes that 
subregion possibly the largest hub in Africa for heroin 
trafficked onward to the European markets. Heroin, 
departing from South-West Asia, including Iran (Islamic 
Republic of), Pakistan and Turkey, and destined mainly 
for the illicit markets of Europe is increasingly transit-
ing West Africa. Increased maritime smuggling of 
Afghan opiates to Africa continues to be a problem in 
the region. 
276. Cannabis is being cultivated and seized in almost 
all countries in Africa. Nigeria remains the country with 
the largest seizures of cannabis in the region, followed by 
Egypt. There was a 10-fold increase in seizures of canna-
bis herb in Mozambique from 2010 to 2011, and a two-
fold increase in seizures in Burkina Faso from 2009 to 
2011. Morocco, along with Afghanistan, remains the big-
gest source of cannabis resin in the world, although pro-
duction in Morocco is decreasing. Spain remains the 
main entry point in Europe for cannabis resin origina-
ting in Morocco and the gateway to markets in Western 
and Central Europe. 
277. The smuggling through Africa of cocaine from 
South America destined for Europe appears to have 
diminished since 2009, while the use of containerized 
consignments and maritime shipping of cocaine through 
West Africa to Europe is on the increase. At the same 
time, because of Africa’s growing population, there is the 
potential for the demand-driven expansion of the region’s 
cocaine market. In 2012, increase in seizures of cocaine 
in North and East Africa could be observed.
278. There is an emerging market for amphetamine-
type stimulants in Africa, and at the same time those sub-
stances are being trafficked from the region to the 
countries of East and South-East Asia and Oceania. 
279. Trafficking in precursors, especially ephedrine, has 
increased in Africa, with seizures being reported by 
Benin, Botswana, Côte d’Ivoire, the Democratic Republic 
of the Congo, Guinea, Namibia, Nigeria and Zimbabwe. 
The increase in trafficking in ephedrine could indicate the 
establishment in Africa of new laboratories for the illicit 
manufacture of amphetamine-type stimulants.
280. The abuse of opioids, cannabis, amphetamine-type 
stimulants and cocaine is increasing in Africa. The preva-
lence of cannabis abuse continues to be high in Africa—
nearly double the global average—while the abuse of 
amphetamine-type stimulants, cocaine and opiates 
remains close to the global average. West and Central 
Africa continue to have a prevalence of cocaine abuse that 
is significantly higher than the global average, while the 
prevalence of abuse of cannabis and opioids in those two 
subregions remains relatively high.
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2. Regional cooperation
281. In the period under review, regional cooperation 
focused on upgrading current regional drug control 
strate gies, as well as strengthening law enforcement and 
judicial cooperation in drug trafficking cases and enhan-
cing drug demand reduction efforts.20 
282. The African Union Plan of Action on Drug Control 
for the period 2013-2017 was adopted at the fifth session 
of the African Union Conference of Ministers for Drug 
Control, held in Addis Ababa in October 2012. The Plan 
pays particular attention to capacity-building in research, 
information collection and the development of monitor-
ing systems with a view to increasing monitoring of 
changing and emerging trends, the implementation of 
evidence-based responses and the ability to assess the 
effectiveness of those responses.
283. The Heads of State and Government of the 
Economic Community of West African States (ECOWAS) 
Authority at its forty-second ordinary session, held in 
February 2013, decided to extend the period of the 
Regional Action Plan to Address the Growing Problem 
of Illicit Drug Trafficking, Organized Crime and Drug 
Abuse in West Africa (2008-2011) until 2015, in order to 
sustain the fight against drug trafficking, organized crime 
and drug abuse and to consolidate the base of financial 
support for its effective implementation.
284. In support of the implementation of the ECOWAS 
Regional Action Plan, United Nations entities and 
INTERPOL are implementing the West Africa Coast 
Initiative, which targets five post-conflict countries: Côte 
d’Ivoire, Guinea, Guinea-Bissau, Liberia and Sierra Leone. 
The transnational organized crime units established under 
that Initiative in Guinea-Bissau, Liberia and Sierra Leone 
have been active in carrying out coordinated interdiction 
activities, including in the area of drug trafficking.
285. INCB provided training to representatives of the 
national competent authorities of 12 West African coun-
tries in Addis Ababa from 17 to 21 June 2013. Organized 
in collaboration with the United Nations Interregional 
Crime and Justice Research Institute and hosted by the 
Economic Commission for Africa, the seminar was aimed 
at strengthening the capacity of the participating national 
competent authorities to ensure adequate availability of 
controlled substances for medical purposes and comply 
with their reporting obligations under the international 
 20 Lists of selected regional cooperation meetings for all regions are 
available in English on the INCB website (ww.incb.org), published in con-
junction with the annual report.
drug control treaties. The Board reiterates the importance 
of the continuation of such training in other regions, 
which contributes to improving the availability and moni-
toring of medicinal products containing controlled sub-
stances in furtherance of the implementation of the drug 
control treaties. 
3. National regulation, policy and 
action
286. In June 2013, South Africa’s Cabinet of Ministers 
approved the National Drug Master Plan (2013-2017), 
aimed at preventing and reducing alcohol and substance 
abuse and the associated social and economic conse-
quences for South African society, and which places 
emphasis on the four pillars of prevention: early inter-
vention, treatment, aftercare and reintegration. The Plan 
also calls for the creation of a nationwide database to 
track drug crimes. A new asset forfeiture unit and an 
independent police anti-corruption agency became oper-
ational in 2012.
287. In November 2012, Cabo Verde adopted its 
National Integrated Programme in the Fight against 
Drugs and Crime for the period 2012-2016. The 
Programme, developed together with UNODC, has four 
areas: (a) prevention and research; (b) improvement of 
the health, treatment and the social and professional 
reintegration of drug addicts; (c) combating illicit traf-
ficking, organized crime and terrorism; and (d) justice 
and integrity. In addition, the Government adopted a 
new decree-law in 2012 to amend money-laundering 
 legislation, which extended the powers of the financial 
intelligence unit.
288. The Government of Liberia has finalized draft 
 legislation on controlled substances and on the Liberia 
Drug Enforcement Agency. Once approved, the two legal 
instruments will provide a comprehensive set of drug-
related offences, while empowering the Agency to enforce 
those laws.
289. The President of the Sudan issued a directive in 
June 2012 to form a Supreme Council for Drug Control 
under his chairmanship as a policymaking and coordi-
nating body for drug control.
290. In April 2013, the Government of Egypt adopted a 
national action plan against drug abuse to address increas-
ing drug abuse in the country. The action plan addresses 
four aspects of the illicit drug phenomenon: (a) monitor-
ing and analysis of the drug situation in the country, 
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(b) preliminary prevention and early detection, (c) treat-
ment and rehabilitation, and (d) supply reduction. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
291. Morocco, together with Afghanistan, continues to 
be the biggest source of cannabis resin in the world, espe-
cially for the illicit markets of Western and Central 
Europe, but production in Morocco is decreasing (com-
pared with the previous national survey, for the period 
2003-2005). North Africa is the subregion with the larg-
est amounts of seizures of cannabis resin in Africa. 
According to the customs seizure data of the World 
Customs Organization, approximately 116 tons of canna-
bis resin (65 per cent of the total amount seized globally 
by customs authorities) come from Morocco. 
292. Spain is the main entry point to Europe for can-
nabis resin originating in Morocco and the gateway to 
markets in Western and Central Europe, accounting for 
34 per cent of global seizures of cannabis resin in 2011, 
while seizures by Moroccan authorities accounted for 
12 per cent. In 2011, 90 per cent of the detections made 
by Moroccan customs authorities were of shipments 
contained in lorries on ferries heading for Spain. A sig-
nificant seizure was made by Spanish customs authori-
ties at Algeciras port on 15 March 2012, when 8,362 kg 
of cannabis resin were seized in the port’s commercial 
freight sector, in a load consigned in Morocco and des-
tined for France. 
293. There are reports of numerous seizures of speed 
boats, departing from the western shores of Algeria des-
tined for France and Spain, containing cannabis resin 
believed to be trafficked to Algeria from Morocco. Major 
seizures of cannabis resin were carried out by Algerian 
authorities in March 2013 at the Algerian-Moroccan bor-
der (of cannabis resin entering Algeria) or close to the 
Algerian border with Libya (of cannabis being trafficked 
out of Algeria). According to Algerian authorities, 42 tons 
of cannabis resin were seized in the country in the first 
quarter of 2013, of which 18 tons were seized at the 
 border with Morocco. 
294. The Government of Mauritania estimates that one 
third of cannabis resin produced in Morocco transits the 
States of the Sahel region. Moroccan cannabis resin is 
trafficked to Mauritania overland via Algeria or Western 
Sahara or by ship. It is then either taken along a north-
ern route entering the northernmost area of Mali or is 
transported along the Nouakchott-Nema road, entering 
Mali through the country’s Timbuktu region. From north-
ern Mali, cannabis resin smuggling routes partly overlap 
with those serving the cocaine trade, traversing northern 
Niger or southern Algeria leading to Libya. The drugs are 
then either trafficked to Europe via the Balkans or trans-
ported to Egypt and Israel. Another route runs via Chad 
and the Sudan to the Arabian peninsula. 
295. In 2012, authorities of Egypt, one of the destination 
countries in the region for Moroccan cannabis resin, 
seized 12.3 tons of cannabis resin and 77.1 tons of canna-
bis herb. In early 2013, Egyptian authorities, in collabora-
tion with the Italian navy participating in NATO maritime 
forces, seized 32 tons of cannabis resin coming from 
Morocco by sea, destined for the Egyptian illicit market.
296. Cannabis herb continues to be widely cultivated 
in Africa and to be seized by authorities. Nigeria once 
again had the largest volume of cannabis herb seizures 
in the region (139 tons seized between July 2011 and 
April 2012), followed by Egypt (73 tons seized in 2011). 
There was a 10-fold increase in seizures of cannabis herb 
in Mozambique from 2010 (3 tons) to 2011 (32 tons), 
and the total quantity of cannabis herb seized in 
Burkina Faso doubled between 2009 (17 tons) and 2011 
(33  tons). At the same time, data on seizures made by 
customs authorities showed that in 2012 North Africa, 
followed by West Africa, was the African subregion with 
the largest seizures of cannabis. Total seizures of can-
nabis by the customs authorities in North Africa in 2012 
(24.2  tons) represented a 150 per cent increase over 
2011 (9.7 tons), while West Africa saw a 40 per cent 
decrease in seizures in 2012 (10.9 tons) compared with 
2011 (18.1 tons). 
297. Cannabis originating in Afghanistan also finds its 
way to North Africa. Egyptian authorities seized 3 tons 
of such cannabis on the shores of the Red Sea in a sin-
gle operation in 2012. That seizure reflects the attempts 
of traffickers to open new markets for cannabis from 
Afghanistan in North Africa, especially in Egypt, where 
demand is high.
298. Cannabis continues to be produced and consumed 
locally in most countries in Southern Africa, as well as 
being smuggled to Europe. Southern African criminal 
groups are increasingly engaged in the online sale of illicit 
drugs. 
299. There was an overall increase in seizures of heroin 
in Africa in the biennium 2010-2011 compared with the 
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preceding biennium. That increase was particularly steep 
in East Africa. Since 2009, there has been a fivefold 
increase in seizures of heroin in East, West and Central 
Africa. 
300. Maritime smuggling of Afghan opiates to Africa 
continues to increase, with most seizures being made at 
the sea borders. Individual seizures made at the sea bor-
ders of Africa were of large volumes. For example, 127 kg 
of heroin were seized off the coast of Benin in January 
2013, and 210 kg of heroin were seized in the United 
Republic of Tanzania in January 2012. 
301. Heroin seizures in Egypt, the country of greatest 
consumption of heroin in North Africa, have continued 
at the rate of 50-100 kg per year in recent years. 
302. Heroin is increasingly transiting West Africa, espe-
cially by means of commercial air couriers. In 2012, a 
total of 220 kg of heroin was seized in the West African 
subregion. Ghana and Nigeria, in particular, regularly 
seized medium-sized shipments of heroin. Most of the 
heroin departs from South-West Asia, including Iran 
(Islamic Republic of) and Pakistan, and is destined mainly 
for the European illicit market. 
303. Shipping containers have also been used recently 
to transport large volumes of heroin, particularly from 
Pakistan, to the countries of the Gulf of Guinea. Those 
shipments are then redistributed to the major cities of 
West Africa for their eventual transportation by air to 
European or East Asian markets. 
304. Although trafficking of heroin through East Africa 
has been taking place since the 1980s, seizures of her-
oin in East Africa since 2009 increased almost 10-fold, 
making the subregion an active hub for smuggling 
onward to further destinations. It is estimated that the 
local market in East Africa consumes at least 2.5 tons of 
heroin per year, worth some $160 million in local mar-
kets, while the total volume of heroin smuggled into the 
subregion appears to be much larger: close to 22 tons. 
Maritime transportation is becoming the preferred 
method for smuggling heroin, over air transportation 
and couriers. 
305. Seizure data for the period 2010-2012 suggests that 
heroin originating in Afghanistan is trafficked, using 
dhows and to a lesser extent container shipments, from 
Iran (Islamic Republic of) and Pakistan towards the sea 
borders of Kenya and the United Republic of Tanzania, 
for further transportation by road to South Africa. Since 
early 2010, 1,895 kg of heroin, in large consignments, 
have been seized along the Swahili coast or from dhows 
in the Indian Ocean. In 2013, more than 1 ton of heroin 
was seized in international waters off the coast of East 
Africa.
306. Kenyan authorities reported that the national ter-
ritory is also being used as a transit point for heroin 
smuggled to Europe and the United States, indicating 
India, in addition to Iran (Islamic Republic of) and 
Pakistan, as the departure point of heroin entering Kenya 
by sea and air. Nigerian authorities pointed to Ethiopia 
as one of the main transit countries for heroin arriving 
on its soil. 
307. The rapid increase in seizures in East Africa could 
be due to the increased enforcement efforts in the sub-
region that benefit from international assistance, including 
the Combined Maritime Forces, a 29-nation partnership, 
and/or to an increase in the actual flows of heroin. The 
increase in actual flows of heroin might be the more likely 
cause, given the growth in local demand and the growth 
in the use of East Africa as a transit area. 
308. Although air transportation is not as common as 
maritime shipments to smuggle heroin into East Africa, 
flights between Pakistan and East African countries that 
pass through the international airports of Dubai and 
Doha, as well as flights of local African airlines, are also 
being used to smuggle heroin. 
309. An increase in heroin seizures had been observed 
in Southern Africa until 2009, but since then there has 
been a lack of comprehensive seizure data for the sub-
region. Most heroin smuggled into Southern Africa 
enters by means of maritime transport from South-
West Asia through East Africa, including Kenya, 
Mozambique and the United Republic of Tanzania, or 
is brought in by air passengers on increasingly indirect 
routes. Heroin is then either consumed in a local mar-
ket or transported onward to Europe and elsewhere. In 
November 2012, an exceptionally large seizure of her-
oin (451 kg) was made by the Netherlands customs 
authorities from a shipment departed from South Africa, 
transiting via the Netherlands and bound for Canada. 
Development of new harbours such as the Port of 
Ngqura on the east coast (Indian Ocean) of South 
Africa and expansion of existing harbours such as the 
Port of Durban in South Africa, continue to be tested 
by traffickers as possible entry points for smuggling 
drugs into Southern Africa. 
310. Africa’s importance as a transit area for cocaine 
originating in South America destined for Europe appears 
to have declined between 2009 and 2011, while countries 
in the Caribbean region, especially the Dominican Republic, 
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are becoming more important for the trans-shipment of 
cocaine to Europe. At the same time, in Africa, given its 
increasing population, there is the potential for the 
demand-driven expansion of the local illicit cocaine mar-
ket. In 2012, cocaine seizures increased in most countries 
of North Africa, indicating the demand-driven growth of 
the market. The Egyptian Anti-Narcotics General 
Administration reported total seizures of 41 kg of cocaine 
in 2012, compared with 1.5 kg in 2011. 
311. There is an increase in seizures of cocaine in East 
Africa, where cocaine consumption has so far been limi-
ted. The United Republic of Tanzania reported seizures 
of 65 kg in 2010, a significant increase from previous 
years. Partial data show that that country’s total seizures 
in the period January-April 2011 were 85 kg, mostly of 
cocaine coming from Brazil. Mozambique intercepted 
12 shipments of cocaine totalling 65 kg at Maputo inter-
national airport in 2011; the shipments were being sent 
on drug trafficking routes going from India to Ethiopia, 
then Mozambique. Kenya carried out five interceptions 
of a total quantity of 21 kg of cocaine in 2011. Although 
East Africa is not part of a major route from South 
America, the individual seizures in 2011 suggest that 
shipping containers being used to smuggle cocaine pass 
through the subregion on their way to their destination 
of illicit markets in Europe. There has also been some 
detection of minor cocaine courier traffic, some destined 
for the Far East, through the airports of Dubai and 
Addis Ababa. 
312. Containerized consignments and maritime ship-
ping are being used more frequently to transport cocaine 
from South America to Europe via West Africa, in addi-
tion to the traditional means of air courier and postal 
shipments. Between 2005 and 2011, approximately 
5.7 tons of cocaine were seized from shipping containers 
sent from Latin America to Europe through West Africa, 
including 2.1 tons seized in 2011. More recently, in 
February 2013, 282 kg of cocaine were seized in the Port 
of Tema (Accra), Ghana, from a container originating in 
the Plurinational State of Bolivia. In a joint operation by 
the authorities of Spain, Portugal and the United Kingdom 
of Great Britain and Northern Ireland, 2 tons of cocaine 
were seized in the Atlantic ocean, about 700 miles south-
west of Cabo Verde, destined for northern Portugal and 
Spain, at the end of March 2013. 
313. The number of couriers travelling from West Africa 
to Europe has decreased. Fewer than one fifth of the 
cocaine couriers arriving in Europe are coming from West 
Africa, since more trafficking is taking place by means of 
direct air travel from Latin America and the Caribbean. 
In addition, many West African traffickers prefer to sell 
the drug locally as they do not have the necessary links 
and networks and are afraid of the risks associated with 
smuggling drugs into Europe. Moreover, there is a sub-
stantial local market for cocaine, as the number of local 
abusers of cocaine in West Africa is growing. 
(b) Psychotropic substances
314. There is an emerging market for amphetamine-
type stimulants in Africa, which is evidenced by the 
increase in diversions of precursors, seizures and meth-
amphetamine manufacture. 
315. Methamphetamine is being increasingly trafficked 
from West Africa, namely Benin, Côte d’Ivoire, the 
Gambia, Ghana, Guinea, Mali, Nigeria, Senegal and Togo, 
to East and South-East Asia, as well as Oceania. It is esti-
mated that the volume of methamphetamine trafficked 
from West Africa to Asia was about 1.5 tons in 2012. 
Benin and Nigeria have been the most prominent coun-
tries of origin for the trafficked methamphetamine, while 
it is suspected that the substance is being illicitly manu-
factured on a large scale in Côte d’Ivoire, the Gambia, 
Ghana and Mali. In 2012, the most significant seizures 
made by European customs authorities of amphetamine, 
departing from West Africa and bound for Asian coun-
tries were made in Germany (72 seizures totalling 
247 kg), France (23 seizures totalling 51 kg) and Sweden 
(4 seizures totalling 22 kg). From January to June 2013, 
about 14 kg of methamphetamine were seized at the 
Lomé international airport and 2 kg at the Cotonou inter-
national airport. Eight arrests of transiting drug couriers 
coming from Banjul, the Gambia, and en route to East 
Asia were made in London and Paris airports. In June 
2013, Belgian authorities reported the seizures of more 
than 34 kg of methamphetamine smuggled in a cargo 
shipment, which had been sent from Cotonou to Kuala 
Lumpur via Brussels and Doha.
316. Nigeria is the only country in West Africa to offi-
cially report illicit methamphetamine manufacture, as the 
country’s National Drug Law Enforcement Agency seized 
two methamphetamine laboratories in the period 2011-
2012 and three in the first half of 2013.
317. There have been reports of illicit methamphetamine 
manufacture and trafficking in East Africa, as well as 
reports of the arrest in Kenya, South Africa and the United 
Republic of Tanzania of suspects believed to be members 
of organized criminal networks involved in its manufac-
ture. Mozambique reported seizures of methamphetamine 
on the India/Ethiopia/Mozambique route. Amphetamine-
type stimulants and methaqualone (Mandrax) continue to 
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be illicitly produced in Mozambique for smuggling to 
South Africa and beyond. 
318. While South Africa has been successful in disman-
tling laboratories manufacturing methcathinone and 
methamphetamine, amphetamine-type stimulants con-
tinue to be illicitly manufactured in the country and 
exported. Reports from the South African police indicate 
trafficking of amphetamine-type stimulants by couriers 
through airports in the Gulf region to Asia and possibly 
Australia. Southern African criminal groups are increas-
ingly selling illicit drugs online, and the distributors of 
Mandrax were particularly active in 2012.
319. According to the World Customs Organization, 
customs services of countries in all African subregions 
except North Africa reported seizures of psychotropic 
substances. In Central and West Africa, there was an 
increase in cases between 2011 and 2012, both in terms 
of the number of seizures and the quantities inter-
cepted. The number of seizures in East and Southern 
Africa decreased, but the total amounts seized remained 
unchanged. 
320. The main reason for the lack of data on amphetamine- 
type stimulants in the African region is the general lack 
of awareness among authorities in the continent, where 
law enforcement efforts are geared mainly towards inter-
dicting cannabis and cocaine.
(c) Precursors
321. Trafficking in precursors continued throughout the 
region. Ephedrine seizures have been reported by several 
African countries, including Benin, Botswana, Côte 
d’Ivoire, the Democratic Republic of the Congo, Guinea, 
Namibia, Nigeria and Zimbabwe. The substance was 
seized in bulk quantities and in the form of pharmaceu-
tical preparations. The increase in trafficking in ephed-
rine could indicate the establishment of new clandestine 
laboratories in Africa. As noted above, Nigeria disman-
tled three illicit methamphetamine laboratories in the first 
half of 2013. In June 2013, Kenyan authorities reported a 
case of dismantling a clandestine laboratory for illicit 
manufacture of amphetamine-type stimulants. In the first 
half of 2013, 226 kg of ephedrine were intercepted by the 
authorities of Benin, a country in which no quantities of 
that substance had been seized in the previous nine years. 
322. The tools available to monitor the international 
flow of chemical precursors are used by few Governments 
in Africa. Therefore, the picture of the overall situation 
of precursor diversion in Africa remains incomplete. 
Governments are being requested by the Board to improve 
their existing control and reporting mechanisms for sub-
stances under international control in order to reduce 
attempts to divert chemical substances for the illicit 
manu facture of drugs.
(d) Substances not under international 
control
323. Khat (Catha edulis), a plant containing the con-
trolled substances cathinone and cathine, is cultivated and 
consumed for its stimulant effects mainly in East Africa, 
in particular in Djibouti, Ethiopia, Kenya and Somalia, as 
well as in some parts of the Middle East. Khat is legal in 
Djibouti, Ethiopia, Kenya and Somalia, but controlled in 
Eritrea, Rwanda, the Sudan and the United Republic of 
Tanzania. The abuse of khat has been increasing in cer-
tain parts of Africa. There is no comprehensive study of 
the extent of khat abuse in the region, but the individual 
reports from Djibouti, Ethiopia and Kenya indicate sub-
stantial increases in abuse of this plant-based substance 
over the past few years. For example, in Djibouti, annual 
prevalence of abuse of khat among women increased 
from 3 per cent in 1996 to 7 per cent in 2006, and dou-
bled again to almost 14 per cent by 2011.
324. Somalia is the main consumer country of khat in 
Africa, while exports to overseas markets are often des-
tined for the Ethiopian, Kenyan, Somalian and Yemeni 
expatriate communities. The substance was being exported 
to the United Kingdom until July 2013, when the United 
Kingdom Government decided to control khat as a class 
C drug under the Misuse of Drugs Act of 1971. Western 
European countries and the United States together 
accounted for 99 per cent of the total khat seizures made 
by customs authorities in 2012. Khat seized was destined 
mainly for the illicit markets in Canada, Denmark, 
Norway, Sweden and the United States. 
325. Abuse of and trafficking in tramadol, a synthetic 
opioid not under international control, continues to be a 
serious concern in a number of countries of North and 
West Africa.21 The Egyptian authorities reported that they 
seized a total amount of 620 million tablets of tramadol 
in 2012, most of which were illicit shipments in contain-
ers coming from India through the ports of Dubai and 
Yemen. Benin, Ghana, the Niger, Senegal and Togo con-
tinue to serve as transit hubs for the smuggling of tram-
adol. From November 2012 until September 2013, about 
84 tons of tramadol were seized from containers by joint 
 21 For a more detailed and global analysis of abuse of tramadol, see 
chapter II.E.3. (Global developments in the non-medical use of tramadol).
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port control units of Benin and Togo under the Container 
Control Programme of UNODC and the World Customs 
Organization. Of the 15 seizures made during that period 
by the joint port control units in Benin and Togo, in 
14  cases, the containers from which the tramadol was 
seized had been sent from India and in one case, from 
China, and all but one of those containers were destined 
for the Niger. In most cases, the drug appeared to be a 
genuine pharmaceutical product, but the amount of tram-
adol contained in the medicine was greater than the regu-
lated amounts. In certain other cases, seizures were 
carried out because the importer did not have the appro-
priate licence.
326. In 2012, most seizures of new psychoactive sub-
stances in Africa were of synthetic cannabinoids. Africa 
was the only world region where there were no reports 
of the emergence or seizure of synthetic cathinones and 
phenethylamines. 
5. Abuse and treatment
327. Although there is a lack of reliable and compara-
ble information on drug abuse in Africa, it is estimated 
that there continues to be a high annual prevalence of 
cannabis abuse (7.5 per cent of the population aged 
15-64) in the region, nearly double the global average. 
The abuse of amphetamine-type stimulants (0.9 per cent), 
cocaine (0.4 per cent) and opiates (0.3 per cent) remain 
comparable with global averages.
328. West and Central Africa, in particular, continue to 
have a relatively high annual prevalence of abuse of can-
nabis (12.4 per cent of the population aged 15-64) and 
opioids (0.4 per cent). The same subregions still have a 
significantly higher prevalence of abuse of cocaine 
(0.7  per cent, or an estimated 1.6 million people) than 
the global average (0.4 per cent), with potential to increase 
due to the expanding cocaine market in the subregions. 
329. A survey on the prevalence of psychoactive sub-
stance abuse in Cabo Verde conducted in 2012 and pub-
lished in April 2013 showed that 7.6 per cent of the Cabo 
Verdean population had used or tried an illicit drug at 
least once in their lifetime, 2.7 per cent had used an illicit 
drug in past 12 months, and 1.6 per cent had used an 
illicit drug in the past 30 days. Cannabis was the drug of 
abuse of choice (7.2 per cent lifetime prevalence rate; 
2.4  per cent reporting use in the past 12 months, and 
1.5  per cent reporting use in the past month), followed 
by cocaine (0.9 per cent, 0.2 per cent and 0.1 per cent, 
respectively) and “cocktail” (a mixture of “crack” cocaine 
and cannabis) (0.3 per cent lifetime prevalence, and 
0.1  per cent reporting use in the past 12 months). 
Amphetamine consumption is also becoming a matter of 
concern, with a lifetime prevalence rate of 0.1 per cent 
being reported. To respond to the drug abuse problem, 
drug abuse prevention initiatives are being implemented 
by the Government and civil society organizations and 
non-governmental organizations throughout the country, 
targeting local communities, families and young people. 
330. The abuse of opioids, cannabis and cocaine is 
increasing in Africa. Cocaine trafficking in West Africa 
and heroin trafficking in East Africa have caused the 
supply- driven increase of abuse of those substances in the 
respective subregions. 
331. Recent studies conducted in Kenya and Seychelles 
have revealed that heroin was the primary drug of abuse 
of those who inject drugs. Cannabis remains the most 
commonly abused substance in Nigeria, while the abuse 
of opioids in the country is also increasing.
332. Polydrug abuse, including use of cannabis com-
bined with either flunitrazepam, methaqualone or meth-
amphetamine, is also becoming a common practice in 
Africa. Authorities in Kenya and South Africa specifically 
reported this matter as a public health concern.
333. South Africa reports an increase in the abuse of 
heroin, methamphetamine and methcathinone. 
334. Within North Africa, the situation with drug abuse 
is varied. The number of drug abusers in Algeria is cur-
rently estimated at more than 300,000. According to the 
Algerian National Federation of the Fight against Drugs 
and Drug Addiction (FNLDT), the annual prevalence of 
drug abuse was 1.15 per cent in 2012. Most drug abus-
ers are aged 20-39 years. The country reported an increase 
in the abuse of cannabis, tranquillizers and sedatives. 
Morocco also reported an increase in the abuse of cocaine 
and opiates. 
335. The prevalence of HIV among injecting drug abus-
ers remains a cause of concern in Africa. In Ghana, about 
4 per cent of new HIV infections are attributed to inject-
ing drug abuse, while HIV prevalence among injecting 
drug abusers in Senegal is 9.2 per cent. In Nigeria, an 
analysis in 2010 of the modes of HIV transmission 
showed that injecting drug abuse accounted for 9 per cent 
of new infections, while the prevalence of HIV among 
injecting drug abusers was estimated at 4.2 per cent. In 
Kenya, injecting drug use is responsible for nearly 
4  per  cent of new HIV infections, and the prevalence of 
HIV among injecting drug users is about 6.2 per cent.
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336. Availability of evidence-based treatment and reha-
bilitation facilities in Africa is substantially below the 
world average. Approximately one in six problem drug 
users globally receives treatment for drug abuse disor-
ders or dependence each year. However, in Africa only 
one in 18 problem drug users has access to treatment 
services, predominantly for treatment related to canna-
bis abuse. Of particular concern in North Africa is the 
lack of community-based and gender-sensitive drug 
treatment programmes with adequate access to treatment 
facilities for women.
B. Americas
Central America and the Caribbean
1. Major developments
337. The Central America and Caribbean region con-
tinues to be exploited by organized criminal groups as a 
transit and trans-shipment route for illicit drugs heading 
to North America and Europe. It is estimated that more 
than 90 per cent of all cocaine trafficked to the United 
States is of Colombian origin and transits Mexico and the 
Central American corridor. Conversely, the flow of 
cocaine through the Caribbean region has declined sig-
nificantly in recent years as traffickers have looked for 
alternative routes, particularly along the border between 
Guatemala and Honduras. 
338. As cocaine trafficking remains the most lucrative 
source of income for organized criminal groups in Central 
America, the intensified competition in cocaine traffick-
ing has increased the level of violence in the region. The 
most recent wave of violence is in particular affecting the 
northern part of Central America: Belize, El Salvador, 
Guatemala and Honduras. The national murder rate in 
Honduras continues to be one of the highest on record. 
The areas of highest concern with regard to violence lie 
along the Honduran coast, on both sides of the 
Guatemalan/Honduran border, and in Guatemala along 
the borders with Belize and Mexico. 
339. Drug trafficking through these countries has been 
a contributory factor to high levels of violence and drug-
related corruption, as well as a further burden on already 
overloaded criminal justice systems. It is estimated that 
there are more than 900 gangs, called “maras”, with over 
70,000 members, currently active in Central America. In 
El Salvador, Guatemala and Honduras, 15 per cent of 
homicides are gang-related. 
340. The Board continues to follow closely the drug 
 policy discussion in the region, which includes propos-
als to establish regulatory regimes for substances under 
international control that are not fully in line with the 
international drug control treaties. Proponents assert that 
such policy changes would contribute to reducing crime, 
violence and corruption in the region. The Board wishes 
to draw attention to the fact that some of those propos-
als, if enacted, would contravene the text, objective and 
spirit of the treaties (namely, to preserve the health and 
well-being of mankind), to which all States of the region 
are parties. Those proposals would have a serious impact 
on the health of their populations, particularly young 
people, at a time when there is increasing scientific evi-
dence of the harm caused by drug use and abuse, and 
could further contribute to illegal markets, crime, traf-
ficking, corruption and violence, as well as transmit 
ambiguous messages regarding the health dangers of drug 
use and abuse. 
341. Notwithstanding action taken by Governments in 
the region to tackle the diversion of precursor chemicals, 
the region continues to be used for the trafficking of these 
materials, perhaps as an alternative route in the face of 
strengthened controls in Mexico.
2. Regional cooperation
342. Central America and the Caribbean remains a hub 
for drug trafficking, thus making it an important area for 
regional cooperation. UNODC works with Governments 
of the region. During the past year, regional cooperation 
focused on law enforcement cooperation, tackling drug 
trafficking, preventing the diversion of precursors and 
reducing drug demand. 
343. Operation Lionfish, led by INTERPOL and aimed 
at maritime trafficking of drugs and illicit firearms by 
organized criminal groups across Central America and 
the Caribbean, was carried out from 27 May to 10 June 
2013. During the operation, nearly 30 tons of cocaine, 
heroin and cannabis, with an estimated value of $822 mil-
lion, were seized. The operation involved 34 countries 
and territories in the region and also resulted in 142 
arrests, as well as the seizure of 15 vessels, eight tons of 
chemical precursors, 42 guns and approximately $170,000 
in cash. 
344. Another operation, under the code name 
“Icebreaker”, led by INTERPOL and supported by the 
Board and the World Customs Organization, took place 
during October 2012. The operation focused on combat-
ing methamphetamine manufacture and smuggling across 
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the Americas, and resulted in the seizure of more than 
360 tons of chemicals, 200 kg of methamphetamine, 
cocaine and lysergic acid diethylamide (LSD), and $2 mil-
lion in cash. Four illicit methamphetamine laboratories 
were also dismantled. Eleven countries in the region par-
ticipated in the operation, which led to the launching of 
35 investigations across the region.
345. On 1 November 2012, UNODC and the Government 
of Panama launched the Regional Anti-Corruption 
Academy, with a view to enhancing capacities and increas-
ing cooperation to fight corruption (including drug-
related corruption) in the region.
3. National legislation, policy and 
action
346. In Belize, the Domestic Banks and Financial 
Institutions Act was approved and enacted on 1 January 
2013. The Act (a) enhances the regulatory and supervi-
sory framework of domestic banks and financial institu-
tions so that they can comply with international standards 
and best practices set by the Basel Committee on Banking 
Supervision; and (b) improves compliance and efficiency 
by setting administrative penalties for non-compliance 
with the requirements of the Act. Furthermore, Belize 
continues to implement its national anti-drug strategy for 
the period 2011-2014, which was updated in 2011. 
347. El Salvador continues to implement a national anti-
drug strategy, covering the period 2011 to 2015, which 
tackles demand reduction and control of drugs and drug-
related offences. The principal aim of the strategy is to 
reduce the abuse of drugs and to combat illicit drug traf-
ficking and drug-related crime. 
348. In June 2013, the Inter-institutional Commission 
for the Revision of National Legislation on Drug 
Trafficking of Honduras presented to the President of the 
country a proposal for a new law on national security 
protection in the fight against drug trafficking and related 
crimes. The proposal provides, inter alia, for the classi-
fication of drug-related offences, including stricter pen-
alties for serious drug trafficking offences, defines the 
substances to be controlled, including those under inter-
national control, and provides, inter alia, for the extra-
dition of Honduran nationals for drug trafficking 
activities.
349. In August 2013, the Government of Panama signed 
into law amendments to Law 23 on drug-related crimes. 
The amendments provide for the custody and manage-
ment of seized drug-related assets and property during 
the conduct of the judicial proceedings and, once a judge-
ment for their confiscation has been made, for their trans-
fer to the National Commission for the Study and 
Prevention of Drug-related Crimes (CONAPRED), which 
would adjudicate them to the institutions that are mem-
bers of the Commission or proceed to their disposal 
through public auction. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
350. Jamaica and Saint Vincent and the Grenadines 
continued to be major sources of cannabis. The quanti-
ties of cannabis produced in those two countries not only 
meet the demand in the region but also are trafficked to 
international markets. Jamaica reportedly continues to 
be the largest Caribbean supplier of cannabis to the 
United States; however, some amounts of the drug are 
also smuggled to Belgium, Germany, the Netherlands 
and the United Kingdom of Great Britain and Northern 
Ireland. Based on an analysis of individual cannabis sei-
zure data covering the period from 2001 to 2012, Jamaica 
was listed among the 10 countries most frequently men-
tioned as countries of provenance. Another important 
source of cannabis in the region is Costa Rica, where 
authorities seized 1,214,056 cannabis plants in the first 
half of 2013.
351. Shipments of cocaine to Costa Rica have increased 
in recent years. While an average of five tons were seized 
annually between 2000 and 2005, those amounts 
increased to an average of 20 tons per year between 2006 
and 2010. That trend has been further confirmed, with 
total seizures of almost 15 tons during 2012. It is esti-
mated that nearly 80 per cent of cocaine reaches Costa 
Rica by air. In addition, it has been identified as a major 
transit country of cocaine for further smuggling to 
Europe by couriers on commercial flights. This route 
seems to have been used to a lesser extent in more recent 
times. This development is perhaps related to the increas-
ing role of the Dominican Republic as a transit country 
for cocaine smuggled on commercial air flights to Europe. 
Maritime vessels in transit through the Caribbean are 
another important means of transport for cocaine des-
tined for Europe. 
352. According to Salvadorian authorities, only small 
quantities of cocaine transit their country, mostly because 
the country has no Atlantic coast. 
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353. Increased air trafficking from the border area 
between Colombia and the Bolivarian Republic of 
Venezuela to airstrips in central Honduras has been 
reported, in parallel with a decrease in activity along more 
established routes via Haiti and the Dominican Republic. 
In terms of maritime trafficking, remote coastal areas of 
Honduras and parts of northern Nicaragua are also used. 
In Nicaragua, most cocaine is seized in remote areas 
along the Atlantic coast. In 2012, the Nicaraguan author-
ities seized 9.3 tons of cocaine. In addition, 986 kg of can-
nabis, 4 kg of crack cocaine and 13 kg of heroin were 
seized, and 43,252 cannabis plants were destroyed.
354. There has nevertheless been some disruption in the 
chain of supply of cocaine, as a result of law enforcement 
interventions and inter-cartel violence in Central America, 
with seizures moving closer to the source in South America. 
355. Guatemala continues to grow opium poppy des-
tined for the domestic market but also for other coun-
tries in the region. While there is a lack of precise data 
concerning the areas where opium poppy is cultivated, 
the eradicated areas of opium poppy plant tripled from 
less than 500 ha in 2007 to over 1,500 ha in 2011. 
356. Seizures of heroin in the Caribbean remained  stable 
between 2010 and 2011. In terms of seizure weight, the 
Dominican Republic has accounted for over 75  per  cent 
of reported heroin seizures in the Caribbean since 2006. 
Forty-two kg were seized in the country during 2011, 
compared with 30 kg in 2010. A similar amount of  heroin 
(39 kg) was seized in the Dominican Republic in 2012.
(b) Psychotropic substances
357. The manufacture of amphetamine-type stimulants 
in the region, which was unknown several years ago, has 
become an issue of serious concern. Belize, Guatemala 
and Nicaragua have reported such manufacture since 
2009. In particular, large-scale manufacture of metham-
phetamine has been reported by Guatemala, which dis-
mantled 13 laboratories manufacturing the substance 
between January and September 2012. Photographic evi-
dence from those laboratories confirms the very signifi-
cant size of the illicit operations. This trend was confirmed 
by the seizure of 15 large-scale methamphetamine labo-
ratories in Guatemala during 2013.
(c) Precursors
358. Despite the strengthened controls over precursors of 
amphetamine-type stimulants in the region, Central 
America continues to be affected by trafficking in precur-
sors, particularly of non-controlled chemical substances, 
such as pre-precursors and made-to-order chemicals, which 
are not controlled under the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988. This poses new challenges to regula-
tory and law enforcement authorities, which have to iden-
tify which chemicals are being used in the production 
processes. For example, in 2012 Mexican authorities seized 
195 tons of methylamine, a substance not under interna-
tional control which is used in the illicit manufacture of 
methamphetamine, bound for Guatemala and Nicaragua.
359. In 2012, Guatemala seized large amounts of chemi-
cals. The country remains an important transit point for 
pseudoephedrine shipments originating in Bangladesh in the 
form of pharmaceutical preparations and in India in bulk 
form. Honduras also reported the seizure and destruction of 
over 22 tons of pseudoephedrine of unknown origin.
360. In 2013, Guatemala reported, via PICS, a seizure 
of 240 litres of methyl ethyl ketone and 26,000 litres of 
one non-controlled substance, both of which are used as 
solvents for illicit drug manufacture, and 16,000 kg of 
ethyl phenylacetate destined for the illicit manufacture of 
methamphetamine. 
361. Large quantities of precursor chemicals used in the 
production of methamphetamine are believed to transit 
Belize on the way to Mexico. In 2012, over 156 tons of 
such chemicals were seized and destroyed by Belizean 
authorities. 
362. Another related challenge that authorities, par-
ticularly in Guatemala, are facing is the disposal of 
seized chemicals, as there is a lack of facilities to prop-
erly store these chemicals and the infrastructure to dis-
pose such materials is insufficient. In that country, large 
amounts of precursor chemicals are awaiting disposal, 
which poses a high risk to the environment. In 2013, 
15 clandestine laboratories were dismantled. The Board 
once again encourages the international community 
and interested Governments to support the countries 
of the region in effectively dealing with and resolving 
that serious issue. In addition, UNODC published the 
Guidelines for Safe Handling and Disposal of Chemicals 
Used in the Illicit Manufacture of Drugs, which provides 
information on methods for the safe handling and dis-
posal of chemicals used in the illicit manufacture of 
different drugs.
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(d) Substances not under international 
control
363. Costa Rica and Panama are among the 70 coun-
tries that reported the appearance of new psychoactive 
substances, a growing trend which poses challenges to the 
regulatory and enforcement authorities and carries seri-
ous health consequences, as the effects of such substances 
on the human body are not fully understood or known. 
In 2012, Costa Rica reported N-benzylpiperazine (BZP) 
and 1-(3-trifluoromethylphenyl)piperazine (TFMPP). 
5. Abuse and treatment
364. In recent years, trends and patterns related to 
cannabis abuse in the Central America and the 
Caribbean region have remained relatively stable. The 
annual average prevalence rate of cannabis has been 
estimated at 2.6  per  cent in Central America and 
2.8  per  cent in the Caribbean. In 12 Caribbean coun-
tries (Antigua and Barbuda, Barbados, Dominica, 
Grenada, Guyana, Haiti, Jamaica, Saint Kitts and Nevis, 
Saint Lucia, Saint Vincent and the Grenadines, Suriname 
and Trinidad and Tobago), the average age at which stu-
dents reported using cannabis for the first time was 
around 13 years of age. 
365. As regards the use of opioids and “ecstasy” in 
Central America, UNODC has estimated the annual 
prevalence rate at 0.2  per  cent and 0.1  per  cent, respec-
tively, which is well below the global average. 
366. The estimated average prevalence rate for the abuse 
of cocaine in Central America and the Caribbean, at 
0.6 per cent and 0.7 per cent, respectively, remains higher 
than the global average.
367. In 2012 in Costa Rica, a national survey of drug 
use among secondary students was carried out to deter-
mine levels of drug abuse among students attending pub-
lic and private high schools. In total, 5,508 students from 
seven provinces were interviewed. According to the sur-
vey, the average age of initiation of cannabis use was 
14.3 years. The results of the survey indicate a significant 
increase in cannabis use, from 6.8  per  cent in 2009 to 
9.7 per  cent in 2012.
368. In comparison with the global average, the region 
continues to experience high levels of abuse of 
amphetamine- type stimulants, with an estimated annual 
prevalence rate of 1.3  per  cent. In particular, the abuse 
of pharmaceutical preparations containing stimulants is 
widespread. At the same time, significant abuse of 
sedatives in the form of prescription medicines has been 
reported by Costa Rica and El Salvador. For example, 
according to UNODC, El Salvador ranks ninth in the 
world, with an annual prevalence rate for non-medical 
use of tranquillizers and sedatives among the general 
population of 7.8  per  cent.
North America
1. Major developments
369. Although prevalence rates for abuse of most illicit 
drugs in North America have remained relatively  stable, 
they continue to significantly exceed global averages. 
The region’s higher rates of drug abuse have had signif-
icant public health implications. According to informa-
tion provided by Governments in the region, there were 
almost 48,000 drug-related deaths in North America in 
2011, representing a mortality rate of 155.8 per million 
inhabitants aged 15-64, the highest rate in the world.
370. In August 2013, the United States Justice 
Department issued a memorandum addressed to United 
States attorneys clarifying its position with respect to the 
adoption of laws in a number of the country’s states to 
allow the use of cannabis for “medical” or recreational 
purposes. The Attorney General had pledged to clarify 
his Department’s position with respect to that issue, in 
particular in the aftermath of ballot initiatives approved 
by voters in the states of Colorado and Washington in 
November 2012, legalizing cannabis use for recreational 
purposes. The Controlled Substances Act, however, con-
tinues to prohibit cannabis production, trafficking and 
possession, listing cannabis in its Schedule I, which con-
tains substances having a high potential for abuse and no 
scientifically proven medical value and for which there is 
a lack of acceptance that the drug can be safely used 
under medical supervision.
371. In the Federal District of Mexico, draft bills pro-
viding for the legalization of cannabis are currently being 
prepared for consideration by the Legislative Assembly. 
Pursuant to the forum on drug policy held by the 
Legislative Assembly of the Federal District in early 
September 2013, the President of the Assembly stated that 
the Assembly would work on a new legislation focusing 
on treatment, prevention, reduction of risk and human 
rights with respect to use and abuse of licit and illicit sub-
stances. The forum also clearly identified the legal limits 
(international conventions and federal law) which any 
possible new law must observe.
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372. In March 2013, the Government of Canada released 
its first national strategy to address the widespread prob-
lem of prescription drug abuse. The strategy was devel-
oped by the Canadian Centre on Substance Abuse in 
conjunction with various stakeholders at the federal and 
provincial levels, as well as with aboriginal groups. 
2. Regional cooperation
373. Regional cooperation among the countries in the 
region is extensive and generally considered to be effec-
tive, including cooperation in the form of intelligence-
sharing, joint law enforcement activities and border 
control initiatives. A list of regional cooperation meetings 
for North America is available in English in electronic 
form on the INCB website (www.incb.org), published in 
conjunction with the annual report.
3. National legislation, policy and 
action
374. In the United States, 21 states and the District of 
Columbia have now enacted legislation allowing for the 
establishment of medical cannabis programmes, with the 
state Governors of Illinois, Maryland and New Hampshire 
having signed implementing legislation into law in 2013. 
In May 2013, the Governor of the State of Maryland 
signed a bill allowing the use of medical cannabis. The 
legislation creates a 12-member independent panel to 
administer a so-called “compassionate use” programme 
for seriously ill patients for whom traditional treatment 
options are deemed insufficient. Only state-regulated 
research programmes tied to university medical centres 
are eligible. The appointed panel will set criteria for 
patient participation in the programme and will assume 
responsibility for licensing cultivators. Patients will not 
be entitled to grow cannabis themselves or to purchase it 
directly from private dispensaries licensed by the State. 
In June 2013, the Governor of New Hampshire signed a 
bill into law establishing a process to set up “alternative 
treatment centers”, which will dispense cannabis for quali-
fied patients with “chronic or terminal diseases” or “debil-
itating medical conditions”. Under the process, the 
cultivation of cannabis for  personal use will remain ille-
gal. In August 2013, the Governor of Illinois approved a 
bill to create a four-year, state-regulated pilot programme 
through which cannabis will be distributed to eligible 
patients through a network of 60 licensed dispensaries, 
which must comply with strict rules established by the 
state government. The law specifies 35 eligible medical 
conditions, such as muscular dystrophy, cancer, multiple 
sclerosis and HIV/AIDS. Cultivation by patients or 
caregivers will remain forbidden. The Board reminds all 
governments in jurisdictions having established “medical 
cannabis” programmes, or considering doing so, that the 
Single Convention on Narcotic Drugs of 1961 sets out 
specific requirements for the establishment, administra-
tion and monitoring of such programmes and notes that 
many existing programmes are not in line with the pro-
visions of the treaty. 
375. In response to the recent referendums in the states 
of Washington and Colorado, the Deputy United States 
Attorney General issued a memorandum to United States 
attorneys with respect to federal law enforcement activi-
ties, including civil enforcement and criminal investiga-
tions and prosecutions, concerning cannabis in all states. 
The memorandum reaffirms the determination made by 
Congress that cannabis is a dangerous drug and that the 
illegal distribution and sale of that substance is a serious 
crime and reaffirms the commitment of the Department 
of Justice to enforcing federal law accordingly. The memo-
randum sets forth “enforcement priorities”, which aim to 
prevent the distribution of cannabis to minors, the use of 
cannabis sales revenues by organized crime groups and 
cartels, the diversion of cannabis from states where it is 
legal to states where it is not, violence and the use of fire-
arms in the cultivation and distribution of cannabis, 
drugged driving, the growing of cannabis on public land 
and the possession or consumption of cannabis on fede-
ral property. The memorandum urges states having 
authorized the use of cannabis in any form, to ensure the 
establishment of an effective regulatory and enforcement 
framework that addresses threats to public safety, public 
health and law enforcement associated with this use and 
ensures that federal enforcement priorities are not under-
mined. The Board wishes to reiterate that the 1961 
Convention limits the use of cannabis to medical and 
scien tific purposes within the strict conditions set forth 
in the Convention. 
376. In June 2013, the Government of Canada intro-
duced Bill C-65, entitled the Respect for Communities 
Act. The bill aims to create a legal framework that would 
be applicable to requests for exemptions under the 
Controlled Drugs and Substances Act involving activities 
with controlled substances, including the establishment 
and operation of supervised drug injection sites. Under 
current legislation, the Minister of Health has the author-
ity to grant an exemption to undertake activities using 
controlled substances for medical or scientific purposes, 
or in the public interest. Bill C-56 would require appli-
cations for activities involving controlled substances at a 
supervised drug consumption site in Canada to be 
accompanied by evidence of extensive consultations, 
including stakeholder views, before such applications 
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could be considered by the Minister. In July 2013, the 
Toronto Board of Health adopted a decision to prepare 
a submission to the federal Government expressing its 
opposition to Bill C-65 and recommending the develop-
ment of a simplified application process for the establish-
ment of supervised injection sites. The Board of Health 
also decided to solicit the financial support of the pro-
vincial government of Ontario for the integration of 
supervised injection services, on a pilot basis, into exist-
ing  provincially-funded clinical health services for peo-
ple in Toronto who use drugs. INCB wishes to reiterate 
its position that the establishment and operation of drug 
consumption facilities is inconsistent with the provisions 
of the drug control conventions.22
377. In April 2013, the United States Government 
released its 2013 National Drug Control Strategy, which 
aims to reduce drug abuse and its consequences by balan-
cing public health and public safety considerations. The 
Strategy contains a broad set of measures to address drug 
abuse, grouped in the following categories: prevention, 
early intervention in health care; the integration of sub-
stance abuse treatment into the health-care system; 
addressing the link between drug abuse, crime, delin-
quency and incarceration; the disruption of domestic 
drug trafficking and production; the strengthening of 
international partnerships; and the improvement of infor-
mation systems for analysis, assessment and local man-
agement. The Strategy also sets two national goals to be 
attained by 2015, namely, the curtailing of illicit drug 
 consumption and the improvement of public health and 
public safety by reducing the consequences of drug abuse. 
The Office of National Drug Control Policy also released 
its 2013 National Southwest Border Counternarcotics 
Strategy, which measures progress made in strengthening 
law enforcement efforts along the south-west border and 
fostering increased cooperation with Mexican authorities. 
The Strategy sets strategic goals and objectives related to 
information-sharing, control measures at ports of entry, 
investigations and prosecutions, money-laundering and 
smuggling of weapons and establishes indicators for 
measuring progress. 
378. Through the release in March 2013 of its first 
national strategy on the topic, entitled First Do No 
Harm: Responding to Canada’s Prescription Drug Crisis, 
the Government of Canada hopes to address the wide-
spread abuse of prescription drugs in the country. The 
strategy is the result of widespread consultations and 
cooperation between various stakeholders led by the 
Canadian Centre on Substance Abuse. The document 
 22 See the Report of the International Narcotics Control Board for 2006 
(E/INCB/2006/1), paras. 175-179.
lays out a comprehensive 10-year strategy centred on 
five streams of action: prevention, education, treatment, 
monitoring and surveillance, and enforcement. The 
strategy addresses prescription drugs that have legal 
 status and therapeutic uses, together with a high poten-
tial for harm, including opioid pain relievers, stimulants, 
 sedative-hypnotics and medications used to treat addic-
tion. In order to stem abuse of those substances, the 
strategy addresses the diversion of licit substances from 
the authorized supply chain; inappropriate prescription 
and dispensing behaviour; and addiction, mental health, 
co-morbidities, concurrent disorders and pain. In addi-
tion, special emphasis is placed on environmental and 
social conditions that increase risk among women, 
youth, seniors, aboriginal populations and newborns. 
Provision is also made for the adoption of measures to 
address prescription drug abuse in geographically 
remote, rural and isolated communities. 
379. In August 2013, the United States Attorney General 
announced plans to reform the criminal justice system 
with the stated objective of ensuring a more equitable and 
more efficient enforcement of federal laws. The five goals 
identified by the Department of Justice in the implemen-
tation of the reform were the following: to ensure that 
finite resources are devoted to the most important law 
enforcement priorities; to promote fair enforcement of 
the laws; to ensure proportionate punishment for low-
level non-violent offences; to bolster prevention and 
social reinsertion efforts and reduce recidivism and; to 
strengthen protection for vulnerable populations. Under 
the proposed reform, individuals having committed “low-
level, non-violent drug offences” will no longer be charged 
under criminal provisions that impose minimum manda-
tory sentences so long as their conduct was not violent 
and did not involve the use of a weapon or sales to minors 
and the individual is not the leader of a criminal organ-
ization, has no ties to criminal gangs or drug cartels and 
has “no significant criminal history”.
380. The Government of Canada has continued to 
implement the transition from its existing medical can-
nabis programme, the Marihuana Medical Access 
Program, to the Marihuana for Medical Purposes 
Regulations, a new medical cannabis scheme aimed at 
reducing the risk of diversion into illicit channels, increas-
ing public security and improving access by programme 
participants to medical cannabis. The new measures gov-
erning the production and distribution of medical can-
nabis include the phasing-out of cultivation for personal 
consumption and the strengthening of regulatory require-
ments applicable to licensed medical cannabis producers. 
The two programmes will operate concurrently until 
March 2014, when the Marihuana Medical Access 
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Program will end. The Board wishes to acknowledge the 
positive changes that have been made to the medical can-
nabis access scheme in Canada, in particular the phasing- 
out of  personal cultivation, and the adoption of other 
measures aimed at preventing diversion.
381. Legislative and administrative measures to address 
the public health threat posed by the abuse of synthetic 
cannabinoids and cathinones in the United States have 
gained momentum at the state and federal levels. In June 
2013, a bill banning the sale and possession of all syn-
thetic cannabinoids in the State of Maine was adopted by 
the state legislature. The sale and possession of cathinones 
has been illegal in the State since 2011. Also in June, the 
New York State Senate passed a bill criminalizing the sale 
and possession of synthetic cannabinoids and cathinones 
(sold as “bath salts”). While the sale of cathinones has 
been illegal in the State of New York since 2011, posses-
sion had remained legal. The penalties set out in the bill 
for possession of synthetic cannabinoids and cathinones 
would be similar to those for possession of cannabis and 
methamphetamines, respectively. The legislation also 
establishes the Statewide Synthetic Cannabinoid and 
Substituted Cathinone Surrender Program, which would 
allow individuals to turn in any products containing those 
substances at designated disposal points for a 90-day period 
following the law’s entry into force. A database of trade 
names, physical descriptions, brand names and images of 
products known to contain those substances would be 
created to inform retailers, members of the general pub-
lic and law enforcement officials. 
382. In response to the continued threat posed by new 
psychoactive substances, the United States Drug 
Enforcement Administration has made further use of its 
temporary and emergency scheduling procedures to 
impose strict control measures on new substances of 
abuse. In April 2013, the Administration published a final 
rule to  permanently schedule 3,4-methylenedioxy-N-
methylcathinone (methylone) under schedule I of the 
Controlled Substances Act. In May 2013, the 
Administration issued a final order to temporarily sched-
ule the three synthetic cannabinoids UR-144, XLR-11, 
and AKB-48 under schedule I of the Controlled Substances 
Act for a two-year  period. The final order was based on 
the finding that the placement of those substances and 
their salts, isomers and the salts of isomers was neces-
sary to avoid an imminent threat to public safety. As a 
result of the order, the criminal, civil and administrative 
penalties provided under the Controlled Substances Act, 
as well as the regulatory controls for schedule I sub-
stances, will be applicable to the manufacture, distribu-
tion, possession, importation and exportation of those 
three substances. 
383. In the United States, the Drug Enforcement 
Administration has continued to take action against retail 
pharmacy chains for violations of the provisions of the 
Controlled Substances Act, which imposes civil mone-
tary penalties for violations of the Act’s record-keeping 
and dispensing requirements. Following civil claims 
brought against them under the Act, two of the country’s 
biggest pharmacy chains agreed to multi-million dollar 
out-of-court settlements, one of which being the largest 
such settlement in the history of the Drug Enforcement 
Administration. 
384. In early 2013, Public Safety Canada released a 
report entitled “Building a safe and resilient Canada: pre-
scription drug return initiatives in Canada”, which exam-
ines existing prescription drug return programmes 
already in operation in Canada at the provincial and 
local levels with a view to providing a reference docu-
ment for best practices for the establishment of similar 
programmes. 
385. In Canada and the United States, prescription drug 
“take-back” initiatives were held in order to reduce the 
supply of unused prescription drugs in households, which 
has been acknowledged to constitute the main source of 
these drugs in cases of diversion, trafficking and abuse. 
In the United States, the Drug Enforcement Administration 
organized two national prescription drug “take-back” 
days in April 2013 and in October 2013, which resulted 
in the collection of 371 tons of unused prescription drugs. 
In total, the Drug Enforcement Administration has col-
lected more than 1,409 tons of prescription drugs in six 
such “take-back” days. In Canada, the first ever National 
Prescription Drug Drop-off Day was held in May 2013, 
building upon the success of previous prescription drug 
return initiatives at the municipal and regional levels. 
According to figures provided by the Government, a total 
of 2 tons of unused prescription drugs were collected. The 
Board encourages Governments in the region to continue 
to implement initiatives aimed at reducing the availabil-
ity of prescription drugs that are no longer needed and 
liable to abuse and to raise awareness among their popu-
lations of the health risks associated with prescription 
drug abuse. In that regard, the Board would like to draw 
the attention of Governments to the special topic on pre-
scription drug disposal initiatives contained in chapter II 
of the present report.
386. In January 2013, the United States Food and 
Drug Administration issued a document entitled 
“Guidance for industry: abuse-deterrent opioids— 
evaluation and labelling”, to advise the pharmaceutical 
industry on scien tific methodologies to be used to test 
and evaluate new opioid drug formulations having 
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abuse-deterrent properties, and advise on the formula-
tion of appropriate labelling claims based on the spe-
cific tamper-resistant properties of each formulation. In 
April 2013, the United States Food and Drug 
Administration approved “abuse-deterrent labelling” for 
OxyContin, which indicates the tamper-proof physical 
and chemical properties of the reformulated substance, 
making it more difficult to crush, break or dissolve, ren-
dering intravenous and intranasal abuse more difficult. 
The Food and Drug Administration also indicated that, 
given the known abuse associated with the original for-
mulation of OxyContin, it would not approve any new 
generic drugs based on the original formulation. In 
Canada, the Minister of Health refused a request by 
provincial health authorities to withhold approval of 
OxyContin generics due to their potential for abuse, 
because the law did not permit approval to be withheld 
on the basis of misuse if the drug was otherwise con-
sidered safe and effective for its recommended use. In 
the light of the difference in approach being taken in 
the two countries and the possible risk of diversion it 
created, the Federal Minister of Health of Canada 
emphasized the need for Canada and the United States 
to work together to develop joint evidence-based guid-
ance on abuse deterrence that could be used on both 
sides of the border.
387. Through its participation in Operation Pangea 
VI, the largest Internet-based action of its kind, the 
United States Food and Drug Administration targeted 
websites selling unapproved and potentially dangerous 
prescription medicines that could pose significant 
threats to public health. As a result, the Administration’s 
Office of Criminal Investigations seized and shut down 
1,677 illegal pharmacy websites. As part of its work 
against illegal Internet pharmacies, the Food and Drug 
Administration has added a feature to its website allow-
ing members of the public to report suspicious Internet 
pharmacies and has issued guidelines on how to iden-
tify legitimate online pharmacies. 
388. In June 2013, the Canadian Community 
Epidemiology Network on Drug Use issued a “drug alert” 
regarding illicit fentanyl analogues being produced in 
clandestine laboratories in Canada and the United States. 
The alert warns that illicit fentanyl analogues have been 
appearing in several cities in both countries, in pill and 
powder form, and are being sold as oxycodone, heroin 
and other substances, leading to increased potential for 
overdose. The substances were first reported by police in 
the province of Quebec in May 2013 but they have since 
spread to other parts of the country. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
389. North America accounts for roughly half of all can-
nabis seized globally, primarily due to large quantities 
seized in the United States and Mexico. According to sei-
zure information submitted by Governments in the region 
to the Board, however, cannabis seizures in North 
America have continued to decline. In the United States, 
the amount of cannabis reported seized in 2012 was over 
1,756 tons, compared with 1,834 tons reported for 2011. 
In Canada and Mexico, the decrease was more significant. 
Cannabis herb seizures in Mexico fell from nearly 
1,796  tons in 2011 to under 1,300 tons in 2012, while in 
Canada, seizures decreased by more than 50 tons, from 
111.4 tons in 2011 to 61.1 tons in 2012. 
390. Owing to differences in consumption preferences, 
cannabis is consumed mainly in the form of cannabis 
herb in the Americas. In 2011, total seizures of cannabis 
herb in the region were more than 800 times greater than 
seizures of cannabis resin. The Americas accounted for 
only 0.5  per  cent of global seizures of cannabis resin in 
2011, with Canada accounting for the majority of those 
seizures. In the United States, over 443 kilograms (kg) of 
cannabis resin were seized in 2012, representing an 
increase of 268  per  cent compared with the 165.3  kg 
reported seized in 2011. In Canada, the amount of can-
nabis resin seized declined from 4.75  tons in 2011 to 
3.2  tons in 2012.
391. Cocaine manufactured in South America contin-
ues to be smuggled into North America via transit points 
in Central America and the Caribbean. Cocaine seizures 
for the region in 2012 present a mixed picture, with the 
United States and Canada reporting significant increases 
in seizures and Mexico showing a steep drop. The amount 
of cocaine seized in the United States increased from 
58.23 tons in 2011 to 67.79 tons in 2012, while in Canada, 
cocaine seizures rose sharply, from 4.6 kg in 2011 to just 
under 1.7  tons in 2012. In Mexico, however, cocaine sei-
zures fell from 9.46 tons in 2011 to just over 3.39 tons in 
2012.
392. Mexico also reported a significant drop in heroin 
seizures, from 685.5  kg in 2011 to 214.9  kg in 2012. In 
the United States, heroin seizures increased from 2.9 tons 
in 2011 to just over 3.3 tons in 2012. Over the same period, 
heroin seizures in Canada also increased from 39.4 kg to 
195.6 kg. Canada remains the only country in the Americas 
in which heroin is sourced primarily from Asia (mostly 
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Afghanistan) rather than from other countries on the con-
tinent, while heroin abused in the United States is pro-
duced mostly in Colombia and Mexico. In fact, the Heroin 
Domestic Monitor Program of the United States Drug 
Enforcement Administration revealed that 50  per  cent of 
the heroin samples analysed by the Administration in 2011 
originated in South America, 46  per  cent in Mexico and 
only 4 per cent in South-West Asia. 
393. While seizures of opium in 2012 remained rela-
tively stable in Mexico, increasing slightly from nearly 
1,452  kg to just over 1,471 kg, opium seizures in the 
United States plummeted from 48.5  kg in 2011 to only 
0.07 kg in 2012, while Canada registered a strong increase 
in seizures, up from 87.7  kg reported seized in 2011 to 
388.3 kg in 2012. 
(b) Psychotropic substances
394. Although States are not required to submit infor-
mation relative to seizures of psychotropic substances to 
the Board, information is available from other sources. 
According to figures for 2012 released by the World 
Customs Organization, the number of incidents of sei-
zures of psychotropic substances in North America, as 
reported by customs agencies, has remained relatively sta-
ble, dropping slightly from 2,986 in 2011 to 2,947 in 2012. 
During that period, however, the quantity of psychotropic 
substances seized by customs authorities more than tri-
pled, from 10.5  tons in 2011 to over 34.6  tons in 2012. 
395. Although North America has accounted for just 
1 per cent of global amphetamine seized in recent years 
(2005-2011), the seizures by North American customs 
authorities were equivalent to 50 per cent of all amphet-
amine seizures reported by customs agencies worldwide 
in 2012, owing in great part to the large seizures in the 
United States. According to the World Customs 
Organization, the source country of most of the 
amphetamine seized in the United States was Mexico, 
and most amphetamine was smuggled into the country 
by vehicle. 
396. Methamphetamine seizures in Mexico continued 
to increase, reaching 33.1  tons in 2012, after more than 
doubling from 13  tons in 2010 to 31  tons in 2011. By 
2011, Mexico was reporting the world’s largest total meth-
amphetamine seizures, ahead of the United States and 
China. Mexico has been identified also by United States 
customs officials as the primary country of origin of 
methamphetamine seized, with roughly 80 per cent of the 
substance seized by United States customs being manu-
factured in Mexico. 
397. Customs officials in the United States reported sei-
zures of 1.18  tons of MDMA in 2012, primarily manu-
factured in Mexico and Canada, also there are indications 
that domestic manufacturing still accounts for a signifi-
cant proportion of the MDMA abused in the United 
States. Seizures of certain chemicals in Mexico frequently 
used in the manufacture of MDMA suggest that the drug 
may be being manufactured in Mexico to a greater extent 
than previously believed. 
398. In addition to the abuse of psychotropic sub-
stances, the Canadian Centre on Substance Abuse has 
drawn attention to the fact that methylphenidate prepa-
rations used to treat Attention Deficit Hyperactivity 
Disorder are increasingly being abused by students in 
North America to boost concentration and improve 
academic performance.
(c) Precursors
399. The use of non-scheduled esters of phenylacetic 
acid remain the predominate starting material in large-
scale illicit manufacture of methamphetamine in Mexico, 
where the substances have been under national control 
since November 2009. While ephedrines continue to be 
seized in the region, seizures totalled just 270 kg in 2012, 
far lower than the annual multi-ton seizures reported in 
earlier years. The reliance upon those precursor chemi-
cals in the illicit manufacture of methamphetamine is 
now limited to the numerous small-scale laboratories in 
the United States and larger-scale laboratories in Canada, 
where loopholes in domestic legislation allow for contin-
ued diversion. 
400. A detailed overview of the situation in North 
America with respect to the control of precursor chemi-
cals can be found in the 2013 report of the Board on the 
implementation of article 12 of the 1988 Convention.23
(d) Substances not under international 
control
401. The United States identified 158 new psychoactive 
substances in 2012, making it the country having identi-
fied the largest number of these new substances of abuse. 
The substances identified were mostly synthetic cannab-
inoids and synthetic cathinones. In Canada, authorities 
identified 59 new psychoactive substances over the first 
two quarters of 2012, a rate similar to that in the United 
States. As in the United States, the substances identified 
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were mostly synthetic cannabinoids and synthetic cathi-
nones but also included phenethylamines. The abuse of 
new psychoactive substances in North America also 
includes plant-based substances such as Salvia divinorum 
and khat. The Board encourages Governments in the 
region to continue their efforts to deal with the public 
health menace posed by new psychoactive substances by 
sharing information on new substances of abuse, by iden-
tifying and implementing best practices aimed at address-
ing them and by subjecting these substances to national 
control measures.
402. The abuse of Salvia divinorum, a herb native to 
Mexico, in Canada and the United States has continued, 
making the substance one of the most abused new psy-
choactive substances in the region. Although legislative 
measures aimed at curbing access to the herb have mul-
tiplied in recent years, particularly at the state level in the 
United States where more than 20 states have now banned 
it, Salvia divinorum remains widely available throughout 
the region. In Canada, the sale and distribution of prod-
ucts containing Salvia divinorum are regulated by the 
country’s Food and Drugs Act, with no authorizations 
having been granted for the sale of products containing 
the substance since early 2011. Despite a process initiated 
by the Government of Canada in 2011 to control Salvia 
divinorum under the Controlled Drugs and Substances 
Act, the measure has not yet been adopted.
403. According to data provided by the Canada Border 
Services Agency, there has been a significant increase in 
attempts to smuggle khat into the country, where it is ille-
gal. In the Greater Toronto Area alone, more than 13 tons 
of khat have been seized by the Agency in approximately 
13,000 seizures effected between 1 January 2012 and 31 
May 2013. In 2012, the total amount seized in the Greater 
Toronto Area was over 10 tons. 
5. Abuse and treatment
404. North Americans with substance addiction prob-
lems have greater access to treatment than people in other 
regions, with an estimated one in three problem drug 
users in the region receiving some sort of treatment inter-
vention  per year, compared to one in six problem users 
globally. 
405. According to figures released by UNODC, the 
illicit cocaine market in North America has decreased sig-
nificantly over the period 2006-2012, both in absolute and 
relative terms. In 2011, roughly 4.6 million people in 
North America reported using cocaine in the past year, 
a decrease of approximately 2 million over the amount in 
the period 2004-2005. Over the same period, the propor-
tion of cocaine users in North America decreased from 
49  per  cent of the world total to 27  per  cent, although 
the reasons for that decline also include increases in other 
regions. 
406. According to the 2012 Canadian Alcohol and Drug 
Use Monitoring Survey released by Health Canada, the 
prevalence of past-year cannabis abuse among Canadians 
aged 15 years and older increased slightly in 2012, from 
the 9.1 per cent reported in 2011 to 10.2 per cent. Despite 
that increase, prevalence of past-year cannabis abuse in 
2012 was still significantly lower than the 14.1  per  cent 
registered in 2004. In terms of differences among various 
age groups, the survey reveals a past-year prevalence 
among youth (defined as 15 to 24 years of age) of 
20.3  per  cent against 8.4  per  cent for adults (defined as 
25 years of age or older). The survey also found a slight 
increase in the age of initiation to cannabis, rising from 
15.6 years in 2011 to 16.1 years in 2012. Past-year preva-
lence for the abuse of other illicit drugs identified by the 
Survey was as follows: “ecstasy”, 0.6  per cent; hallucino-
gens (including Salvia divinorum), 1.1  per cent; cocaine 
or “crack” cocaine, 1.1  per  cent. The Survey also exam-
ined the use and abuse of opioid pain relievers, tranquil-
lizers and sedatives. Among respondents over the age of 
15 having used any of those substances in the previous 
year, 6.3  per  cent reported to have abused the drug in 
order to get high. 
407. In the United States, recent studies have revealed 
drugged driving to be more common than initially 
thought, with 9.4 million people (i.e., 3.4 per cent of the 
population aged 12 or older) reported to have driven 
under the influence of illegal drugs in 2011. Of those hav-
ing tested positive for drugged driving, 66  per  cent also 
tested positive for alcohol. 
408. According to statistics released in July 2013 by the 
Centers for Disease Control and Prevention, prescription 
drug abuse, in particular of opioid analgesics, has contin-
ued to constitute a serious threat to public health in the 
United States, with women increasingly and dispropor-
tionately affected. Although the number of annual deaths 
related to overdose of prescription opioids continues to 
be higher among men than among women, the Centre’s 
figures reveal that the number of deaths among women 
between 1999 and 2011 has increased disproportionally, 
by 400 per cent, compared with an increase of 265 per cent 
among men. For the years in question, almost 48,000 
women died of prescription opioid abuse, averaging about 
18 deaths per day in 2010. The Centre estimates that for 
every woman who dies of prescription opioid abuse, 
another 30 women are admitted to hospital emergency 
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rooms across the United States for painkiller misuse or 
abuse—roughly one every three minutes. 
409. In Mexico, the National Institute of Women 
(INMUJERES) has called for a review of public policies 
relative to the prevention and treatment of drug abuse in 
order to include gender perspectives that take into account 
the particularities of the effects of drug abuse on women. 
The Institute points out that drug abuse among women 
in Mexico has doubled in the past decade and that the 
health consequences of drug abuse among women mani-
fest themselves more quickly and are more severe than 
among men using similar quantities of the same drug for 
similar amounts of time. Women are also more at risk of 
being victims of drug-related domestic violence, crime 
and sexual assault. INMUJERES also highlights that 
women in Mexico are less likely than men to seek out 
treatment due to social stigma and fear of rejection by 
their partners or families. The Board encourages 
Governments in the region, in the preparation of their 
national drug abuse prevention and treatment strategies, 
to take gender  perspectives into account and to involve 
groups representing women in the elaboration of these 
strategies.
410. In February 2013, the United States National 
Institute on Drug Abuse released the results of its 
Monitoring the Future survey for 2012 on drug use 
among adolescents. The survey was based on a sample 
group of 45,400 eighth, tenth and twelfth grade students 
at 395 secondary schools across the United States. 
According to the study, increases in cannabis use among 
secondary school students, which had been noted for the 
past four years, ceased. Nonetheless, current cannabis use 
in 2012, based on past-month prevalence data, was 
20 per cent higher than in 2007. The rise in use seems to 
have been mainly linked to falling risk  perceptions. The 
study found that the  perceived risk associated with can-
nabis use has been in decline among adolescents for the 
past six years and that disapproval of cannabis use has 
declined for the past three to four years in line with ongo-
ing discussions on the legalization of cannabis in various 
states of the United States. The study also examined 
the  perceived availability of cannabis as an alternative 
explanation for the rise in cannabis use. Availability of 
cannabis, however, was not found to have changed. 
Increase in cannabis use over the past few years did not 
affect only youth. The National Survey on Drug Use and 
Health, published in September 2013, revealed an increase 
of 20  per  cent in the annual prevalence of cannabis use 
among the general population aged 12 and older over the 
2007-2012  period, from 10.1  per  cent in 2007 to 
11.5 per cent in 2011 and 12.1 per cent in 2012, the high-
est such rate found over the past decade. 
411. Past-year use of synthetic cannabinoids (known as 
“Spice” or “K2”) for 2012 among twelfth grade students 
remained relatively unchanged, at 11.3  per  cent (com-
pared with 11.4 per cent for 2011), and remained the sec-
ond most widely used group of substances after cannabis. 
The 2012 survey, the first in which eighth grade and tenth 
grade students were asked about past-year use of syn-
thetic cannabinoids, reported prevalence rates of 
4.4 per cent and 8.8 per cent respectively. Annual preva-
lence rates for cathinones (“bath salts”) for 2012 were 
0.8  per  cent, 0.6  per  cent and 1.3  per  cent for grades 8, 
10 and 12 respectively. Lower rates of abuse were noted 
for heroin, “ecstasy” and sedatives. 
412. In June 2013, the Federal District of Mexico 
released the results of a survey on the use of drugs among 
students in Mexico City. Based on a sample of over 26,500 
high school and higher education students, the survey 
reveals an increase in illegal drug abuse led by cannabis, 
cocaine, “crack” cocaine and hallucinogenics. The most 
significant increase was noted for cannabis: past-year 
usage rose by four  percentage points, from 8.2  per  cent 
in 2009 to 12.2 per cent in 2012. In contrast to declining 
prevalence rates for cocaine abuse in North America as 
a whole, the figures for past-year cocaine abuse among 
those students also rose, from 1.7  per  cent in 2009 to 
2.5 per  cent in 2012. 
413. In February 2013, the Centers for Disease Control 
and Prevention warned of multiple cases of acute kid-
ney injury associated with synthetic cannabinoid use 
reported by the health authorities in several states of the 
United States. Figures released by the American 
Association of Poison Control Centers in April 2013 
indicated that there were over 5,200 calls to poison cen-
tres across the United States for exposure to synthetic 
cannabinoids in 2012. 
414. According to the 2012 Arrestee Drug Abuse 
Monitoring Program released in May 2013 in the United 
States, 60  per  cent of adult males arrested in the five 
regions covered by the survey had at least one illicit drug 
in their system at the time of their arrest, the drugs most 
commonly detected being cannabis, cocaine and meth-
amphetamine. While the detection of cannabis in the 
urine samples of male arrestees increased by 17 per cent 
over the  period 2007-2012, the detection of cocaine fell 
by 37  per  cent over the same  period, possibly due to 
declines in cocaine manufacture in Colombia and stronger 
law enforcement actions by the Mexican authorities 
against the Mexican drug cartels trafficking cocaine. The 
proportion of urine samples from male arrestees testing 
positive for methamphetamine increased slightly between 
2007 and 2012. Among the arrestees having tested 
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positive for illicit drug consumption, 70  per  cent had 
never received any kind of drug treatment. 
415. Over the past decade, intravenous drug abuse in 
North America has declined significantly. In the United 
States alone, the number of people injecting drugs 
dropped by more than 400,000 between 2008 and 2011. 
Notwithstanding that decline, figures for 2011, published 
in the World Drug Report 2013, show that an estimated 
0.63-0.68  per  cent of North Americans aged 15 to 64 
years of age continue to inject drugs. Approximately 
13.5 per cent of intravenous drug users in the region are 
estimated to be infected with HIV. In Canada, drug injec-
tion remains relatively high at 1.3 per cent of the general 




416. The availability of South American cocaine in illicit 
global markets appears to have stabilized or even declined 
since the  period 2005-2007. Large seizures of cannabis 
reported by countries in South America suggest a possi-
ble increase in cannabis production in the region in 
recent years. Illicit cultivation of opium poppy continues 
to occur to some extent in South America; however, its 
magnitude is rather limited.
417. In 2012, the total area of coca bush cultivation 
decreased by a quarter in Colombia, to 48,000 ha. It also 
decreased slightly in Bolivia (Plurinational State of), to 
25,300 ha, and  Peru, to 60,400 ha. The total area under 
coca bush cultivation in South America in 2012 was esti-
mated at 133,700 ha, indicating a sizeable decrease from 
the 153,700 ha reported in 2011. 
418. In 2013, the Plurinational State of Bolivia reac-
ceded to the Single Convention on Narcotic Drugs of 
1961 as amended by the 1972 Protocol, with a reserva-
tion on coca leaf. Since February 2013, the chewing of 
coca leaf and the consumption and use of the coca leaf 
in its natural state for “cultural and medicinal purposes” 
are  permitted on the territory of the Plurinational State 
of Bolivia by the virtue of the reservation.
419. The past two years have seen intensive discussion 
on drug policies in the Americas, including South 
America (for a discussion of this issue in the context of 
Central America and the Caribbean, see para. 340, above). 
The Board notes that in November 2012, the member 
countries of the Organization of American States approved 
a new procedure for the Multilateral Evaluation 
Mechanism for assessing drug policies in the Americas. 
The new procedure takes into account new standards set 
by the Hemispheric Drug Strategy and its plan of action. 
2. Regional cooperation
420. There is a high level of cooperation and coordina-
tion among the countries in South America, and the 
Americas as a whole, in terms of the number of dedi-
cated forums and activities to confront the underlying 
problems related to illicit cultivation and to the illicit pro-
duction, manufacture, trafficking and abuse of drugs in 
the region. The Board acknowledges the number of 
regional cooperation activities organized by the 
Governments of the countries in the region in coopera-
tion with the Inter-American Drug Abuse Control 
Commission and UNODC. 
421. The issue of drug control became an integral part 
of the cooperation programmes of various communities 
of countries in South America, including the Common 
Market of the South, the Andean Community, the Union 
of South American Nations and the Community of Latin 
American and Caribbean States. The Board also takes note 
of the efforts of the American Police Community, which 
aims to promote police cooperation and judicial assistance 
among police forces in the western hemisphere.
422. In 2012 and 2013, in addition to high-level meet-
ings on national and regional drug control policies, health 
and law enforcement experts from Latin America at 
diverse technical forums shared their views and experi-
ences on drug-related issues, such as the abuse of smoke-
able forms of cocaine, the achievements of drug treatment 
courts or the forecasting of trafficking in drugs in the 
western hemisphere by 2020. 
3. National legislation, policy and 
action
423. In January 2013, the Secretariat for Planning the 
Prevention of Drug Abuse and the Fight against Drug 
Trafficking of Argentina launched an online system that 
records all national transactions in chemical precursors. 
The system will assist the competent national authorities 
in reducing the risk of diversion of precursor chemicals 
for the illicit manufacture of drugs. 
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424. In 2013, the Colombian drug observatory launched 
an early warning system that is aimed at identifying and 
issuing alerts about domestic consumption of new psy-
choactive substances, analysing their potential effects on 
health and reporting findings to the interested commu-
nities, including the health sector and other entities 
responsible for drug control in the country. 
425. In November 2012, Ecuador joined the Hemi-
spheric Information Exchange Network for Mutual 
Assistance in Criminal Matters and Extradition, estab-
lished in 2000 to increase and improve the exchange of 
information between States members of the Organization 
of American States in the area of mutual assistance in 
criminal matters.
426. The Board notes that, in response to a higher rate 
of misuse and abuse of narcotic drugs and psychotropic 
substances among the student population in  Peru, in 
November 2012 the  Peruvian National Commission for 
Development and Life without Drugs (DEVIDA) initiated 
a pilot programme for drug prevention at universities, 
which is aimed at creating awareness among students 
about the harmful effects of drug abuse and the need to 
develop healthy lifestyles. 
427. In March 2013, DEVIDA and UNODC agreed to 
establish in Peru a centre of excellence for Latin America 
and the Caribbean for the prevention and control of sup-
plies and precursor chemicals. 
428. With a view to promoting shared responsibility 
among local communities in preventing drug trafficking 
and drug abuse, at the beginning of 2013 the Government 
of the Bolivarian Republic of Venezuela, in cooperation 
with State institutions, initiated public consultations on 
the National Drug Plan 2013-2019.
429. The Board notes with concern that in July 2013, 
the lower house of Uruguay approved new legislation that 
would allow the State to assume control over and regu-
late activities related to the importation, production or 
acquisition of any title, storage, sale or distribution of can-
nabis or its derivatives, under terms and conditions to be 
determined by a regulation, for the purpose of non- 
medical use. The law has yet to be approved by the Senate. 
The Board wishes to point out that such legislation, if 
approved, would be contrary to the provisions of the 
international drug control conventions. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
430. The data on cannabis cultivation in South America 
are scarce. Increased seizures of cannabis have been 
reported by several countries in the region in recent years. 
For example, Colombia and Paraguay reported increases 
of over 100  per  cent in seizures of cannabis herb when 
comparing the  period 2002-2006 with the  period 2007-
2011. Those increased seizures may warrant closer exam-
ination to determine whether they are primarily the result 
of strengthened law enforcement activities or whether 
they may indicate increased illicit cultivation of cannabis 
plant in the region. 
431. The Board noted the high volumes of cannabis 
plant and cannabis herb seized in the Plurinational State 
of Bolivia in recent years. From 2008 to 2011, the Bolivian 
authorities seized 3,500  tons of cannabis. In 2012, they 
seized a further 407  tons of the drug of local origin 
(403 tons of cannabis plant and 4 tons of cannabis herb), 
25  tons more than in 2011. 
432. Illicit cannabis cultivation in Brazil is destined pri-
marily for local abuse. In 2012, seizures of cannabis herb 
decreased significantly, from 174  tons in 2011 to only 
11.2 tons. In that year, the Brazilian authorities eradicated 
a total of 21.7 ha of area under illicit cannabis cultivation 
in their country and assisted in joint operations, to erad-
icate illicit cannabis cultivation in Paraguay.
433. Cannabis that has been illicitly cultivated in 
Paraguay continues to be smuggled to Southern Cone 
countries. According to the Paraguayan National Anti-
Drug Secretariat, the eradication of illicit cannabis plant 
grown in the country has decreased gradually, from 
1,776 ha eradicated in 2008 to 721 ha in 2011. In 2012, 
seizures of cannabis herb in the country amounted to 
175.7 tons, a decrease of 43  per  cent from the level of 
the previous year. The Board wishes to encourage the 
Government of Paraguay to increase its efforts to address 
decisively the illicit cultivation of cannabis plant on its 
territory. 
434. In Peru, a total of 722.7 tons of cannabis plant was 
seized in the  period from 2000 to 2011. In 2012, 
the  Peruvian authorities seized 979  tons of cannabis 
plant. Large seizures of cannabis plant continued in 2013, 
with the authorities seizing some 700  tons in the first 
half of the year. 
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435. In Uruguay, seizures of cannabis herb in 2012 
amounted to only 2 tons, the same as in 2011. Venezuelan 
authorities seized 17.9  tons of cannabis herb in 2012, 
including cannabis herb containing high levels of 
tetrahydrocannabinol.
436. Most indicators, including cultivation of coca bush, 
manufacture of cocaine, seizures of the substance and 
prevalence estimates in the major consumer countries, 
suggest that in recent years the cocaine market, on the 
whole, has been declining. 
437. In 2011, UNODC estimated that the total global 
potential manufacture of cocaine ranged from 776 to 
1,051 tons. As the research to determine the ratios for the 
conversion of coca leaf to cocaine in South America is 
ongoing, UNODC did not provide any estimate of the 
global potential manufacture of cocaine in 2012. 
438. The total area under coca bush cultivation in South 
America in 2012 decreased to 133,700 ha, 13 per cent less 
than the total area in 2011. Peru accounted for 45 per cent 
of that total, followed by Colombia and Bolivia 
(Plurinational State of), which accounted for 36 per cent 
and 19 per  cent, respectively.
439. In 2012, the total area under illicit coca bush cul-
tivation in the Plurinational State of Bolivia decreased to 
25,300 ha, 7  per  cent less than in 2011. In 2012, a total 
of 11,044 ha of coca bush were manually eradicated in 
the country. That total area of annual eradication was the 
second largest reported since 2000. 
440. In 2012, about 30,486 ha of illicitly cultivated coca 
bush were eradicated manually in Colombia and a fur-
ther 100,549 ha were sprayed by aircraft. Those eradica-
tion efforts resulted in a 25 per cent decrease in the area 
under illicit coca bush cultivation over the year. The final 
estimated total area under illicit coca bush cultivation 
amounted to 48,000 ha, the smallest in the country since 
1995. The potential cocaine manufacture in Colombia 
decreased accordingly in 2012 to 309 tons, 39  tons less 
than in 2011.
441. Despite annual eradication of illicit coca bush rang-
ing from 6,400 ha to 12,000 ha from 2001 to 2011, there 
was still a gradual increase in the total area under illicit 
cultivation in  Peru, from 46,200 ha to 62,500 ha, over 
that  period. The area under illicit coca bush cultivation 
in the country was, however, still about half the area of 
two decades before.
442. The Peruvian National Drug Control Strategy 2012-
2016 provides for a gradual stepping up of eradication 
efforts aimed at reducing the potential production of coca 
leaf in the country by 30 per cent by 2016, from the level 
in 2011. In 2012, the Peruvian authorities eradicated 
14,170 ha of illicit coca bush, 170 ha more than the tar-
get set for that year. By June 2013, the authorities reported 
eradicating 10,400 of the 22,000 ha of coca bush planned 
to be eradicated by the end of the year. 
443. At the end of 2012, the total area under illicit coca 
bush cultivation in Peru decreased to 60,400 ha, 3 per cent 
less than in 2011.
444. Cocaine produced in South America, in addition 
to its local consumption, is trafficked from the region, 
mainly to North America and Europe. While rates of 
cocaine abuse have been falling in the United States in 
the past few years, large quantities of cocaine continue to 
be trafficked to that country and to Canada, notably from 
Colombia, through Ecuador, Mexico and countries in 
Central America. 
445. The use of speedboats and submersible and semi-
submersible vessels for trafficking of cocaine from South 
America continued to be reported by countries in the 
subregion. A breakdown of cocaine seizures in Colombia 
suggests that the Atlantic route is gaining importance, in 
comparison with the Pacific route, for the smuggling of 
cocaine.
446. Brazil, with its extensive land borders with all three 
major cocaine manufacturing countries and a long coast-
line, in addition to being a destination country for large 
amounts of cocaine, also affords easy access to the Atlantic 
Ocean for onward trafficking to West and Central Africa 
and from there to Europe and farther afield. In 2012, the 
cocaine seized in Brazil had originated in Bolivia 
(Plurinational State of), Peru and Colombia, in descend-
ing order of quantities seized. 
447. The Government of the Bolivarian Republic of 
Venezuela reports that the decrease in the trafficking of 
illicit drugs through its territory is partly due to the con-
tinued implementation of systems for the detection of and 
severe penalties for drug trafficking. 
448. In 2012, several countries in South America, 
including Colombia, Chile, Peru, Paraguay and Uruguay, 
reported that greater quantities of cocaine hydrochloride 
had been seized than in 2011. In 2012, Colombian 
authorities seized 188 tons of cocaine hydrochloride (an 
increase of 29  per cent), constituting a large proportion 
of potential cocaine production in the country. The 
Chilean authorities, in addition to 9.7 tons of coca paste, 
also seized 3.2  tons of cocaine hydrochloride, 1.3  tons 
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more than in 2011. In Peru seizures of cocaine hydro-
chloride of domestic origin increased in 2012 by 1.9 tons, 
to 12.7 tons seized. In the first half of 2013, 4 more tons 
of the substance were seized in Peru. In Paraguay, sei-
zures of cocaine hydrochloride doubled from 2011 to 
2012, when they amounted to 3.1 tons. It was the fourth 
consecutive increase since 2008, when 0.3  tons of the 
substance was seized. In Uruguay such seizures increased 
from 266 kg in 2011 to 685 kg in 2012. In 2012, seizures 
of cocaine hydrochloride decreased in Bolivia 
(Plurinational State of) to 4.2 tons, 1.4  tons less than in 
2011, while those of cocaine base increased by 3.8 tons, 
to 32.1 tons. In Brazil, seizures of cocaine hydrochloride 
totalled 19.9 tons, 19  per  cent less than in the previous 
year. In the Bolivarian Republic of Venezuela, seizures of 
cocaine hydrochloride remained stable in 2012, totalling 
27.4 tons. 
449. In South America, most of the laboratories manu-
facturing cocaine hydrochloride are found in the three 
coca-growing countries: Bolivia (Plurinational State of), 
Colombia and Peru. Cocaine hydrochloride laboratories 
have also been destroyed in a number of other countries, 
including Argentina, Chile, Ecuador, Venezuela (Bolivarian 
Republic of), and the United States. 
450. The number of illicit cocaine laboratories disman-
tled in the Plurinational State of Bolivia decreased by 
24 per cent in the past three years, from 5,956 laborato-
ries in 2010 to 4,508 laboratories in 2012.
451. In Colombia, the number of both coca base and 
cocaine hydrochloride processing laboratories dismantled 
has gradually decreased by one third from 2008 to 2011, 
following a decreasing trend in illicit cultivation of coca 
bush. In 2012, 2,110 laboratories processing coca base and 
246 manufacturing cocaine hydrochloride were destroyed. 
452. In Peru in 2012, 26 cocaine hydrochloride process-
ing laboratories and 1,145 coca base processing laborato-
ries were dismantled, respectively the highest and lowest 
numbers in the past five years. 
453. Illicit cocaine laboratories discovered in Ecuador 
were primarily purification laboratories or laboratories 
processing coca base into cocaine hydrochloride. In 2012, 
four cocaine laboratories were dismantled in Ecuador. 
The Chilean authorities reported the destruction of eight 
laboratories processing coca base in their country in 2012. 
454. There is no illicit cultivation of coca bush in the 
Bolivarian Republic of Venezuela. However, since 2007, 
the Venezuelan authorities have dismantled on average 
18 illicit cocaine hydrochloride processing laboratories 
per year. In 2012, those authorities destroyed 24 such 
laboratories. 
455. Although there is some illicit cultivation of opium 
poppy in South America, its magnitude is negligible. In 
2012, illicit opium poppy in Colombia was cultivated on 
an estimated area of 313 ha, equivalent to only about 
0.1 per cent of global area under illicit opium poppy cul-
tivation. During the first four months of 2013, the 
Colombian authorities eradicated 324 ha of illicit opium 
poppy cultivation. The potential manufacture of heroin 
in Colombia has been stable for several years at about 
1 ton. In 2012, 18 ha of opium poppy were reported erad-
icated in Peru. 
456. In 2012, the following seizures of heroin were 
reported in South America: 10  kg in Brazil, 814  kg in 
Chile, 464 kg in Colombia and 2 kg in Peru. In addition, 
Peru reported a seizure of 71 kg of opium of local origin 
and Chile reported seizures of 120 kg of morphine. 
(b) Psychotropic substances
457. The problem of the manufacture, trafficking and 
abuse of psychotropic substances in South America 
encompasses all main groups of those substances, includ-
ing amphetamine-type stimulants, sedatives and tranquil-
lizers and hallucinogens, as well as psychoactive substances 
that are not under international control. The characteris-
tics and magnitude of the problem differ from country 
to country.
458. According to the Government of Brazil, the illicit 
manufacture of synthetic drugs does not occur in the 
country. Synthetic drugs are trafficked to Brazil from 
Europe, on some occasions in exchange for cocaine. In 
2011, Brazil reported its highest figure for seizures of 
MDMA (“ecstasy”) in the past two decades, 70 kg; over 
the past 10 years the amounts of the annual seizures of 
the substance in the country have usually been smaller 
than 1 kg. In 2012, Brazil seized 339,000 tablets of 
“ecstasy” and 10,000 units of amphetamine. 
459. The Government of Colombia reported on 
increased seizures of synthetic drugs, which may indicate 
increased abuse of those substances in the country. In 
2012, the Colombian authorities seized almost 39,700 tab-
lets of “ecstasy”. 
460. In 2010, Peru reported the seizure of 250,000 units 
of “ecstasy”, the largest amount in the past decade. In 2011 
seizures of “ecstasy” amounted to 229 units, and in 2012 
the country did not report any such seizures. The 
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Uruguayan authorities reported the seizure of 60,000 
units of “ecstasy” in 2011; in 2012 the country did not 
report any seizures of the substance. 
461. From 2011 to 2012, seizures of amphetamine and/
or methamphetamine were reported by Argentina, Brazil, 
Chile, Colombia and Venezuela (Bolivarian Republic of). 
462. In 2011, a number of countries in South America, 
including Argentina, Brazil, Chile, Colombia and 
Uruguay, reported the largest amounts of hallucinogens 
seized since 2007. In 2012, seizures of hallucinogens, in 
particular LSD, were reported by Brazil (65,000 units), 
Chile (4,200 units), Colombia (100 units) and Uruguay 
(2,000 units). According to the Chilean authorities, 
most of the LSD seized in the country had originated 
in Argentina. 
(c) Precursors
463. In all countries that are major sites for coca bush 
cultivation, the efficiency of illicit cocaine manufacture 
has been improving. Potassium  permanganate remains 
the key oxidizing agent used in the manufacture of 
cocaine hydrochloride in the region, although the extent 
of its illicit use and the methods used for its diversion 
have changed in South America in the past few years. In 
2012, countries in South America accounted for two 
thirds of global seizures of potassium  permanganate 
(92.7 tons). In that year, Colombia seized 55.7 tons, Peru 
3.1 tons, Venezuela (Bolivarian Republic of) 2.4 tons and 
Bolivia (Plurinational State of) 960  kg of the substance. 
464. In Colombia, in addition to the recycling and reuse 
of solvents, traffickers have begun to manufacture some 
precursor chemicals, including potassium permanganate, 
ammonia and hydrochloric acid. In 2012 the Colombian 
authorities dismantled eight illicit laboratories manufac-
turing potassium permanganate. 
(d) Substances not under international 
control
465. The problem of new psychoactive substances has 
also emerged in countries of Latin America. Reported 
substances of abuse include ketamine and plant-based 
substances, notably Salvia divinorum, followed by piper-
azines, synthetic cathinones, phenethylamines and, to a 
lesser extent, synthetic cannabinoids. Brazil also reported 
the emergence of mephedrone and DMMA (a pheneth-
ylamine); Chile reported the emergence of Salvia divino-
rum and tryptamine. 
5. Abuse and treatment
466. In January 2013, the Andean Community pre-
sented the results of the second Andean epidemiological 
study on drug use among university students. The study 
found that the prevalence of drug abuse among univer-
sity students in the Andean countries was quite hetero-
geneous: the last-year prevalence of abuse of any illicit 
drug, including inhalants, was 4.6  per  cent in Bolivia 
(Plurinational State of), 16.7  per  cent in Colombia, 
10.1 per  cent in Ecuador and 5.6 per  cent in Peru.
467. Cannabis continues to be the most abused drug in 
South America, where about 14.9 million  persons aged 
15 to 64 were estimated to have taken the substance in 
the past year, 4.5 times the number of  persons who 
abused cocaine. According to UNODC data, the preva-
lence of cannabis abuse has significantly increased in the 
region in recent years, particularly in Brazil.
468. The Board notes with concern the low  perception 
of risk regarding cannabis abuse by the young population 
in some South American countries: according to the fifth 
national survey on the abuse of drugs among the second-
ary school population, published in October 2012, up to 
60  per  cent of students in Uruguay aged 13 to 17, con-
sider recreational use of cannabis to pose little or no risk.
469. The past-year prevalence of cocaine abuse among 
the general population in South America (1.3  per cent) 
is the third highest in the world, after North America and 
Oceania (1.5  per  cent each), and it is about triple the 
global average prevalence (0.4  per cent). According to 
UNODC, the past-year prevalence of cocaine abuse 
increased in particular in Brazil, from 0.7 per cent (pop-
ulation aged 12-65) in 2005 to 1.75 per cent (population 
aged 16-64) in 2011.
470. The high prevalence of cocaine use in South 
America is also reflected in the demand for treatment for 
cocaine abuse. According to UNODC, treatment for 
cocaine abuse accounted for 46 to 83 per cent of all drug-
related treatment in, in ascending order, Peru, Ecuador, 
Venezuela (Bolivarian Republic of), Argentina and Chile 
from 2010 to 2011. Demand for treatment for cannabis 
abuse was also significant in Ecuador, and in Peru, where 
nearly 40  per  cent of treatment demand was for canna-
bis abuse.
471. A study of cocaine base paste over four decades, 
published in April 2013 by DEVIDA, indicates that abuse 
of cocaine base paste in South America commenced in 
the 1970s, particularly in Bolivia (Plurinational State of), 
Colombia and Peru, and that over the past 10 years it has 
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spread to other countries in the region, including 
Argentina, Chile and Uruguay. The study calls attention 
to the quick onset of dependence to cocaine base paste 
and the challenges of its clinical treatment. According to 
the study, in Peru, 59.6  per  cent of  persons who had 
abused cocaine base paste in the past 12 months showed 
signs of drug dependence, compared with 47.8  per  cent 
of those who had abused cocaine. 
472. The annual prevalence of opioid abuse (mainly 
non-medical use of prescription opioids) in South 
America is estimated to be 0.3 per cent of the adult popu-
lation, corresponding to 790,000 to 860,000 people aged 
15 to 64. 
473. Past-year prevalence of abuse of amphetamine-
type stimulants (excluding MDMA (“ecstasy”)) among 
the general population in South America (0.4-
0.6 per cent) is lower than in Central America or North 
America (1.3 per cent). Past-year prevalence of “ecstasy” 
abuse among the general population is even lower, at 
0.1-0.2  per  cent. 
474. The second Andean epidemiological study also 
pointed to the increasing abuse of hallucinogenic sub-
stances in the Andean countries. According to the study, 
the past-year prevalence of LSD abuse had increased four-
fold among the university population in the region, from 
0.23  per  cent in 2009 to 0.95  per  cent in 2012. In 
Colombia, the past-year prevalence of abuse of LSD was 
3.16  per  cent and that of hallucinogenic mushrooms 
1.02  per  cent. Abuse of hallucinogenic mushrooms had 
also increased recently in the Plurinational State of 
Bolivia, in particular among university students, and 
became the second most abused drug in the country, after 
cannabis, among that population.
C. Asia
East and South-East Asia
1. Major developments
475. The manufacture of and demand for heroin in East 
and South-East Asia continues to be of major concern to 
the Board. In the mid 2000s the Governments of the Lao 
People’s Democratic Republic, Myanmar and Thailand 
undertook successful opium poppy eradication pro-
grammes. In recent years, there has been an upsurge in 
cultivation, threatening the positive gains made over the 
past decade. From the low of 24,157 ha reported to have 
been cultivated in 2006, the total area of illicit cultivation 
of opium poppy in the Lao People’s Democratic Republic 
and Myanmar increased substantially, amounting to 
58,000 ha in 2012. In the Lao People’s Democratic 
Republic, the area of cultivation in 2012 amounted to 
about 25 per cent of the area of cultivation in 1998, when 
illicit cultivation reached its peak. Myanmar, which also 
reported an increase in cultivation, had the largest total 
area of opium poppy cultivation in the region, at 
51,000  ha. However, the increase in demand for heroin 
in East and South-East Asia is so great that even with the 
reported increase in illicit cultivation in the three above-
mentioned countries, Afghan opium is reportedly now 
being smuggled into East and South-East Asia in order 
to satisfy demand—in an area where approximately one 
quarter of the world’s opiate abusers live.
476. The region’s long-established demand for 
amphetamine- type stimulants showed no signs of weak-
ening. Demand for amphetamine-type stimulants both 
increased and diversified, with a growing demand for 
crystalline methamphetamine among the new trends in 
the region. Illicit manufacture of amphetamine-type stim-
ulants continued to be prevalent, and in 2011 hundreds 
of illicit synthetic drug manufacturing facilities were 
reported to have been dismantled by the Governments of 
Cambodia, China, Indonesia, Malaysia, Myanmar, the 
Philippines and Thailand. In addition, the abuse of non-
controlled substances has become more prevalent, with 
the abuse of synthetic cannabinoids and synthetic cathi-
nones being reported. Ketamine remained the most 
widely reported abused substance among those sub-
stances not under international control.
477. As part of the regional response aimed at reducing 
high levels of drug abuse, in particular of amphetamine-
type stimulants, there was a noticeable move by 
Governments towards enhancing community-based treat-
ment programmes.
2. Regional cooperation
478. Countries in the region continued to look at ways 
to enhance cooperation at the ministerial level and 
between law enforcement agencies in order to focus on 
combating the supply of illicit drugs. The increasing num-
ber of regional meetings on drug control issues highlights 
the existing political will to use multilateral mechanisms 
to exchange information and enhance cooperation in 
order to more effectively combat illicit manufacture and 
use of drugs. 
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479. A list of selected regional cooperation meetings 
in East and South-East Asia is available in English in 
electronic form on the INCB website (www.incb.org), 
published in conjunction with the annual report.
3. National legislation, policy and 
action
480. In June 2012, Brunei Darussalam introduced the 
Criminal Asset Recovery Order, which consolidates pro-
cedures and powers in asset recovery and removes the 
complexities of previous legislation containing measures 
to counter money-laundering.
481. The newly formed China Food and Drug 
Administration, which started operations in March 2013, 
merged the functions of a number of separate depart-
ments in an effort to improve supervision and regulation. 
In 2011, China also carried out a nationwide campaign 
to stop the use of the Internet for drug-related crime. The 
campaign resulted in the arrest of over 800  persons and 
the dismantlement of 144 groups suspected of using the 
Internet to commit drug-related offences, the destruction 
of 22 sites used for illicit drug manufacture and the sei-
zure of 308 kg of illicit drugs. 
482. Cambodia’s Law on Drug Control, promulgated on 
2 January 2012, extends the scope of activities related to 
drug control in the country and contains provisions on, 
among other things, money-laundering and access to 
treatment for drugs users. The Law is aimed at reducing 
drug abuse and drug-related offences in the country. 
483. In early 2013, Indonesia increased controls on the 
import and export of pharmaceutical preparations con-
taining precursors with medical applications, such as 
ephedrine, pseudoephedrine, ergotamine, ergometrine 
and calcium  permanganate. It also introduced controls 
over raw materials, and bulk, intermediate and end prod-
ucts containing those substances.
484. In April 2013, the Government of Thailand 
enhanced measures to prevent the diversion of pseudo-
phedrine and preparations containing that substance by 
issuing a ministerial notification prohibiting the transport 
of those preparations through the country. 
485. In August 2012, the Government of Viet Nam 
adopted the national target programme on drug abuse pre-
vention and control for the period 2012-2015. The new pro-
gramme updated the country’s drug control strategy and 
focuses on expanding methadone substitution  treatment 
among the country’s large population of HIV-vulnerable 
injecting drug users. 
486. In January 2013, the Government of the Lao 
People’s Democratic Republic amended article 146 of the 
penal code so that a person who consumes, purchases or 
possesses less than two grams of heroin, morphine, 
cocaine, amphetamines or other psychotropic substances 
shall be considered a victim and be sent for treatment.
4. Cultivation, production, 
manufacture and illicit trafficking
(a) Narcotic drugs
487. The worrying trends of increased illicit cultivation 
of opium poppy and increased demand for heroin have 
continued. The rebound in illicit opium poppy cultivation 
in the Lao People’s Democratic Republic since the coun-
try’s low in cultivation in 2005 has attracted international 
attention. Taken together with the already high and ris-
ing cultivation levels in Myanmar, this indicates increas-
ing demand for heroin in the region. The area of 
cultivation in the Lao People’s Democratic Republic con-
tinued its upward climb, reaching 6,800 ha by the end of 
2012. Similarly, cultivation in Myanmar has risen from 
its record low of 21,600 ha in 2006 to 51,000 ha in 2012.
488. China reported having nearly 1.3 million registered 
opioid abusers in 2012. That represented nearly 60 per cent 
of all drug abusers in China and an increase from the 
1.2  million registered abusers in 2011. This increase in 
demand in China may be driving the increased demand 
for heroin produced elsewhere in the region.
489. Although significantly high, cultivation levels are 
below the peaks recorded in 1998. Thailand continued to 
report almost zero cultivation and the era of large-scale 
cultivation which once gave rise to the area’s designation 
as the Golden Triangle, has not returned. Nevertheless, 
the gains made in eradication are at risk of being rolled 
back. The Board therefore urges the Governments of the 
Lao People’s Democratic Republic and Myanmar to con-
tinue their efforts to eliminate opium poppy cultivation.
490. There are indications that Afghan heroin is being 
smuggled into the region to cater to the rising demand. 
This suggests that the traditional sources supplying the 
drug, i.e., the Golden Triangle, are not satisfying regional 
demand and that demand may increase pressure to 
expand opium poppy cultivation. Seizures of heroin also 
suggest that the region is increasingly being targeted by 
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traffickers attempting to smuggle heroin manufactured 
outside the subregion. For example, authorities in 
Malaysia seized nearly 750  kg of heroin in 2011, com-
pared with just over 300  kg in 2010; Thailand seized 
nearly 550  kg of heroin in 2011 compared with about 
150  kg in 2010; and China seized just over 7.2  tons of 
heroin. Other countries, such as Viet Nam and Indonesia, 
have not reported declines in the amounts seized over the 
same  period. The Lao People’s Democratic Republic 
seized 45  kg of heroin in 2012, compared with about 
43.4 kg in 2011.
491. The cultivation of cannabis plant in East and South-
East Asia continues to be centred in Indonesia and the 
Philippines, although cultivation is also reported in the 
Lao People’s Democratic Republic. With respect to eradi-
cation efforts, in 2011 the Philippines destroyed over 
1.1 million cannabis plants; Indonesia seized over 22 tons 
of cannabis herb, China seized 4.2  tons of cannabis herb 
and the Governments of Cambodia, Japan, the Lao 
People’s Democratic Republic, Myanmar, the Republic of 
Korea and Thailand all reported seizures. The Lao People’s 
Democratic Republic seized 2,836 kg of cannabis in 2012 
compared with about 1,617 kg in 2011. 
492. The great potential for more widespread abuse of 
cocaine in the region is also a source of serious concern 
for the Board. From the  period 2008-2009 to the  period 
2010-2011, seizures of cocaine increased by almost 
70  per  cent throughout the region, with Hong Kong, 
China, seizing 650  kg in one seizure alone in 2012. 
Philippines also reported large quantities of seizures.
(b) Psychotropic substances
493. The high levels of abuse of amphetamine-type 
stimulants in the region have shown no sign of abating. 
A total of 227 million tablets were seized in the region 
in 2012, and abuse of amphetamine-type stimulants 
expanded, with 11 countries reporting increased abuse of 
methamphetamine. China reported seizing 16  tons of 
methamphetamine in 2012, an increase of nearly 2  tons 
over the preceding year. In 2011, large seizures of 
 amphetamine-type stimulants in Indonesia, Malaysia and 
Thailand highlighted the fact that the problem remained 
significant. Japan reported that quantities of methamphet-
amine seized were the largest in the past decade. Japan 
customs officials seized 482  kg of methamphetamine in 
2012, with a marked increase in the abuse of international 
mail service and commercial cargo, used to smuggle 
amphetamine-type stimulants into the country. While 
high levels of methamphetamine abuse are not new, of 
note were the 8.8  tons of crystalline methamphetamine 
seized, indicating that the regional market of amphetamine- 
type stimulants had become more diversified. Record sei-
zures of that substance were made in Cambodia, China, 
Indonesia, Malaysia and Thailand in 2011. The Lao 
People’s Democratic Republic seized 10.7 million tablets 
of amphetamine-type stimulants in 2012 compared with 
about 4.6 million tablets in 2011.
494. Amphetamine- type stimulants abused in the region 
appear to be mostly supplied by clandestine laboratories 
located within the region, with 401 illicit synthetic drug 
manufacturing laboratories dismantled in 2011. China 
remained the country with the highest number of illicit 
laboratories dismantled: 357 laboratories were dismantled 
in 2011 and 326 in 2012. However, in terms of amount 
manufactured, Myanmar was the main source of meth-
amphetamine and crystal methamphetamine, a situation 
that has not changed from when the Board highlighted 
that fact in its annual report for 2012. However, clandes-
tine laboratories have also been dismantled by authorities 
in Cambodia, Indonesia, Malaysia and the Philippines, 
highlighting in stark terms that illicit manufacture of 
methamphetamine is a problem shared by many coun-
tries in the region.
495. In 2011, the majority of MDMA (“ecstasy”) sei-
zures were made in China and Indonesia. Although large 
increases in seizures were reported in 2011 by Cambodia, 
Japan, Malaysia, the Philippines and Thailand, the over-
all trend across East and South-East Asia is one of declin-
ing seizures of MDMA. This may indicate reduced 
availability of MDMA as use of amphetamine-type stimu-
lants has become more diversified in recent years, with 
increased abuse of crystalline methamphetamine in par-
ticular. Arrests in the region for possession, manufacture 
or trafficking of “ecstasy” fell by 34  per  cent from 2010 
to 2011, and overall seizures were down by 13  per  cent. 
The fact that ketamine was being sold as “ecstasy” sug-
gests there may be difficulty in manufacturing MDMA, 
which may be linked to China’s decision to increase con-
trol over 3,4-MDP-2-P, a key precursor used in illicit 
MDMA manufacture.
(c) Precursors
496. The region continued to be a major centre for traf-
ficking in precursors used in the illicit manufacture of 
amphetamine-type stimulants. The Board has raised this 
issue in the past, and countries in the region, including 
China, the Republic of Korea and Thailand, have 
responded positively by broadening their legislation in 
order to reduce the diversion of pharmaceutical prepara-
tions containing ephedrine and pseudoephedrine. In 
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particular, the region continues to experience cases of 
diversion of large amounts of pseudoephedrine prepara-
tions. Given that situation, it is clear that regulating in 
the region access to pharmaceutical preparations contain-
ing pseudoephedrine, for example through the systematic 
use of a prescription system, could have a strong positive 
impact on the availability of the main precursor used to 
make amphetamine-type stimulants in the region.
(d) Substances not under international 
control
497. East and South-East Asia did not escape the world 
trend of growing abuse of new psychoactive substances. 
Brunei Darussalam, China, including Hong Kong, 
Indonesia, Japan, the Philippines, Singapore, Thailand 
and Viet Nam all reported evidence of their abuse. This 
worrying trend manifested itself in the indications of 
increased availability of synthetic cannabinoids, with sei-
zures and abuse reported in Hong Kong, China, the 
Republic of Korea and Singapore. Mephedrone, a syn-
thetic cathinone, has been identified in China and 
Thailand. In the face of increasing abuse of new psycho-
active substances, Thailand decided to include BZP, 
TFMPP, mephedrone, methylone and methylenedioxypy-
rovalerone (MDPV) on its national list of controlled 
substances.
498. Ketamine and kratom (Mitragyna speciosa) were 
identified as the two main substances of abuse not under 
international control. High levels of ketamine abuse con-
tinued in the past year, with it being widely reported as 
one of the top five drugs of abuse in Asian countries. The 
fact that 86  per  cent of global seizures of ketamine took 
place in Asia confirms that trend. Furthermore, the drug 
is often sold as a substitute for or misrepresented as 
“ecstasy”. The abuse of kratom, a plant with stimulant 
effects and hallucinogenic properties, is increasing, and 
seizures and related arrests have soared dramatically in 
countries such as Thailand (23  tons were seized in 2012, 
up from 1.7  tons in 2005), Malaysia and Myanmar.
5. Abuse and treatment
499. Rates of methamphetamine abuse in the region 
remained high. Indications are that abuse of amphetamine- 
type stimulants has diversified, with seizures of crystalline 
methamphetamine increasing by 23 per cent, indicating a 
large increase in supply of and demand for the substance. 
Methamphetamine is the most common drug of abuse in 
the Lao People’s Democratic Republic and Thailand, and 
is the secondary illicit drug of abuse in Cambodia, China 
and Viet Nam. However, China represents the region’s 
largest consumer market in absolute terms, with half of 
the region’s seizures occurring in that country. 
500. The level of cannabis abuse in the region remained 
high. While a decrease in abuse was noted in Indonesia, 
cannabis continued to be the most abused drug in the 
country, with a 7.1  per  cent lifetime prevalence rate 
among the general population. The Philippines reported 
a lifetime prevalence rate of about 10.5 per  cent. 
501. Life-time prevalence rates for cocaine abuse in the 
region remain relatively low, at about 0.03 per cent of the 
population aged 15-64. However, the rising  per capita 
wealth suggests that cocaine traffickers might consider the 
region to be a market with considerable prospects for 
expansion. 
502. East and South-East Asia reported high levels of 
injecting drug abuse, accounting for 27  per  cent of all 
injecting drug users worldwide injecting heroin, 
amphetamine- type stimulants, tranquillizers and seda-
tives. The public health risks include a higher prevalence 
of HIV/AIDS among drug injecting users. Statistics from 
Indonesia indicate a 42  per  cent prevalence rate of HIV 
among injecting drug users. In Myanmar, there has also 
been a reported shift from smoking opium to injecting 
heroin and amphetamine-type stimulants, which has con-
tributed to the high HIV infection rates among drug 
abusers in the country. Heroin is the most widely abused 
illicit drug in Viet Nam. The HIV prevalence rate among 
drug abusers injecting heroin is 20  per  cent and up to 
50  per  cent in some provinces, with the result that 
Viet  Nam has one of the highest rates of HIV transmis-
sion through injecting drug use. In 2012, the HIV preva-
lence rate among the estimated 1,900 injecting drug users 
in Cambodia was 24.8  per  cent, an increase from the 
 previous year. 
503. Across East and South-East Asia, community-
based treatment initiatives have been expanded as an 
alternative to compulsory drug treatment, with the active 
support of the international community and support from 
Governments in the region. Community-based treatment 
promotes local access to treatment and drug prevention 
services for all drug users. Community-based drug treat-
ment programmes supported by the United Nations 
Office on Drugs and Crime were expanded in Cambodia, 
the leading country in the region in terms of support for 
that approach to drug treatment. The approach has also 
been introduced recently in the Lao People’s Democratic 
Republic. In Timor-Leste, availability of drug treatment 
facilities is extremely limited. The extent of drug abuse in 
the country is not well known, and, as such, prevention, 
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treatment and rehabilitation facilities for drug abusers 
remain underdeveloped. The Board encourages Govern-
ments in the region to continue to expand treatment 
 services provision, including the introduction and devel-
opment of voluntary treatment alternatives, such as com-
munity-based treatment, and to facilitate access to 
treatment and drug prevention services for all drug users.
504. China reported that there were 2.1 million drug-
dependent persons in 2012. Of those 60 per cent reported 
abuse of heroin, with abuse of amphetamine-type stimu-
lants at less than 29  per  cent, (602,481 individuals). 
China referred 136,000 people to community-based drug 
treatment programmes, and a further 202,000 individu-
als were placed in 678 compulsory drug treatment cen-
tres. In 2012, there were 756 methadone maintenance 
treatment clinics providing services to 384,000 patients. 
Abuse of “ecstasy” was prevalent in Timor-Leste, accord-
ing to a recent study, and is now more abused than 
methamphetamine.
505. The Board has noted that data on the nature and 
extent of drug abuse in many countries in the region are 
out of date and unreliable. The Board once again urges 
Governments in the region to conduct new national 
assessments to determine the true extent and nature of 
the drug abuse problem in the region and so aid in plan-




506. South Asia is facing a serious and growing drug 
abuse problem, including the abuse of pharmaceutical 
preparations containing narcotic drugs and psychotropic 
substances. For example, abuse of codeine preparations 
and “yaba” tablets containing methamphetamine has 
reached a high level and is growing rapidly in Bangladesh; 
drug abuse among youth is growing in Bhutan; prescrip-
tion drug abuse is growing in India; in Maldives, where 
the first national drug use survey revealed a serious drug 
abuse problem, and in Nepal, the recorded number of 
users of drugs is increasing rapidly. Governments of 
countries in the region continue to implement measures 
to prevent and tackle drug abuse and drug trafficking. 
Drugs enter South Asia’s illicit drug markets through a 
number of different channels, including diversion from 
India’s pharmaceutical industry, illicit cultivation and/or 
manufacture within the region, and smuggling from other 
countries, including Afghanistan (through Pakistan) and 
Myanmar.
2. Regional cooperation
507. Governments in South Asia continue to respond 
strongly to the threat of drug trafficking and abuse in the 
region, including through an array of cooperation 
arrangements, both within and extending beyond the 
region. That cooperation takes the form of information-
sharing among law enforcement agencies, training and 
technical assistance, cooperation on drug abuse preven-
tion and treatment activities and training for treatment 
practitioners, as well as other activities in the area of 
reducing drug demand. 
508. Bangladesh has close partnerships on drug abuse 
prevention and control with the Colombo Plan for 
Cooperative Economic and Social Development in Asia 
and the Pacific and 19 countries including China, 
Myanmar and the South Asian Association for Regional 
Cooperation member States. Those partnerships involve 
the exchange of information and technical assistance.
509. Bangladesh and India have close cooperation 
mechanisms for law enforcement and drug control, 
including regular meetings at the political and technical 
levels. The two countries have also agreed to share infor-
mation on drug trafficking on a real-time basis and to 
assist one another in the investigation of drug cases. The 
Board welcomes those measures taken by Bangladesh and 
India. Given the continuing high levels of drug smuggling 
across the India-Bangladesh border, ensuring that bor-
der’s security is paramount.
510. India currently has mutual legal assistance treaties 
with 36 countries and territories, including Bangladesh 
and Sri Lanka, providing a legal framework for legal assis-
tance in criminal matters. India has bilateral agreements 
or memorandums of understanding on drug-related mat-
ters with Bangladesh, Bhutan and a further 27 countries. 
India also has an ongoing agenda of cooperation with the 
Association of Southeast Asian Nations on combating 
drug trafficking.
511. Bhutan and India have a joint group on border 
management to take joint action against threats to the 
security of their common border. India and Nepal main-
tain mechanisms to prevent cross-border drug trafficking 
and other cross-border threats.
512. At a meeting in New Delhi in January 2013, the 
Ministers for External Affairs of India and Sri Lanka 
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signed an agreement on combating international terror-
ism and illicit drug trafficking.
513. The Colombo Plan for Economic and Social 
Development in Asia and the Pacific’s Asian Centre for 
Certification and Education of Addiction Professionals 
has published new curricula, including a curriculum on 
psychoeducation for clients and families in drug treat-
ment and rehabilitation.
514. The Colombo Plan also carries out a number of 
other initiatives targeting the drug problem, including 
treatment, rehabilitation and aftercare services and facil-
ities, in partnership with Governments, non- governmental 
organizations and communities; preventive drug educa-
tion and early intervention, in partnership with civil soci-
ety, including youth leaders; and training of law 
enforcement officers in chemical testing and control. The 
Colombo Plan has also launched the International Journal 
of Prevention and Treatment of Substance Use Disorders 
in order to advance scientific literature in this area. 
3. National legislation, policy and 
action
515. The authorities of Bangladesh have continued their 
efforts to raise awareness of and provide education on the 
dangers of drug abuse among prison inmates. Prison 
authorities in Bangladesh have partnered with UNODC 
and non-governmental organizations to deliver, over 
the  period 2007-2013, training sessions in prisons on 
drug abuse and associated health risks.
516. FATF has developed action plans with the 
Governments of Bangladesh and Nepal to address weak-
nesses in their frameworks against money-laundering and 
terrorist financing. Both countries have made progress in 
implementing the respective action plans, but as of June 
2013 some measures had not yet been implemented. The 
Board reminds Governments that anti-money-laundering 
measures are a key element of tackling drug trafficking. 
517. The Governments of India and Sri Lanka have been 
strengthening their frameworks against money- laundering 
and terrorist financing. In June 2013, FATF recognized 
that both countries had made significant progress in this 
area, and as a result removed them from FATF regular 
follow-up process.
518. In the context of the five-year plan for the  period 
2008-2013, the Bhutan Narcotic Control Agency is to 
carry out a survey on drug abuse in the country and 
 produce annual drug status reports and drug prevention 
education materials.
519. In March 2013, the Ministry of Finance of India 
issued an order under the country’s legislation on nar-
cotic drugs and psychotropic substances that, among 
other measures, specifies that the Government can sched-
ule any substance under the schedules in India’s national 
legislation. Accordingly, ketamine was placed under 
national control.
520. In addition to its existing plans to improve border 
security, as referred to in the Board’s annual report for 
2012, the Government of India has decided to build 
approximately 1,400 kilometres of strategic roads along 
its border with Nepal. India has also deployed 13 battal-
ions of troops and established 131 border outposts along 
its border with Bhutan. Along its border with Myanmar, 
India has deployed 15 battalions of border guards, who 
are responsible for action against cross-border drug 
smuggling, among other duties.
521. In response to problems with the abuse of and traf-
ficking in phensedyl (a codeine-based cough syrup), the 
Indian State of Bihar, which is close to India’s border with 
Bangladesh, has placed restrictions on the sale of phense-
dyl within its territory. Pharmacists have been instructed 
not to stock more than 1,000 bottles of phensedyl at any 
one time.
522. The Ministry of Social Justice and Empowerment 
of India collaborates with Nehru Yuva Kendra Sangathan 
(an autonomous body under the Ministry of Youth Affairs 
and Sports) and the National Bal Bhavan (an autonomous 
body under the Ministry of Human Resource 
Development) on a public-awareness campaign on drug 
abuse. Nehru Yuva Kendra Sangathan has reached young 
people in 3,750 villages in two provinces in India. The 
Narcotics Control Bureau of India is also undertaking a 
campaign in cooperation with the authorities of Delhi to 
raise awareness of the consequences of drug trafficking 
and abuse in Delhi.
523. The National Drug Agency of Maldives has part-
nered with UNODC to support non-governmental organ-
izations in Maldives in raising awareness of drug abuse 
and improving access to aftercare and support services 
for former drug abusers and their families. The Board 
welcomes the current initiative of the Government of Sri 
Lanka of undertaking a national drug abuse survey. The 
Cosmetics, Devices and Drugs Technical Advisory 
Committee of Sri Lanka decided on 18 April 2013 that 
all tablets and syrups containing ephedrine or pseudo-
ephedrine should be removed from the country’s market. 
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The Committee also decided not to accept the registra-
tion of cough and cold products that contain, inter alia, 
analgesics or caffeine in combination with ephedrine and/
or pseudoephedrine.
524. The National Dangerous Drugs Control Board of 
Sri Lanka has launched a project to develop a drug-free 
model village in an area within a high prevalence of drug 
abuse, for which it will provide services in the village. The 
National Dangerous Drugs Control Board has also 
launched an outreach and awareness-raising campaign 
targeting underserved settlements in Colombo, which has 
been identified as an area with a high prevalence of drug 
abuse.
525. Access to internationally controlled substances for 
medical purposes (particularly opiates for pain relief) is 
limited in the region. Some of the main opioids used for 
pain management are codeine, dextropropoxyphene, 
dihydrocodeine, fentanyl, hydromorphone, ketobemi-
done, morphine, oxycodone, pethidine, tilidine and tri-
meperidine. Average consumption of those opioids in 
Bhutan in the  period 2010-2012 was 635 defined daily 
doses for statistical purposes (S-DDD) per million inhab-
itants24 (i.e., for every 1 million inhabitants in Bhutan, 
635 daily doses of opioids were consumed). In Maldives, 
71 S-DDD  per million inhabitants were consumed, and 
24 S-DDD per million inhabitants in Sri Lanka. In coun-
tries with a larger population, the number of daily doses 
consumed  per million inhabitants was considerably 
lower: India, 10 S-DDD; Bangladesh, 8 S-DDD; and 
Nepal, 8 S-DDD. The Board has identified levels of con-
sumption that it considers to be inadequate (consump-
tion of opioid analgesics in quantities between 100 and 
200  S-DDD  per million inhabitants  per day) or very 
inade quate (consumption of opioid analgesics in quanti-
ties equal to or less than 100 S-DDD).
4. Cultivation, production, 
manufacturing and trafficking
(a) Narcotic drugs
526. Pharmaceutical preparations containing narcotic 
drugs and psychotropic substances continue to be diverted 
from India’s pharmaceutical industry and are trafficked 
domestically or at the international level, including 
 24 The term “defined daily doses for statistical purposes” are technical 
units of measurement defined by the Board for the purpose of statistical 
analysis and not recommended prescription doses. More details are avail-
able in part four of the technical publication on narcotic drugs for 2013 
(E/INCB/2013/2), in the notes on table XIV.
through illegal Internet pharmacies. Despite the efforts 
made by the Government of India to tackle the problem, 
diversion from licit channels in the country remains a 
major source of pharmaceutical preparations trafficked in 
the region. For example, one of the most commonly traf-
ficked pharmaceutical preparations is phensedyl; seizures 
of phensedyl in neighbouring Bangladesh continued to 
rise significantly in 2012. The Board recognizes the steps 
taken by the Government of India to prevent diversion 
from its pharmaceutical industry, including through 
implementation of previous recommendations of the 
Board, and calls on the Government of India to maintain 
and, where appropriate, strengthen its efforts to prevent 
the diversion of pharmaceutical preparations and their 
trafficking within and out of the country’s territory.
527. In addition to phensedyl, the narcotic drugs that 
are most commonly smuggled into or trafficked within 
Bangladesh include heroin and other drugs that are 
abused by injection. In Bangladesh in 2012, about 1.3 mil-
lion bottles of codeine preparations were seized, com-
pared with some 900,000 bottles in 2011, and about 2,500 
loose litres of codeine-based solutions were seized, an 
amount that has decreased over the past two years, as 
about 4,000 litres were seized in 2010. Seizures of heroin 
in Bangladesh increased from about 107  kg in 2011 to 
about 125 kg in 2012. Heroin smuggled into Bangladesh 
is mostly sourced from India. There is also some traffick-
ing of heroin originating in the countries of the Golden 
Triangle that is intended to be smuggled onward by sea 
to Europe and the Americas. While trends in the quan-
tities of seized drugs can be observed, it is not always 
possible to infer that the actual volume of trafficking of 
those drugs follow the same trend.
528. Drugs that tend to be abused by injection are being 
smuggled into Bangladesh in rapidly increasing amounts, 
as reflected by seizure data: about 70,000 ampoules of 
drugs for abuse by injection (pethidine and morphine) 
were seized in 2010, and about 160,000 ampoules of drugs 
for abuse by injection were seized in 2012. Seizures of 
opium in Bangladesh have fallen progressively, from 
about 12 kg in 2010 to about 5 kg in 2012.
529. Seizures of cannabis in Bangladesh have fluctuated 
in recent years but fell from 2011, when about 54  tons 
were seized, to 2012, when seizures totalled about 39 tons. 
Cannabis is smuggled into Bangladesh mostly from India 
and Nepal. Illicit cultivation of cannabis plant also takes 
place in remote areas of Bangladesh, and cannabis plant 
grows wild in Bangladesh. The level of illicit cultivation 
of cannabis plant has declined dramatically in recent 
years in Bangladesh. Quantities seized have also declined 
dramatically: in 2007, about 25,000 cannabis plants were 
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seized, while in 2012 fewer than 500 such plants were 
seized. There is illicit cultivation of opium poppy plant in 
Bangladesh, close to the border with Myanmar. Bhutan 
did not record seizures of pharmaceutical preparations in 
2012.
530. In India, data on seizures give a mixed picture of 
developments in trafficking in that country. However, the 
overall number of convictions for drug trafficking fell 
from about 8,600 in 2011 to about 6,200 in 2012. In evalu-
ating those statistics, it should be kept in mind that the 
prosecution of individual cases may take years to com-
plete. Seizures of cannabis herb have been steadily 
decreasing, down from 209  tons in 2009 to 69  tons in 
2012. Seizures of cannabis resin also fell, from 4.3  tons 
in 2010 to 2.2  tons in 2012. The area of illicit cannabis 
cultivation eradicated by the authorities has also been fall-
ing, from about 3,000 acres in 2011 to none in 2012. Large 
quantities of the illicit cannabis of India are exported: 
India remained one of the five main source countries for 
illicit cannabis resin mentioned by Governments world-
wide in seizure reports in 2011. In addition, India was 
identified as the source country for over 10  tons of can-
nabis herb recorded in the World Customs Organization’s 
Customs Enforcement Network database in 2012. Seizures 
of heroin in India have fluctuated since 2009 and increased 
from 528 kg in 2011 to 853 kg in 2012. In addition,  heroin 
is smuggled from India to countries including Bangladesh 
and Kenya. The quantity of opium seized in India has 
been increasing since 2009, when about 1.7  tons were 
seized, to more than 3  tons in 2012. However, the area 
of opium poppy cultivation destroyed by authorities 
decreased significantly, from about 14,000 ha in 2011 to 
about 2,900 ha in 2012. Seizures of morphine in India 
have risen since 2010, when 25 kg were seized, to 131 kg 
in 2012. 
531. In Maldives, the amount of heroin seized by the 
authorities decreased to 2.6  kg in 2012; in 2011, 3.2  kg 
had been seized by the Maldives customs service. The 
authorities of Maldives seized about 2.4  tons of cannabis 
resin in 2012. Maldives did not report seizures of phar-
maceutical preparations in 2012.
532. In Nepal, locally sourced cannabis and foreign-
sourced opium are the drugs most commonly trafficked. 
Authorities in Nepal seized 47  tons of cannabis in 2012, 
which is a 30 per  cent increase from 2011. State author-
ities in Bihar, India, indicate that phensedyl is also being 
smuggled from India into Nepal. Some of the drugs that 
transit through Nepal are destined for the United States.
533. In Sri Lanka, 2,547 people (some 0.01  per  cent of 
the population) were arrested for drug-related offences in 
the first half of 2012, which was about 70  per  cent less 
than in the first half of 2011. The number of arrests 
related to heroin declined by around 70 per cent and the 
number of arrests related to cannabis declined by about 
50  per  cent. Seizures of heroin in Sri Lanka decreased 
from 142  kg in 2010 to 39  kg in 2011 and to 33  kg in 
2012. The amount of cannabis seized in Sri Lanka fell 
from about 200  tons in 2011 to about 74  tons in 2012. 
Over 60 per cent of those arrested had between 5 and 10 
years of school education. Sri Lanka did not report sei-
zures of pharmaceutical preparations in 2012.
534. Although cocaine trafficking has historically been 
very limited in South Asia, it appears to be rising signifi-
cantly. Forty-two  kg of cocaine were seized in India in 
2012, up from 14  kg in 2011. In Sri Lanka, 7.5  kg of 
cocaine were seized in 2012, down from the approxi-
mately 10 kg seized in 2011, but significantly higher than 
in the period 1999-2009, when annual seizures of cocaine 
in Sri Lanka were less than 1 kg.
(b) Psychotropic substances
535. Amphetamine-type stimulants are both smuggled 
into South Asia and illicitly manufactured in the region. 
In South Asia, Bangladesh, India, Nepal and Sri Lanka 
have reported seizures of methamphetamine. Crystalline 
methamphetamine manufactured in South Asia is smug-
gled to Oceania and South-East Asia.
536. Seizures of amphetamine declined significantly 
from a peak of about 470  kg in 2011 to 30  kg in 2012. 
However, India continued to be a main source of illicit 
amphetamine-type stimulants manufactured and traf-
ficked in South Asia. Amphetamine and methampheta-
mine in powder form are illicitly manufactured in India. 
Tablets containing amphetamine-type stimulants traf-
ficked in India are mostly smuggled into the country 
from Myanmar. In 2012, 30  kg of amphetamine were 
seized in India. Amphetamine is smuggled from India to 
Bangladesh, often by people travelling on foot.
537. Seizures of methaqualone in India have increased 
steadily from 5  kg in 2009 to 178  kg in 2012, although 
that amount is still much lower than the approximately 
2.4 tons seized in 2008. However, from 2010 to 2012 (the 
latest year for which data are available), no illicit metha-
qualone manufacturing facilities were detected in India. 
Buprenorphine is smuggled into Bangladesh from India 
through Bangladesh’s south-west border.
538. “Yaba” (methamphetamine) is smuggled into 
Bangladesh from Myanmar. The quantities being 
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smuggled into the country are rapidly increasing. In 
2012, authorities seized almost 2 million tablets contain-
ing amphetamine-type stimulants—often “yaba”—which 
was a sizeable increase from the some 1.4 million tab-
lets seized in 2011. Overall seizures of methampheta-
mine exceeded 550 kg. Most of the “yaba” smuggled into 
Bangladesh is illicitly manufactured in the region of 
Myanmar that borders China (in Shan State and Kachin 
State) and is smuggled through Yangon and then by sea 
to Bangladesh, or smuggled to Maungdaw and then over-
land to Bangladesh.
539. Drug traffickers are attempting to smuggle 
amphetamine- type stimulants from India to Australia. 
India and China (including Hong Kong, China) were 
the origin of over 62  per  cent of illicit shipments of 
amphetamine-type stimulants (excluding MDMA) 
detected entering Australia in 2010 and 2011.
(c) Precursors
540. India is frequently cited as a source country for 
ephedrine and pseudoephedrine smuggled into Myanmar. 
Ephedrine is often smuggled from India to Myanmar, 
where the substance is used in the illicit manufacture of 
“yaba”. In India, 4.4 tons of ephedrine were seized in 2012, 
down from 7.2 tons in 2011. Seizures of acetic anhydride 
increased from none in 2011 to about 360 kg in 2012.
541. Drug traffickers in South Asia extract ephedrine 
and pseudoephedrine from pharmaceutical preparations 
and manufacture ephedrine from 1-phenyl-1-propanone 
(P-1-P). Asia continues to be targeted by organized crim-
inal groups as a source of precursors for the illicit manu-
facture of amphetamine-type stimulants, in particular 
ephedrine and pseudoephedrine.
(d) Substances not under international 
control
542. India remains one of the two countries in Asia 
(China is the other) most commonly mentioned as the 
source of new psychoactive substances. Nepal has also 
reported that new psychoactive substances are being sold 
in its territory. 
543. Ketamine is smuggled from India to destinations 
in East and South-East Asia. A large proportion of the 
seizures of ketamine effected in India have been made in 
southern India. Ketamine is seized at airports, from cou-
rier parcels and sea cargo and during the drug’s 
transportation within the country. Ketamine is now con-
trolled under national law.
544. Khat is smuggled to India mainly from Ethiopia, 
the Kenyan highlands and Yemen. Khat is illegal in India.
5. Abuse and treatment
545. Most countries in South Asia do not have national 
drug surveys; information on abuse and prevalence in the 
region must therefore be obtained from other sources.
546. According to UNODC, the prevalence of drug 
abuse by injection among the population aged 15-64 years 
in South Asia in 2011 was 0.03  per  cent, which is the 
lowest prevalence of any region. The prevalence of drug 
abuse by injection is also 0.03 per cent in India, accord-
ing to UNODC.
547. In Bangladesh, cannabis continues to be the most 
commonly abused drug; while there is no official survey 
on cannabis abuse, some estimates indicate that 1.2 mil-
lion people in the country abuse cannabis. An estimated 
300,000 people receive outpatient counselling services for 
drug addiction in Bangladesh, while an estimated 100,000 
receive inpatient drug treatment. About 43  per  cent of 
those admitted for treatment in 2011 were treated for 
 heroin addiction, about 28  per  cent were admitted for 
buprenorphine addiction, 17  per  cent were admitted for 
cannabis addiction, and 1.4  per  cent were admitted for 
sedative, hypnotic and/or tranquillizer addiction. 
Two  per  cent of drug abusers admitted for treatment in 
Bangladesh in 2011 indicated that they abused codeine 
cough syrup. Women make up a very low proportion of 
those receiving drug treatment in Bangladesh.
548. In Bangladesh, there have been many cases of 
women working for drug traffickers—transporting, ped-
dling, packing or storing drugs—who are forced to 
become addicted to drugs, as can be women who are 
married to male drug addicts. The most commonly cited 
cause of drug abuse among those who are admitted for 
drug treatment in Bangladesh is peer pressure (in 
55  per  cent of cases). Codeine-based cough syrups are 
often abused in Bangladesh, in part owing to the taste of 
those products and to their easy availability. Drug abus-
ers belonging to the educated upper class tend to abuse 
codeine-based cough syrups instead of heroin due to pre-
vious public awareness campaigns highlighting the health 
dangers of heroin abuse. According to the Department of 
Narcotics Control of Bangladesh, drug abuse can be con-
strued as a symbol of sophistication in affluent urban 
Bangladeshi society.
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549. The abuse of volatile solvents is common in 
Bangladesh, mainly among street children, but such abuse 
has been spreading to other segments of the population. 
About 1  per  cent of people admitted for drug treatment 
in Bangladesh in 2011 were admitted for sniffing adhe-
sives. Adhesives abused in Bangladesh often contain tolu-
ene, a precursor that is under international control and 
under national control in Bangladesh. Drug abuse by 
injection, while currently at a very low level, is also grow-
ing rapidly, mainly due to buprenorphine abuse.
550. Abuse of prescription drugs is increasing in India. 
India’s National AIDS Control Organisation supports 
more than 50 opioid substitution treatment centres pro-
viding treatment for about 4,800 people who abuse drugs 
by injection. Opioid substitution treatment centres run 
by non-governmental organizations are contracted by 
state AIDS control societies to implement opioid substi-
tution treatment after the centres have undergone an 
independent accreditation by the National Accreditation 
Board for Hospitals and Health-care Providers. A national 
plan currently being implemented seeks to establish 
300  opioid substitution treatment centres, which would 
serve 20  per  cent of the estimated number of people in 
India who abuse drugs by injection. By December 2012, 
India’s National AIDS Control Organisation had provided 
free opioid substitution treatment to approximately 
11,500  people who abused drugs by injection. The 
Organisation has also established a programme for men-
toring and building the capacity of staff working in opi-
oid substitution treatment centres, delivered by experts in 
the field. Opioids are the drugs most commonly abused 
by injection in India.
551. The Government of India has also started to imple-
ment a scheme under which non-governmental organi-
zations working with people who abuse drugs by injection 
partner with state hospitals to improve the effectiveness 
of opioid substitution treatment. The non-governmental 
organizations encourage people who abuse drugs by 
injection to visit a state-run hospital for opioid substitu-
tion treatment and follow up with the hospital if they 
drop out of the treatment.
552. In February 2013, Maldives published a report on 
the results of its first national drug use survey (covering 
people aged 15-64 years for the  period 2011-2012). The 
estimated annual prevalence of illicit drug use was 
6.64 per cent in Malé and 2.02 per cent in the atolls. Since 
different methodologies were used to estimate illicit drug 
use prevalence in different localities, a national prevalence 
cannot be accurately calculated. The drugs most com-
monly abused, in addition to alcohol, were cannabis and 
opioids. The survey provides a picture of the drug abuse 
problem in the country, which seems to affect mostly men 
who have been in conflict with the law, are sexually active 
and engage in buying sex. In Malé, more than one third 
of opioid and cannabinoid users were likely to be depend-
ent, while in the atolls 65  per  cent of opioid users were 
likely to be dependent. Among drug abusers in Malé, 
5  per  cent are injecting drug users, and in the atolls, 
10  per  cent are injecting drug users. The Board com-
mends the Government of Maldives for undertaking the 
survey and looks forward to being informed of action 
taken on the basis of the results of the survey. The Board 
also looks forward to hearing the results of similar initi-
atives by other countries in the region.
553. In Nepal, about 0.34 per cent of the population cur-
rently abuse cannabis resin, hallucinogens, inhalants, opi-
ates, stimulants, tranquillizers or other drugs, as measured 
in the Government’s 2013 survey. The survey did not 
include those who abuse only cannabis herb. The num-
ber of those reported to abuse the above-mentioned drugs 
doubled from 2012 to 2013, and the vast majority were 
male. About 94  per  cent reported abuse of opiates, and 
about 57 per  cent indicated drug abuse by injection.
554. The first ever “Low-cost community-based care 
and support camp” in Nepal for drug abusers took place 
in November 2012, organized by UNODC in collabora-
tion with non-governmental organizations. The camp 
used the sublingual administration of buprenorphine for 
the medical management of opioid withdrawal. A further 
five such camps are planned to be held in Nepal.
555. In Sri Lanka, from January to June 2012, a total of 
2,547 persons were arrested for drug-related offences. Of 
that group, about 2,000 people were drug abusers. The Sri 
Lankan Drug Abuse Monitoring System collects informa-
tion on drug-related arrests and the number of drug abus-
ers seeking treatment. The System recorded 217 people 
as having sought treatment for drug abuse in 2012, which 
was 40  per  cent less than in 2011. No women were 
reported to have received drug abuse treatment in 
Sri Lanka in 2012.
West Asia
1. Major developments 
556. West Asia remains central to the global illicit 
opium economy. Illicit opium poppy cultivation in 
Afghanistan set new records in 2013, reaching 209,000 ha, 
36 per cent more than the previous year. More than half 
of Afghanistan’s 34 provinces now cultivate illicit opium 
poppy, with production of opium in 2013 jumping by 
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49 per cent over the previous year, to 5,500 tons, even as 
poor weather conditions persisted.
557. In 2013, illicit cultivation of opium poppy and can-
nabis plant continued to take place throughout 
Afghanistan, involving nearly 200,000 farmers. The major-
ity of the farmers surveyed in 2012 cited the high income 
derived from the sale of opium poppy as the predomi-
nant reason for cultivation, and increased cultivation was 
reported in nearly every opium-producing province in 
2013. Illicit crops continue to be attractive for Afghan 
farmers as their sale value far exceeds the value of licit 
crops such as wheat. However, new initiatives have been 
undertaken by the Government to try and address that 
situation, such as expanding the “food zone” programme 
and other programmes (see chapter II.B.2, above).
558. Owing to its geographical location and the contin-
uing instability in the Middle-East, particularly in Egypt 
and the Syrian Arab Republic, West Asia is vulnerable to 
criminal activities and drugs syndicates operating in the 
region. Drug trafficking in the region has brought an 
increase in drug abuse and related crimes, which con-
tinue to represent a threat for countries neighbouring 
Egypt and the Syrian Arab Republic, in particular 
Lebanon. The growing number of displaced persons and 
refugees may create additional tension within the region. 
Firearms, cash and communication equipment are often 
found together with illicit drugs in seizure.
559. Abuse of stimulants, including amphetamine, 
methamphetamine and, to a lesser degree, cocaine, is 
increasing in parts of West Asia, where seizures and 
preva lence levels have increased. Saudi Arabia reported 
having seized a total of 48.6 million tablets containing 
amphetamine sold as Captagon in 2012, the largest 
amount of total seizures in the region. Methamphetamine 
abuse has been identified for the first time in Pakistan, 
where an estimated 22,000 adults abused the substance 
in the past 12 months. Methamphetamine seizures and 
abuse have also been reported to be on the rise in Iran 
(Islamic Republic of) and Israel—in the latter country 
primarily in the form of “yaba” tablets from South-East 
Asia. Cocaine trafficking in the Middle East has been 
growing, with consignments from South America arriv-
ing via air courier and by sea.
560. Trafficking in and abuse of amphetamine-type 
stimulants continue to be the principal concern in the 
region. Seizures of illicitly manufactured amphetamine 
sold as Captagon, which is the most frequently seized 
substance in the region, continues unabated as indicated 
by the detection of an illicit Captagon laboratory and sei-
zures of significant amounts of such tablets in Lebanon. 
The region has also witnessed an increase in seizures of 
methamphetamine, smuggled and trafficked mainly by 
means of express couriers.
561. There are indications that illicit drug shipments 
may be increasingly smuggled through the Middle East, 
in particular through Iraq. Iraq has become an important 
hub in the drug trafficking route leading from the “Golden 
Crescent” (Afghanistan, Iran (Islamic Republic of) and 
Pakistan) to the Gulf States as well as to Lebanon and the 
Syrian Arab Republic. There has been an increase in the 
smuggling of drugs across Iraq’s eastern border with the 
Islamic Republic of Iran to the Gulf countries, Lebanon 
and Israel and smuggling from Central Asia through 
northern Iraq to Eastern Europe.
562. Trafficking in and abuse of prescription medicines, 
in particular benzodiazepines such as alprazolam, diaze-
pam and clonazepam, has spread throughout the region 
and has been reported by almost all countries in the 
Middle East. In some countries, the prevalence of abuse 
of such substances among women has increased noticea-
bly. Further, trafficking in and abuse of substances not yet 
under international control, in particular the synthetic 
opioid analgesic tramadol, have continued to increase, as 
shown by the numerous seizures reported by authorities 
in various countries in the region and have been associ-
ated with drug-related deaths in some countries.
563. Another matter of great concern to the Board is 
the rapidly developing synthetic drug market and the 
emergence of new psychoactive substances in the Middle 
East, including synthetic cannabinoids (e.g. Spice). 
Attempted smuggling and seizures of such substances 
were reported by Bahrain, Israel, Jordan, Oman, Saudi 
Arabia and the United Arab Emirates.
564. The costs of corruption have an increasingly sig-
nificant impact on the people and institutions of West 
Asia. For example, the estimated cost of corruption in 
Afghanistan has increased by 40  per  cent over the past 
three years, costing the people of the country an esti-
mated $3.9 billion in 2012, costs associated in part with 
the region’s significant illicit drug economy. It was esti-
mated that in that same year half of the citizens of 
Afghanistan paid a bribe to receive a public service, and 
almost 30  per  cent of the population paid a bribe when 
requesting a non-government service. Corruption is 
increasing and becoming more  pervasive and an accept-
able part of day-to-day life in the country; in 2009, less 
than half (42 per cent) of those surveyed found it accept-
able for government employees to augment their income 
by accepting bribes for service, and the number finding 
it acceptable grew to 68  per  cent by 2012. In addition, 
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the frequency of bribery increased, from an average of 
4.7 bribes to 5.6 bribes per bribe-payer, with the average 
bribe amount paid increasing 29  per  cent to $214  per 
bribe and a total of $1,198 a year. Twelve per cent of Iraqi 
citizens also paid bribes to speed up or receive better pub-
lic service in 2012, with bribe-payers paying an average 
of just under four bribes annually. More than half 
(54 per cent) of Iraqis now indicate corruption to be more 
widespread than in the previous two years.
2. Regional cooperation 
565. West Asia is an important hub for global traffick-
ing in drugs and precursors, making the region an impor-
tant area for regional cooperation. UNODC operates 
programmes in most countries throughout the region. In 
2013, regional cooperation focused on the international 
community’s shared responsibility of development and 
drug control support after the planned conclusion of the 
ISAF mission in Afghanistan in 2014. 
566. The Cooperation Council for the Arab States of the 
Gulf (GCC) is the main regional forum for cooperation 
among its six member countries and with other regional 
entities. The enhanced cooperation made possible by the 
joint action programme of GCC and the European Union 
promotes the fight against money-laundering and terror-
ist financing.
567. The Board notes the inauguration of the GCC 
Criminal Information Centre to Combat Drugs in 
February 2013 in Doha. The Centre aims to promote and 
facilitate the collection of information, investigation and 
surveillance operations in coordination with competent 
entities in the region and the suppression of drug traf-
ficking. It also gathers information on all illicit trade in 
drugs and chemicals.
568. The Centre and UNODC undertook several activ-
ities related to technical cooperation and signed memo-
randums of understanding and letters of intent, or were 
preparing to do so, notably for training Dubai police. The 
Centre also concluded agreements with INTERPOL, the 
World Customs Organization Regional Intelligence 
Liaison Office for the Middle East and the Police Training 
Institute of the Ministry of Interior of Qatar.
3. National legislation, policy and 
action 
569. The Government of Kazakhstan approved its pro-
gramme of measures against drug abuse and the drug 
trade for the  period 2012-2016, aimed at further devel-
oping the system of effective countermeasures by intro-
ducing a range of legislative initiatives including the 
establishment of compulsory treatment programmes, 
instead of incarceration, for drug addicts committing 
minor criminal offences.
570. In recent years Kyrgyzstan has adopted several 
reso lutions and amendments to strengthen its drug con-
trol legislation. Resolution No. 54 (2011) established 
requirements for recording, storage and use of narcotic 
drugs, psychotropic substances and precursors for all 
pharmaceutical, health-care and educational organiza-
tions. Resolution No. 132 (2011) strengthened the State 
Drug Control Service apparatus. Resolution No. 654 
(2012) established the composition and regulation of the 
State coordination committee for drug control.
571. Turkey’s Council of Ministers amended national 
legislation in 2011, adding synthetic cannabinoids to the 
table of controlled substances. The change was a response 
following the first seizures of synthetic cannabinoids to 
occur in the country, in 2010—substances found to have 
originated in China, the United States of America and 
various European countries.
572. Bahrain and Saudi Arabia have introduced emer-
gency scheduling to temporarily ban new psychoactive 
substances. Furthermore, the United Arab Emirates has 
recently placed synthetic cannabinoids, such as Spice and 
K2, together with other synthetic cannabinoids, in table  I 
of banned narcotics drugs and psychotropic substances of 
its Federal Law No. 14 of 1995. It is the first Arab country 
to take legal measures to include synthetic cannabinoids 
within its drug law. It is expected that the measure will 
reinforce the law enforcement response to the increasing 
smuggling of synthetic cannabinoids into the country. 
573. Furthermore, in their efforts to control new syn-
thetic drugs, the Government of Israel included analogues 
of amphetamine, methamphetamine, cathinone and 
methcathinone in its Dangerous Drug Ordinance. Since 
2012, the country has added several synthetic cannabi-
noids to the Dangerous Drugs Ordinance, and in May 
2013 the Government adopted a comprehensive amend-
ment to the Ordinance, which included synthetic cannab-
inoid families and their derivatives. The legislation is 
similar to that adopted in areas of the United Kingdom 
of Great Britain and Northern Ireland, Ireland and in 
some states of the United States.
574. The Board welcomes the steps taken by the 
Government of Saudi Arabia against money-laundering, 
notably the adoption of a law that sets stiff penalties for 
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money-laundering offenders. The Government of Israel 
has taken legislative measures to combat criminal activi-
ties linked to drug trafficking, including by providing 
for stricter penalties in anti-money-laundering cases 
involving trafficking in narcotic drugs and psychotropic 
substances.
4. Cultivation, production, 
manufacture and trafficking 
(a) Narcotic drugs 
575. According to a 2013 joint survey by the Ministry 
of Counter-Narcotics of Afghanistan and UNODC, illicit 
opium poppy cultivation in Afghanistan was estimated at 
a record 209,000 ha, an increase of 36 per cent over 2012. 
The number of opium poppy-free provinces in Afghanistan, 
which increased notably from 2004 to 2011, has since 
fallen with opium poppy cultivation in excess of 100 ha 
now occurring in more than half of the country’s 34 prov-
inces. Opium poppy cultivation remained concentrated 
in the south, notably Helmand province, but increased 
cultivation was reported in nearly every opium poppy-
producing province in 2013.
576. An estimated 191,500 households in Afghanistan 
depend on illicit drug crops such as opium poppy and 
cannabis for income, for which prices remain high. The 
2012 farm-gate price for fresh opium was $163 per kilo-
gram, triple the value just five years ago, but dropped in 
2013 to $143 as production soared. Three quarters of 
Afghan village leaders surveyed in 2013 said the high sale 
price of illicit opium poppy was their primary reason for 
growing opium poppy, as it offered farmers far greater 
profitability than licit agricultural products (see table 
below).
577. Eradication of fields of illicit opium poppy is but 
one component of reducing the amount of opium avail-
able for heroin production. The greatest eradication 
efforts in West Asia are those of Afghanistan, where in 
2013, 7,348 ha of opium poppy cultivation were verifia-
bly eradicated in 18 provinces (see figure I). That repre-
sents roughly a third of the amount eradicated at the peak 
of eradication efforts in 2007, when 19,000 ha were 
eradicated.
Table 1. Changes in Afghanistan farm-gate prices of select licit and illicit crops, 2009-2013
Price 
(United States dollars per kilogram)
Agricultural product 2009 2010 2011 2012 2013
Fresh opium 48 128 180 163 143
Dry opium 64 169 241 196 172
Cannabis 
(first garda/resin) 35 86 95 68 . .
Cannabis  
(second garda/resin) 24 66 63 41 . .
Cannabis  
(third garda/resin) 12 39 39 26 . .
Rice 1.1 1.0 1.0 1.2 . .
Wheat 0.6 0.3 0.4 0.5 . .
Maize 0.4 0.3 0.3 0.3 . .
Sources: UNODC and Afghanistan, Ministry of Counter-Narcotics, Afghanistan: Opium Survey 2013 (November 2013) and previous years, and 
the opium surveys of previous years; UNODC and Afghanistan, Ministry of Counter-Narcotics, Survey of Commercial Cannabis Cultivation 
and Production 2012 (Vienna 2013) and the surveys of previous years; UNODC, Afghanistan Cannabis Survey 2010 (June 2011).
Note: Garda is powdered cannabis resin, with the highest level of quality being “first garda”. Two dots (. .) indicate that data are not 
available.
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Figure I. Opium poppy eradication efforts in 
selected West Asian countries, 2005-2013
Sources: UNODC and Afghanistan, Ministry of Counter- Narcotics, 
Afghanistan: Opium Survey 2013 (November 2013); UNODC and 
 Afghanistan, Ministry of Counter- Narcotics, “Afghanistan: opium 
risk assessment 2013”, and risk assessments of previous years; 
World Drug Report 2013 ( United   Nations publication, Sales No. 
E.13.XI.6).
Note: Data for Pakistan for 2013 were not available at the time of 
publication.
578. According to UNODC, Afghanistan, Lebanon and 
Pakistan are among the five countries worldwide most 
commonly identified as the source of seized cannabis 
resin. A 2011 survey on illicit cannabis plant cultivation 
in Afghanistan identified 12,000 ha of cultivation—among 
the world’s largest known cultivation amounts—most of 
which was destined for the production of cannabis resin. 
The area of cultivation declined to 10,000 ha in 2012. 
However, production of cannabis resin increased by 
8 per cent from 2011, to 1,400 tons. In Kyrgyzstan, about 
10,000 ha of cannabis grows wild, with cannabis herb and 
resin produced illicitly in the country (see paras. 49-53, 
above). Cannabis plant eradication efforts in 2012 were 
reported in other countries of Central Asia (including the 
South Caucasus), such as Tajikistan (2.2 million plants 
eradicated) and Azerbaijan (7,538 plants eradicated).
579. Illicit cultivation of cannabis plants continued in 
some areas throughout the Middle East, in particular in 
the Bekaa valley in Lebanon, where eradication efforts are 
rendered difficult by the instable security that prevails in 
the region. Cannabis plants and seeds are frequently seized 
in Bahrain. It also appears that indoor cannabis plant cul-
tivation is getting more sophisticated in that country, as 
seen by the indoor cultivation site seized in May 2013. 
580. Cannabis seizures in Kuwait amounted to 944  kg 
in 2012, more than double the quantity seized in 2011. 
There has been a considerable number of cannabis sei-
zures in Israel, near the border with Egypt, from where 
the drug is smuggled to other destinations in Israel. In 
the first half of 2013, more than 300 kg of cannabis were 
seized in Israel. 
581. UNODC estimates suggest that most Afghan  heroin 
(44  per cent) is trafficked via Pakistan, with 32  per  cent 
being smuggled via the Islamic Republic of Iran and the 
remaining quarter of it transiting a variety of Central 
Asian countries. Total heroin seizures by Central Asian 
authorities have steadily declined since 2003 primarily due 
to the decreases reported in Tajikistan, suggesting the 
expansion of other trafficking routes. Increasingly, mari-
time routes are being utilized for Afghan heroin via ports 
in Iran (Islamic Republic of) and Pakistan, with countries 
in East Africa a frequent destination.
582. Turkey is a significant crossing point from West 
Asia into Europe, and accordingly, significant amounts of 
Afghan opiates are seized there annually, primarily in the 
form of heroin. In 2012, authorities of the Anti-Smuggling 
and Organized Crime Department of Turkey seized 
11 tons of heroin destined primarily for Albania, Germany 
and the Netherlands (a 72-per-cent increase over seizures 
in 2011). For the third consecutive year, no morphine sei-
zures were reported in Turkey. Cannabis is the most 
widely trafficked and abused illicit drug in Turkey, and 
seizures have increased 262  per  cent over the past five 
years, with 74.6 tons seized in 2012. Most cannabis seized 
by Turkish authorities originated in the country. However, 
the total of 4 tons of cannabis resin seized originated pri-
marily in Iran (Islamic Republic of), Iraq and the Syrian 
Arab Republic. 
583. New heroin smuggling routes through the region 
are reportedly emerging. Heroin is smuggled out of 
Afghanistan through Iran (Islamic Republic of) or 
Pakistan, and is then smuggled through Iraq and other 
countries in the Middle East. According to national data 
provided, seizures of heroin in Lebanon increased from 
less than 3  kg in 2008 to more than 20  kg in 2012, and 
seizures of heroin in Oman totalled nearly 100 kg in 2012, 
compared with less than 9 kg in 2008. 
584. There has been an increase in seizures of heroin in 
Bahrain; in most cases, the heroin is ingested by so-called 
“mule smugglers”, arriving from Pakistan. In addition, 
numerous controlled deliveries led to seizures of parcels 
containing heroin sent by express courier. The parcels 
originated in Afghanistan and Iraq and were destined for 
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of heroin took place at the Bahrain international airport 
in August 2012, when more than 4.5 kg of heroin impreg-
nated in clothing was seized.
585. Cocaine seizures reported by countries in West 
Asia have increased—both in number and amount—with 
total seizures in the region rising to nearly 1 ton in 2011 
(see figure II). Turkey’s Anti-Smuggling and Organized 
Crime Department seized 402  kg of cocaine in 2012—
nearly double the amount reported in 2010—and reported 
that the number of cocaine seizures was increasing stead-
ily, as was the average amount  per seizure. Heroin traf-
ficking networks have increasingly shifted to trafficking in 
cocaine, while West African crime syndicates appear to 
be taking a more significant role in the supply of cocaine 
to Turkey. Bartering heroin for cocaine is an emerging 
phenomenon in Pakistan, where cocaine enters the coun-
try via Africa, as well as through East Asia and Europe. 
586. Illicit trafficking and abuse of cocaine has also 
increased in the Middle East, as consignments from South 
America are reaching the region via air courier and by sea. 
Cocaine originating in the Americas is transported to the 
Middle East mostly using express mail companies or con-
cealed in shipping containers sent by sea. In Yemen, 115 kg 
of cocaine were seized from a container sent from Brazil. 
In Lebanon, 13  kg of cocaine were seized in an aircraft 
arriving from Brazil via Qatar. In Saudi Arabia, a parcel 
from the Americas containing 153 g of cocaine was seized.
Figure II. Cocaine seizures in West Asia, 
2003-2011
Sources: World Drug Report 2013 (United Nations Publication, 
Sales No. E.13.XI.6) and previous years; World  Customs Organiza-
tion, Drugs Report 2010 (Brussels, 2011).
(b) Psychotropic substances 
587. Global seizures of amphetamine-type stimulants 
grew by 66 per cent in 2011 to a record total of 123 tons, 
driven by increases in methamphetamine and ampheta-
mine seizures. The largest total seizures of amphetamine 
continue to be those of countries in West Asia, where sei-
zures in 2011 totalled 20 tons, a 55-per-cent increase over 
the previous year. The largest amount of amphetamine 
seizures was that reported by Saudi Arabia (11 tons), 
where tablets containing amphetamine sold as Captagon 
continue to be in high demand. The Syrian Arab Republic 
and Jordan each reported having seized 4 tons of amphet-
amine. Large seizures of amphetamine tablets sold as 
Captagon in West Asia confirm that the demand for that 
drug, in particular in the countries of the Middle East, 
remains high. Most tablets seized were en route to the 
countries of the Arabian peninsula. 
588. According to the World Customs Organization, the 
main destination of the 3,881 kg of Captagon tablets that 
were seized in the Middle East in 2012, was, as in the 
past, Saudi Arabia. Almost 83  per  cent of all seizures in 
the region were effected in Saudi Arabia, followed by 
Jordan and the United Arab Emirates. Jordan and the 
Syrian Arab Republic were the main countries of con-
signment of the seized drugs reported by Saudi Arabia.
589. There are indications that local clandestine manu-
facture of Captagon is expanding. Laboratory equipments 
and chemicals used for the manufacture of drugs includ-
ing amphetamine sold as Captagon were seized by the 
Lebanese customs services. The material seized had 
arrived from China. In March 2013, Lebanese law enforce-
ment authorities dismantled an illicit laboratory for the 
manufacture of amphetamine sold as Captagon and more 
than 1 million amphetamine tablets sold as Captagon pills 
were also seized. The Board is concerned about the 
observed growing capacity of illicit manufacture of that 
drug in the region, which will increase the drug’s availa-
bility and demand for it. The Board therefore urges coun-
tries in the region, in particular Lebanon, to increase their 
vigilance and strengthen cooperation and joint operations 
to fight criminal networks involved in illicit drug 
manufacture. 
590. In Turkey, methamphetamine seizures increased 
between 2009 and 2012, with 403  kg of methampheta-
mine seized by authorities of the Anti-Smuggling and 
Organized Crime Department in 2012. The Islamic 
Republic of Iran, which has one of the highest rates of 
seizure of the substance in the world, was identified as 
the source of almost all methamphetamine seized in 
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591. In several controlled deliveries, parcels sent by 
express courier from the Philippines to Saudi Arabia were 
intercepted in Bahrain. The parcels were found to con-
tain methamphetamine, a drug being seized in increas-
ing quantities. One parcel seized in November 2012 
contained 1.16 kg of the drug.
592. The growing abuse of pharmaceuticals containing 
psychotropic substances, in particular benzodiazepines, 
continues to be a serious concern in the region. Some 
65  kg of clonazepam were seized in a single incident at 
the Istanbul airport; the substance was being smuggled 
by a passenger arriving from Pakistan via Dubai.
(c) Precursors
593. Most acetic anhydride destined for use in 
Afghanistan continues to be smuggled into the country 
after diversion from other countries’ domestic distribu-
tion channels. Although seizures of the chemical occur 
throughout the region, backtracking investigations, sub-
sequent communications remain inconsistent. For exam-
ple, Afghanistan did not provide the Board with an 
annual report of information on seizures of chemicals 
used in the illicit manufacture of drugs for 2012 (form 
D). However, the continuing decline in the black market 
price of acetic anhydride in Afghanistan suggests that the 
precursor’s availability has increased relative to the illicit 
demand. The Board urges more use of backtracking 
investigations of seizures of acetic anhydride and other 
chemicals to determine their source of diversion and to 
communicate seizures of those substances through PICS 
without delay.
594. The Board noted in its annual report for 2012 that 
few countries in the region had exercised their right to 
be informed of chemical shipments prior to their depar-
ture from the exporting country under article 12, para-
graph 10  (a), of the 1988 Convention, putting those 
shipments at heightened risk of diversion. The Board 
notes with satisfaction that in 2013, Armenia, Iraq, 
Kyrgyzstan, Qatar and the Syrian Arab Republic invoked 
their rights to require pre-export notification for all sub-
stances included in Tables I and II of the Convention. 
The Board calls on the eight Governments of the region 
yet to do so, namely Bahrain, Georgia, Iran (Islamic 
Republic of), Israel, Kuwait, Turkmenistan, Uzbekistan 
and Yemen, to exercise their rights under article 12, par-
agraph 10 (a) of the 1988 Convention.
(d) Substances not under international 
control
595. The misuse of tramadol, a synthetic opioid analge-
sic, in the Gulf countries is becoming a matter of genu-
ine concern, with some countries even reporting 
tramadol-related fatalities. The trafficking and abuse of 
tramadol, which is not under international control, is 
being reported by many countries in the Middle East. 
Significant seizures of tramadol are regularly made by 
enforcement authorities in the region. In Jordan, trama-
dol is diverted from domestic distribution channels, at 
the retail level, and through sales without the requisite 
medical prescription.
596. According to information collected by the Board, 
tramadol has been placed under national control in 
almost all the countries in the region. The substance is 
already controlled under national legislation for psycho-
tropic substances and/or narcotic drugs in Bahrain, 
Jordan, Qatar and Saudi Arabia. In Lebanon, where more 
than 5  per  cent of individuals in treatment for polydrug 
abuse are found to abuse tramadol, the authorities are 
considering placing the substance under national 
control. 
597. According to the information available, Egypt is the 
country of origin of the tramadol seized in Qatar, and 
Saudi Arabia has reported increasing smuggling of that 
drug from Egypt into its territory. Likewise, most of the 
tramadol seized in Lebanon arrives from Egypt, where its 
abuse is widespread. The Board calls on the countries in 
the region to remain vigilant vis-à-vis the apparently 
growing non-medical use and/or abuse of tramadol and 
urges countries where diversion and illicit trafficking 
already occur to consider the adoption of more stringent 
control measures over the trade in and distribution and 
dispensing of tramadol to ensure that preparations con-
taining tramadol are dispensed for legitimate medical use 
and to limit their diversion into illicit distribution 
channels. 
598. New psychotropic substances were reported by 
some countries in the Middle East such as Bahrain, Israel, 
Jordan, Oman, Saudi Arabia and the United Arab 
Emirates. In addition to ketamine, the emergence of syn-
thetic cannabinoids (Spice) and mephedrone (4-methyl-
methcathinone) was also reported. In Israel, synthetic 
drugs such as synthetic cannabis products have been sold 
as “incense” for several years, with most of the consum-
ers being teenagers between the ages of 14 and 17. 
According to the customs authorities of the United Arab 
Emirates, 126 smuggling attempts involving a total of 
23.5 kg of synthetic cannabinoids were intercepted in the 
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first eight months of 2012. All consignments had arrived 
in parcels. It is believed that the drug was destined for 
both local market and other destinations. 
599. Khat (Catha edulis) remains the main substance of 
abuse in Yemen, where the plant is cultivated, in addition 
to being imported from East Africa. A large proportion 
of the Yemeni adult population of both genders chews 
fresh khat leaves on a regular basis. The authorities of 
Bahrain and Oman reported the seizure of 1.7  kg and 
748 kg of khat, respectively, in 2012. 
5. Abuse and treatment 
600. The annual prevalence of opiate abuse (heroin and 
opium, excluding prescription opioids) remains high in 
many countries of West Asia. UNODC estimates the 
highest rates of past-year opiate abuse among adults aged 
15-64 years to be those of Afghanistan (2.3-3  per cent), 
Azerbaijan (1.3-1.7  per cent), Iran (Islamic Republic of) 
(2.3  per cent) and Pakistan (0.6-1.2  per cent). However, 
the true extent of abuse is unclear as most prevalence 
estimates in West Asia are either unrepresentative of the 
country’s total population or are outdated. For example, 
the estimated prevalence rates for past-year opiate abuse 
among the general population (aged 15-64) for countries 
in the region are, on average, more than six years old (i.e., 
many are based on data from around 2007 or even ear-
lier). But since 2007, annual Afghan opium poppy culti-
vation, global heroin seizures and heroin treatment 
admissions in West Asia have all been reported to have 
increased notably. Additionally, there are many countries 
in West Asia, particularly countries in the Middle East 
such as Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar and 
Yemen, for which there are no reliable estimates of opi-
ate use. The Board calls on UNODC to assist Governments 
in West Asia so that reliable, accurate and timely esti-
mates of prevalence of drug abuse can be carried out. 
601. A new joint report of the Government of Pakistan 
and UNODC on drug abuse in Pakistan estimates that 
5.8  per  cent of adults aged 15-64 years in Pakistan (6.4 
million individuals) used drugs in 2012, of which nearly 
two thirds (4.1 million individuals) are thought to be 
drug dependent. Cannabis was found to be the most com-
monly abused drug in Pakistan, with an adult annual 
prevalence of 3.6  per  cent, followed by opioids, at 
2.4  per  cent. Compared with other national estimates, 
opiate use is very high in Pakistan, with 1 per cent of the 
population using heroin or opium and 1.5 per cent abus-
ing opioid-based prescription painkillers for non-medical 
purposes over the last year. There are about 420,000 peo-
ple who inject drugs in Pakistan, which is 0.4 per cent of 
the adult population. Addiction treatment capacity is low 
compared with demand and is able to serve less than 
30,000 drug abusers  per year. However, new drug treat-
ment protocols aimed at enhancing the capacity of drug 
treatment professionals were launched in November 2012, 
in collaboration with the World Health Organization.
602. Methamphetamine abuse is spreading among 
some countries of West Asia. Abuse in the Islamic 
Republic of Iran is increasingly widespread, with research 
now documenting cases across a variety of community 
settings, including in emergency departments of hospi-
tals, among students and patients in opioid substitution 
treatment and among people who inject drugs. Although 
smoking is the most common route of methampheta-
mine administration, a new trend of methamphetamine 
injection has been reported, bringing increased risks of 
blood-borne infections, such as hepatitis and HIV/
AIDS. In Pakistan, the first study to generate data on 
the use of amphetamine-type stimulants in the country 
has revealed a new pattern of drug consumption; an esti-
mated 22,000 adults abuse amphetamine-type stimu-
lants—often methamphetamine.
603. The Board notes that a number of countries in the 
Middle East are devoting special attention and efforts to 
the treatment and rehabilitation of drug abusers. Saudi 
Arabia has developed a triple-faceted strategy addressing 
prevention and suppression and drug abuse rehabilita-
tion. In response to the increasing number of drug 
addicts, Oman plans to set up drug rehabilitation centres 
in each governorate of the country. 
604. The Government of Qatar has made increasing 
efforts in awareness-raising and drug abuse prevention by 
organizing seminars and lectures at schools, colleges, 
sports and cultural clubs, places where young people 
gather and military institutes. Similarly, the Board notes 
the commitment of the Government of Kuwait in the area 
of drug prevention and its dedication to implementing 
security and awareness plans and projects to combat the 
abuse of drugs. In that context, the  personnel of the 
national anti-drug abuse media project “Ghiras” has 
signed cooperation agreements with, among other organ-
izations, UNODC, the World Health Organization, the 
Gulf Cooperation Council Health Bureau and the Mentor 
Foundation for drug prevention. 
605. There have been no recent epidemiological studies 
providing an assessment of the extent of drug abuse in 
Lebanon in recent years. However, the number of people 
who inject drugs is estimated at between 2,000 and 4,000 
individuals, and about 5.7  per  cent of people with HIV 
in Lebanon are injecting drug users.
78  INCB REPORT 2013
606. Drug trafficking in prisons raises the risk of the 
spreading of HIV among prisoners, in particular those 
who inject drugs. More than 70  per  cent of the people 
who inject drugs had injected drugs on the day they 
entered prison, and 7  per  cent shared needles while in 
the prison. 
607. The Government of Lebanon launched an opioid 
substitution treatment programme at the beginning of 
2012. The programme is now fully operational, and 
since its launch about 700 patients have joined the 
programme.
608. Treatment admissions data reported by the coun-
tries of the Central Asian and Transcaucasian subregion 
in 2011 showed that the proportion of those entering 
treatment primarily for opioid abuse ranged widely: in 
Tajikistan, 99  per  cent of those admitted for treatment 
had primarily abused opioids; in Georgia, 96 per cent; in 
Uzbekistan, 89  per cent; in Kyrgyzstan, 84  per cent; and 
in Kazakhstan, 64 per  cent. However, treatment capacity 
throughout this subregion remains limited.
D. Europe
1. Major developments
609. Rates of abuse of narcotic drugs and psychotropic 
substances in Western and Central Europe appear to be 
continuing to stabilize or decline, although at historically 
high levels. The use of amphetamine-type stimulants 
remains stable in Eastern and South-Eastern Europe, with 
a small increase reported in few countries. Cannabis 
remains the most widely abused drug in Europe. Heroin 
is the most abused opiate, followed by opium and mor-
phine in Eastern and South-Eastern Europe. The emerg-
ing abuse of prescription opioids is of concern in Western 
and Central Europe, with seizures reaching record levels 
in a few countries of the subregion and with treatment 
demand for abuse of opioids other than heroin increas-
ing. Opioid-related deaths have decreased overall in 
Western and Central Europe, but the proportion of deaths 
attributable to fentanyl and methadone has increased in 
some countries. 
610. The abuse of new psychoactive substances poses a 
major challenge, especially in view of the unprecedented 
number and variety of substances identified in 2012, often 
sold as “bath salts”, “legal highs” or “plant food”. New psy-
choactive substances are an emerging drug phenomenon 
in Eastern and South-Eastern Europe, where they have 
recently begun to have an impact. While those substances 
are primarily transported in bulk from Asia, for process-
ing, packaging and distribution in Europe, there are indi-
cations of limited manufacture in Europe. The supply of 
new psychoactive substances poses increasing challenges, 
as some are legally commercialized. 
611. Illicit indoor cannabis cultivation continues to 
increase in the subregion of Western and Central Europe, 
although with a tendency towards the use of multiple, 
smaller sites. Cannabis resin seizures have decreased in 
the subregion, while seizures of cannabis herb have 
increased. Cannabis herb is grown throughout Eastern 
and South-Eastern Europe, with large-scale cultivation 
detected in many countries, particularly Albania. 
612. While the Balkan route remains the most com-
monly used route for drug trafficking in the subregion of 
Eastern and South-Eastern Europe, the amount of heroin 
trafficked declined in the past year. Consequently, declines 
in heroin seizures have been reported by countries in the 
subregion. 
613. Cocaine trafficking routes are increasingly diversi-
fied, for instance with some trafficking of cocaine through 
the Baltic countries or along the Balkan route tradition-
ally used for the trafficking of heroin from Afghanistan 
to Europe. An increase in cocaine trafficking has been 
reported in particular through ports of the Black Sea, 
together with the increasing influence of foreign criminal 
organizations in the region. 
614. Illicit methamphetamine manufacture appears to 
be spreading to new locations in Europe. New laborato-
ries for its manufacture have been uncovered in Bulgaria, 
Romania, the Russian Federation and Ukraine. Seizures 
of MDMA (commonly known as “ecstasy”) have increased 
in Western and Central Europe, indicating a possible 
resurgence of the substance; at the same time, illicit manu-
facture of the substance has shifted away from Europe.
2. Regional cooperation
615. The regional Operation Channel Transport took 
place in the framework of the regional anti-drug initia-
tive, Operation Channel, under the auspices of the 
Collective Security Treaty Organization, in December 
2012. The main objective of Operation Channel Transport 
was to detect and prevent drug trafficking and to sup-
press channels of trafficking of synthetic drugs from 
Western and Central Europe to States members of the 
Collective Security Treaty Organization, as well as traf-
ficking of heroin and cannabis from Afghanistan to the 
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countries of the Customs Union of Belarus, Kazakhstan 
and the Russian Federation.
616. In December 2012, the Council of the European 
Union adopted the European Union drugs strategy for 
the  period 2013-2020. The strategy comprises cross- 
cutting themes of coordination; international coopera-
tion; and research, information, monitoring and 
evaluation. The strategy’s first action plan, for the period 
2013-2016, adopted in June 2013, includes actions to 
tackle the misuse of prescription and over-the-counter 
opioids, improve drug-abuse related health-care measures 
in prisons and after release, tackle new psychoactive sub-
stances and polydrug abuse (including licit/illicit combi-
nations) and promote alternatives to coercive sanctions 
for drug-using offenders. 
617. Various events were held in the past year with a 
view to further enhancing regional and international 
cooperation in drug control. 
3. National legislation, policy and 
action
618. In Austria, in October 2012, the Psychotropic 
Substances Decree was amended with regard to, inter alia, 
the prescription of benzodiazepines in order to reduce 
the combined use of opioids and benzodiazepines. In the 
Russian Federation, Government Decision No. 1178 of 19 
November 2012 introduced amendments to the list of 
narcotic drugs, psychotropic substances and precursor 
chemicals subject to control in the Russian Federation. In 
late 2012, the Ukrainian authorities developed a national 
integrated anti-drug strategy, expected to be approved by 
the Government by the end of 2013. In Estonia, as part 
of the national health plan for the  period 2009-2020, an 
action plan for the  period 2013-2016 was adopted; the 
action plan includes drug supply and drug demand reduc-
tion as part of an integrated public health approach. 
619. In Croatia, the new criminal code came into force 
on 1 January 2013. The manufacture and abuse of nar-
cotic drugs is now controlled under three of the code’s 
articles: unauthorized manufacture and trade in drugs 
(article 190), enabling the use of drugs (article 191) and 
unauthorized manufacture and trade in substances pro-
hibited in sport (article 191a). Production of drugs with-
out intention to sell is defined as a distinct offence 
punishable by six months to five years imprisonment. The 
possession of small quantities for  personal use is treated 
as a misdemeanour under the Law on Combating Drug 
Addiction, punishable by a fine between 650 and 2,600 
euros (about $820-$3,250). Assessment of what comprises 
a “small” quantity is left to the state prosecutor or court. 
The new Code urges the court to use alternative punish-
ments to imprisonment for cases with sentences of up to 
six months prison terms. 
620. In March 2013, the Government of the Russian 
Federation launched a comprehensive new state pro-
gramme of the Russian Federation on countering illicit 
drug trafficking (2013-2020). The document includes a 
number of key measures intended to strengthen cooper-
ation and coordination among law enforcement agencies, 
promote legal reforms, increase operational and research 
activities, inquiries, investigations, enhance coordination 
of anti-drug activities at the federal level, as well as inter-
national cooperation against illicit drug trafficking. 
621. In Ukraine, on 13 May 2013 the Government 
approved resolution 333, which establishes procedures for 
acquisition, transportation, storage, dispensing, use and 
disposal of narcotic drugs, psychotropic substances and 
precursors in all health-care institutions in the country. 
In 2013, the Government of Montenegro prepared a draft 
national drug strategy for the  period 2013-2020 and its 
action plan for the period 2013-2016, in cooperation with 
UNODC; adoption of those documents is expected by the 
end of 2013. 
622. In October 2012, the Austrian Narcotic Drugs 
Decree was amended to allow the prescription of phar-
maceutical products containing cannabis extract that are 
authorized in Europe. In April 2013, amendments to the 
act on dependency-producing substances of the Czech 
Republic came into force, allowing the cultivation, pro-
duction and use of cannabis for medical purposes. In the 
United Kingdom, statutory instruments that came into 
force in April 2013 placed the cannabis-based medicine 
Sativex under part 1 of Schedule 4 of the Misuse of Drugs 
Regulations so that the product is governed by the regu-
latory framework for medicines that are also controlled 
drugs. 
623. In January 2013, in the Netherlands, a rule limit-
ing access to so-called “coffee shops” to residents of the 
country came into effect nationwide, after having been 
introduced in three southern provinces (Limburg, 
Noord-Brabant and Zeeland) on 1 May 2012. However, 
municipalities were  permitted to implement the new 
rule gradually and in accordance with local “coffee-shop” 
and security policies. The Government announced that, 
as of June 2013, 70 per cent of the 103 municipalities of 
the country were already implementing or were plan-
ning to implement the residency criterion. Planned 
restrictions that were to enter into force in January 2013 
to limit access to such venues to a maximum of 
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2,000  “members”  per year were revoked by the 
Government in November 2012. The Government also 
announced in November 2012 that the planned increase 
in the minimum distance between such venues and sec-
ondary and vocational schools to 350 metres would not 
be imposed by national rules. While noting those devel-
opments, the Board reiterates its position that such 
 “coffee shops” are in contravention of the provisions of 
the international drug control conventions.
624. In Switzerland, amendments to the Narcotics Act 
were to come into force in October 2013, enabling the 
punishment by fine of possession by adults of less than 
10 grams of cannabis.
625. Countries in the region have continued to take 
legislative measures to address the challenge of new psy-
choactive substances, at both the national and regional 
levels. In March 2013, the Council of the European 
Union decided to subject to control measures 4-methyl-
amphetamine (known as “4-MA”), a synthetic derivative 
of amphetamine that has been associated with fatalities 
in Europe. In October 2013, the Council decided to ban 
5-(2-aminopropyl)indole (known as “5-IT”), a synthetic 
stimulant with stimulant and hallucinogenic effects that 
has been associated with deaths in a number of 
countries.
626. In September 2013, the European Commission 
proposed legislation that would develop further the pro-
cedures for risk assessment and control of new psycho-
active substances, which would provide for the introduction 
of temporary measures restricting the sale of new psy-
choactive substances to consumers across the European 
Union, in cases of immediate risk, and permanent meas-
ures within 10 months. In case of substances assessed to 
pose a severe risk, even industrial use could be restricted. 
The measures would be directly applicable to European 
Union member States and would not need to be trans-
posed into national law.
627. Many countries have placed numerous new psy-
choactive substances under control. For example, in 2012, 
28 new synthetic substances were placed under control 
in Germany, and 46 new “research chemicals” were placed 
under control in Switzerland. In April 2013, 15 substances 
were placed under national control in Belgium. In 2012, 
tapentadol was placed under control in Austria, Finland 
and the Netherlands, and mephedrone was placed under 
control in Finland and the Netherlands. 
628. In April 2013, legislation was introduced in 
Portugal that provides for the closure of retail outlets, also 
known as “smart shops” or “head shops”, selling new 
psychoactive substances. Under the legislation, new psy-
choactive substances can be subject to temporary bans in 
cases where there is no authorized legitimate use and 
removed from the market until the substance is con-
firmed to pose no health risk.
629. In Latvia, in February 2013, a generic system was 
introduced in the list of controlled substances, and 
17  generic chemical substance groups comprising more 
than 200 new psychoactive substances were placed under 
control. Lithuania placed five groups of substances under 
control in 2012. Also in 2012, methoxetamine became 
the first drug to be controlled under a temporary drug 
order in the United Kingdom, and in February 2013, 
methoxetamine, together with related substances, 
O-desmethyltramadol, additional categories of synthetic 
cannabinoids and compounds related to ketamine and 
phencyclidine were brought under the control of the 
Misuse of Drugs Act. In 2013, decisions were taken to 
control benzofuran substances (also known as “benzo-
fury”), such as 5-APB and 6-APB, in Belgium and as a 
temporary measure in the United Kingdom. In 
Luxembourg in 2012, the plants Salvia divinorum and 
Kratom (Mitragyna speciosa) were placed under national 
control. Khat was placed under control in the Netherlands 
in January 2013, and in July 2013 a decision was taken 
to control the plant in the United Kingdom. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
630. The illicit cultivation of cannabis plant, both in pri-
vate homes and in larger plantations, in many countries 
in Europe has continued to increase, reportedly facilitated 
in some countries by the sale of seeds and equipment 
through the Internet. The involvement of organized crim-
inal groups in the large-scale illicit production of canna-
bis has been noted, but there is also increasing evidence 
of a move towards multiple small-scale sites, such as seen 
in the United Kingdom, where large numbers of illicit 
commercial-scale operations have been discovered and 
where there is evidence of a stabilization in the number 
of detections of cannabis farms. The number of proper-
ties (residential and commercial) in which cannabis has 
been illicitly cultivated on a large scale has increased in 
some countries. For example, in the Czech Republic a 
record 199 seizures of cannabis “grow houses” were made 
in 2012, a third of which contained over 500 plants each, 
compared with 165 such seizures in 2011. In 2012, 
48  cannabis cultivation sites were uncovered in Romania, 
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and a total of 3,125 cannabis plants were seized. Of those, 
12 cannabis outdoor cultivation sites were detected, and 
36 sites were indoors. Ukraine reported a total of 98,000 
eradicated outdoor sites. In Bulgaria, in 2012 a total of 
42 indoor facilities and greenhouses growing cannabis 
were detected compared with 35 in 2011. 
631. In 2011, 5,435 indoor cultivation sites were dis-
mantled in the Netherlands, which was not a significant 
change from previous years, although illicit cannabis pro-
duction has been estimated to be increasing since 2008, 
with the main destinations reported to be Germany, Italy, 
the United Kingdom and the Scandinavian countries. A 
record 1,070 plantations were seized in Belgium in 2011, 
representing an increase of almost 10 per cent compared 
with the previous year, following the increasing trend that 
began in 2007, with an increase in the number of plan-
tations containing 6-49 plants, which represented about 
one third of sites seized, whereas the proportion of large 
and industrial scale plantations remained stable. Seizures 
of cannabis plantations in Germany increased from 717 
in 2011 to 809 in 2012, but there was a decline in the 
number of seized indoor large plantations and increases 
in indoor and outdoor small plantations. There is still 
widespread outdoor cultivation of cannabis in southern 
Italy.
632. During the past year there was a significant increase 
in the seizures of cannabis in South and South-Eastern 
Europe, mainly cannabis herb and, to a much lesser 
extent, cannabis resin. Important seizures of cannabis 
were made along the route traversing Albania, Montenegro 
and Croatia before arriving in Western European coun-
tries. In 2012, the Bulgarian Customs Agency seized 
4.2 tons of cannabis resin. In Romania, cannabis herb sei-
zures represent 42 per cent of the total amount of drugs 
seized, followed by seizures of cannabis plants 
(37  per  cent), and cannabis herb seizures increased by 
33 per cent compared with 2011. Cannabis resin seizures 
in Romania in 2012 increased by more than 50 per cent 
compared with 2011. In Montenegro, cannabis seizures 
rose by 90 per cent in the first four months of 2013 com-
pared with the same period in 2012, pointing to the grow-
ing importance of Montenegro as a transit country for 
Albanian cannabis herb. The primary illicit markets for 
Albanian cannabis herb continue to be Greece and Italy. 
633. In recent years, the number of seizures of canna-
bis herb in Western and Central Europe has continued to 
increase, while seizures of cannabis resin have decreased. 
However, the total quantity of cannabis resin seized 
remains much higher than that of cannabis herb. The 
quantity of cannabis resin seized in Western and Central 
Europe continued to decrease, from 526  tons in 2010 to 
483  tons in 2011, which is much less than the 900  tons 
seized in 2008. Europe as a whole now accounts for 
almost half of global cannabis resin seizures, compared 
with about three quarters over a decade ago. While Spain 
accounts for about one third of global cannabis resin sei-
zures and about three quarters of seizures in Western and 
Central Europe, cannabis resin seizures in the country fell 
by about one half between 2008 (683 tons) and 2012 
(326  tons). The quantity seized annually in France has 
remained relatively stable at around 50-56  tons in 
the  period 2009-2012, but decreased from 55.6  tons in 
2011 to 51.1  tons in 2012. In the United Kingdom, can-
nabis resin seizures in England and Wales increased by 
4  per  cent from 18.7  tons in 2010/11 to 19.5  tons in 
2011/12, compared with 12.6  tons in 2009/10, which is 
nonetheless much less than the 64  tons seized in 2004. 
While annual seizures of cannabis resin in Italy had 
remained at around 20 tons in 2010 and 2011, an increase 
to 22  tons was seen in 2012. Cannabis resin seizures in 
Portugal decreased significantly, from 34.7  tons in 2010 
to 14.6  tons in 2011.
634. Most cannabis resin seized in Europe still appears 
to have been produced in Morocco. Cannabis resin from 
Morocco is primarily trafficked to Europe by sea to the 
Iberian peninsula, typically Spain, for consumption in 
that country and transit to other countries in Western 
and Central Europe, with over 90 per cent of seizures by 
Spain reported to be seizures from commercial vessels. 
Belgium and the Netherlands have been identified as traf-
ficking hubs for cannabis resin and herb. 
635. While the number of cannabis herb seizures in 
Western and Central Europe has increased around six-
fold over the past decade, the quantity seized has remained 
relatively stable, at 55-65 tons annually between 2004 and 
2010, then increasing to 92  tons in 2011, which is still 
much less than the 124 tons seized in 2002. In the United 
Kingdom, seizures in England and Wales of cannabis herb 
increased by 6  per  cent from the 20.7  tons seized in 
2010/11 to 22  tons in 2011/12, yet seizures of cannabis 
herb have decreased by a third since 2008. The amount 
of cannabis herb seized by Spain increased dramatically 
from 2.7 tons in 2010 to 17.5 tons in 2011, then decreased 
in 2012 to 10.5 tons. Seizures in Greece increased from 
7.7  tons in 2010 to 13.4  tons in 2011, continuing the 
increasing trend of recent years. Around two thirds of the 
total quantity of seized cannabis in Greece in recent years 
was reported to have originated in Albania, trafficked 
mainly overland. In Italy, seizures of cannabis herb 
 doubled from 5.5 tons in 2010 to 10.9 tons in 2011, then 
doubled again to 21.5 tons in 2012. At the same time, the 
number of cannabis plants seized in Italy increased from 
72,000 plants in 2010 to 1 million in 2011 and over 
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4  million in 2012. In Belgium, total annual seizures of 
cannabis herb remained between 5.1 and 5.2  tons in 
the period 2010-2011, while in the Netherlands, there was 
a 10  per  cent increase in annual seizures, from 4.5 to 
5  tons over the same  period; in France, after having 
increased by 20  per  cent from 2010 to 2011, reaching 
5.5 tons, total cannabis herb seizures decreased to 3.2 tons 
in 2012. Organized criminal groups continue to be 
involved in the illicit trafficking of cannabis.
636. With no sizeable local market in South-Eastern 
Europe, cocaine is trafficked onward to Western European 
countries either by boat from Greece or by land through 
Bulgaria, Romania and Hungary. Cocaine continues to 
be trafficked in small amounts through ports in Bulgaria, 
Greece and Romania. The total amount of cocaine seized 
in Romania in 2012 was 54.7 kg, approximately one third 
of the quantity seized in 2011 (161 kg). A single signif-
icant seizure (48.5 kg) made at the Romanian border 
with Hungary constituted most of the total quantity 
seized in 2012. 
637. The amount of cocaine seized in Western and 
Central Europe has remained stable at about 60 tons since 
2008, after a peak level of 120  tons in 2006. The total 
amount of cocaine seized in Spain and Portugal com-
bined decreased from a peak of 84 tons in 2006 to 20 tons 
in 2011, a level similar to that of Belgium and the 
Netherlands combined (18  tons in 2011). The quantity 
seized in the Netherlands has remained stable at about 
10 tons per year, while seizures in Belgium have steadily 
increased from 2.5  tons in 2007 to 8  tons in 2011. Spain 
accounted for one quarter of cocaine seized in Europe in 
2011 (16.7 tons, the lowest level since 2000), and the 
amount seized increased by almost 25  per  cent to 
20.7  tons in 2012. The amount of cocaine seized in 
Portugal has remained below 5 tons since 2008. In 2011, 
there were record seizures of cocaine in France (10.8 tons) 
and Italy (6.3 tons), which were increases of 163 and 
65 per cent over 2010 respectively. However, the amount 
of cocaine seized in France in 2012 almost halved, fall-
ing to 5.6  tons and also decreased in Italy (falling by 
16  per  cent to 5.3 tons). In the United Kingdom, in 
England and Wales, the amount of cocaine seized 
increased from 2.4 tons in 2010/11 to 3.5 tons in 2011/12, 
a level similar to that of 2007/08.
638. Seizures of cocaine by customs authorities in Western 
Europe remained relatively similar in 2011 (34.2 tons) and 
2012 (35.9 tons), representing almost half of the total 
amount of cocaine seized globally by customs authorities. 
Of seizures of cocaine of 1 ton or more by customs author-
ities in Western Europe, the identified countries of consign-
ment were Ecuador (14.4 tons), the Dominican Republic 
(3.2 tons), Brazil (2.3 tons), Colombia (2.3 tons),  Peru 
(2.2  tons), Argentina (1.5 tons) and Chile (1.5 tons).
639. The diversification of cocaine trafficking routes to 
Western and Central Europe continued. Authorities have 
noted the possible emergence of routes that partially over-
lap the Balkan route for trafficking of more limited quan-
tities of cocaine to Central and Eastern Europe. Some 
countries have noted the increased trafficking of cocaine 
in smaller quantities, as well as trafficking by airmail or 
courier. Europol has reported that, since 2007, the amount 
of cocaine seized in containers has increased, in particu-
lar in Belgium, Germany, Spain and the United Kingdom, 
while the amount seized on vessels but not in containers 
has decreased. Increased trafficking via container ship-
ments may have contributed to an increase in the use by 
traffickers of the ports of Belgium and the Netherlands 
and other western European countries. A sharp increase 
in the amount of cocaine seized in the Baltic countries 
in 2010, which was not repeated in subsequent years, was 
seen as an indication of increased trafficking by sea into 
those countries, possibly for trafficking onward to other 
parts of Europe. West Africa continues to be used to traf-
fic cocaine to Europe but land routes could be becoming 
more significant, with a shift away from flights to 
European airports and northbound maritime routes along 
the African coast.
640. In 2012, heroin from Afghanistan continued to be 
moved along the so-called Balkan route from Turkey into 
South-Eastern Europe and then onward to destination 
markets in Western Europe. Total heroin seizures in 
South-Eastern Europe remained low and continued their 
declining tendency with the notable exception of Albania 
and the former Yugoslav Republic of Macedonia, which 
reported increases. Seizures in 2012 suggest a predomi-
nance of trafficking of heroin by land through Turkey to 
Bulgaria, Romania and Hungary and onward to Western 
Europe. The quantity of heroin seized in Romania 
increased almost 3.7 times, from 12.2 kg in 2011 to 45.2 kg 
in 2012. In 2012, the Romanian authorities made their 
largest ever single opium seizure, of 9.8 kg. Heroin sei-
zures in the Russian Federation in 2012 totalled 2,176 kg.
641. The diversification of trafficking routes of opiates 
from Afghanistan to Western and Central Europe contin-
ued. In addition to the traditional land routes, heroin traf-
ficked from Iran (Islamic Republic of) and Pakistan 
entered Western Europe by air or sea, either directly or 
via East and West African countries, such as Kenya. In 
November 2012, customs authorities in the Netherlands 
made a seizure of 450 kg of heroin at Amsterdam airport 
in a shipment identified as having been consigned in 
South Africa and bound for Canada. 
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642. The amount of heroin and morphine seized in 
Western and Central Europe in 2011 (6 tons) was simi-
lar to the amount seized in 2010. However, the amount 
of opiates seized by customs authorities in Western 
Europe more than doubled, from 1.4  tons in 2011 to 
3.3 tons in 2012. The amount of heroin seized in England 
and Wales in the United Kingdom, increased by 
153  per  cent to 1.8  tons in 2011/12 from 0.7  tons in 
2010/11, after having halved from 2009/10 (1.5 tons). In 
France, the amount of heroin seized decreased by more 
than 40 per cent between 2010 and 2012, to 0.6 tons, the 
lowest level since 2004. In Germany, heroin seizures 
declined only slightly from 2011 (498 kg) to 2012 
(489 kg), while opium seizures decreased from 112 kg in 
2011 to 81  kg in 2012. In Spain, the amount of heroin 
seized fell by 45  per  cent from 2011 to 2012 (229 kg). 
Seizures in Belgium and Greece declined in 2011 to 
140 kg and 312 kg respectively. Seizures in Austria more 
than tripled, from 65 kg in 2011 to 222 kg in 2012.
643. In Estonia, seizures of fentanyl, a synthetic opioid 
analgesic, increased from 0.9  kg in 2011 to 1.7  kg in 
2012, and seizures of methadone doubled from 1.1 kg to 
2 kg. Carfentanyl, a highly potent analogue of the syn-
thetic opioid fentanyl, normally used in veterinary med-
icine and not suitable for humans, and which is not 
under international control, suddenly appeared on the 
illicit drug market in Latvia in late 2012 and early 2013, 
where it is reported to have caused a number of fatal 
overdoses.
644. In the Russian Federation, in 2012, law enforce-
ment agencies detected 1,770 drug trafficking cases. The 
volume of drugs seized increased 1.8 times and totalled 
86.9 tons. In Romania, in 2012 there was an increase of 
about 60  per  cent in the total quantity of drugs seized 
compared with the previous year. In the former Yugoslav 
Republic of Macedonia, the quantity of drugs seized in 
2012 remained low, continuing a downward trend, and 
cannabis cultivation, mainly for local consumption, has 
also been reported. 
(b) Psychotropic substances
645. Seizures of amphetamine by customs authorities in 
Western Europe increased from 1.8  tons in 2011 to 
2.5  tons in 2012, continuing the trend seen since 2010, 
but was still less than the amount seized in 2009. After 
having reached peak levels of between 7  tons and 8  tons 
of annual total seizures in the period 2007-2009, the total 
amount of amphetamine seized in Western and Central 
Europe decreased to 5.2 tons in 2010 and 5.6 tons in 2011. 
Germany accounted for approximately one quarter of the 
amount seized in 2011, with the Netherlands and the 
United Kingdom each accounting for almost one fifth of 
the total. Seizures in Germany reached peaks of 1.4  tons 
in 2009 and 2011, then decreased to 1.1  tons in 2012, a 
level similar to that of 2010. Seizures in the Netherlands 
had decreased from 2.4 tons in 2009 to 0.6 tons in 2010, 
then increased to 1.1 ton in 2011. In the United Kingdom, 
seizures increased from 0.7  tons in 2010/11 to 1 ton in 
2011/12, still less than the peak of 2.9  tons in 2008/09. 
In the former Yugoslav Republic of Macedonia, in 2012, 
police forces raided, for the first time, a laboratory manu-
facturing synthetic drugs, near Skopje, and seized 4 litres 
of liquid amphetamines and some 3,000 tablets. With 
regard to amphetamine-type stimulants, a sharp decrease 
has been reported in the number of tablets seized in 
Romania, falling from 7,315  tablets in 2011 to only 
34 tablets seized in 2012, and methamphetamine seizures 
dropped from 24.3 kg in 2011 to 3.3 kg in 2012.
646. The expansion of the illicit manufacture of and 
trafficking in methamphetamine in Europe has contin-
ued. The number of laboratories illicitly manufacturing 
methamphetamine detected during the year further 
increased to 350 in 2011, the majority of which were in 
the Czech Republic, where the number of seizures of 
such laboratories decreased from a peak of 434 in 2008 
to 235 in 2012, and where methamphetamine seizures 
peaked in 2012 at 31.9 kg, compared with 3.6 kg in 2009. 
Four methamphetamine laboratories were seized in the 
Russian Federation, and seizures of amphetamines 
increased from 142  kg in 2010 to more than 2  tons in 
2011. Increased activity was also reported in Belarus, 
where nine laboratories were seized in 2011. Large-scale 
methamphetamine laboratories have been detected in 
Bulgaria, Germany, the Netherlands and the United 
Kingdom, with illicit laboratories also detected in Austria, 
Belgium, Hungary, Ireland, Lithuania, Poland and 
Slovakia. Seizures of methamphetamine by Western 
European customs authorities increased from 74  kg in 
2011 to 361  kg in 2012. Total amounts of annual meth-
amphetamine seizures in Western and Central Europe 
increased from about 300 kg in 2008 and 500 kg in 2009 
and 2010, to 636 kg in 2011; in 2011, the largest propor-
tion of methamphetamine in the subregion was seized in 
Norway, followed by Lithuania and Sweden. In Norway, 
methamphetamine accounts for 60  per  cent of amphet-
amines seized, with a decrease in 2011 seizures of meth-
amphetamine (163 kg) compared with the 2009 peak of 
234 kg. In Lithuania, seizures have fluctuated from 18 kg 
in 2010 to 134  kg in 2011, decreasing in 2012 to 54 kg; 
in Sweden, total annual seizures decreased over the period 
2009-2012 from 164  kg to 47 kg. In Germany, seizures 
of methamphetamine peaked at 75 kg in 2012, compared 
with 40  kg in 2011.
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647. Customs seizures of “ecstasy” have remained rela-
tively constant in Western Europe over 2011 and 2012 
(481 and 438 kg). Overall, in Western and Central Europe, 
which accounts for around 13 per cent of global “ecstasy” 
seizures, the number of tablets seized has increased from 
2 million in 2009 to 4.3 million in 2011, which nonethe-
less is much less than the peak of 23 million tablets seized 
in 2002, with France, Germany, the Netherlands and the 
United Kingdom together accounting for 87  per  cent of 
the amount seized. The increase has been taken as an 
indication of a possible “recovery” of the illicit market for 
the substance, especially in France and the Netherlands. 
The number of illicit laboratories manufacturing “ecstasy” 
that were dismantled in Western and Central Europe 
declined from a peak of 50 in 2000, to 3 in 2010 and 5 
in 2011, with the Netherlands and Belgium having 
reported the largest number of such laboratories over the 
past decade. In August and October 2013, two large-scale 
laboratories used for the illicit manufacture of “ecstasy” 
were seized in Belgium. At the same time, the illicit 
manu facture of “ecstasy” has shifted away from Europe 
towards other regions.
648. A number of countries have noted the continued 
availability on the illicit drug market of Subutex, a prepa-
ration containing buprenorphine, an opioid controlled 
under the Convention on Psychotropic Substances of 
1971. In Finland, heroin has to a large extent been 
replaced by Subutex, seizures of which reached their 
highest level in five years in 2012 (48,700 tablets seized 
compared with 31,700 tablets in 2011). At the same time, 
the amounts of other preparations seized (mainly benzo-
diazepines and some opiates) doubled in recent years. 
While seizures of Subutex trafficked between Estonia and 
Finland decreased, it is trafficked on a large scale from 
France, with increased trafficking through and from 
Norway and Sweden, and with emerging trafficking from 
the United Kingdom. 
(c) Precursors
649. The use of pre-precursors or non-controlled pre-
cursors in the illicit manufacture of drugs in Europe con-
tinues. alpha-Phenylacetoacetonitrile (APAAN), which is 
converted into P-2-P for the illicit manufacture of amphet-
amine and methamphetamine, is becoming more prom-
inent in the region. Since 2009, APAAN had been seized 
in Belgium, the Netherlands and Poland, with the 
Netherlands reporting the seizure of a number of labora-
tories where the substance was being converted to P-2-P. 
In Belgium in 2012, there was a sharp increase in airport 
seizures of APAAN, purchased mainly in China. In 2012, 
authorities identified several cases of APAAN being sent 
to private companies in Latvia from companies in China, 
possibly for onward transit to other countries of Western 
and Central Europe. In 2012, Hungary reported, as a new 
phenomenon, the trafficking of APAAN from China to 
European ports for onward transport in smaller quanti-
ties to illicit laboratories in Western Europe. That trend 
was also seen in Poland in 2012. Since their emergence 
as pre-precursors, as of 2012, PMK-glycidate and BMK-
bisulfite can be traded and used in the Netherlands only 
with a licence. 
(d) Substances not under international 
control
650. New psychoactive substances continue to pose a 
significant challenge in Europe, with a record number of 
73 new such substances identified through the European 
Union early warning system in 2012, compared with 
49  substances in 2011 and 41 substances in 2010. Of 
those, 30 were synthetic cannabinoids, 19 were from “less 
known or more obscure chemical groups” and 14 were 
substituted phenethylamines. New psychoactive sub-
stances are an emerging drug phenomenon in Eastern 
and South-Eastern Europe. Bulgarian authorities report 
that about 30 new such substances appeared on the mar-
ket every month in the past year. In Romania, the use of 
new psychoactive substances (synthetic cathinones and 
synthetic cannabinoids) has been reported to be decreas-
ing due to the new control legislative measures adopted 
in November 2011. Since 2009, Romania has consistently 
reported seizures of new psychoactive substances. 
651. The substances seized in Western and Central 
Europe are reported to come mainly, and often in bulk 
quantities, from China and, to a lesser extent, India. 
Facilities for the processing and packaging of those sub-
stances have been seized within the region. There is some 
illicit manufacture of new psychoactive substances in 
Europe for direct sale on the illicit market, including in 
Belgium (mainly manufacture of synthetic cannabinoids) 
and Ireland, the Netherlands and Poland; some new psy-
choactive substances, such as meta-chlorophenylpipera-
zine (mCPP), are sourced primarily from within Europe. 
Products containing synthetic cannabinoid receptor ago-
nists have been detected in virtually all Western and 
Central European countries; they are usually imported 
from Asia, with processing and packaging in Europe. The 
role of the Internet in the marketing and sale of new psy-
choactive substances continues.
652. In the United Kingdom, there have been increased 
seizures of ketamine, possibly diverted from India and 
trafficked to the United Kingdom by mail and courier 
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services, and recently larger quantities have been seized 
from sea containers. Seizures of ketamine in France have 
also become more prominent in recent years. However, 
seizures of the substance have decreased in Hungary.
653. Seizures of khat by customs authorities in Western 
Europe in 2012 increased from 54.1  tons in 2011 to 
60.6  tons in 2012, representing more than half of the 
global customs seizures of the substance. Customs sei-
zures of khat increased in Germany, which accounted for 
almost half of the amount seized in the subregion of 
Western Europe, from 23.8  tons to 27.5 tons, but total 
seizures of khat by law enforcement authorities decreased 
slightly, from around 46 tons in 2011 to 45 tons in 2012. 
Of the total of 118 tons of khat seized by customs author-
ities globally in 2012, 40  per  cent was bound for 
Scandinavian countries (28 tons for Denmark, 10 tons for 
Sweden and 9 tons for Norway). Seizures of khat by cus-
toms authorities increased in Denmark, from 6.6  tons in 
2011 to 7.6  tons in 2012 but decreased in Sweden (from 
12.8 to 9.5  tons in the same period) and Norway (8.3 to 
6.4 tons). Seizures of khat by police and customs author-
ities in Finland continued to increase, reaching a peak of 
5.8  tons in 2011 before decreasing to 1.9  tons in 2012. 
5. Abuse and treatment
654. In Western and Central Europe, cannabis contin-
ues to be the most abused drug, with an average annual 
prevalence among adults of 7.6  per  cent. A study by 
EMCDDA found that on average 1 per cent of the adult 
population in 22 countries in the region abused cannabis 
on a daily or almost daily basis, and the rate was almost 
double (1.9 per cent) among those aged 15-34 years. On 
average, annual prevalence of cannabis abuse was 
11.7  per  cent among individuals aged 15-34 years and 
14.9  per  cent among young people aged 15-24 years. 
Levels of cannabis abuse in many but not all countries of 
the region are considered to be stable or declining, 
although they remain at historically high levels. Among 
school students, the trend is towards increased levels of 
abuse in countries with lower prevalence rates and 
decreases in countries with higher prevalence rates. 
655. In Italy, while there was a decrease in annual preva-
lence of cannabis abuse among adults from 5.3  per  cent 
in 2010 to 4.0 per cent in 2012, annual prevalence among 
school students aged 15-19 increased from 17.9 per cent 
in 2011 to 19.1 per cent in 2012. In Spain, annual preva-
lence of cannabis abuse among adults decreased from 
10.6  per  cent in 2009 to 9.6  per  cent in 2011. Annual 
prevalence levels among adults in England and Wales in 
the United Kingdom decreased from 6.9  per  cent in 
2011/12 to 6.4 per cent in 2012/13, the lowest level since 
reporting commenced in 1996 (9.5  per cent). Among 
people aged 16-24 years, annual prevalence fell from 
15.7 per cent in 2011/12 to 13.5 per cent in 2012/13, also 
the lowest level since 1996 (26 per cent). Despite the over-
all stability or declining trend in levels of cannabis abuse, 
the number of people in the European Union entering 
treatment for the first time for cannabis-related problems 
has risen by one third from around 45,000 in 2006 to 
60,000 in 2011. Between 2005 and 2010, cannabis was the 
primary drug of abuse for at least half of new admissions 
to treatment in France, Germany and Hungary and, by 
2010, also in Cyprus, Denmark and the Netherlands. 
656. While the level of abuse of cocaine in Western and 
Central Europe remains nearly three times the global 
average, it appears to be stabilizing or decreasing, with 
annual prevalence among adults declining from 
1.3 per cent in 2010 to 1.2 per cent in 2011. Among per-
sons aged 15-34 years in the European Union, annual 
prevalence is estimated at 1.9 per  cent, with higher than 
average levels ranging from 2.5  per  cent to 4.2  per  cent 
in the United Kingdom, Spain, Ireland and Denmark, in 
descending order. Levels of abuse are decreasing in those 
countries with higher levels of prevalence, but increasing 
in some other countries, such as France and Poland. For 
example, in the United Kingdom, in England and Wales, 
annual prevalence continued to decrease, from 2.2 per cent 
in 2011/12 to 1.9 per cent in 2012/13 among adults, and 
from 4.2  per  cent in 2011/12 to 3.0  per  cent in 2012/13 
among those aged 16-24 years. In Spain, annual preva-
lence among adults decreased from 2.6  per  cent in 2009 
to 2.2  per  cent in 2011. In Italy, annual prevalence 
decreased from 0.9  per  cent in 2010 to 0.6  per  cent in 
2012 among adults, and from 2  per  cent in 2011 to 
1.86 per cent in 2012 among school students aged 15-19. 
While annual prevalence in Ireland remained relatively 
stable in 2010/11 at 1.5  per  cent among adults and 
2.8  per  cent among young adults, lifetime prevalence 
increased from 5.3 per cent in 2006/07 to 6.8 per cent in 
2010/11 among adults and from 8.2 per cent to 9.4 per cent 
among young adults. 
657. The abuse of heroin is a major problem in many 
European countries but levels of abuse of heroin appear 
to be stabilizing or decreasing in Western and Central 
Europe, where annual prevalence of abuse of opioids is 
0.4  per  cent and 0.3  per  cent for opiates. A high preva-
lence of opiate abuse has been reported in Eastern and 
South-Eastern Europe: 1.2  per  cent of population aged 
15-64. Regarding heroin use, indicators suggest a trend 
towards low use and availability. In Eastern and South-
Eastern Europe, drug dependence treatment is mainly 
targeted at the population of heroin users. Recent survey 
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data in Italy showed a decrease in annual prevalence of 
heroin abuse among adults from 0.24 per cent in 2010 to 
0.12 per  cent in 2012 and from 0.41 per  cent in 2011 to 
0.32  per  cent in 2012 among school students aged 
15-19 years. 
658. The emerging non-medical use of prescription opi-
oids is evident in a number of countries, and the num-
ber of new treatment cases attributed to abuse of opioids 
other than heroin has increased. In Estonia, fentanyl was 
the primary drug of abuse in 76  per  cent of treatment 
cases, and its use was reported to be widespread among 
those who abuse drugs by injection. Annual prevalence 
of abuse of fentanyl in Estonia was estimated at 
0.1 per  cent among adults but 1.1 per  cent among those 
aged 15-24. Notable increases in abuse of fentanyl by 
injection had also been reported in Bulgaria and Slovakia. 
Abuse of fentanyl in Finland, Germany, Greece, Italy, 
Sweden and the United Kingdom had also been reported, 
even if at a localized level in some countries. In Finland, 
buprenorphine accounts for most first-time opioid-related 
treatment cases, and in Denmark and Sweden opioids 
other than heroin account for more than half of first-time 
opioid-related treatment clients. 
659. Amphetamine-type stimulants remain the most 
commonly used synthetic stimulants in Europe, and 
recent data suggest increasing availability of methamphet-
amine. In Western and Central Europe, the annual preva-
lence of abuse of amphetamine-type stimulants and 
“ecstasy” has remained stable (at 0.7  per  cent and 
0.8  per  cent among adults, respectively). Among adults 
aged 15-34 in European Union countries, average annual 
prevalence of abuse of amphetamines is 1.3 per cent, with 
stable or decreasing trends in most countries with recent 
surveys. Methamphetamine, the abuse of which was rela-
tively low in Europe compared with other regions and 
limited to the Czech Republic and Slovakia, continues to 
replace amphetamine as a substance of abuse in some 
countries, in particular in the north of Europe (Finland, 
Latvia, Norway and Sweden). Indications of problem use 
of methamphetamine have been reported for Cyprus, 
Germany and Greece. Most countries in Western and 
Central Europe report stable or declining trends in abuse 
of “ecstasy”, with annual prevalence among young adults 
ranging from 0.1  per  cent to 3.1  per  cent, but there are 
indications of a resurgence in the popularity of the sub-
stance. In Spain, annual prevalence among adults 
decreased from 1.2  per  cent in 2007 to 0.7  per  cent in 
2011, while in Ireland the prevalence of “ecstasy” abuse 
decreased among adults, from 1.2 per cent to 0.5 per cent 
and among young adults from 2.4 per cent to 0.9 per cent. 
In the United Kingdom, the annual prevalence of abuse 
among those aged 16-24 years in England and Wales fell 
in 2012/13 to 2.9 per cent, the lowest level on record, and 
adult prevalence fell from 1.4 per cent to 1.3 per cent in 
the past year.
660. The abuse of new psychoactive substances contin-
ues to pose a major health threat in Europe, particularly 
with the record number of new substances of abuse iden-
tified in 2012 and reports of health problems linked to 
these substances. While the number of people using new 
psychoactive substances is reported to still be relatively 
low in general in most European countries although more 
prevalent among particular populations, national surveys 
present a varied picture of the situation. In Ireland, which 
according to earlier surveys had the highest lifetime 
preva lence of abuse of new psychoactive substances 
(16.3  per  cent among those aged 15-24 in 2011) in 
Europe, there are indications that levels of abuse may 
have stabilized or declined following legislative changes, 
prevention activities and a reduction in the number of 
retail outlets selling such substances. A decline in admis-
sions to accident and emergency services related to abuse 
of new psychoactive substances was reported in 2011, the 
first such decline in a number of years. Ireland’s 2010/11 
drug prevalence survey indicated that annual prevalence 
of abuse of new psychoactive substances was 3.5 per cent 
among adults and 9.7  per  cent among those aged 
15-24  years, second only to the prevalence of cannabis 
abuse. In England and Wales, in the United Kingdom, 
levels of abuse of new psychoactive substances started to 
decline in 2011/12 following increases in the years prior; 
and annual prevalence levels of abuse of mephedrone 
among adults fell from 1.1  per  cent in 2011/12 to 
0.5  per  cent in 2012/13, and fell from 3.3  per  cent to 
1.6 per cent among young adults aged 16-24 years. Over 
the same  period, annual prevalence of ketamine abuse 
among adults in England and Wales fell from 0.6 per cent 
to 0.4  per  cent, and the rate among 16-24 year olds fell 
from 1.8 per cent to 0.8 per cent. Survey results indicated 
that 0.3 per cent of adults and 1.1 per cent of young peo-
ple aged 16-24 in England and Wales had used Salvia 
divinorum in the past year.
661. Record levels of treatment, mainly in outpatient 
settings, have been reported by EMCDDA, with opioids 
accounting for the largest proportion of treatment cases, 
followed by cannabis and cocaine. It is estimated that 
approximately half of problem opioid users received opi-
oid substitution treatment, the rate varying by country 
from 3 to 70  per  cent, increasing to over 700,000 indi-
viduals in 2011, compared with 650,000 individuals in 
2008. The number of new treatment cases associated 
with abuse of heroin in the European Union continues 
to decline, from a peak of 59,000 in 2007 to 41,000 in 
2011. However, abuse of opioids continues to account 
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for the greatest proportion of treatment cases: almost 
half of new treatment cases in the subregion in 2011, 
and around 30 per cent of first-time treatment entrants, 
with heroin reported in 88  per  cent of opioid-related 
cases. Authorities in some countries have noted increases 
in cases related to opioid abuse. In Portugal, the num-
ber of first-time treatment entrants is reported to have 
increased from 2002 to 2012, accompanied by an 
increase in readmissions to treatment, in particular read-
missions associated with heroin abuse. The number of 
new cocaine-related treatment cases in Western and 
Central Europe has fallen, including in Italy, Spain and 
the United Kingdom, for the first time, but acute and 
chronic problems related to cocaine abuse continue to 
be reported. 
662. In Belarus, by the beginning of 2013, a total of 
14,467 people were registered as suffering drug addiction. 
In 2012, the number of opiate users increased 13.2 per cent, 
mainly due to an increase in the number of persons using 
homemade extracted opium. The majority of registered 
drug injectors (96.9  per cent) used homemade opium. 
The number of registered heroin users decreased by 
35.4 per cent, and the users of illegal methadone decreased 
by 8.5 per  cent. 
663. The number of drug users in the Russian Federation 
is estimated to be between approximately 2 million and 
2.5 million, which is about 5-6  per  cent of the popula-
tion aged 15-30. According to figures from the Russian 
Ministry of Health, as of 1 January 2012, 35,203 adoles-
cents aged 15-17 were diagnosed as suffering from a “sub-
stance dependence disorder”.
664. Cannabis is now the most frequently mentioned 
drug of abuse among those admitted for first-time treat-
ment in Western and Central Europe, with the propor-
tion of cannabis use among all treatment entrants as high 
as 69  per  cent in Hungary. In France, for example, can-
nabis abuse was reported by almost half of new treatment 
entrants, three quarters of whom reported daily use; the 
increase in levels of admission to treatment for cannabis 
abuse has been partially attributed to court referrals to 
treatment centres. In Denmark, 73  per  cent of first-time 
treatment entrants cite cannabis as the primary drug of 
abuse; in 2011 cannabis was the primary drug of abuse 
among 80 per cent of treatment patients aged 18-24, com-
pared with 46 per cent in 2003. In the United Kingdom, 
the number of new cases for treatment of cannabis abuse 
doubled from 2004 to 2011, by which time they accounted 
for one fifth of all new treatment cases and one third of 
first-time cases, with almost 80  per  cent of treatment 
entrants admitted for cannabis abuse being under the age 
of 25 years.
665. A stable trend has been noted in first-time admis-
sions to treatment for abuse of amphetamines, which 
accounted for 6  per  cent of new treatment cases in the 
European Union area in 2011. Amphetamine accounted 
for a considerable proportion of first-time treatment 
entrants in Latvia, Poland and Sweden, whereas the large 
proportion of first-time treatment cases for methamphet-
amine further increased in the Czech Republic and 
Slovakia; in the Czech Republic, individuals abusing 
methamphetamine accounted for 69.1 per cent of all new 
treatment clients. 
666. Overdose deaths, mainly related to abuse of opi-
oids, declined in recent years, from around 7,000 in 2010 
to 6,500 in 2011 in European Union countries. Overall, 
the number of opioid-related deaths has decreased, 
although increases have been seen in some countries, 
including Estonia (primarily due to fentanyl), France, 
Ireland, Lithuania and Sweden. In the United Kingdom, 
the proportion of deaths related to heroin and morphine 
declined from 41 per cent in 2010 to 32 per cent in 2011, 
while the proportion of deaths involving methadone 
increased by 4 per cent and those involving other opiates 
or opioid analgesics increased 6 per cent. In Scotland, the 
number of deaths related to methadone exceeded those 
related to heroin for the first time since 1997. Abuse of 
alcohol and benzodiazepines has been implicated in many 
of those deaths in the United Kingdom. Deaths in Europe 
due to cocaine abuse appear to have declined slightly, in 
particular in Ireland, Spain and the United Kingdom, 
while an increase was reported in Germany.
667. A high prevalence of injecting drug use is reported 
in Eastern and South-Eastern European countries: 
1.3  per  cent of the population aged 15-64, of whom 
14.9 per cent have been diagnosed with HIV/AIDS. About 
30 per cent of the global population of injecting drug users 
infected with HIV/AIDS live in Eastern and South-Eastern 
Europe. At about 22 per cent, Ukraine has the largest HIV/
AIDS-infected population among injecting drug users. In 
Western and Central Europe, there has been an overall 
decrease in recent years in the prevalence of injecting drug 
use among those entering treatment for heroin abuse for 
the first time. Newly reported HIV infections among 
injecting drug users declined from 2004 to 2010, yet 
increased slightly in 2011, to a prevalence of 6.7 per cent. 
As a result of the HIV infection outbreaks among those 
who abuse drugs by injection in Greece and Romania, the 
proportion of such diagnoses in these two countries of the 
total for the European Union and Norway increased from 
2 per cent in 2010 to 23 per cent in 2011. The proportion 
of acute cases of hepatitis C infection attributable to inject-
ing drug use in Western and Central Europe has fallen 
from 40.6 per cent in 2006 to 33.3 per cent in 2011. 
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E. Oceania
1. Major developments
668. Oceania is the only region in which seizures of all 
the main types of drugs (amphetamine-type stimulants, 
cannabis, opiates and cocaine) have recently increased. 
Largely driven by significant increases in Australia, those 
increases are partly attributable to improvements in law 
enforcement and  perhaps to greater efforts by organized 
criminal groups to access the illicit drug market in 
Australia.
669. The proximity of the Pacific islands to major illicit 
markets for amphetamine-type stimulants and routes 
used for trafficking in other types of drugs makes that 
subregion particularly susceptible to drug abuse and traf-
ficking. While cannabis, the most prevalent drug in 
Oceania, continues to be smuggled into and within the 
region, large quantities of cocaine have been seized in 
Australia over the past few years. Lured by the huge prof-
its to be made in those illicit markets, methamphetamine 
and its precursor chemicals are also smuggled through 
the region.
670. Drug monitoring systems are relatively under-
developed in all countries in Oceania except Australia 
and New Zealand. In addition, the collection of data on 
amphetamine-type stimulants is hindered by a lack of 
drug testing equipment and forensic facilities. 
671. There continues to be a lack of reliable and up-to-
date drug-related data for most countries in Oceania, 
especially the Pacific island States, which makes a com-
prehensive assessment and understanding of the regional 
situation difficult. The Board notes that even some of 
those States that have adhered to international drug con-
trol conventions, such as Fiji, Micronesia (Federated 
States of) and Papua New Guinea, fail to comply with 
their reporting obligations under the treaties. In a region 
where increasing seizures and trafficking have been 
reported over the recent years, the collection and compi-
lation of drug-related data is of particular importance. 
There is a need for all Governments, including the author-
ities of non-metropolitan territories in that region, to 
improve the collection of drug-related data and to  comply 
with their reporting obligations under the international 
drug control treaties.
672. Over the past few years, an illicit market for new 
psychoactive substances has rapidly developed, present-
ing serious challenges to law enforcement authorities in 
Oceania, which are being addressed by authorities of 
Australia and New Zealand. Such substances have a short 
production cycle and can be quickly distributed through 
the Internet. The ability of the authorities to curb the 
illicit trade in such substances and control the spread of 
their abuse has been weakened further by complications 
involved in testing such substances for analogues. The 
illicit market for new psychoactive substances continues 
to grow, as traffickers make use of loopholes in existing 
legal systems and market such substances as “legal” sub-
stitutes for controlled substances. Closer monitoring, 
 proactive initiatives by the relevant authorities and better 
collaboration among law enforcement agencies within the 
region, as well as international action, are required to 
reverse the growing trend.
2. Regional cooperation
673. A “declaration of partnership” was signed by the 
Board of Management of the Pacific Transnational Crime 
Network in February 2013. The declaration commits the 
members of the Network to sharing with other members 
information on their efforts to reduce transnational 
organized crime. Both Australia and New Zealand con-
tinue to provide technical support to other countries in 
Oceania. During a drug identification course conducted 
by New Zealand authorities at the headquarters of the 
Tonga Defence Services, in Nuku’alofa, in March 2013, 
the topics discussed included drug trafficking in the 
Pacific, methods of concealment, presumptive field test 
kits, the changing situation in the Pacific and the impact 
of methamphetamine. To facilitate the exchange of infor-
mation and better cooperation within Oceania, annual 
meetings of drug control authorities and other competent 
national authorities were held in different countries. 
3. National legislation, policy and 
action
674. In response to challenges presented by new psycho-
active substances in New Zealand, a psychoactive sub-
stance act, which prohibits the sale of all psychoactive 
substances unless approved by a regulator, was adopted 
in July 2013. According to the act, manufacturers or 
importers of such substances must prove that the prod-
ucts in question do not pose undue harm. As a result, 
the onus of proof lies with the manufacturers and retail-
ers and not with the authorities. Those who violate the 
new legislation shall be subject to prosecution and sub-
stantial penalties—up to 10,000 New Zealand dollars for 
an individual and $NZ 50,000 for a body corporate. 
675. Since May 2012, when the Government of Australia 
included synthetic cannabinoids in the standard for the 
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uniform scheduling of medicines and poisons, various 
states in the country (New South Wales, Northern 
Territory, Victoria, Queensland and Western Australia) 
have followed suit. Other recent initiatives launched by 
the Government have focused on raising the awareness 
of youth regarding the harm associated with illicit drug 
use and on promoting services for the treatment of drug 
and alcohol abuse among vulnerable populations. 
4. Cultivation, production, 
manufacture and trafficking 
(a) Narcotic drugs
676. The illicit cannabis markets in countries in Oceania 
continue to be supplied by domestic production—there 
is little evidence of large-scale smuggling of cannabis 
between countries in the region. While cannabis contin-
ues to be illicitly cultivated both indoors and outdoors in 
Oceania, because of the favourable climate the majority 
of cannabis plants eradicated in the region had been illic-
itly cultivated on outdoor sites. In 2011, illicitly cultivated 
cannabis plants were eradicated on 2,131 outdoor sites in 
New Zealand, the third largest number in the world. 
677. Recent data suggest that there has been a moder-
ate increase in cannabis seizures in both Australia and 
New Zealand. In Australia, the amount of cannabis seized 
rose by 34.8  per  cent, to 5,452 kg, in the financial year 
2011/12,25 reaching the third highest level reported in the 
preceding 10-year  period. In New Zealand, the amount 
of cannabis seized increased to 693  kg in 2012. Given 
the relatively well-established illicit markets for cannabis 
in both countries, the situation is unlikely to change 
significantly.
678. Oceania is one of the regions in which cocaine traf-
ficking has only recently become significant. The total 
amount of cocaine seized in Oceania rose from 290  kg 
in 2009 to 1.8 tons in 2011. That sharp increase is largely 
attributable to the increase in cocaine seizures in Australia. 
The routes used for cocaine trafficking in Australia are 
becoming more diverse. In addition to the main coun-
tries used as transit countries by cocaine traffickers, 
Canada has been identified as a transit country used for 
smuggling significant quantities of cocaine into Australia.
679. In New Zealand, despite occasional spikes regis-
tered in cocaine seizures, the total amount of cocaine 
 25 In Australia, the financial year begins on 1 July and ends the 
 following year on 30 June.
seized each year is usually relatively small (less than 
5  kg  per year in the  period 1980-2010). In 2012, how-
ever, about 16  kg of cocaine was seized in the country, 
much more than in the previous year (0.615 kg). With 
the cocaine market in Australia expanding, it is possible 
that the illicit supply of cocaine in that country could also 
be used to supply the illicit market in New Zealand.
680. Australia continues to be an attractive country of 
destination for heroin consignments. The estimated 
street price of heroin in the country is between 228 and 
300 Australian dollars  per gram. In the financial year 
2011/12, 388 kg of heroin was seized in Australia, slightly 
more than the amount seized in the previous year 
(376  kg). The majority of the heroin seized in Australia 
originated in Afghanistan and Myanmar. In recent years, 
heroin has entered Australia from about 20 different 
countries, the most prominent being Malaysia, followed 
by Pakistan, Viet Nam, Cambodia and Singapore. Several 
heroin seizures have been reported in Fiji, Papua New 
Guinea and Vanuatu. As there is limited illicit demand 
for heroin in the Pacific island countries, vigilance is 
needed to ensure that those countries do not become a 
trans-shipment area. 
(b) Psychotropic substances
681. The illicit markets for amphetamine-type stimu-
lants (excluding MDMA) in Australia and New Zealand 
are mainly supplied by domestic manufacture, although 
some imports of such stimulants have been recorded. The 
large amounts of precursors seized in Australia over the 
past few years suggest a considerable amount of 
amphetamine- type stimulants is being illicitly manufac-
tured in the country. Some illicit manufacture of such 
stimulants has also been detected in the Pacific island 
countries since 2004.
682. In Australia, seizures of amphetamine-type stimu-
lants (excluding MDMA) increased significantly in the 
financial year 2011/12, reaching a total of 347 kg, com-
pared with 105 kg in the financial year 2010/11. In terms 
of the number of consignments of amphetamine-type 
stimulants (excluding MDMA) detected at the Australian 
border, the most prominent points of embarkation of the 
detected consignments were in India, followed by Hong 
Kong, China; and China’s mainland. In terms of the total 
weight of the detected consignments, the most prominent 
point of embarkation was in Mexico.
683. The price, purity level and availability of metham-
phetamine on the illicit market in New Zealand seem to 
have remained stable, despite the Government’s increased 
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efforts to counter methamphetamine trafficking over the 
past few years. In 2012, the total amount of amphetamine 
seized in New Zealand rose to 133.4 kg (up from 2.7 kg 
in 2011), but the total amount of methamphetamine 
seized declined to 6.9  kg (from 33.8  kg in 2011). The 
range of groups involved in transnational organized crime 
in New Zealand has increased. 
684. In the financial year 2011/12, 12 kg of MDMA was 
detected at the Australian border. The most prominent 
points of embarkation of the detected consignments were 
in the Netherlands, followed by Canada and New Zealand; 
consignments from those countries accounted for 
89 per cent of the total weight of MDMA detected at the 
Australian border. MDMA remains in short supply in 
Australia, but global manufacture of the substance is 
expected to rise as alternative precursor chemicals become 
more available.
685. Although the total number of MDMA (“ecstasy”) 
tablets seized in New Zealand in 2011 nearly tripled 
(128,897 tablets), the number of such tablets seized at that 
country’s border showed a significant drop. Thus, the 
increase in the number of MDMA (“ecstasy”) tablets 
seized in New Zealand in 2011 was mainly attributable 
to an increase in the illicit production of such tablets 
within that country. In 2012, the total number of MDMA 
(“ecstasy”) tablets seized in New Zealand increased to 
173,715, largely as a result of the dismantlement in August 
2012 of a criminal ring that had been responsible for most 
of the illicit manufacture and distribution of MDMA 
 tablets in the country.
(c) Precursors
686. With the smuggling of ephedrine and pseudo-
ephedrine in bulk and in preparation forms, considera-
ble amounts of methamphetamine continues to be illicitly 
manufactured in Oceania. The importation of pseudo-
ephedrine in the form of a pharmaceutical preparation 
from China continues to pose significant challenges to 
competent national authorities in the region, particularly 
in Australia and New Zealand. 
687. In Australia, a very large number of clandestine 
drug manufacturing laboratories (809) were detected in 
the financial year 2011/12, the majority of which had 
been illicitly manufacturing methamphetamine; they 
were mainly small laboratories located in residential 
areas. A total of 109 clandestine methamphetamine 
manu facturing laboratories were dismantled by the 
New Zealand authorities in 2011, three of those labora-
tories had also been illicitly manufacturing MDMA 
(“ecstasy”) and gamma-butyrolactone (GBL). Although 
the amount of ephedrine and pseudoephedrine seized in 
New Zealand has continued to drop, there has been no 
indication that the availability of ephedrine and pseudo-
ephedrine has changed. 
(d) Substances not under international 
control
688. Countries in Oceania, which have some of the 
highest prevalence rates in the world, seem to have been 
hit particularly hard by the emergence of new psycho-
active substances. In the first half of 2012, 44 new psycho-
active substances were identified in the region, accounting 
for more than 25  per  cent of all new psychoactive sub-
stances identified worldwide in that  period. The emer-
gence of new psychoactive substances, together with 
other non-controlled substances more commonly used in 
the western Pacific (such as kava which is often used in 
combination with alcohol), presents new challenges to 
existing legal systems and law enforcement and health 
authorities in the region.
689. Fast growth in the manufacture and use of new 
psychoactive substances has been observed in both 
Australia and New Zealand for the past few years. In 
New  Zealand, which had been dominated by the spread 
of pipe razines prior to the period 2007-2008, the demand 
for synthetic cannabinoids has replaced the demand for 
pipe razines. Similarly, in Australia, synthetic cannabi-
noids and cathinones, in particular mephedrone 
(4-methyl methcathinone), have attracted significant pub-
lic attention. During the first six months of 2012, 
Australian authorities identified 33 new psychoactive 
substances, the majority of which were synthetic cathi-
nones and phenethylamines. A recent survey suggested 
that the widespread use of synthetic cannabinoids 
stemmed from the misconception that they were legal to 
buy, regardless of the changes in national legislation.
5. Abuse and treatment
690. Cannabis continues to be the most prevalent drug 
in Oceania. In 2011, the annual prevalence of cannabis use 
in the region was estimated at 10.9 per cent of the popu-
lation aged 15-64 which is much higher than the global 
average (3.9 per cent). The prevalence of cannabis use has 
been estimated to be 10.6  per  cent in Australia and 
14.6  per  cent in New Zealand. Although relevant quanti-
tative data are lacking for most of the other countries in 
the region, national experts have indicated that cannabis 
use is also widespread in some Pacific island countries.
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691. The prevalence of the abuse of opioids in 2011 
was estimated to be 3.0 per cent in Oceania—3.4 per cent 
in Australia and 1.1  per  cent in New Zealand. In 
Australia, drug abuse surveys have indicated that the 
proportion of recent heroin abusers have remained rel-
atively stable. While similar stability has also been reg-
istered for New Zealand, methadone and morphine are 
the opioids most commonly abused by  persons who 
abuse drugs by injection.
692. There has been a global decline in the abuse of 
MDMA (“ecstasy”). In 2011, Oceania remained the region 
with the highest prevalence of abuse of MDMA (“ecstasy”) 
(2.9  per cent). Decreases in the abuse of MDMA 
(“ecstasy”) among police detainees were recorded in 
Australia: only 5  per  cent of police detainees reported 
having abused the substance in 2010 and 2011, half 
the  percentage reported in 2009. In New Zealand, 
MDMA-type drugs are now one of the most widely 
abused drugs—second only to cannabis; since a number 
of other illicit drugs, such as N-benzylpiperazine (BZP), 
mephedrone and 4-methyl-N-ethylcathinone, are com-
monly used as a substitute for MDMA and marketed as 
“ecstasy”, the “ecstasy” in New Zealand is likely to con-
tain not MDMA but illicit drugs with effects similar to 
those of MDMA.
693. The abuse of amphetamine-type stimulants (exclud-
ing MDMA), in particular crystalline methamphetamine 
and methamphetamine, has long been a matter of con-
cern in the region. The prevalence of abuse of 
amphetamine- type stimulants was reported to be 
2.1 per cent in Australia (in 2010) and New Zealand (in 
2008). Both of those countries have devoted significant 
resources to tackling the problem. In New Zealand, 
Tackling Methamphetamine: an Action Plan has been in 
place since 2009. For many of the Pacific island coun-
tries, however, lack of resources and quantitative data has 
made it difficult to curb such abuse. 
694. Increases in the abuse of cocaine have been noted 
in Oceania. In 2011, the annual prevalence of cocaine 
abuse in the region was estimated to be 1.5  per  cent. In 
Australia, the prevalence of cocaine abuse was 2.1 per cent 
in 2010—twice the rate in that country in 2004 
(1.0  per  cent) and five times the global average 
(0.4  per  cent). High prices for cocaine have made the 
illicit market for cocaine in Australia attractive to organ-
ized criminal groups, but those high prices have also 
helped to keep the actual consumption of cocaine low—
despite the high prevalence of cocaine abuse in the coun-
try. That is reflected in, inter alia, the low demand for 
treatment related to cocaine abuse in Australia, as well as 
in the fact that the levels of cocaine and benzoylecgonine, 
the main cocaine metabolite, detected in wastewater 
analy sis in Australia were low compared to the levels 
detected in North America or Europe. In New Zealand, 
the illicit market for cocaine is even smaller than in 
Australia; cocaine abuse is limited to a small segment of 
the population of New Zealand, as shown in the relatively 
low prevalence of cocaine abuse (0.6 per  cent in 2008).
695. The lack of statistics on illicit drug use, production 
and trafficking in the Pacific island countries does 
not  permit an assessment of the overall situation with 
regard to drug control in Oceania. While the use of can-
nabis and kava (Piper methysticum) has long been con-
sidered to be widespread, the misuse of prescription 
opioids, including tramadol, is also increasingly being 
reported in the Pacific islands.
696. A number of treatment options are available to 
drug-dependent  persons in the region. According to the 
latest figures, in Australia the number of episodes reported 
in 659 facilities for the treatment of alcohol and drug 
dependence increased to 153,668 (an increase of 
2 per cent) in the financial year 2011/12. In all states and 
territories in Australia except South Australia, where 
amphetamines are more common, alcohol and cannabis 
are the most two common drugs of concern, and differ-
ent types of treatment such as counselling, withdrawal 
management and support and case management) are 
used. (In New Zealand, opioid substitution treatment is 
also available.) In a comprehensive review of the recent 
spending by the Government of Australia on drug con-
trol, however, concern was expressed over the drop in 
spending on demand reduction during a  period of 




Recommendations to Governments,  
the United Nations and other relevant 
international and regional organizations
697. The present chapter highlights, by subject, some of 
the key recommendations contained in chapters II and 
III of this report. For detailed recommendations regard-
ing the economic consequences of drug abuse, please 
refer to the relevant paragraphs of chapter I, above. 
Specific recommendations related to controls over chemi-
cal precursors are contained in the 2013 report of the 
Board on the implementation of article 12 of the 1988 
Convention (the report on precursors). 
698. The Board would appreciate being informed of any 
action taken by Governments and international organi-
zations to implement the recommendations below. In par-
ticular, feedback on experiences and difficulties in 
fulfilling treaty obligations or following the recommen-
dations of the Board would be appreciated. 
Prevention, treatment and rehabilitation
699. Prevention, treatment and rehabilitation pro-
grammes are essential to reducing demand for drugs and 
ensuring social welfare, as part of a balanced approach to 
drug control. 
Recommendation 1: The Board encourages Governments 
to ensure that an adequate and sustained level of invest-
ment is made in prevention, treatment and rehabilita-
tion programmes, even in times of financial austerity, 
noting the potential savings that can be made in terms 
of health and social costs that would otherwise result 
from drug abuse and addiction and drug-related crime 
and violence.
Cannabis
700. The Board is concerned that a number of States 
that are parties to the 1961 Convention are considering 
legislative proposals intended to regulate the use of can-
nabis for purposes other than medical and scientific ones. 
The Board stresses once again the importance of the uni-
versal implementation of the drug control treaties by all 
States parties and urges all parties to take the necessary 
measures to ensure full compliance with the international 
drug control treaties in the entirety of their respective 
territories. 
Recommendation 2: The Board therefore urges all 
Governments and the international community to care-
fully consider the negative impact of such developments. 
In the Board’s opinion, the likely increase in the abuse of 
cannabis will lead to an increase in related public health 
costs. 
701. Medical cannabis programmes should be subject to 
the control measures for cannabis cultivation, trade and 
distribution set forth in articles 23, 28 and 30 of the 1961 
Convention. However, the Board notes that in a number 
of countries, or jurisdictions within countries, that have 
established such programmes, the control measures man-
dated by that treaty are not being fully implemented, 
 giving rise to non-compliance with treaty obligations.
Recommendation 3: The Board reiterates its urgent call to 
all those Governments of countries where medical can-
nabis schemes are in place or the establishment of such 
programmes is being considered to ensure the full 
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implementation, within the entirety of their territory, of 
the provisions of the 1961 Convention to which they are 
a party. Moreover, the Board invites WHO, in view of its 
mandate under the 1961 Convention, to evaluate the 
potential medical utility of cannabis and the extent to 
which cannabis poses dangers to human health.
Internet pharmacies
702. This year’s annual report of the Board pays special 
attention to the issue of illegal Internet pharmacies (see 
chapter II.E. (Special topics), above, for details). 
Recommendation 4: The Board calls on Governments to 
continue to take action against illegal Internet pharmacies 
by, inter alia, empowering the appropriate authorities to 
investigate and take appropriate legal action against such 
establishments and to further develop and promote good 
professional practices for the provision of pharmaceutical 
services via the Internet. In these efforts, the Board 
encourages Governments to use the INCB Guidelines for 
Governments on Preventing the Illegal Sale of Internationally 
Controlled Substances through the Internet.
Availability of opiates for pain relief 
703. The latest data available indicate that the amount 
of opiate raw material available for the manufacturing of 
narcotic drugs for pain relief is more than sufficient to 
satisfy current demand levels as reported by Governments 
and that global stocks are increasing. The Board has con-
tinuously drawn attention to the fact that consumption 
of narcotic drugs for pain relief is concentrated within a 
limited number of countries. 
Recommendation 5: The Board recommends that all 
Governments ensure that internationally controlled sub-
stances used for pain relief are accessible to people who 
need them and asks Governments to make every effort 
to facilitate this process, including through the educa-
tion of health professionals. In that connection, the 
Board once again draws attention to the Report of the 
International Narcotics Control Board on the Availability 
of Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes,26 a supplement 
to its report for 2010, and invites Governments to make 
use, as appropriate, of its Guide on Estimating 
Requirements for Substances under International Control,27 
jointly developed with WHO.
 26 United Nations publication, Sales No. E.11.XI.7.
 27 Available from www.incb.org.
Cooperation with industry 
704. The Board notes that cooperation by the pharma-
ceutical industry with the competent national authorities 
is key to effective collection and reporting of mandatory 
statistical data on narcotic drugs and psychotropic 
substances. 
Recommendation 6: The Board calls upon Governments 
to encourage dialogue with manufacturing and trading 
companies in the pharmaceutical industry with a view to 
improving the collection and reporting of statistical data 
on narcotic drugs and psychotropic substances. 
705. Cooperation with the chemical industry is also a 
key element of efforts to prevent the diversion of precur-
sors for the illicit manufacture of drugs. 
Recommendation 7: The Board urges Governments to 
develop partnerships with industry to prevent the illicit 
use of precursors by establishing mechanisms, to include 
legislation, codes of practice, memorandums of under-
standing and guidelines, with a view to enhancing coop-
eration between the authorities and relevant industries 
and increasing their vigilance with regard to suspicious 
trade in precursors. In that connection, the Board 
encourages Governments to make increased use of its 
Guidelines for a Voluntary Code of Practice for the 
Chemical Industry.28
Prescription drugs
706. The Board draws the attention of States to the 
growing public health consequences of prescription drug 
abuse. The Board notes that in many countries, prevalence 
rates for the abuse of prescription drugs are comparable 
to, if not higher than, those for other internationally con-
trolled drugs. Factors contributing to this phenomenon 
include the lack of training of medical professionals in 
prescribing practices, the lack of prescription monitoring 
schemes to prevent “doctor shopping” and diversion into 
illicit channels, insufficient public awareness initiatives to 
inform the public of the health dangers associated with 
prescription drug abuse, and the large amounts of unused 
and unneeded prescription drugs in circulation. 
Recommendation 8: The Board urges all Governments 
that have not yet done so to consider developing com-
prehensive strategies to address prescription drug abuse, 
including the provision of adequate training for medical 
professionals and effective mechanisms for prescription 
 28 United Nations publication, Sales No. E.09.XI.17.
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monitoring, as well as for ensuring the safe return and 
disposal of medications possessing psychoactive proper-
ties, particularly those containing narcotic drugs or psy-
choactive substances.
Import and export of controlled 
substances
707. The Board has noted that the format and the con-
tent of the import and export authorizations for narcotic 
drugs and psychotropic substances currently in use in 
some countries do not fully meet the relevant require-
ments of the international drug control treaties. For 
example, some import and export authorizations do not 
contain all the mandatory elements of information listed 
in article 31 of the 1961 Convention and article 12 of 
the 1971 Convention. Furthermore, in some cases, 
Governments of importing countries have attempted to 
introduce an electronically generated “import authoriza-
tion” that does not contain all the necessary information 
and does not allow the authorities of the exporting coun-
try to verify with certainty the authenticity of the related 
import authorization. 
Recommendation 9: The Board calls upon Governments 
to review the format of their import and export authori-
zations currently in use and, wherever necessary, to bring 
them into full conformity with the international drug 
control treaties. 
Precursors 
708. The Board has raised the issue of the need to 
address the serious problems related to the domestic 
diversion of precursors, in particular acetic anhydride and 
pharmaceutical preparations containing ephedrine and 
pseudoephedrine, used to illicitly manufacture heroin and 
amphetamine-type stimulants, respectively. In accordance 
with article 12, paragraph 8, of the 1988 Convention, 
Governments should take adequate measures to control 
the domestic manufacture and distribution of scheduled 
chemicals. Such measures may include, for example, sys-
tems for end-user registration and declarations, adequate 
estimates of legitimate requirements for chemicals, 
including those with little or no legitimate use. 
Recommendation 10: The Board recommends that 
Governments enhance their cooperation at all levels and 
exchange pertinent and timely information with all rele-
vant national, regional and international counterparts to 
support domestic and international investigations target-
ing organized criminal networks for trafficking chemicals 
and drugs and to enhance operational and information-
sharing activities to that end. 
Recommendation 11: The Board invites all Governments 
and relevant international bodies to use the existing tools 
provided by INCB to enhance precursor control, in par-
ticular PEN Online and PICS, the mechanisms and oper-
ations under Projects Prism and Cohesion and the INCB 
Precursors Task Force, for the exchange of information 
and common investigations. 
Non-scheduled substances
709. The Board is concerned about the growing threat 
posed by non-scheduled precursor chemicals and new 
psychoactive substances. The emergence of new psycho-
active substances poses a particular challenge to the 
health and drug control systems of many countries. Given 
the current absence of an established international frame-
work to deal with new psychoactive substances, the early 
and systematic sharing of all available operational infor-
mation at the global level is essential to prevent their traf-
ficking and diversion, to conduct investigations and 
prosecutions and, importantly, to alert authorities else-
where of modus operandi and new trends. 
Recommendation 12: Noting similarities in current issues 
related to precursors and to new psychoactive substances, 
the Board calls for urgent practical measures to effectively 
prevent and counter this new and dangerous trend and 
recommends that Governments support the development 
of adequate multilateral mechanisms to communicate to 
INCB incidents involving new psychoactive substances 
and products containing them, with a view to establish-
ing or confirming emerging trends and contributing to 
devising early countermeasures.
710. The lack of pharmacological and toxicological data 
poses serious challenges to the assessment of the health 
and social risks associated with the use of new psycho-
active substances. For example, in Europe, there is an 
unprecedented number and variety of substances, often 
sold as “bath salts”, “legal highs” or “plant food”, that have 
been identified over the past two years.
Recommendation 13: The Board is aware of isolated stud-
ies being conducted to generate the necessary data and 
therefore recommends that WHO play an active role in 
the coordination of relevant research and in the genera-
tion, collection and dissemination of the results of the 
assessments of the health risks of new psychoactive sub-
stances conducted by WHO and national and regional 
bodies.
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Capacity-building in regulatory drug 
control and training of national drug 
control authorities
711. The Board reiterates the importance of training 
national competent authorities in order to help them 
comply with their obligations under the international 
drug control treaties. This need is particularly acute in 
several regions of the world. 
Recommendation 14: The Board reiterates its recommen-
dation that UNODC develop and implement a programme 
for building national capacities for the regulatory control 
of internationally controlled substances. It is essential that 
the training of national drug control administrators 
remain a major component of such a programme.
Promoting the consistent application of 
the international drug control treaties
712. The Board has noted with concern a draft law 
under consideration in Uruguay that, if adopted, 
would  permit the production, sale and consumption of 
cannabis herb for non-medical use. The Board underlines 
that such legislation would not be in conformity with the 
international drug control treaties, particularly the 1961 
Convention. 
Recommendation 15: The Board urges the authorities of 
Uruguay to ensure that the country remains fully com-
pliant with international law, which limits the use of nar-
cotic drugs, including cannabis, exclusively to medical 
and scientific purposes. The Board further urges the 
Government of Uruguay to carefully consider all possi-
ble consequences on the health and welfare of its popu-
lation, in particular its youth, before embarking on a 
course of action that would  permit the sale of cannabis 
herb for non-medical purposes. 
713. The Board is concerned about the implementa-
tion of the ballot initiatives that legalized cannabis for 
non-medical purposes in two states of the United States 
in 2012. The Board underlines that such legislation is 
not in conformity with the international drug control 
treaties.
Recommendation 16: The Board urges the Government of 
the United States to continue to ensure the full imple-
mentation of the international drug control treaties on its 
entire territory.
714. Afghanistan remains the centre of illicit cultivation 
of opium poppy and illicit manufacture of heroin. Its 
importance as a source of cannabis resin for the world 
markets has also been growing. The Board, while noting 
the commitment expressed by the Government of 
Afghanistan, is concerned about the deterioration of the 
drug control situation in the country. 
Recommendation 17: The Board urges the Government of 
Afghanistan to translate its national drug control strat-
egy, as well as the drug policies it adopted in 2012, into 
concrete actions and ensure progress in the fields of alter-
native development, anti-drug trafficking and drug 
demand reduction. 
715. The political situation in West Africa in 2012 and 
2013 was marked by serious security risks, including drug 
smuggling. The territories of several countries of the 
region are being exploited by transnational criminal net-
works for trafficking of drugs, especially cocaine, due to 
the weak law enforcement and security responses in those 
countries.
Recommendation 18: The Board calls upon all Governments 
and relevant international and regional organizations, 
including UNODC, ECOWAS and INTERPOL, to step 
up their efforts to address the threat posed by drug 
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Annex I.
Regional and subregional groupings used in the 
report of the International Narcotics Control 
Board for 2013
The regional and subregional groupings used in the report of the International Narcotics Control Board for 2013, 














Côte d’Ivoire Sao Tome and Principe











Kenya United Republic of Tanzania
Lesotho Zambia
Liberia Zimbabwe
 aSince 25 October 2013, “Cabo Verde” has replaced “Cape Verde” as the short name used in the United Nations.
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Central America and the Caribbean






Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America








Ecuador Venezuela (Bolivarian Republic of)




Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand























Republic of Moldova Ukraine
South-Eastern Europe
Albania The former Yugoslav Republic of Macedonia
Bosnia and Herzegovina Montenegro
Bulgaria Romania
Croatia Serbia
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Italy United Kingdom of Great Britain and 




Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands





Current membership of the International 
Narcotics Control Board
Wayne Hall
Born in 1951 in Australia. Trained as a research psycho-
logist and worked as an epidemiologist. Currently 
Professor and National Health and Medical Research 
Council Australia Fellow, University of Queensland 
Centre for Clinical Research; and Visiting Professor, 
National Addiction Centre, Institute of Psychiatry, King’s 
College London (both since 2009).
Professor of Public Health Policy, School of Population 
Health, University of Queensland (2006-2010); Professor 
and Director, Office of Public Policy and Ethics, Institute 
for Molecular Bioscience, University of Queensland 
(2001-2005); Professor and Director, National Drug and 
Alcohol Research Centre, University of New South Wales 
(1994-2001). Author and co-author of over 700 articles, 
chapters and reports on addiction, drug use epidemi-
ology and mental health. Member, World Health 
Organization Expert Committee on Drug Dependence 
(1996), and the Australian National Council on Drugs 
(1998-2001). 
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012). Vice-Chair of the Standing Committee 
on Estimates (2013) and Member of the Committee on 
Finance and Administration (2013). 
David T. Johnson
Born in 1954. National of the United States of America. 
Consultant and retired diplomat. Bachelor’s degree in 
Economics from Emory University; graduate of the 
National Defence College of Canada.
United States Foreign Service officer (1977-2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007-2011). Deputy Chief of 
Mission (2005-2007) and Chargé d’affaires, a.d., (2003-
2005) United States Embassy, London. Afghan Coordinator 
for the United States (2002-2003). United States 
Ambassador to the Organization for Security and 
Cooperation in Europe (1998-2001). Deputy Press 
Secretary at the White House and Spokesman for the 
National Security Council (1995-1997). Deputy Spokesman 
at the State Department (1995) and Director of the State 
Department Press Office (1993-1995). United States 
Consul General, Vancouver (1990-1993).
Member of the International Narcotics Control Board 
(since 2012). Member of the Committee on Finance and 
Administration (2012 and 2013).
Galina Korchagina
Born in 1953. National of the Russian Federation. Deputy 
Director of Research at the National Centre for Research 
on Drug Addiction, Ministry of Health, Russian Federation 
(since 2010). 
Leningrad Paediatrics Institute, Russian Federation 
(1976); Doctor of Medicine (2001). Doctor, boarding 
school, Gatchina, Leningrad region, (1976-1979). Head of 
the Organizational and Policy Division, Leningrad 
Regional Drug Clinic (1981-1989); Lecturer, Leningrad 
Regional Medical Academy (1981-1989); Head Doctor, 
City Drug Clinic, St. Petersburg (1989-1994); Assistant 
Lecturer (1991-1996) and Professor (2000-2001), 
Department of Social Technologies, State Institute for 
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Services and Economics; Assistant Lecturer (1994-2000), 
Associate Professor (2001-2002) and Professor (2002-
2008), Department for Research on Drug Addiction, St. 
Petersburg Medical Academy of Postgraduate Studies; 
Chief Professor and Head of the Department for Medical 
Research and Healthy Lifestyles, Herzen State Pedagogical 
University of Russia (2000-2008); Professor, Department 
for Conflict Studies, Faculty of Philosophy, St. Petersburg 
State University (2004-2008); member of numerous asso-
ciations and societies, including: Association of 
Psychiatrists and Drug Addiction Specialists of Russia 
and St. Petersburg; Kettil Bruun Society for Social and 
Epidemiological Research on Alcohol; International 
Council on Alcohol and Addictions; International Society 
of Addiction Medicine: head of the sociology of science 
aspects of medical and biological research section of the 
Research Council on the Sociology of Science and the 
Organization of Scientific Research, St. Petersburg 
Scientific Centre of the Russian Academy of Sciences 
(2002-2008). Author of more than 100 publications, 
including more than 70 works published in the Russian 
Federation, chapters in monographs and several practical 
guides. Award for excellence in health protection, awarded 
by the Ministry of Health of the Union of Soviet Socialist 
Republics (1987). Consultant, Global Business Coalition 
on HIV/AIDS, Tuberculosis and Malaria (since 2006); co-
trainer, WHO programme “Skills for change” (since 
1995); participant in meetings of the Commission on 
Narcotic Drugs (2002-2008); expert on the epidemiology 
of drug addiction, Pompidou Group of the Council of 
Europe (1994-2003); temporary representative, WHO 
(1992-2008).
Member of the International Narcotics Control Board 
(since 2010). Vice-Chair of the Standing Committee on 
Estimates (2011, 2012). First Vice-President of the Board 
(2013).
Alejandro Mohar Betancourt 
Born in 1956. National of Mexico. Director General of 
the National Cancer Research Institute of Mexico (2003-
2013) and member of the National System of Researchers 
of Mexico, the National Academy of Medicine, the 
Mexican Academy of Sciences and the American Society 
of Clinical Oncology.
Doctor of Medicine, National Autonomous University 
of Mexico (UNAM) (1980); Postgraduate studies in 
anatomical pathology, National Institute of Nutrition 
(1985), Master of Sciences (1986) and Doctor of 
Sciences in Epidemiology (1990), Harvard School of 
Public Health. 
Recipient of academic and research support from the 
National Council on Science and Technology (CONACYT) 
and the Mexican Foundation of Health. Head of the 
Department of Epidemiology (1988-1989), Deputy 
Director of Clinical Research (1993-1999) and Director 
of Research (1999-2003), National Cancer Research 
Institute of Mexico. Lecturer and Research Associate, 
Harvard School of Public Health (1988-1990). Lecturer 
and Director of master and doctoral dissertations at the 
Faculty of Medicine, UNAM (since 1991). Coordinator of 
the Unit for Biomedical Research on Cancer, Biomedical 
Research Institute, UNAM (1998). Author of more than 
110 scientific and popular works, 70 of which appear in 
indexed journals, including “Intratypic changes of the E1 
gene and the long control region affect ori function of 
human papillomavirus type 18 variants”, “Screening breast 
cancer: a commitment to Mexico (preliminary report)”, 
“Impact of diabetes and hyperglycemia on survival in 
advanced breast cancer patients”, “Ovarian cancer: the 
new challenge in gynaecologic oncology?” and “Validation 
of the Mexican-Spanish version of the EORTC QLQ-C15-
PAL questionnaire for the evaluation of health-related 
quality of life in patients on palliative care”. 
Awarded various recognitions including the following: 
Miguel Otero Award for clinical research, General Health 
Council (2012); third place for best pharmacoeconomic 
work, Mexican College for Pharmacoeconomics and 
International Society for Pharmacoeconomics and 
Outcomes Research, Mexico chapter (2010); member of 
the Group of the 300 Most Influential Leaders of Mexico; 
recognition for participation in the meeting of the Global 
Health Strategic Operations Advisory Group of the 
American Cancer Society (2009); member of the Board 
of Governors of the National Autonomous University of 
Mexico (2008); Distinction of Edward Larocque Tinker 
Visiting Professor, Stanford University (2000); member of 
the External Advisory Group for the Mexico Report on 
Social Determinants of Health (2010); member of the jury 
for the Aaron Sáenz Annual Prize for Paediatric Research, 
Féderico Gómez Children’s Hospital of Mexico and the 
“General y Lic. Aarón Sáenz Garza, A.C” Association 
(2010); member of the Global Health Strategic Operations 
Advisory Group of the American Cancer Society (2010); 
Certificate of Achievement for dedication and commit-
ment to establishing a national cancer plan for Mexico, 
American Cancer Society (2006); member of the Scientific 
Committee of the Mexican Association of Pathologists 
(1993-1995).
Member of the International Narcotics Control Board 
(since 2013).a
 a Elected by the Economic and Social Council on 7 November 2013.
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Marc Moinard
Born in 1942. National of France. Retired law officer. 
School of Political Sciences, Paris; Paris Law Faculty; 
Faculty of Arts, Poitiers. Public Prosecutor, Beuvais (1982-
1983); Public Prosecutor, Pontoise (1990); Public 
Prosecutor, Lyon (1990-1991); Public Prosecutor, Bobigny 
(1992-1995); Public Prosecutor in the Court of Appeal, 
Bordeaux (1999-2005), introducing major reforms into 
the legal system involving: the creation of centres for legal 
advice and mediation; the provision of legal advice in 
deprived areas; the establishment of a new system of 
cooperation between the courts and the police services 
allowing for the immediate handling of criminal offences; 
and the creation of a new category of judicial personnel—
assistant prosecutors.
Senior administrative posts in the Ministry of Justice: 
Director of Record Offices (1983-1986); President of the 
teaching board, National School of Clerks to the Court; 
Director of Legal Services; member of the Board of 
Directors, French National School for the Judiciary; 
Representative of the Minister of Justice in the Supreme 
Council of Justice (1995-1996); Director, Criminal Matters 
and Pardons (1996-1998); President, French Monitoring 
Centre for Drugs and Drug Addiction; Secretary-General, 
Ministry of Justice (2005-2008); President, Law and 
Justice Mission, responsible for the reform of the judicial 
map; President, Commission on Information Technology 
and Communication; Head of the International Affairs 
Service, Ministry of Justice. Lecturer, Paris Institute of 
Criminology (1995-2005); President, Fondation 
d’Aguesseau, a welfare body. Recipient of the following 
awards: Commander of the National Order of Merit; 
Commander of the Legion of Honour. 
Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2012). Member of the Committee on Finance 
and Administration (2012). Member of the Standing 
Committee on Estimates (2013).
Lochan Naidoo
Born in 1961. National of South Africa. Family Practitioner, 
Durban, South Africa (since 1985). 
Bachelor of Medicine and Bachelor of Surgery (MBChB), 
University of Natal, South Africa (1983). Professional in 
Residence Programme: Hanley Hazelden (1995); Member 
of the South African Medical Association (since 1995); 
Member and Vice-Chairman of the Bayport Independent 
Practitioners Association (1995-2000). Certified Chemical 
Dependency Counsellor, National Board of Addiction 
Examiners (NBAE) (1996); Member of the American 
Society of Addiction Medicine (1996-1999). Diploma in 
Business Management, South African Institute of 
Management (1997). Founding member, International 
Society of Addiction Medicine (1999); Programme 
Designer and Principal Addictions Therapist of the Jullo 
Programme, a multi-disciplinary treatment model for pri-
mary, secondary and tertiary prevention of addiction dis-
orders and dual diagnoses (since 1994); Clinical Director, 
Serenity Addiction Treatment Unit, Merebank, Durban, 
South Africa (since 1995). Member of the KwaZulu-Natal 
Managed Care Coalition (since 1995); Member of the 
Durban South Doctors’ Guild (since 2000); Honorary 
Lecturer, Nelson R. Mandela School of Medicine, 
University of KwaZulu-Natal, South Africa (2005-2011). 
Curriculum Committee undergraduate Lifestyle Medicine, 
University of KwaZulu-Natal (2005-2011). Drafter of the 
National Detoxification Policy and Procedure for the 
Department of Health of South Africa (2006); designer 
of the Roots connect software program, an Internet-driven 
emotional and addiction psychoeducation delivery sys-
tem (2007); Member of the Opiate Advisory Board of 
South Africa (2006-2008); Member of the Board, Central 
Drug Authority of South Africa (2006-2010); Member of 
the Governance Committee, Central Drug Authority of 
South Africa (2006-2010). Member of the Expert 
Committee on Opiate Treatment (2007-2008); Central 
Drug Authority representative to the Western Cape 
Province, South Africa (2007-2010); established “Roots 
HelpPoints” for early intervention and primary preven-
tion among high-risk individuals (2008). Co-author of 
“Guidelines for opiate treatment in South Africa”, South 
African Medical Journal (2008). Member of the Suboxone 
Advisory Board (2009). Co-author of “Opiate treatment 
update”, South African Medical Journal (2010); Designer 
of “RehabFlow” cloud computing software for addiction 
and co-morbidity management (2010); Management 
Committee Member of eThekweni District Mental Health 
and Substance Abuse Forum (2010). Rehabilitation and 
addictions trainer for health-care practitioners. Medical 
educator for undergraduate and postgraduate medical 
practitioners (since 1995); Patron of Andra Maha Sabha 
of South Africa; founder, Merebank West Community 
Coalition (1995). Trustee, Merebank Community Trust 
(2000-2005). 
Chief Executive Officer and Executive Director of Healing 
Hills Specialist Psychiatric Hospital, South Africa. 
Designer of Roots Online programme for prevention and 
aftercare of substance abuse disorders. Director of Access 
to Addiction Care (ATAC), a non-profit organization for 
advocacy and delivery of care to addicts in South Africa.
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Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (2011). Member of the Committee on Finance 
and Administration (2011). First Vice-President of the 
Board (2012).
Rajat Ray
Born in 1948. National of India. Professor and Head of 
the Department of Psychiatry and Chief, National Drug 
Dependence Treatment Centre (NDDTC), All India 
Institute of Medical Sciences (AIIMS), New Delhi. 
Graduate of Medicine (MBBS), Medical College in 
Calcutta (1971). M.D. (Psychiatry), AIIMS (1977). 
Member of the faculty, Department of Psychiatry, National 
Institute of Mental Health and Neuro Sciences, Bangalore 
(1979-1988). Author of several technical reports and arti-
cles in peer reviewed national and international journals. 
Assistant Editor, Addiction Biology. Member of the 
International Advisory Board, Mental Health and 
Substance Use: Dual Diagnosis and the Editorial Board, of 
the scientific journal International Drug Sciences and 
Drug Policy.
Recipient of research support from various bodies at the 
national level (such as the Ministry of Health and Family 
Welfare and the Indian Council of Medical Research) and 
the international level (such as UNODC and WHO). 
Member of a study on HIV/AIDS, a collaborative project 
of NDDTC, AIIMS and the Centre for Interdisciplinary 
Research in Immunology and Disease, University of 
California, Los Angeles (UCLA), United States of 
America. Member of the WHO Expert Advisory Panel 
on Drug Dependence and Alcohol Problems. Member of 
the expert group to discuss mental health and substance 
use disorder at the primary care level, an activity of the 
WHO Regional Office for South-East Asia. Member of 
the WHO expert group on regional technical consulta-
tion to reduce harmful use of alcohol. Coordinator of 
various activities in India on substance use disorder, 
sponsored by WHO (since 2004). Member of the National 
Drug Abuse Control Programme, India, and the Technical 
Guidelines Development Group on Pharmacotherapy of 
Opioid Dependence, a joint project of UNODC and 
WHO. Member and Chairperson of the Technical 
Resource Group on Injecting Drug Use, a project of the 
National AIDS Control Organization. Member of the 
project advisory committee on the prevention of trans-
mission of HIV among drug users in South Asian 
Association for Regional Cooperation (SAARC) member 
States, a project of the UNODC Regional Office for South 
Asia. Member of the Subcommittee on Postgraduate 
Medical Education, Medical Council of India. Chairperson, 
Working Group on Classification of Substance—Related 
and Addictive Disorder, International Advisory Group 
for the Revision of ICD-10 Mental and Behavioural 
Disorders (2011); Principal investigator, WHO Project 
“Web-Based Intervention (Portal) for Alcohol and 
Health”, Geneva (since 2010); principal investigator, 
NDDTC, Global Fund to Fight AIDS, Tuberculosis and 
Malaria Round 9 and Nodal Regional Resource and 
Training Centre; Principal Coordinator, National Policy 
and Twelfth Five-Year Plan of India, covering the period 
2012-2017, areas relating to control of alcohol and drug 
problems, Ministry of Social Justice and Empowerment, 
Government of India; Principal Investigator, opioid sub-
stitution therapy in India: issues and lessons learned, a 
joint project of NDDTC, AIIMS, the National AIDS 
Control Organisation, the government of Punjab and the 
Department for International Development (UK aid)—
Technical Assistance Support Team, targeted intervention 
(since 2010); member of the Expert Committee on 
Psychotropic Substances and New Drugs, Drug Controller 
General of India (2011). Reviewer and contributor, Indian 
Journal of Medical Research, official publication of the 
Indian Council of Medical Research (since 2010).
Member of the International Narcotics Control Board 
(since 2010). Member (2010) and Chair (2011) of the 
Standing Committee on Estimates. Second Vice-President 
of the Board (2011). Member of the Standing Committee 
on Estimates (2012). Member of the Standing Committee 
on Estimates (2013).
Ahmed Kamal Eldin Samak
Born in 1950. National of Egypt. Graduated with a Law 
and Police Licence in 1971. Worked in the field of anti-
narcotics for more than 35 years, until becoming the 
Minister Assistant of Police and Head of the Anti-
Narcotics General Administration (ANGA) of Egypt 
which is considered the first organization of anti-narcot-
ics in the world founded in 1929. Independent adviser in 
the field of anti-narcotics and crime. First-rank badge of 
honour on the occasion of the police festival (1992). 
Contributed to several missions, such as to Jordan, for 
anti-narcotics training (1988); India, for the signing of an 
agreement between India and Egypt to strengthen anti-
narcotics and security cooperation to combat crime and 
terrorism (1995); France, for cooperation between Egypt 
and INTERPOL relating to drugs and money-laundering 
(1996); Palestine, to participate in a regional anti- narcotics 
workshop (1999); Saudi Arabia, to participate in a 
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training programme related to drug cases (2001); United 
Arab Emirates, to represent the Ministry of the Interior 
at the thirty-sixth session of the committee concerned 
with illegal trade in drugs (2001); to the Libyan Arab 
Jamahiriya,b to participate in the celebration of the 
International Day against Drug Abuse and Illicit 
Trafficking (2002); Kenya, to participate in the twelfth and 
seventeenth conferences of African national anti- narcotics 
department leaders (2002 and 2007); Mauritius, for the 
second ministerial anti-narcotics meeting (2004); 
Lebanon, to participate in the conference “Drugs are a 
social epidemic” organized by Lebanese organizations for 
human rights (2004); Tunisia, to participate in the seven-
teenth to twenty-first Arab conferences of anti-narcotic 
department leaders (2003-2007); United States (2004); 
Austria, to represent the Ministry at the forty-fifth, forty-
sixth and forty-eighth to fiftieth sessions of the Commission 
on Narcotic Drugs (2002-2007); Saudi Arabia, as a mem-
ber of a scientific organization to prepare an article about 
arrest and investigation procedures (2007); United Arab 
Emirates, for the Regional Seminar for Strategic and 
Cooperative Planning in the Field of Anti-Narcotics 
(2007). Member of the National General Trust Fund for 
Anti-Narcotics and Addiction; and the Committee of 
National Strategy Planning on Anti-Narcotics.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012). 
Werner Sipp
Born in 1943. National of Germany. Lawyer (Universities 
of Heidelberg, Germany, and Lausanne, Switzerland, 
University Institute of European Studies, Turin, Italy).
Assistant lecturer in Public Law, University of Regensburg 
(1971-1977). Senior administrative posts in several fede-
ral ministries (1977-2008). Head of the Division for 
Narcotic Law and International Narcotic Drugs Affairs in 
the Federal Ministry of Health (2001-2008);  permanent 
Correspondent of Germany in the Pompidou Group of 
the Council of Europe (2001-2008); Legal Correspondent 
of Germany in the European Legal Database on Drugs, 
Lisbon (2002-2008); Chairman of the Horizontal Working 
Party on Drugs of the Council of the European Union 
(2007); Coordinator of the German delegation to the 
Commission on Narcotic Drugs (2001-2009). 
Expert Consultant to the German Federal Ministry of 
Health and the Drug Commissioner of the Federal 
Government in international drug matters (2008-2009); 
Expert Consultant on drug issues to the Deutsche 
Gesellschaft für Internationale Zusammenarbeit (GIZ) 
(2008-2011); Expert on several European Union drug 
projects (such as “Implementing the national strategy to 
fight drug abuse in Serbia” (INSADA) and the Central 
Asia Drug Action Programme (CADAP).
Member of the International Narcotics Control Board 
(since 2012), Member of the Standing Committee on 
Estimates (2012 and 2013). Rapporteur (2013).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
Bachelor of Science degree in Chemistry (1976), Chiang 
Mai University. Bachelor’s degree in Pharmacy (1979), 
Manila Central University. Master’s degree in Clinical 
Pharmacology (1983), Chulalongkorn University. He then 
took apprenticeship in narcotic drugs epidemiology at St. 
George’s University of London in England in 1989. Doctor 
of Philosophy, Health Policy and Administration (2009), 
National Institute of Administration. Member of the 
Pharmaceutical Association of Thailand. Member of the 
Pharmacological and Therapeutic Society of Thailand. 
Member of the Thai Society of Toxicology. Author of nine 
books in the field of drug prevention and control, includ-
ing Drugging Drinks: Handbook for Predatory Drugs 
Prevention and Déjà vu: A Complete Handbook for 
Clandestine Chemistry, Pharmacology and Epidemiology of 
LSD. Columnist, Food and Drug Administration Journal. 
Recipient of the Prime Minister Award for Drug Education 
and Prevention (2005). 
Member of the International Narcotics Control Board 
(since 2010). Member of the Standing Committee on 
Estimates (since 2010). Chair of the Committee on 
Finance and Administration (2011). Second Vice-
President and Chair of the Standing Committee on 
Estimates (2012). Chair of the Committee on Finance and 
Administration (2013) and Member of the Standing 
Committee on Estimates (2013).
 bSince 16 September 2011, “Libya” has replaced “Libyan Arab Jamaa-
hiriya” as the short name used in the United Nations.
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Sri Suryawati
Born in 1955. National of Indonesia. Professor and Head, 
Division of Medicine Policy and Management, Director 
of Centre for Clinical Pharmacology and Medicine Policy 
Studies, Gadjah Mada University, Yogyakarta. Educational 
background includes pharmacy (1979). specialist in 
pharmacology (1985); doctoral degree in clinical 
pharmaco kinetics (1994), certificate in medicine policy 
(1997). Lecturer in Pharmacology/Clinical Pharmacology 
(since 1980); supervisor for more than 130 masters’ and 
doctoral theses in the areas of medicine policy, essential 
 medicines, clinical pharmacology, pharmacoeconomics, 
and pharmaceutical management.
Member of the WHO Expert Advisory Panel for Medicine 
Policy and Management. Member of the Executive Board 
of the International Network for the Rational Use of 
Drugs (INRUD). Member of the WHO Expert Committee 
on the Selection and Use of Essential Medicines (2002, 
2003, 2005 and 2007). Member of the WHO Expert 
Committee on Drug Dependence (2002 and 2006). 
Member of the United Nations Millennium Project Task 
Force on HIV/AIDS, Malaria and Tuberculosis and 
Access to Essential Medicines (Task Force 5) (2001-2005). 
Consultant in essential medicine programmes and pro-
moting rational use of medicines in Bangladesh (2006-
2007), Cambodia (2001-2008), China (2006-2008), Fiji 
(2009), the Lao People’s Democratic Republic (2001-
2003), Mongolia (2006-2008) and the Philippines (2006-
2007). Consultant in medicine policy and drug evaluation 
in Cambodia (2003, 2005 and 2007), China (2003), 
Indonesia (2005-2006) and Viet Nam (2003). Facilitator 
in various international training courses in medicine pol-
icy and promoting the rational use of medicines, includ-
ing WHO and INRUD courses on promoting the rational 
use of medicines (1994-2007), training courses on hospi-
tal drugs and therapeutics committees (2001-2007) and 
international courses on medicine policy (2002-2003).
Member of the International Narcotics Control Board 
(since 2007). Member (2008, 2011 and 2013), Vice-Chair 
(2009) and Chair (2010) of the Standing Committee on 
Estimates. Second Vice-President of the Board (2010). 
Rapporteur (2011). Second Vice-President of the Board 
and Chair of the Standing Committee on Estimates (2013). 
Francisco E. Thoumi
Born in 1943, national of Colombia and the United States. 
Bachelor of Arts and Doctor of Philosophy in Economics. 
Senior member of the Colombian Academy of Economic 
Sciences and Corresponding member of the Royal 
Academy of Moral and Political Sciences (Spain).
Has been a Professor at the University of Texas, Rosario 
University (Bogota) and California State University, 
Chico. Worked for 15 years in the research departments 
of the World Bank and the Interamerican Development 
Bank. Founder and Director, Research and Monitoring 
Center on Drugs and Crime, Rosario University (August 
2004-December 2007); Research Coordinator, Global 
Programme against Money Laundering, Proceeds of 
Crime and the Financing of Terrorism; Coordinator for 
the World Drug Report, United Nations Office on Drugs 
and Crime (UNODC), Vienna (August 1999-September 
2000); Researcher, Comparative Study of Illegal Drugs in 
Six Countries, United Nations Research Institute for 
Social Development, Geneva (June 1991-December 1992); 
Fellow, Woodrow Wilson International Center for Scholars 
(August 1996-July 1997); Research Coordinator, Research 
Programme on the Economic Impact of Illegal Drugs in 
the Andean Countries, United Nations Development 
Programme, Bogota (November 1993-January 1996).
Author of two books and co-author of one on illegal 
drugs in Colombia and the Andean region. He has also 
edited three volumes and written over 60 academic jour-
nal articles and book chapters on those subjects.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012-2014). 
Member of the International Narcotics Control Board 
(since 2012). Rapporteur (2012). Member of the Standing 
Committee on Estimates (2013).
Raymond Yans
Born in 1948. National of Belgium. Graduate in Germanic 
philology and in philosophy (1972). 
Belgian Foreign Service: Attaché, Jakarta (1978-1981); 
Deputy-Mayor of Liège (1982-1989); Consul, Tokyo 
(1989-1994); Consul, Chargé d’affaires, Luxembourg 
(1999-2003); Head of the Drug Unit, Ministry of Foreign 
Affairs (1995-1999 and 2003-2007); Chairman of the 
Dublin Group (2002-2006); Chairman of the European 
Union Drug Policy Cooperation Working Group during 
the Belgian Presidency of the European Union; charged 
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with the national coordination of the ratification and 
implementation process of the Convention on 
Psychotropic Substances of 1971 and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (1995-1998); liaison 
between the Ministry of Foreign Affairs and the National 
Police for drug liaison officers in Belgian embassies 
(2003-2005); participation in the launching by the 
European Union Joint Action on New Synthetic Drugs 
of an early warning system to alert Governments to the 
appearance of new synthetic drugs (1999); active in the 
creation of the Cooperation Mechanism on Drugs 
between the European Union, Latin America and the 
Caribbean (1997-1999). Author of numerous articles and 
speeches including: “The future of the Dublin Group” 
(2004) and “Is there anything such as a European Union 
Common Drug Policy” (2005). Member of the Belgian 
delegation to the Commission on Narcotic Drugs (1995-
2007); all the preparatory sessions (on amphetamine-
type stimulants, precursors, judicial cooperation, 
money-laundering, drug demand reduction and alterna-
tive development) for the twentieth special session of the 
General Assembly; European Union Seminar on Best 
Practices in Drug Enforcement by Law Enforcement 
Authorities, Helsinki (1999); Joint European Union/
Southern African Development Community Conferences 
on Drug Control Cooperation, Mmabatho, South Africa 
(1995) and Gabarone (1998); United Nations Office on 
Drugs and Crime/Paris Pact round tables, Brussels 
(2003), Tehran and Istanbul (2005); meetings of the 
High-level Dialogue on Drugs between the Andean 
Community and the European Union, Lima (2005) and 
Vienna (2006).
Member of the International Narcotics Control Board 
(since 2007). Member of the Standing Committee on 
Estimates (2007-2010). Member of the Committee on 
Finance and Administration (2007-2010). Rapporteur 
(2010). First Vice-President of the Board (2011). President 
of the Board (2012 and 2013).
The International Narcotics Control Board (INCB) is an 
independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the inter-
national drug control treaties. It had predecessors under 
the former drug control treaties as far back as the time 
of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by the World Health Organization (WHO) and 10 
members are elected from a list of persons nominated by 
Governments. Members of the Board are  persons who, 
by their competence, impartiality and disinterestedness, 
command general confidence. The Council, in consulta-
tion with INCB, makes all arrangements necessary to 
ensure the full technical independence of the Board in 
carrying out its functions. INCB has a secretariat that 
assists it in the exercise of its treaty-related functions. 
The INCB secretariat is an administrative entity of the 
United Nations Office on Drugs and Crime, but it reports 
solely to the Board on matters of substance. INCB closely 
collaborates with the Office in the framework of arrange-
ments approved by the Council in its resolution 1991/48. 
INCB also cooperates with other international bodies 
concerned with drug control, including not only the 
Council and its Commission on Narcotic Drugs, but also 
the relevant specialized agencies of the United Nations, 
particularly WHO. It also cooperates with bodies outside 
the United Nations system, especially the International 
Criminal Police Organization (INTERPOL) and the 
World Customs Organization.
Functions
The functions of INCB are laid down in the following 
treaties: the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol; the Convention on 
Psychotropic Substances of 1971; and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
  (a) As regards the licit manufacture of, trade in 
and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
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does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
  (b) As regards the illicit manufacture of, trafficking 
in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contributes 
to correcting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of 
drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
 (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
 (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
 (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
 (d) Maintains a permanent dialogue with Govern-
ments to assist them in complying with their obligations 
under the international drug control treaties and, to that 
end, recommends, where appropriate, technical or finan-
cial assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. If, 
however, INCB notes that the measures necessary to rem-
edy a serious situation have not been taken, it may call 
the matter to the attention of the parties concerned, the 
Commission on Narcotic Drugs and the Economic and 
Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing 
and potential situations that may endanger the objec-
tives of the international drug control treaties. INCB 
draws the attention of Governments to gaps and weak-
nesses in national control and in treaty compliance; it 
also makes suggestions and recommendations for 
improvements at both the national and international 
levels. The annual report is based on information pro-
vided by Governments to INCB, United Nations enti-
ties and other organizations. It also uses information 
provided through other international organizations, 
such as INTERPOL and the World Customs Organization, 
as well as regional organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also pub-
lished as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
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1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the interna-
tional drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of 
illicit drug promotion
1998:  International control of drugs: past, present 
and future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001: Globalization and new technologies: 
 challenges to drug law enforcement in the twenty-
first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the microlevel 
impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005: Alternative development and legitimate 
livelihoods
2006: Internationally controlled drugs and the 
unregulated market
2007: The principle of proportionality and drug-
related offences
2008: The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
2011: Social cohesion, social disorganization and 
illegal drugs
2012: Shared responsibility in international drug 
control 
Chapter I of the report of the International Narcotics 
Control Board for 2013 is entitled “Economic conse-
quences of drug abuse.”
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide con-
trol of all licit activities related to narcotic drugs and psy-
chotropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents some of the major developments in 
drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by 
addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, the United Nations Office on 
Drugs and Crime, WHO and other relevant international 
and regional organizations.
 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
aUnited Nations Office on Drugs and Crime.
bThe INCB secretariat reports on substantive matters to INCB only.
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